


Login to **My ISPE Conference** to elevate your conference experience
<https://www.pharmacoepi.org/meetings/34ICPE>



34TH ICPE
INTERNATIONAL CONFERENCE ON PHARMACOEPIDEMIOLOGY
& THERAPEUTIC RISK MANAGEMENT
AUGUST 22-26, 2018
PRAGUE CONGRESS CENTRE
PRAGUE, CZECH REPUBLIC

SCIENTIFIC PROGRAM

JOINTLY SPONSORED BY:



CHARLES UNIVERSITY
Faculty of Pharmacy
in Hradec Králové

UIPS Utrecht Institute for
Pharmaceutical Sciences



Universiteit Utrecht



BOARD OF DIRECTORS & VOLUNTEER LEADERS



ISPE OFFICERS & BOARD OF DIRECTORS

OFFICERS

Jesper Hallas, FISPE, President
 Alison Bourke, FISPE, President-Elect
 Kiyoshi Kubota, FISPE, Immediate Past President
 Tobias Gerhard, FISPE, Vice President Finance
 Krista Huybrechts, FISPE, Vice President Finance - Elect
 Mark H Epstein, Executive Secretary

DIRECTORS

Morten Andersen	Malcolm Maclure
Dorothee Bartels, FISPE	Lisa Pont, FISPE
Stanley A Edlavitch, <i>Lifetime Emeritus</i>	June Raine
Cynthia J Girman, FISPE	Jennita Reefhuis
Wan-Ting Huang	Rachel Sobel, FISPE
Michelle Jonsson Funk, FISPE	Montse Soriano Gabarro
Olaf Klungel, FISPE	Sabine Strauss
Vin Lo Re III, FISPE	Jasmanda Wu, FISPE

2018 ICPE SCIENTIFIC PROGRAM COMMITTEE

Olaf Klungel, FISPE, Chair

CORE PROGRAM COMMITTEE

Ian Douglas	Niklas Noren
Mark H. Epstein	Robert Platt
Helga Gardarsdottir, FISPE	Anton Pottegard
Tobias Gerhard, FISPE	Nicole Pratt
Lamiaie Grimaldi	Robert Reynolds, FISPE
Susanna Gutthann-Perez, FISPE	Mary Ritchey
Jesper Hallas, FISPE	Harry Seifert, FISPE
Krista Huybrechts, FISPE	Soko Setoguchi Iwata, FISPE
J. Bradley Layton	Amelia Smith
Deborah Layton	Montse Soriano Gabarro
Charles Leonard	Til Sturmer, FISPE
Adrian Levy	Gianluca Trifiro
Vincent Lo Re III, FISPE	Tjeerd Van Staa
Frank May, FISPE	Jiří Vlček
Yola Moride, FISPE	Jasmanda Wu, FISPE

CHAIRS/CO-CHAIRS & LIAISONS

COMMITTEES

Archives & History Hugh Tilson, FISPE
Bylaws & Policies Stella Blackburn, FISPE
 Frank May, FISPE
Development Dimitri Bennett, FISPE
 Doug Kou
Education Anton Pottegard
 Jaclyn Bosco
 Darren Toh, FISPE
Fellowship & Awards Kiyoshi Kubota, FISPE
Finance Tobias Gerhard, FISPE
 Krista Huybrechts, FISPE
Global Development K. Arnold Chan, FISPE
 Wei Zhou, FISPE
Management Oversight Kiyoshi Kubota, FISPE
Membership Alicia Gilsenan
 Quazi Ataher
Nominating Kiyoshi Kubota, FISPE
Public Policy & Ethics Lisa Pont, FISPE
 Meredith Smith
Publications & Communications Rhonda Bohn, FISPE
 Kourtney Davis
Scholarship Jesper Hallas, FISPE
 David Miller, FISPE
Scientific Program Olaf Klungel, FISPE
Strategic Planning Alison Bourke, FISPE

COUNCILS

Academic Deborah Layton
 Kevin Lu
Government/Regulatory Sabine Straus
 Gianpiero Mazzaglia
Industry/Service Providers Dan Fife, FISPE
 John Acquavella, FISPE
Student Amelia Smith
 Lindsay Wong

SPECIAL INTEREST GROUPS

Adherence Julie Lauffenburger
 Sarah-Jo Sinnott
AsPEN Edward Chia-Cheng Lai
 Kenneth Man
Biologics & Biosimilars Amanda Keatley Golembesky
Benefit Risk Assessment, Communication and Evaluation (BRACE) Rachel Sobel, FISPE
 Meredith Smith
Comparative Effectiveness Research (CER) Hongo Yuan
Databases Ellen Ming
 Matthew Reynolds
Drug Utilization Veronika Wirtz
 Doug Steinke



VOLUNTEER LEADERS & COMMITTEES

Medical Device	Katherine Etter Macarius Donneyong
Medications In Pregnancy	Deborah Covington, FISPE Hedvig Nordeng
Molecular Epi/Biomarkers/ Pharmacogenetics	Kelly Filipski Leah Sansbury
Oncology	Andrew Freedman Dorian Murariu
Pediatrics	Susan dosReis, FISPE Lina Titievsky
Rare Diseases	Jasmanda Wu, FISPE
Vaccines	Harry Seifert, FISPE James Stark

LIAISONS

CIOMS	Sabine Straus
ENCePP	Yola Moride, FISPE
FDA	Christian Hampp, FISPE
International Network for Epidemiology in Policy	Lisa Pont, FISPE

REGIONAL CHAPTERS

Africa	Kwame Appenteng Irene Berita Murima
Brazil	Luciane C Lopes Claudia Gracia Serpa Osório de Castro Juan Sebastian Franco
FarmacoEpiEnRed - Gulf Region	Elisa Martín-Merino Tariq Alhawassi Nasser Alqahtani
Spanish Chapter Latin America	Daniel Prieto-Alhambra, FISPE Rene Soria-Saucedo Marcella Jiron

STUDENT CHAPTERS

- ◆ Basel Pharmacoepidemiology Unit, University of Basel, Switzerland & the Boston Collaborative Drug Surveillance Program, Boston University, USA
- ◆ Center for Drug Safety & Effectiveness, Department of Epidemiology, Johns Hopkins School of Public Health, USA
- ◆ Center for Drug Safety & Pharmaceutical Health Services Research Graduate Program, University of Maryland School of Pharmacy, USA
- ◆ Clinical and Population Health Research Program, Department of Quantitative Health Sciences, University of Massachusetts Medical School, USA
- ◆ College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Canada

- ◆ College of Pharmacy, University of Cincinnati, USA
- ◆ Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, USA
- ◆ Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago, USA
- ◆ Department of Pharmacy Practice, KMCH College of Pharmacy, Coimbatore, India
- ◆ Harvard University School of Public Health, USA
- ◆ Health Outcomes and Pharmacy Practice, The University of Texas at Austin, USA
- ◆ Faculty of Pharmacy, JSS University, Mysore, India
- ◆ Graduate Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Canada
- ◆ Pharmacoepidemiology and Pharmacoeconomics, University of Rhode Island, USA
- ◆ Pharmacoepidemiology Program, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, USA
- ◆ Program for Clinical Pharmacy and Pharmaceutical Sciences, National Chen-Kung University, Taiwan
- ◆ Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, USA
- ◆ Touro College of Pharmacy, New York City, USA
- ◆ University of Bordeaux, France

2018 ICPE LOCAL HOST COMMITTEE

- Jiří Vlček, Chair, Czech Republic
 Ria Benko, Hungary
 Jurjen Duintjer Tebbens, Czech Republic
 Christos Kontogiorgis, Greece
 Josef Malý, Czech Republic
 Jana Mladá, Czech Republic
 Jan Petráček, Czech Republic
 Agneizska Skowron, Poland
 Martin Wawruch, Slovak Republic

ISPE DEVELOPMENT COMMITTEE

- | | |
|-----------------------------------|-------------------------|
| Dimitri Bennnett, FISPE, Chair | Nick Everage |
| Doug Kou, Co-Chair | Joann Lem |
| Kirk Midkiff, Past Chair, Advisor | Susan Oliveria, FISPE |
| Alex Asiimwe | Syd Phillips |
| Dawn Campbell | Maribel Salas, FISPE |
| Susan Colilla | Kate Saltus |
| Andrzej Czarnecki, FISPE | Nancy Santanello, FISPE |
| Mark Cziraky | Mayura Shinde |
| Mark H. Epstein | Jasmanda Wu, FISPE |



ORGANIZATIONAL MEMBERS & IN THIS PROGRAM

ORGANIZATIONAL & INSTITUTIONAL MEMBERS

PHARMACEUTICALS

GlaxoSmithKline
Sanofi-Aventis
UCB BioSciences

SERVICE PROVIDERS

RTI Health Solutions

GOVERNMENT/REGULATORY AGENCY

Department of Epidemiology, Lazio Regional Health Service

ACADEMIC PROGRAMS

- ◆ Charles University in Prague, Faculty of Pharmacy
- ◆ Center for Drug Safety & Effectiveness, Department of Epidemiology, Johns Hopkins School of Public Health
- ◆ Center for Drug Safety & Pharmaceutical Health Services Research Graduate Program, University of Maryland School of Pharmacy
- ◆ Center for Pharmacoepidemiology Research and Training (CPeRT), Perelman School of Medicine at the University of Pennsylvania
- ◆ Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida
- ◆ Drug Safety Research Unit, Associated Department, School of Pharmacy, Portsmouth University
- ◆ Harvard School of Public Health
- ◆ London School of Hygiene and Tropical Medicine
- ◆ McGill Pharmacoepidemiology Research Unit, McGill University
- ◆ Pharmacoepidemiology Program, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
- ◆ Russian National Society of Evidence-Based Pharmacotherapy
- ◆ Rutgers Center for Pharmacoepidemiology and Treatment Science
- ◆ University of Massachusetts Medical School - Clinical and Population Health Research
- ◆ University of Texas at Austin - College of Pharmacy

IN THIS PROGRAM

34TH ICPE AGENDA

Tuesday, August 21.....	12
Wednesday, August 22	12
Thursday, August 23.....	20
Friday, August 24.....	31
Saturday, August 25.....	42
Sunday, August 26	54

34TH ICPE POSTERS

Poster Guidelines	65
Poster Session A.....	66
Poster Session B.....	80
Poster Session C.....	95

INDEXES

Abstract Index	111
Advertisers Index.....	134



**INTERNATIONAL CONFERENCE ON PHARMACOEPIDEMIOLOGY
& THERAPEUTIC RISK MANAGEMENT**
AUGUST 22-26, 2018
PRAGUE CONGRESS CENTRE
PRAGUE, CZECH REPUBLIC

Norazida Ab Rahman
 Victoria Abbing-
 Karahagopian
 John Acquavella, FISPE
 Thomas P Ahern
 Jessica Albano
 Yasser Albogami
 Silvia Alessi-Severini
 G. Caleb Alexander
 Wasem Wasem Alsabbagh
 Thimir Alshammari
 Carlos Alves
 Eric Ammann
 Klaus Andersen
 Elizabeth Andrews, FISPE
 Daniel Ankrah
 Mary Anthony
 Chuka Anude
 Eirini Apostolidou
 Alejandro Arana, FISPE
 Ariel E. Arias, FISPE
 Miia Artama
 Keiko Asao
 Darren Ashcroft
 Alex Asiimwe
 Annlouise Assaf, FISPE
 Quazi Ataher
 Henok Tadesse Ayele
 Shahram Bahmanyar
 Nicole Baker
 Mohammad Bakhriansyah
 Marina Bakker
 Dorothee Bartels, FISPE
 Gillian Bartlett-Esquiland
 Brian Bateman
 Vincent Bauchau
 Daniel C Beachler
 Claudia Becker
 Sigrid Behr
 Dimitri Bennett, FISPE
 Irene Bezemer
 Gouri Shankar
 Bhattacharyya
 Catherine Bishop Johannes
 Stella Blackburn, FISPE
 Bianca Blanch
 Christopher Blanchette
 Patrick Blin
 Pierre-Olivier Blotiere
 Michael Blum
 Priyanka Bobbili
 Rhonda Bohn, FISPE
 Reka Bordas
 Jaclyn Bosco
 Denise Boudreau
 Naomi Boxall
 Joanne Brady
 Kimberly Brodovicz
 Gabriella Broms
 Emily Brouwer
 Joshua Brown

Mehmet Burcu
 Greta Bushnell
 Anne Butler
 Katsiaryna Bykov
 Lauren Bylsma
 Claudia Cabrera Moksnes
 Pia Caduff
 Caitriona Cahir
 Gloria Caldwell
 Raissa Carolina Candido
 Bruce Carleton, FISPE
 Deborah Casso
 Liana Castel
 Ruby Castilla-Puentes
 Gillian Caughey
 Christina Chambers
 Esther Chan
 Chao Chen
 Hungta Chen
 Lei Chen
 Li-Chia Chen
 Mei Chen
 Robert Chen, FISPE
 Teng-Chou Chen
 Ching-Lan Cheng
 Yingkai Cheng
 Hsu-Chih Chien
 Nam-Kyong Choi
 Christian Christiansen
 Carole Chrvala
 Te-yuan Chyou
 Javier Cid Ruzafa
 Noelle Cocoros
 Jacqueline Cohen
 Catherine Cohet
 Alexander Cole
 Susan Colilla
 John Connolly
 Mitchell Conover
 Nicole Cossrow
 Deborah Covington, FISPE
 James Crispo
 Deirdre Cronin Fenton
 Francesca Cunningham
 Andrzej Czarnecki, FISPE
 Benjamin Daniels
 Monica D'Arcy
 Saibal Das
 Nabarun Dasgupta
 Kourtney Davis
 Marie de Bruin
 Christina DeFilippo-Mack
 Petra Denig
 Angela DeVeugh-Geiss
 Ricardo Di
 Domenicantonio
 Mirko Di Martino
 Anne Dilley
 Rachael DiSantostefano
 Tan Doan
 Katherine Donegan

Yaa-Hui Dong
 Macarius Donneyong
 Susan dosReis, FISPE
 Ian Douglas
 Antonios Douros
 Cecile Droz-Perroteau
 Wei Du
 Sascha Dublin
 Genevieve Durrieu
 Lisa Dwyer
 Vera Ehrenstein
 Chioma Ejekam
 Laura Elkayam
 Lisa Ellett
 Alan Ellis
 Soha Elmorsy
 Sherif Eltonsy
 Cheryl Enger
 Emmanuelle Espie
 Daina Esposito
 Katherine Etter
 Nicholas Everage
 Gang Fang
 Niloufar Farzan
 James Feinstein
 Miriam Fenton
 Alina Fernandez
 Kristian Filion
 Evelyn Flahavan
 James Flory
 Robert Flynn
 Joan Forns
 Michael Forstner
 Joan Fortuny
 Michael PF Fralick
 Andrew Freedman
 Jon Fryzek
 Candace Fuller
 Kari Furu
 Myriam Gagne
 Joshua Gagne
 David Gagnon
 Steve Gao
 Helga Gardarsdottir, FISPE
 Nicolle Gatto, FISPE
 Alicia Gayle
 Wenzhen Ge
 Stewart Geary
 Marleen Gelder
 Prethibha George
 Tobias Gerhard, FISPE
 Zsuzsana Gesztesi
 Thijs Giezen
 Alicia Gilsenan
 Rosa Gini
 Cynthia J Girman, FISPE
 Gunnar Gislason
 Cheong Hian Goh
 Mugdha Gokhale
 Robert Goldberg
 Amie Goodin

Michael Goodman
 Jessica Gorgui
 Amandine Gouverneur
 Camelia Graham
 Sonia M. Grandi
 Carlos Grijalva
 Lamiae Grimaldi
 Qi Guan
 Sandra Guedes
 Jason Guertin
 Usha Gungabissoon
 Jeff Guo
 Katrina Hagberg
 Christine Hagemann
 Gillian Hall, FISPE
 Christian Hampp, FISPE
 David Harris
 Ilene Harris
 Abraham Hartzema, FISPE
 Raymond Harvey
 Abdul Haseeb
 Ulrike Haug
 Samuel Hawley
 Kevin Haynes, FISPE
 Maja Hellfritzsich
 Sean Hennessy, FISPE
 Sharon Hensley Alford
 Ron Herings, FISPE
 Inmaculada Hernandez
 Rohini Hernandez
 Laura Hester
 Blanaid H. Hicks
 Juan Hincapie Castillo
 Veena Hoffman
 Mikael Hoffmann
 Thi Hong Nhung
 Ken Hornbuckle, FISPE
 Daniel Horton
 Hsing-Chun Hsieh
 Jason C. Hsu
 Phyo Htoo
 Jason Hu
 Li Ying Huang
 Ting-Ying Huang
 Wan-Ting Huang
 Yujing Huang
 Phillip Hunt
 Krista Huybrechts, FISPE
 Lynn Huynh
 Takuya Imatoh
 Amalia Issa, FISPE
 Jessica Jalbert
 Nakyung Jeon
 Susan Jick
 Cynthia Jones
 Judith Jones, FISPE
 Meghan Jones
 Michelle Jonsson-Funk,
 FISPE
 Juhaeri Juhaeri
 Florentia Kaguelidou

Dan Kajungu
Linda Kalilani
Anokhi Kapasi
Sigal Kaplan
Pär Karlsson
Alison Kawai
Michael Kelsh
Alison Keshishian
Javeed Khan
Vineet Kumar Kharat
Farzin Khosrow-Khavar
Helle Kieler
Sangmi Kim
Tomomi Kimura
Alan Kinlaw
Ursula Kirchmayer
Henry Kirchner
Olaf Klungel, FISPE
Caitlin Knox
Joris Komen
Oleksii Korzh
Richelle Kosse
Alexis A Krumme
Kiyoshi Kubota, FISPE
Veronique Kugener
Hiraku Kumamaru
I Fan Kuo
Edward Chia Cheng, Lai
Leonardo Alfonsius Paulus
Laleno
Suzanne Landi
Stephan Lanes
Kate Lapane, FISPE
Maryse Lapeyre-Mestre
Tamar Lasky, FISPE
Julie Lauffenburger
J. Bradley Layton
Deborah Layton
Tham Le
Hristina Lebanova
Jacinthe Leclerc
Sally Lee
Andreia Leite
Yanina Lenz
Charles Leonard
Michael Lewis, FISPE
Hu Li
Xiaojuan Li
Yan Li
Yi Lian
Chih-Wan Lin
Dora Lin
Jennifer Hsiang-Ling Lin
Joshua Lin
Nancy Lin
Tzu-Chieh Lin
Marie Linder
Shao-Hsien Liu
Shusen Liu
Xinyue Liu
Vincent Lo Re III, FISPE

Feng-Hua Loh
Cristina Longo
Simone Loo
Luciane Cruz Lopes
Sandra Lopez Leon
Zhiqiang Lu
Cynthia Luise
Jennifer Lund
Carlotta Lunghi
Jing Luo
Angela Lupattelli
Theodore Lystig
Marina Machado
Isla Mackenzie
Ramesh Madhan
Terri Madison
Anke-Hilse Maitland-van
der Zee, FISPE
Atheline Major-Pedersen
Katerina Mala
Kenneth Man
Zachary Marcum
Andrea Marcus
Andrea Margulis
Karine Marinier
Morgan Marks
Sophia E. Marsh
Christopher Mast
Ilan Matok
Prithpal S. Matreja
Shinichi Matsuda
Pattra Mattox
Géric Maura
Colleen Maxwell
Frank May, FISPE
Ann McMahon
Hemalkumar Mehta
Vinay Mehta
Cristiane Menezes
Joseph Menzin
Sharon Meropol
Bita Mesgarpour
Kristin Meyers
Brian Miller
David Miller, FISPE
Jea Young Min
Daniel Mines
Eileen Ming
Sara Miranda
Montserrat Miret
Jingping Mo
Maja Mockenhaupt
Anna K. Moffat
Daniela Moga
François Montastruc
Nicholas Moore, FISPE
Yola Moride, FISPE
Elaine Morrato
Jon Morris
Kathleen Mortimer
Julie Mouchet

Cristiano Moura
Mohammad Movahedi
Jerald Mullersman
William Murk
Walter-Rodney Nagumo
Sabina O Nduaguba
Steve Niemcryk
Shinichi Nishiuma
Prasad Nishtala
Shimpei Niwa
Hedvig Nordeng
Beth Nordstrom
Niklas Noren
Mette Norgaard
Rachel Odesanya
Ingvild Odsbu
Maire O'Dwyer
Eniola Ogunmefun
Denise Oleske
Kelly Olsson
Ibrahim Oreagba
Vicki Osborne
Kristin Palmsten
Irene Pan
Catherine Panozzo
Paraskevi Papaioannidou
Rosa Parisi
Catherine Patterson
Sallie-Anne Pearson
Alma Pedersen
Michael Peng
Dinci Pennap
Susana Perez-Gutthann,
FISPE
Rebecca Persson
Paul Petraro
Jeanne Pimenta
Federica Pisa
Estel Plana
Robert Platt
Julie Polisen
Lisa Pont, FISPE
Jennifer R Popovic
Nicole Pratt
Daniel Prieto-Alhambra,
FISPE
Jingjing Qian
Elham Rahme
Thiyagu Rajakannan
Sudha Raman
Darmendra Ramcharran
Emmae Ramsay
Sapna Rao
Jeremy Rassen
Cristina Rebordosa Garcia
Jennita Reefhuis
Mette Reilev
Adriano Reis
Christel Renoux
Christopher Rentsch
Robert Reynolds, FISPE

Kiyon Rhew
Margaret Richards
Kathryn Richardson
Staci Risman
Mary Ritchey
Elena Rivero, FISPE
Giuseppe Roberto
Noah Robinson
Andrew Roddam
Daniel Rosenberg
Kieran Rothnie
Julie Rouette
Elizabeth Roughead
Christianne Roumie
Debabrata Roy
Cynthiya Ruban
Leo Russo
Patricia Saddier
Nuria Saigi-Morgui
Maribel Salas, FISPE
Hager Saleh
Nurrul Salwa Saleh
Catherine Saltus
Francesco Salvo
Ramiro Sanchez-Huesca
Gabriel Sanfelix-Gimeno
Thibaut Sanglier
Nancy Santanello, FISPE
Ameet Sarpatwari
Brian Sauer
Lucie-Marie Scaileux
Wiebke Schaefer
Andrea L. Schaffer
Debra Schaumberg
Jonathan Schelfhout
Fred Schneiweiss
Renate Schulze-Rath
Marissa Seamans
Matthew Secrest
John Seeger, FISPE
Jodi Segal, FISPE
Harry Seifert, FISPE
Soko Setoguchi, FISPE
Yu-Hsuan Joni Shao
Natalia Shcherbakova
Ju-Young Shin
Mayura Shinde
Srikanth Siddalingegowda
Jason Simeone
Scot Simpson
Sonal Singh
Eva Skovlund
Jonathan Slaughter
Amelia Smith
Meredith Smith
Rachel Sobel, FISPE
Henrik Toft Sorensen
Montserrat Soriano
Gabarro
Patrick Sovereign
O'Mareen Spence



Julia Spoenlin
 Chalasani Sri Harsha
 Pakawadee Sriphiromya
 Paul Stang, FISPE
 Michael Steinbuch, FISPE
 Douglas Steinke
 Danijela Stojanovic
 Henrik Stovring
 Walter Straus
 Elizabeth Suarez
 Kristian Svendsen
 Jonathan Swain
 Geert 't Jong
 Mina Tadrous
 Yoshinori Takeuchi
 Varun Talla
 Janet Tate
 John Tazare
 Ali Tehrani
 António Teixeira Rodrigues
 Dana Teltsch
 Trenque Thierry
 Carolyn Tieu
 Darren Toh, FISPE
 Sylvie Tomczyk
 Yelizaveta Torosyan
 Tanja Tran
 Gianluca Trifiro
 Md Jamal Uddin
 Anan Udombhornprabha
 Christine Ulbricht
 Marianne Ulcickas Yood,
 FISPE
 Hisashi Urushihara
 Carla Van Bennekom
 Patricia van den Bemt
 Angela van der Salm
 Tjeerd van Staa
 Robert Vander Stichele
 Zdravko Vassilev
 Priscilla Velentgas
 Anila Verma
 Thomas Verstraeten
 Nataliya Volkova
 Scott Vouri
 Helle Wallach-Kildemoes
 Cunlin Wang
 Florence Wang
 Meng-Ting Wang
 Shirley Wang
 Tian Wang
 Tongtong Wang
 Wei Wang
 Youjin Wang
 Michael Webster-Clark
 Yu-Jung 'Jenny' Wei
 Daniala Weir
 Karen Wells
 Xuerong Wen
 Suzanne West, FISPE

Bjorn Wettermark
 Andrew Wiese
 Rachael Williams
 Jerome Wilson
 Veronika Wirtz
 Lesley Wise
 Robert Wise, FISPE
 Lindsay Wong
 Hui Wong
 Yun Sum Wong
 Mollie Wood
 Chuntao Wu
 Jasmanda Wu, FISPE

Ting Wu
 Keele Wurst
 Richard Wyss
 Yea-Huei Kao Yang, FISPE
 Yu Yang
 Wai Ping Yau
 Yizhou Ye
 Zenas Yiu
 Mellissa Yong
 Takunari Yoshinaga
 Jessica Young
 Yinong Young-Xu
 Muhammad Younus

Onchee Yu
 Hongbo Yuan
 Huifeng Yun
 Wei Zhou, FISPE
 Yanmin Zhu
 Julie Zito
 Arsène Zongo
 Kirsten Zu
 Andrew Zullo
 Stanley A Edlavitch,
*Conference Chair,
 Emeritus*

SAVE THE DATES!



35TH ICPE

AUGUST 24-28, 2019

PENNSYLVANIA CONVENTION CENTER | PHILADELPHIA, PA



ICPE EXHIBITORS & SUPPORTERS



ISPE gratefully acknowledges the generous support of the following organizations, institutions and programs.

Their contributions helped the Society advance the scientific program content and increase attendance at ISPE's 34th annual meeting (ICPE).

EXHIBITORS*

- ◆ Aarhus University Hospital
- ◆ Aetion
- ◆ Analysis Group
- ◆ BHE
- ◆ Clinical Practice Research Datalink (CPRD)
- ◆ Drug Safety Research Unit
- ◆ EU2P
- ◆ Evidera
- ◆ HealthCore
- ◆ IBM Watson Health
- ◆ ICON Clinical Research
- ◆ Ipsos Healthcare
- ◆ IQVIA
- ◆ JMDC Inc.
- ◆ Kantar Health
- ◆ OM1
- ◆ Optum
- ◆ Oxon Epidemiology
- ◆ PharmaLex GmbH
- ◆ PHARMO Institute
- ◆ PrimeVigilance
- ◆ Roche
- ◆ RTI Health Solutions
- ◆ STATinMED Research
- ◆ Syneos Health
- ◆ UBC
- ◆ Uppsala Monitoring Centre
- ◆ WHO Collaborating Centre for Drug Statistics Methodology

BADGES

All attendees at the 2018 ICPE must wear their badges to all events and conference-related functions including the Welcome Reception/Academic Showcase, scientific sessions, exhibit/poster hall, and social event. Badges will be included in the registration material. In some cases, tickets for admission will be required; e.g., courses and guests.

ANNUAL MEETING SPONSORS*

PLATINUM

- ◆ HealthCore

GOLD

- ◆ Aetion
- ◆ Amgen
- ◆ Analysis Group
- ◆ Bayer
- ◆ BHE
- ◆ Biogen
- ◆ Boehringer-Ingelheim
- ◆ Eli Lilly
- ◆ Evidera
- ◆ IBM Watson Health
- ◆ ICON Clinical Research
- ◆ IQVIA
- ◆ Kantar Health
- ◆ MSD/Merck Sharp & Dohme
- ◆ Optum
- ◆ Pfizer
- ◆ PharmaLex GmbH
- ◆ RTI Health Solutions
- ◆ Servier
- ◆ Syneos Health
- ◆ UBC

SILVER

- ◆ Covance
- ◆ Procter & Gamble
- ◆ UCB BioSciences

BRONZE

- ◆ Boston Collaborative Drug Surveillance Program
- ◆ CPI Global CRO
- ◆ Harvard Pilgrim HealthCare Institute (HPHCI)

*As of August 3, 2018

Expert Presentations during ICPE 2018

Workshop

Selection of Databases for Pharmacoepidemiology Research

Evidera speaker: Reynolds MW

Oral Presentation

Long-Term Clinical Outcome Following a Myocardial Infarction among the General Population in England

Evidera authors: Schultze A, Shah R, Teronen T, Lamorell D

Posters

Awareness Strategies, Referral Sources, and Impact on Enrollment in Pregnancy and Lactation Studies

Evidera authors: Covington D, Furst N, Moore T

Cardiovascular Outcomes and Mortality in Type 2 Diabetes with Comorbid Cardio-Renal-Metabolic Conditions in the UK

Evidera authors: MacLachlan S, Hunt P

Overall Survival and Treatment Patterns among Real-World Patients with Metastatic Non-Small Cell Lung Cancer Not Previously Treated with Systemic Therapy for Advanced Cancer

Evidera authors: Simeone JC, Nordstrom B

Overall Survival and Treatment Patterns among Real-World Patients with Metastatic Urothelial Carcinoma Treated with First-Line Therapy

Evidera authors: Simeone JC, Nordstrom B

Treatment Guidelines: Adherence and Use among Type 2 Diabetes Mellitus Providers and Their Patients

Evidera authors: Olsson K, Chitnis M, Hudlin R

Trends in FDA Post-Marketing Commitment Requirements for Pregnancy Registries

Evidera authors: Covington D, Bous B



**Real-World
Evidence**

**Patient-Centered
Research**

**Modeling and
Meta Research**

Market Access

Interventional Studies

Pragmatic Studies

Medical Writing

evidera.com



MEETING-AT-A-GLANCE

TUESDAY, AUGUST 21, 2018

7:00 am	8:00 am	9:00 am	10:00 am	11:00 am	12:00 pm	1:00 pm	2:00 pm	3:00 pm	4:00 pm	5:00 pm	6:00 pm	7:00 pm
7:30am-5:00pm		Speaker Ready Room				Room 2.1			4:00pm-6:00pm Registration		Congress Foyer 0	

WEDNESDAY, AUGUST 22, 2018

7:00 am	8:00 am	9:00 am	10:00 am	11:00 am	12:00 pm	1:00 pm	2:00 pm	3:00 pm	4:00 pm	5:00 pm	6:00 pm	7:00 pm	
7:30am-5:00pm		Speaker Ready Room				Room 2.1							
7:30am-6:00pm		Registration				Congress Foyer 0							
		8:30am-12:30pm Educational Sessions				12:30pm-2:00pm Lunch on Your Own		2:00pm-6:00pm Educational Sessions					
		Adherence to Medication Effective Risk Management Introduction to Pharmacoeconomics Pragmatic Trials Precision Medicine with a Skills-based Focus for the Pharmacoeconomist The Use of Pharmacoeconomics to Study Rare Diseases During the Lifecycle of Drug Development				Club H Club A Panorama Hall South Hall 3 South Hall 1 Club E		Cancer Pharmacoeconomics & Genomics: What You Should Know in the Era of Precision Medicine Comparative Effectiveness Research ISPE Newcomers/Early Stage Investigator Pharmacoeconomics Workshop 2018 Using Field Studies to Value-Add in Pharmacoeconomics Using Pharmacoeconomics Database Resources to Address Drug Safety Research				South Hall 3AB Small Hall South Hall 1 Club H Club E	
						1:00pm-5:00pm ISPE Board of Directors Meeting		Bellevue Room/Corinthia Hotel					

THURSDAY, AUGUST 23, 2018

7:00 am	8:00 am	9:00 am	10:00 am	11:00 am	12:00 pm	1:00 pm	2:00 pm	3:00 pm	4:00 pm	5:00 pm	6:00 pm	7:00 pm	
7:30am-5:00pm		Speaker Ready Room				Room 2.1							
7:30am-6:30pm		Registration				Congress Foyer 0							
		8:30am-12:30pm Educational Sessions				12:30pm-2:00pm Lunch on Your Own		2:00pm-6:00pm Educational Sessions				6:00pm-7:30pm Welcome Reception, International Chapter & Academic Showcase <i>(Full meeting registration includes food, drink and entertainment)</i>	
		Epidemiology of Vaccine Safety Intermediate Pharmacoeconomics Introduction to Drug Utilization Research Modern Pregnancy Pharmacoeconomics Practical Skills in Protocol Writing & Statistical Analytic Programming Relevant to Pharmacoeconomics Propensity Scores in Pharmacoeconomics Prospective Research				Club A South Hall C Club E South Hall 1 Club H South Hall 3AB Small Hall		Advanced Drug Utilization Research Advanced Topics in Pharmaco Epi Medical Device Epidemiology Pediatric Epidemiology Pharmacoeconomics: Considerations for Biologics & Biosimilars Regulatory Pharmacoeconomics Weighing the Benefits & Risks				Small Hall South Hall 3C Club E Club H South Hall 1 South Hall 3AB Club A	
						12:30pm-2:00pm New Member & Early Stage Investigator Luncheon <i>(By invitation only; registration required)</i>		Zoom				7:30pm-9:30pm Students/ Early Career Professionals Meet & Greet Off-Site	

FRIDAY, AUGUST 24, 2018

7:00 am	8:00 am	9:00 am	10:00 am	11:00 am	12:00 pm	1:00 pm	2:00 pm	3:00 pm	4:00 pm	5:00 pm	6:00 pm	7:00 pm	
7:00am-8:00am Poster Session A Set-Up Congress Foyer 2A		7:00am-5:00pm Speaker Ready Room				Room 2.1							
7:00am-8:00am Spotlight Session A Set-Up Congress Foyer 3A		7:00am-6:00pm Registration				Congress Foyer 0							
7:00am-8:00am Coffee & Tea Congress Foyer 2 & 3ABC		7:30am-6:00pm Exhibits/Posters				Congress Foyer 2 & 3ABC							
7:00am-8:00am International Chapter Meetings Africa Zoom Brazil Club A Pharmacoeconomics-Red Club E Gulf Region Chapter Terrace 2A		8:30am-10:00am Keynote Session: Opportunities for 'Big Data' in Medicines Development and Regulatory Science Congress Hall		10:00am-10:30am Break/ Posters/ Exhibits Congress Foyer 2 & 3ABC		10:30am-Noon Symposia & Workshop Applied Sensitivity Analyses in Pharmacoeconomics Database Studies Employing Longitudinal Trajectories to Model Exposure in Perinatal Pharmacoeconomics Research Methodologic Considerations for Non-Interventional Studies Evaluating Outcomes of Originator-to-Biosimilar Switching Long Live the "Medical Data Janitors": International Data Quality Assurance Practices in Distributed Data Networks Rare Disease Development Programs: An Update South Hall 1AB South Hall 2A South Hall 2B		Noon-1:30pm Lunch/Poster Session A/ Exhibits Congress Foyer 2 & 3ABC		Noon-1:30pm Committee Meetings <i>(open to all participants; lunch available)</i> Education Club E Finance Club A Membership Zoom		12:15pm-1:15pm Spotlight Poster Session A Congress Foyer 3A	
		8:30am-10:00am		10:00am-10:30am		10:30am-Noon		Noon-1:30pm		1:30pm-3:00pm		3:00pm-3:30pm	
		Keynote Session: Opportunities for 'Big Data' in Medicines Development and Regulatory Science		Break/ Posters/ Exhibits		Symposia & Workshop		Lunch/Poster Session A/ Exhibits		Concurrent Sessions		Break/ Posters/ Exhibits	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 & 3ABC	
		Congress Hall		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Foyer 2 & 3ABC		Congress Hall		Congress Foyer 2 &	



MEETING-AT-A-GLANCE

SATURDAY, AUGUST 25, 2018

7:00 am	8:00 am	9:00 am	10:00 am	11:00 am	12:00 pm	1:00 pm	2:00 pm	3:00 pm	4:00 pm	5:00 pm	6:00 pm	7:00 pm	
7:00am-5:00pm		Speaker Ready Room			Room 2.1								
7:00am-8:00am Poster Session B Set-Up Congress Foyer 2A		7:00am-6:00pm Registration		Congress Foyer 0									7:30pm-11:30pm Social Evening at the Municipal Building (Shuttle bus begins at 7:00 pm from Entrance 10/Congress Centre)
8:00am-6:00pm Exhibits/Posters Session B Congress Foyer 2A		Congress Foyer 2 & 3ABC											
7:00am-8:00am Spotlight Session B Set-Up Congress Foyer 3A	8:00am-9:30am Concurrent Sessions Diversity in Design Congress Hall	9:30am-10:00am Break/Posters/Exhibits Congress Foyer 2 & 3ABC	10:00am-11:30am Plenary Session: Machine Learning and Artificial Intelligence Congress Hall	11:30am-1:00pm Lunch/Poster Session B/Exhibits Congress Foyer 2 & 3ABC	1:00pm-2:30pm Concurrent Sessions Oral Bisphosphonates & Osteoporosis Congress Hall	2:35pm-3:30pm Annual Meeting of ISPE Members & Awards Ceremony Congress Hall	3:30pm-4:00pm Break/Posters/Exhibits Congress Foyer 2 & 3ABC	4:00pm-5:30pm Symposia & Workshop Moving From RECORD to CORD Congress Hall	5:30pm-6:30pm Council Meetings (open to all participants) Academic Panorama Hall				
7:00am-8:00am Coffee & Tea Congress Foyer 2 & 3ABC	8:00am-9:30am Advances in Vaccine Safety Monitoring Panorama Hall	9:30am-10:00am Psychotropic in Pregnancy South Hall 1AB	10:00am-11:30am Let It Beats South Hall 2A	11:30am-1:00pm Diabetes All Mixed Up South Hall 2B	1:00pm-2:30pm Painful Policy South Hall 3A	2:35pm-3:30pm Geriatric Management & Measures South Hall 2A	3:30pm-4:00pm Pediatric Potpourri South Hall 2B	4:00pm-5:30pm When and Where to Use Blinding South Hall 2A	5:30pm-6:30pm Ten Years of ENCEPP South Hall 1AB	6:00pm-7:00pm Industry/Service Providers South Hall 2A	7:00pm-8:00pm Student South Hall 2A	7:00pm-8:00pm EuroDURG Meeting (open to all participants) South Hall 3A	
7:00am-8:00am Asian DURG Meeting Club C	7:00am-8:00am Geriatric Pharmacoepidemiology SIG South Hall 3A												

SUNDAY, AUGUST 26, 2018

7:00 am	8:00 am	9:00 am	10:00 am	11:00 am	12:00 pm	1:00 pm	2:00 pm	3:00 pm	4:00 pm	5:00 pm	6:00 pm	7:00 pm	
7:00am-3:30pm		Speaker Ready Room			Room 2.1								
7:00am-8:00am Poster Session C Set-Up Congress Foyer 2A		7:00am-4:30pm Registration		Congress Foyer 0									4:45pm-5:15pm The Final Word Congress Hall
8:00am-1:45pm Exhibits/Posters		220BC											
7:00am-8:00am Spotlight Session C Set-Up Congress Foyer 3A	8:30am-10:00am Concurrent Sessions A Methods Stew Congress Hall	10:00am-10:30am Break/Posters/Exhibits Congress Foyer 2 & 3ABC	10:30am-11:30am Symposia & Workshop Adventures in Replication Congress Hall	11:30am-1:00pm Lunch/Poster Session C/Exhibits Congress Foyer 2 & 3ABC	1:00pm-3:00pm Concurrent Sessions Comparative Effectiveness Congress Hall	2:00pm-3:00pm Drug Utilization Research Panorama Hall	3:00pm-3:15pm Hot Topic Session: New Versus Prevalent User Designs in Pharmacoepidemiology Congress Hall	3:15pm-4:45pm ISPE Board of Directors luncheon Terrace 2A	4:00pm-5:00pm Algorithms South Hall 1AB	5:00pm-6:00pm What's Harm Got To Do With It South Hall 2B	6:00pm-7:00pm Safety In Numbers South Hall 3A	7:00pm-8:00pm Spotlight Poster Session C Congress Foyer 3A	
7:00am-8:00am Coffee & Tea Congress Foyer 2 & 3ABC	8:30am-10:00am Yearning to Dig Deep Panorama Hall	10:00am-10:30am Renal Outcomes & Safety South Hall 1AB	10:30am-11:30am Drugs in Pregnancy South Hall 2A	11:30am-1:00pm Keep Your Brain Under Control South Hall 2B	1:00pm-3:00pm Increasing Access to Drug Utilization Data Globally South Hall 2A	2:00pm-3:00pm Challenges and Potential of Vaccine Post-licensure Benefit-Risk Assessments in Resource Limited Countries South Hall 2B	3:00pm-3:15pm ISPE Board of Directors luncheon Terrace 2A	3:15pm-4:45pm ISPE Board of Directors luncheon Terrace 2A	4:00pm-5:00pm ISPE Board of Directors luncheon Terrace 2A	5:00pm-6:00pm ISPE Board of Directors luncheon Terrace 2A	6:00pm-7:00pm ISPE Board of Directors luncheon Terrace 2A	7:00pm-8:00pm ISPE Board of Directors luncheon Terrace 2A	

Save the Date

April 6-9, 2019

ISPE's 2019 Mid-Year Meeting

Radisson Blu es. Hotel
Rome, Italy



PRE-CONFERENCE | TUESDAY, AUGUST 21

7:30 AM – 5:00 PM

Speaker Ready Room*

Room 2.1

*Please arrive 24 hours before your presentation start time to upload or check your presentation.

4:00 PM – 6:00 PM

Registration*

Congress Foyer 0

*If you plan to attend a course on Wednesday, we strongly recommend that you register on Tuesday evening to avoid delays.

PRE-CONFERENCE | WEDNESDAY, AUGUST 22

7:30 AM – 5:00 PM

Speaker Ready Room*

Room 2.1

*Please arrive 24 hours before your presentation start time to upload or check your presentation.

7:30 AM – 6:00 PM

Registration

Congress Foyer 0

8:30 AM – 12:30 PM

EDUCATIONAL SESSIONS: HALF-DAY MORNING COURSES (Ticket Required)

Adherence to Medication

Club H

Content

Adherence to medication is indispensable for achieving clinical goals. Non-adherence is a complex and multifactorial problem leading to poor clinical outcomes, increased morbidity and death rates, and unnecessary healthcare costs. Assessing (non-)adherence is challenging since both subjective and objective measures are applied. This unit is aimed at introducing students to the various constructs of adherence behavior and techniques to evaluate (non-)adherence and data analysis.

Course Faculty

Julie Lauffenburger, *Principles of Adherence*

Jacqueline Hugtenburg, *Subjective Measurements*

Job van Boven, *Objective Measurements*

Jessie Franklin, *Measurement and Modelling Techniques*

Petra Denig, *Interactive Case Study*

Effective Risk Management: Best Practices for Designing, Implementing & Evaluating Risk Minimization Programs

Club A

Content

This course presents an overview of risk management principles, with a focus on best practice methods for designing, implementing and evaluating risk minimization programs. The didactic section will feature experts from regulatory, industry, academia and research organizations who will present the regulatory context, methods, and examples of effective risk minimization program design, implementation and evaluation techniques. The interactive workshop section will provide an opportunity for participants to actively apply what they have learned via a case study approach.

Course Faculty

Alicia Gilsenan, *RTI Health Solutions*

Meredith Smith, *Amgen*

Doris Auth, *US Food & Drug Administration*

Lesley Wise, *Wise Pharmacovigilance and Risk Management, Ltd.*

Elaine Morrato, *Colorado School of Public Health*



Cathedral of St. Lawrence

Understand real-world product performance



HealthCore combines proven epidemiology research expertise with one of the **largest healthcare integrated research environments** to uncover vital evidence on the utilization, safety and effectiveness of biopharmaceuticals and devices in large, real-world patient populations.



HEALTHCORE'S RESEARCH SOLUTIONS

- Direct client access to the HIRD, propelling collaborative insight generation
- HIRD Research Reports, delivering data visualizations most sought after by clients
- Comprehensive studies, go deeper into the data to conduct:
 - Patient and provider surveys
 - Focus groups
 - Medical record reviews
 - Site-based and direct-to-patient/virtual registries
 - Pragmatic clinical trial study design
 - Benefit design



HEALTHCORE'S SPECIALIZED EXPERTISE

Commission HealthCore to leverage demonstrated experience in:

- Machine learning: Mine thousands of potential predictors in claims to find novel predictors and build models with improvements to positive predictive value (PPV) and sensitivity
- Drug and vaccine post-authorization studies
- Risk management and Risk Evaluation and Mitigation Strategy (REMS) studies
- Active surveillance of new medical products and adverse events



HEALTHCORE INTEGRATED RESEARCH DATABASE (HIRD)

- Direct linkage of health plan data with member/patient and provider communities
- 66 million lives across U.S. with eligibility
- 48 million U.S. commercial lives with medical and pharmacy claims, spanning 17 states
- 17 million lives with lab result data
- 10+ years of data
- Integrated clinical and claims oncology database

HealthCore

VISIT US AT BOOTH #13
www.healthcore.com



8:30 AM – 12:30 PM

EDUCATIONAL SESSIONS: HALF-DAY MORNING COURSES *(Ticket Required) (continued)*

Introduction to Pharmacoepidemiology

Panorama Hall

Content

This course will provide participants with a succinct introduction to the basic principles, concepts, and study designs of pharmacoepidemiology. The course includes lectures on (1) cohort studies, (2) case-control studies, as well as (3) confounding and other sources of bias.

Course Faculty

Almut Winterstein, FISPE, *Cohort Studies*
Sonia Hernandez-Diaz, FISPE, *Case-Control Studies*
Tobias Gerhard, FISPE, *Bias & Confounding*

Pragmatic Trials: Design, Methods & Implementation

South Hall 3AB

Content

Pragmatic randomized clinical trials (pRCTs) require the expertise of pharmacoepidemiologists who understand considerations and methodologic challenges that arise with more “pragmatic” RCTs compared with traditional “explanatory” RCTs. This course will highlight issues such as real-world site and patient identification, enrollment and retention, ethical review issues, approach to randomization, selection bias, and defining the appropriate comparator. In addition, choice of study design including cluster randomization, step wedge design or individual randomization, and associated analytic considerations will be highlighted. Randomizing patients to “standard of care (SOC)”; accounting for changes in therapies over time, and other methodological considerations will also be discussed. Operational challenges and lessons learned from conducting pRCTs will be shared along with case examples from pRCTs funded by the Patient Centered Outcomes Research Institute (PCORI) and the Salford Lung Study, funded by GlaxoSmithKline.

Course Faculty

Jennifer Christian, FISPE, *Overview and Introduction to Pragmatic Trials*
Priscilla Velentgas, FISPE, *Study Designs for Pragmatic Trials*
Cynthia Girman, FISPE, *Statistical Analyses for Pragmatic Trials*
Anne Trontell, FISPE, *Recent Case Examples of Pragmatic Trials Funded by PCORI*
Kourtney Davis, FISPE, *Salford Lung Study Case Example*

Precision Medicine with a Skills-based Focus for the Pharmacoepidemiologist

South Hall 1

Content

This course, sponsored by the Molecular Epidemiology, Biomarkers, and Pharmacogenomics (MEBP) SIG will focus on the essentials every pharmacoepidemiologist should know about real world applications of pharmacogenomics epidemiology including (1) the role of epidemiology in pharmacogenomics (pre-course video); (2) definitions of genetic terms and basic genetic concepts (pre-course video); (3) quality control and analytical procedures required in a pharmacogenetic analysis; (4) step-by-step planning guide to designing a pharmacogenomic analysis; (5) phenotyping considerations and breaking down examples of pharmacogenomic successes; (6) databases available to study pharmacogenomics; (7) designing a companion pharmacogenomic diagnostic in drug development; (8) designing a prospective observational cohort or case-control study of pharmacogenomics; (9) designing a clinical utility trial: a guide with examples; (10) clinical utility and policy issues: a debate.

Course Faculty

Amalia Issa, FISPE, *Welcome and Introduction*
Amalia Issa, FISPE, *Precision Medicine in the Real-World Needs Pharmacogenomic Epidemiology*
Bruce Carleton, FISPE, *What You Need to Consider When Applying Pharmacogenomic Research into Clinical Practice*
Anke-Hilse Maitland van der Zee, FISPE, *Pharmacoepidemiologic Methods in Genomics Research: It's all about the application*
Stephen Kimmel, ISPE, *Clinical Utility Research and Pharmacogenomics: Trials and Tribulations*
Amalia Issa, FISPE & Bruce Carleton, FISPE, *Clinical Utility and Policy Issues: The Many Meanings of “Utility”*
Gillian Bartlett, FISPE, *Closing Remarks*



8:30 AM – 12:30 PM

EDUCATIONAL SESSIONS: HALF-DAY MORNING COURSES *(Ticket Required) (continued)*

The Use of Pharmacoepidemiology to Study Rare Diseases during the Lifecycle of Drug Development

Club E

Content

There are over 7,000 rare diseases which affect more than 350 million people worldwide, only 5% of rare conditions have an FDA approved drug treatment. Over the past years, an increasing number of companies have devoted clinical programs to develop new treatments for patients with rare disorders. This creates the need for rare disease epidemiology, as a sub-specialty within pharmacoepidemiology. This unit is aimed at introducing students to the specific methodologic issues arising in rare disease epidemiology and practical approaches used to integrate pharmacoepidemiologic methods/research into rare disease drug development programs.

Course Faculty

Stella Blackburn, FISPE, IQVIA

Marni Stott-Miller, GSK

Susan Oliveria, FISPE, IQVIA

Federica Edith Pisa, Leibniz Institute for Prevention Research and Epidemiology - BIPS

Cunlin Wang, US Food & Drug Administration

Jasmanda Wu, FISPE, Sanofi

It begins with a promise
to discover medicines that make life better.

Since 1876, we have worked tirelessly to discover medicines that make life better, finding ways to come through no matter the odds. From the development of insulin to the discovery of new treatments for mental illness, we have pioneered breakthroughs against some of the most stubborn and devastating diseases. We bring this same determination to our work today, uniting our expertise with the creativity of research partners across the globe to keep finding ways to make life better.

To find out more about our prime level research system, visit the Lilly Research Institute at www.lilly.com/research

Lilly



12:30 PM – 2:00 PM

Lunch on your own

1:00 PM – 5:00 PM

ISPE Board of Directors Meeting*

Bellevue Room/Corinthia Hotel

**Open to ISPE members; members should contact info@pharmacoepi.org if they would like to attend.*



Municipal House Sculpture

2:00 PM – 6:00 PM

EDUCATIONAL SESSIONS: HALF-DAY AFTERNOON COURSES

(Ticket Required)

Cancer Pharmacoepidemiology and Genomics: What You Should Know in the Era of Precision Medicine South Hall 3AB

Content

This course, co-sponsored by the Molecular Epidemiology, Biomarkers, and Pharmacogenomics and Oncology SIGS, will focus on the essentials every pharmacoepidemiologist should know about real world applications of cancer personalized medicine including precision medicine, companion diagnostics, biomarkers and the biomarker development pipeline, and linking databases with genomic information.

Course Faculty

Bruce Carleton, FISPE, *Welcome and Introduction*

Bruce Carleton, FISPE, *Pharmacogenomics in Cancer Research*

Andrew Freedman, *Cancer Pharmacogenomics: It's Not Just Germline Anymore*

Wei Zhou, FISPE, *Pharmacogenomics and Target Therapy in Oncology Drug Development*

Kelly Filipski, *Linking Genomic Information with Databases in Cancer Research*

Leah Sansbury, *The Expanding Roles of Cancer Pharmacoepidemiologists in Industry*

Gillian Bartlett & Geoffrey Liu, FISPE, *Moderators, Precision Medicine in Cancer: Panel Discussion Q & A*

Andrew Freedman, *Closing Remarks*

Comparative Effectiveness Research: Real-World Evidence in Health Technology Assessment Small Hall

Content

Comparative effectiveness research (CER) is increasingly important for generating real-world evidence (RWE) to inform clinicians, patients, regulators, and other decision makers. Some policy makers are reluctant to use real-world evidence to inform health technology assessments (HTA). This year's course will start with an overview of how CER and RWE can enhance HTA, describe CER methods for generating evidence using real-world data, and will discuss how real-world evidence can be used in the changing regulatory landscape. Multiple case studies will be used to facilitate an interactive group discussion and will address how observational, real-world data can be used to evaluate the properties, effects, and impacts of health technology.

Course Faculty

Joshua Gagne, *Brigham and Women's Hospital/Harvard Medical School*

Sebastian Schneeweiss, FISPE, *Brigham and Women's Hospital/Harvard Medical School*



2:00 PM – 6:00 PM

EDUCATIONAL SESSIONS: HALF-DAY AFTERNOON COURSES *(Ticket Required) (continued)*

ISPE Newcomers/Early Stage Investigator Pharmacoepidemiology Workshop 2018

South Hall 1

Content

This ICPE Pre-Conference Course is aimed at early stage pharmacoepidemiologists who have been in the field for less than 3 years. Participation will lead to enhancement in research skills (i.e., grant writing, research presentation, and manuscript writing) and professional development (development of mentor-mentee relationships, enhancing creativity/productivity, professional networking) that are crucial to early success in pharmacoepidemiology.

Course Faculty

Almut Winterstein, FISPE, *Effective Research Grant Writing*

Tarek Hammad, FISPE, *Preparing an Effective Oral Research Presentation*

Darren Toh, *Tips for Successful Manuscript Writing*

Vin Lo Re III, FISPE, *Managing Your Pharmacoepidemiology Research Team & Establishing Productive Mentor-Mentee Relationships*

Enhancing Creativity/Productivity in Pharmacoepidemiology

Caitlin Knox, *Professional Networking in Pharmacoepidemiology*

Nicolle Gatto, FISPE, *How to Get the Most Out of the Early Stage of Your Career in Pharmacoepidemiology*

CHECK OUT YOUR NEWEST MEMBER BENEFIT - THE ISPE EXCHANGE



Welcome to The ISPE Exchange, ISPE's new online community. It is your newest, best way to connect with members, get involved with the Society, join the mentorship program, and connect with new people.

Plan on joining some ISPE communities. Communities allow you to participate in discussions and share resources with other members. ISPE Committees, Special Interest Groups, Councils and Chapters can all have communities on the Exchange.

LOG-IN TODAY AT COMMUNITY.PHARMACOEPI.ORG!

Below are several basic question and responses.

Q: WHAT IS MY USERNAME/PASSWORD?

A: *Your login credentials are the same username and password that you use to log in to the main site. If you have forgotten your login credentials or need assistance with your login information*

Q: HOW DO I JOIN/SUBSCRIBE TO A COMMUNITY AND THE AFFILIATED DISCUSSION GROUP?

A: *Click on "Communities" in the main navigation and click on "All Communities" in order to see a list of available communities. Click on the community that you wish to join and simply click "Join," then choose a delivery option for posts (Real Time, Daily Digest or No Email).*

Q: HOW DO I START A NEW DISCUSSION THREAD?

A: *Go to "Participate" > "Post a message." From an email (HTML version) for a particular discussion forum, you can use the "Post Message" link located at the top of the discussion email.*

Q: HOW DO I FIND RESOURCES THAT MAY HAVE BEEN UPLOADED BY OTHER MEMBERS?

A: *If you know which library the resource might be located in, find the affiliated community via the All Communities page. Click through the community's landing page, then click on the "Library" tab. If you do not know where the resource might be, enter search terms in the main search box the same way you might enter search terms into Google or another search engine.*



2:00 PM – 6:00 PM

EDUCATIONAL SESSIONS: HALF-DAY AFTERNOON COURSES (Ticket Required) (continued)

Using Field Studies to Value-Add in Pharmacoepidemiology

Club H

Content

This course provides basic theory and practical tips in conducting pharmacoepidemiologic studies when required information is not captured in databases or when large databases are not available. Common study designs used to collect data through observations, medical records or questionnaires will be presented and the strengths and limitations of working without large databases discussed. Hands on experience via a workshop will expose course participants to different study designs and rich discussions on how to answer relevant questions about safety and utilization of medicines in primary and secondary care settings using field studies.

Course Faculty

Annie Fourrier-Reglat, *Rationale, Methodological Considerations for Studies Done Without Large Databases: Experiences from a Variety of Diseases and Health Systems Contexts*

Katja Taxis, *Common Study Designs Used to Collect Data Through Observation, Medical Records or Questionnaires*

Lisa Pont, *FISPE, Field Studies to Value Add in Pharmacoepi: Focus on Efficiency in Study Design*

Veronika Wirtz, *Course Moderator and Facilitator*

Using Pharmacoepidemiology Database Resources to Address Drug Safety Research

Club E

Content

Pharmacoepidemiology requires the utilization of database resources to evaluate drug safety. This course will define the different types of data resources available for pharmacoepidemiology and the selection criteria to select the most appropriate resource. The course focuses on the Guidelines for good database selection and use in pharmacoepidemiology research, provides an overview of available resources, addresses the need for outcome validation, and highlights data linkage considerations.

Course Faculty

Gillian Hall, *FISPE, Overview of Database Use in Pharmacoepidemiology*

Matthew Reynolds, *Selection of Databases for Pharmacoepidemiology Research*

Kevin Haynes, *FISPE, Database Selection Workshop Activity*

Daniel Beachler, *Data Validation Approaches in Pharmacoepidemiology*

Sudha Raman, *Linking Pharmacoepidemiology Resources*



Windows of Prague, Czech Republic

A NEW PATH TO YOUR SUCCESS



VIA HUMAN DATA SCIENCE

Research & Development | Real-World Value & Outcomes | Commercialization | Technologies

IMS Health and Quintiles are now IQVIA™ – created to advance your pursuits of human science by unleashing the power of data science and human ingenuity. [Join the journey at iqvia.com/success](https://iqvia.com/success)

IMS Health & Quintiles are now
 IQVIA™



7:30 AM – 5:00 PM

Speaker Ready Room*

Room 2.1

**Please arrive 24 hours before your presentation start time to upload or check your presentation.*

7:30 AM – 6:30 PM

Registration

Congress Foyer 0



Historical Medieval Astronomical Clock

8:30 AM – 12:30 PM

EDUCATIONAL SESSIONS: HALF-DAY MORNING COURSES

(Ticket Required)

Epidemiology of Vaccine Safety

Club A

Content

Vaccines are key tools for global public health. Increasingly, pharmacoepidemiological studies are providing critical evidence needed for risk-benefit assessment to inform immunization policy, both for mature immunization programs and for low- and middle-income countries (LMIC) for which innovative vaccines against challenging diseases (e.g., dengue, Ebola, malaria, etc.) are under development. The annual ICPE has had vaccine-specific sessions for ~15 years and ISPE has a Vaccine Special Interest Group (VAXSIG) since 2014. One of the VAXSIG goals is to offer educational activities on vaccine-related epidemiology, in collaboration with the ISPE Education Committee. The VAXSIG pre-conference course has been offered since the 2015 ICPE.

Course Faculty

S. Rizwan Ahmad, FISPE, *Introduction to the Course*

Robert T. Chen FISPE, *Introduction to Vaccine Preventable Diseases and Vaccine Safety*

Rebecca E. Chandler, *Spontaneous Reporting and Safety Surveillance in Lmic*

Katherine Yih, *Data-Mining for Vaccine Adverse Events Using the Self-Controlled Tree-Temporal Scan Statistic*

Patricia Saddier, *Observational Vaccine Safety Study Designs*

Bruce H. Fireman, *New Twists on Statistical Methods for Surveillance of Vaccine Safety and Effectiveness*

Intermediate Pharmacoepidemiology: Approaches to Unmeasured Confounders

South Hall C

Content

This interactive course will introduce students to multiple approaches to addressing unmeasured confounders through study design and analysis, the requirements and assumptions of each, and an opportunity to compare these approaches through facilitated discussion of a case-study.

Course Faculty

Jennifer Lund, Sudha Raman & Mugdha Gokhale, *Use of Study Design to Control Unmeasured Confounding*

Jennifer Lund, Til Sturmer, FISPE, & Michelle Jonsson Funk, *Analytic Approaches to Unmeasured Confounding*

Michelle Jonsson Funk, *Interactive Case Study*.



8:30 AM – 12:30 PM

EDUCATIONAL SESSIONS: HALF-DAY MORNING COURSES (Ticket Required) (continued)

Introduction to Drug Utilization Research

Club E

Content

This educational session provides an overview of drug utilization research (DUR) and presents essential methods used. The session includes interaction with participants, question, and answer sessions and discussion during and at the end of each presentation. At the end of the session, the participant will be exposed to:

- ◆ Description of the theoretical framework and practical applications of different methods illustrated using selected examples
- ◆ Classification systems used in drug utilization monitoring and research
- ◆ Limitations of data sources and methods
- ◆ Interpretation of aggregate and individual-based data, variation and change
- ◆ Using drug utilization research for public health and implications for policy decisions

Course Faculty

Veronika Wirtz, *Welcome*

Lisa Pont, FISPE, *Introduction to Drug Utilization Research: Methodological Framework and Skills Needed*

Hanne Strom, *The Anatomical Therapeutic Chemical Classification and the Defined Daily Dose Methodology: Classifying and Quantifying Drug Use.*

Bjorn Wettermark, *Drug Utilization Research and Monitoring in Individual Based Registers – Study Designs and Epidemiological Measures of Drug Use.*

TBD, *Drug Utilization in Practice: Drug Utilization to Inform Drug Policy-Eastern European Perspectives*

Modern Pregnancy Pharmacoepidemiology: Minimizing Biases in Various Study Designs

South Hall 1

Content

Students will be presented with the various study designs that are used in research on drug safety in pregnancy in this course. For each of the study designs, challenges with respect to the valid measurement of exposures, outcomes and confounding will be discussed, along with proposed solutions to minimize bias.

The course will consist of four presentations by faculty, with an interactive approach using mobile technology to engage course participants in the discussion. One publication illustrative of each study design will be proposed as pre-reading materials for course registrants a few weeks before the conference.

Course Faculty

Andrea Margulis, *Overview of Study Designs*

Sonia Hernandez-Diaz, FISPE, *Pregnancy Exposure Registries and Other Prospective Studies*

Jennita Reefhuis, *The Role of Case-Control Studies in Medications in Pregnancy Research*

Brian Bateman & Krista Huybrechts, FISPE, *The Role of Large Administrative Databases in Medications in Pregnancy Research*



8:30 AM – 12:30 PM

EDUCATIONAL SESSIONS: HALF-DAY MORNING COURSES (Ticket Required) (continued)

Practical Skills in Protocol Writing and Statistical Analytic Programming Relevant to Pharmacoepidemiology

Club H

Content

Pharmacoepidemiologic studies that involve the use of electronic healthcare data have complex and unique characteristics that must be taken into consideration when planning and conducting these types of studies. This highly interactive course will engage participants in the following topics:

- ◆ Pre-specifying study components of a protocol, including design, analysis, and reporting of the study, along with a science-based rationale for the choices pertaining to these components; and,
- ◆ Translating elements of the study protocol into a statistical analytic program.

Course Faculty

- Chih-Ying Pratt**, *US Food & Drug Administration*
- Christian Hampp**, *FISPE, US Food & Drug Administration*
- Jessica Jalbert**, *Regeneron Pharmaceuticals*
- Nicole Pratt**, *University of South Australia*
- Soko Setoguchi**, *FISPE, Rutgers University*

Propensity Scores in Pharmacoepidemiology

South Hall 3AB

Content

Issues of bias and confounding relate to study design and analysis in the setting of non-random treatment assignment where compared subjects might differ substantially with respect to comorbidities. Failing to address a lack of balance in the covariates between treated and comparison groups can produce confounded estimates of treatment effect.

Course Faculty

- John Seeger**, *FISPE, Optum*
- Jeremy Rassen**, *Aetion*

Prospective Research: Tools & Tips for 21st Century

Small Hall

Content

This course will provide an overview of the methods and applications for studies that use primary data collection for patient registries and other prospective research, including regulatory submissions of real-world data for label approvals or expansions. Topics include data collection from clinicians, electronic health records, or directly from patients without use of clinicians, and will address methodological and logistical challenges with a focus on recruitment and retention. Examples will include working with patient communities, data collection through clinicians, call centers, and digital technologies, and integrating electronic health data, with applications in rheumatology, pregnancy and injury research, among others.

Course Faculty

- Nancy Dreyer**, *FISPE, Principles of Patient Registries and Prospective Research*
- Aji Barot**, *The Role of Patient Communities for Study Recruitment*
- Christina Chambers**, *Working with Trusted Networks to Enroll and Retain Patients in Pregnancy Registries*
- Will Dixon**, *Using Digital Patient-Reported Data*
- Christina Mack**, *Using EHR and Call Centers for Data Collection*

How do you fight an enemy with many faces?

100 years of cancer care

Tip to 100 years of cancer care

CanWeLiveBetter.com

© 2014 Bayer HealthCare Pharmaceuticals Inc. All rights reserved. Bayer is a registered trademark of Bayer AG. Bayer is a registered trademark of Bayer AG. Bayer is a registered trademark of Bayer AG.



DEPARTMENT OF POPULATION MEDICINE



HARVARD
MEDICAL SCHOOL



Harvard Pilgrim
Health Care Institute

Come work with us!

**Pharmacoepidemiologists, Biostatisticians, SAS Programmers,
Research Analysts, Program Managers**

We are the home of the:

- FDA Sentinel Operations Center
- Reagan-Udall Foundation IMEDS Analytics Center
- PCORnet Query Fulfillment Center
- NH Health Care Systems Research Collaboratory Distributed Research Network
- State of Massachusetts MDPHnet Coordinating Center

We look forward to meeting you here at ICPE – look for anyone with the ‘Ask me about Sentinel’ buttons or email us at info@sentinelssystem.org.

Please visit our website for information about our research programs, career, and training opportunities.

www.populationmedicine.org



2:00 PM – 6:00 PM

EDUCATIONAL SESSIONS: HALF-DAY AFTERNOON COURSES *(Ticket Required)*

12:30 PM – 2:00 PM

Lunch on your own

12:30 PM – 2:00 PM

New Member & Early Stage Investigator Luncheon*

Zoom

**Ticket Required.*

By invitation only; registration required.



Dancing House Building in Downtown Prague

Advanced Drug Utilization Research

Small Hall

Content

This interactive educational program includes presentations, question and answer sessions and a final discussion with the faculty panel. The session will involve participants in the:

- ◆ Methods for evaluating the effect of clinical or policy interventions
- ◆ Interpretation of the evaluation data and dissemination of results
- ◆ Application of principles derived from Health Services and Implementation Research to the design of a clinical intervention
- ◆ Use of drug utilisation information from administrative health data to improve medicines use
- ◆ Use of prescribing quality indicators to assess prescribing

Course Faculty

Katja Taxis, *Designing Complex Interventions to Change Drug Utilization*

Lisa Kalisch Ellett, *Evaluating Interventions on Drug Utilisation for Funders and Policy Makers*

Petra Denig, *Assessment of Prescribing Using Quality Indicators*

To Be Announced, *Evaluating Interventions on Drug Utilization: Advanced Methods-Time Series Analysis*

Advanced Topics in PE: Advanced Pharmacoepidemiology

South Hall 3C

Content

This interactive course will address the interplay between observational studies and trials. This moderated course will include presentations about the intersection of interventional and non-interventional research, with examples such as the role of real-world comparators in single-armed trials; healthcare database analyses for regulatory decision making; and the restricted potential outcomes approach.

Course Faculty

Brian Bradbury, *Intersection of Interventional and Non-Interventional Research, with Examples Such as Using Real-World Comparators for Singled-Armed Trials*

Sebastian Schneeweiss, *FISPE, Healthcare Database Analyses for Regulatory Decision Making.*

Jan P. Vandenbroucke, *Causal Inference is Insufficient for Causal Inference.*

Alec Walker, *FISPE, Moderator*



2:00 PM – 6:00 PM

EDUCATIONAL SESSIONS: HALF-DAY AFTERNOON COURSES *(Ticket Required)* (continued)

Medical Device Epidemiology

Club E

Content

There has been increased focus on “real-world evidence” for medical products in recent years. Thus, medical product epidemiology is gaining visibility outside of ISPE. Medical device epidemiology uses methodologies similar to those seen with medicines. However, alternative strategies are often implemented due to the nature of the products, data sources, and situational use. With the changing regulatory and reimbursement environments, it is more important than ever for pharmacoepidemiology researchers to better understand the world of medical device epidemiology, both for study of medical devices and combination products. The nuances of methods may be applicable to other therapeutic products and the data sources may provide deeper understanding of benefits and risks in clinical context. This course provides a foundation for medical device epidemiology and its current applications in the real world.

Course Faculty

- Mary E Ritchey, RTI Health Solutions
- Colin Anderson-Smits, US Food & Drug Administration
- Jessica Jalbert, Regeneron Pharmaceuticals
- Daniel Prieto Alhambra, FISPE, University of Oxford
- Theodore Lystig, Medtronic
- Christina Mack, IQVIA

Pediatric Pharmacoepidemiology

Club H

Content

The increasing use of medications by children and the history of excluding children from clinical trials have created the need for pediatric pharmacoepidemiology, a sub-specialty within pharmacoepidemiology. Unique challenges in studying children, accessing data, defining outcomes, and designing pediatric studies will be discussed. Participants who have a good understanding of pharmacoepidemiology will be introduced to the specific methodologic issues arising in pediatric pharmacoepidemiology and operational approaches used to study medications in children.

Course Faculty

- Tamar Lasky, FISPE, US Food & Drug Administration
- Rachel Sobel, FISPE, Pfizer
- Daniel B. Horton, Rutgers University
- Carmen Ferrajolo, University of Campania Luigi Vanvitelli



Prague, Capital City of Czech Republic



2:00 PM – 6:00 PM

EDUCATIONAL SESSIONS: HALF-DAY AFTERNOON COURSES *(Ticket Required) (continued)*

Pharmacoepidemiologic Considerations for Biologics and Biosimilars

South Hall 1

Content

This workshop will provide participants with information on the following topics:

- ◆ Background on biologics, biosimilars and differences from small molecules
- ◆ Naming and traceability issues for biologics and biosimilars
- ◆ Interchangeability, switching, and automatic substitution from a regulatory, methodological, and clinical perspective
- ◆ Review country-specific regulatory guidelines, particularly focused on post-marketing monitoring, pharmacovigilance, and risk management requirements for biologics and biosimilars
- ◆ Conducting observational studies of biologics and biosimilars, including primary data collection and secondary use of data sources for evaluating patterns of use as well as comparative safety and effectiveness of biologics and biosimilars
- ◆ Special emphasis will be given to the methodological issues concerning post-marketing assessment of the interchangeability of biologics and corresponding biosimilars

Course Faculty

Jaclyn Bosco, IQVIA

Thijs Giezen, SAHZ (Stichting Apotheek der Haarlemse Hospitals)

Gianluca Trifirò, University of Messina

Rohini Hernandez, Amgen

Regulatory Pharmacoepidemiology

South Hall 3AB

Content

Medical product regulation increasingly relies on pharmacoepidemiologic analyses to assess the safety of medical products once they are marketed. This course is aimed at describing how pharmacoepidemiologic analyses are used in regulatory decision making, and the challenges that regulators face when using such analyses.

Course Faculty

June M Raine, MHRA (Medicines and Healthcare Products Regulatory Agency)

Danica Marinac-Dabic, FISPE, US Food & Drug Administration

Weighing the Benefits & Risks: The Science and Methods of Benefit- Risk Assessment in Drug Development

Club A

Content

Benefit-risk assessment is now a fundamental science for understanding and evaluating the development, approval, and continued marketing of drugs and devices. This course is aimed at introducing attendees to core concepts and tools of both the science and practice of benefit-risk assessment.

Course Faculty

Tarek A. Hammad, FISPE, *Overview Of ICH* Expectations and Analytical Considerations for the Development and Presentation of Benefit-Risk Information in New Drug Applications*

* International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use

Juhaeri Juhaeri, *Overview of Leading Quantitative Methods (E.g., Mcd, Smaa) for the Development and Presentation of Benefit-Risk Assessment Information*

Brett Hauber, *Overview of Leading Methods (E.g., Discrete Choice, Direct Elicitation, Threshold, Contingent Valuation) for the Elicitation, Analysis and Presentation of Patient Preference Information*

MEET OUR DECISION SUPPORT AND SALES EXPLORERS AT OUR BOOTH

- + Unrivaled global expertise in physician and patient centered study design
- + World class epidemiological data
- + Clinical network level datasets
- + Drug utilization studies, PMS and other drug safety related studies
- + Data collection through our proprietary validated EDC system


www.kantar.com/usa



Your Source For Real-World Answers

BHE is an independent health analytics company with over two decades of experience in designing and conducting research that assesses the value of medical technologies. We create analytic teams from data scientists to generate evidence on how medical advances can improve patients' health in an affordable way.

Visit Booth #2



Don't forget to stop by our ICPE poster presentations!

www.bhe.com



6:00 pm – 7:30 pm

Welcome Reception/International/International Chapter & Academic Showcase*

Zoom/Panorama

Jiří Vlček, Chair, Local Host Committee

Olaf Klungel, FISPE, Chair, 2018 ICPE Scientific Program Committee

Jesper Hallas, FISPE, ISPE President

International Chapter & Academic Showcase

Participants (As of August 3, 2018)

- ◆ African Chapter
- ◆ Brazil Chapter
- ◆ Center for Drug Safety & Effectiveness Johns Hopkins School of Public Health
- ◆ Charles University of Prague
- ◆ DSRU Pharmacovigilance PgC, PgD and MSc
- ◆ Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham Women's Hospital & Harvard Medical School/ Pharmacoepidemiology Program, Harvard TH Chan School of Public Health

- ◆ Farmacoepienred, the Spanish chapter
- ◆ ISPE Student Council
- ◆ McGill Pharmacoepidemiology Unit (McGill University, Department of Epidemiology, Biostatistics and Occupational Health)
- ◆ Pharmaceutical Health Services Research, University of Maryland School of Pharmacy
- ◆ Pharmacoepidemiology and Pharmacovigilance, London School of Hygiene & Tropical Medicine
- ◆ Rutgers Center for Pharmacoepidemiology and Treatment Science
- ◆ University of Florida, Dept of Pharmaceutical Outcomes and Policy
- ◆ University of North Carolina – Chapel Hill, Gillings School of Global Public Health

7:30 PM – 9:30 PM

Student/Early Career Professional Meet & Greet* (Registration Required–Limited Capacity)

Off-site

- ◆ Open to all students, recent graduates and young professionals
- ◆ Registration required -- limited capacity.
- ◆ Organized by the ISPE Student Council (SISPE). Please contact SISPEchair@gmail.com for more information, and to RSVP.

**Organized by the Student Council. Please contact SISPEchair@gmail.com for more information, and to RSVP.*





7:00 AM – 8:00 AM

Poster Session A & Spotlight Session A Set-up

Congress Foyer 2A (Poster Session) & Congress Foyer 3A (Spotlight)

7:00 AM – 8:00 AM

Coffee & Tea

Congress Foyer 2 & 3ABC

7:00 AM – 8:00 AM

International Chapter Meetings

(Open to all participants.)

- ◆ Africa Zoom
- ◆ Brazil Club A
- ◆ FarmacoepiEnRed Club E
- ◆ Gulf Region Chapter Terrace 2A

7:00 AM – 5:00 PM

Speaker Ready Room Room 2.1

*Please arrive 24 hours before your presentation start time to upload or check your presentation.

7:00 AM – 6:00 PM

Registration

Congress Foyer 0

7:30 AM – 6:00 PM

Exhibits/Posters Session A

Congress Foyer 2 & 3ABC

8:15 AM – 8:30 AM

Welcome

Congress Hall

- ◆ Jesper Hallas, FISPE, ISPE President
- ◆ Jiří Vlček, Chair, Local Host Committee
- ◆ Olaf Klungel, FISPE, Chair, 2018 ICPE Scientific Program Committee

8:30 AM – 10:00 AM

Keynote Session: Opportunities for 'Big Data' in Medicines Development and Regulatory Science

Large volumes of data are becoming available through various sources (routine health care data, patient reported data, wearables, surveys, etc.) allowing to develop new evidence that may substantially add to the benefit/risk assessment throughout the lifecycle of medicines. While creating huge opportunities, there are also significant challenges in the application of these data. In particular, in Europe, data sources are heterogeneous and understanding strengths and limitations of new analytical methods to integrate and analyse these datasets in order to generate valid conclusions which contribute to regulatory decision making is challenging. Fast access to data and, at the same time, compliance with data protection legislation to protect patient confidentiality is critical for securing patient trust.

Speakers

Alison Cave, EMA

Dr. Alison Cave is Principal Scientific Administrator and co-chair of the HMA/EMA Task force on Big Data. She will give a unique European regulatory perspective on the need, challenges, and opportunities of data networks in Europe

Miriam Sturkenboom, FISPE, University Medical Center Utrecht

Prof. Miriam Sturkenboom, FISPE, is a past president of ISPE. She has extensive experience as principal investigator of many European projects on multi-country, multi-database studies and steered the development and testing of workflows to implement these types of studies in the EU. She will provide an overview of the scientific and technical challenges of European networks and the lessons learned from these initiatives for future studies.

10:00 AM – 10:30 AM

Break/Posters/Exhibits

Congress Foyer 2 & 3ABC

10:30 AM – Noon

Symposia and Workshops

Congress Foyer 2 & 3ABC

Applied Sensitivity Analyses in Pharmacoepidemiology

Database Studies [1]

Congress Hall

Sebastian Schneeweiss, Jeremy Rassen, Olaf Klungel, Nicole Gatto, Xavier Kurz. (United States)

Employing Longitudinal Trajectories to Model Exposure in Perinatal

Pharmacoepidemiology Research [2]

Panorama Hall

Gretchen Bandoli, Christina D Chambers, Krista F Huybrechts, Caroline Hurault-Delarue, Lockwood Taylor, Jessica M Franklin, Kristin Palmsten. (United States)

Methodologic Considerations for Non-Interventional Studies Evaluating

Outcomes of Originator-To-Biosimilar Switching [3]

South Hall 1AB

Rishi J Desai, Seoyoung Kim, Joshua Gagne, Jeffrey Curtis, Jaclyn Bosco, Brian Bradbury. (United States)

Long Live the "Medical Data Janitors": International Data Quality

Assurance Practices in Distributed Data Networks [4]

South Hall 2A

Judith C. Maro, Christian G. Reich, Keith Marsolo, Yoshiaki Uyama, Kristian B. Filion, Miriam C. J. M. Sturkenboom. (United States)

Rare Disease Development Programs: An Update [5]

South Hall 2B

Jasmanda Wu, Cunlin Wang, Daniel B. Horton, Irene Petersen, Susan Oliveria, Stella Blackburn, Jieying Jiang, Robert LoCasale. (United States)

Sponsored by the Rare Disease Special Interest Group

Together we improve outcomes.

ICON's Commercialisation & Outcomes experts deliver integrated solutions to identify, generate, synthesise and communicate the outcomes evidence that regulators, payers, providers and patients need to make informed health decisions.

ICON and You.
Partners making a difference.

[ICONplc.com/commercialisation](https://www.ICONplc.com/commercialisation)



A Unique Opportunity

The Reagan-Udall Foundation for the FDA is currently seeking a Scientific Director for our Flagship Program, IMEDS (Innovations in Medical Evidence Development and Surveillance).

- Are you a pharmacoepidemiologist with 5-8 years of related experience using health claims databases?
- Do you have experience as a published principal investigator?
- Do you enjoy working in a team science environment?

This is a distinct opportunity to work on scientific studies utilizing FDA's Sentinel distributed network methods and tools. It allows the industry and researchers to: conduct drug safety surveillance studies; answer post-market research questions; characterize hard to reach populations; access large volumes of patient data; and, analyze risk management impact.

**To learn more, contact: imedse@reaganudall.org
or visit: www.imeds.reaganudall.org**





12:00 PM – 1:30 PM

Lunch/Poster Session A/ Exhibits

Congress Foyer 2 & 3ABC

12:00 PM – 1:00 PM

Committee Meetings

(Open to all participants; lunch available.)

- ◆ Education Club E
- ◆ Finance Club A
- ◆ Membership Zoom

12:15 PM – 1:15 AM

Spotlight Poster Session A:

- ◆ Asian Pharmacoepidemiology Network (AsPEN)
- ◆ Adherence
- ◆ Biologics & Biosimilars
- ◆ Comparative Effectiveness Research (CER)
- ◆ Digital Epidemiology

Congress Foyer 3A

1:30 PM – 3:00 PM

CONCURRENT SESSIONS: ORAL PRESENTATIONS

Methods: It's About Time

Congress Hall

Moderators: Darren Toh & Xiaojuan Li

1:30 PM

Validation of the Reverse Parametric Waiting Time Distribution and Standard Methods to Estimate Prescription Durations for Warfarin [6]

Julie M Petersen, Henrik Støvring, Maja Hellfritzsch, Jesper Hallas, Anton Pottegård. (Denmark)

1:45 PM

Correcting for Differential Depletion of Susceptibles in Time-To-Event Data Using Time-Specific Propensity Scores [7]

Richard Wyss, Joshua J. Gagne, Shirley V. Wang, Rishi J. Desai, Jessica M. Franklin, Sebastian Schneeweiss, Yueqin Zhao, Esther H. Zhao, Sengwee Toh, Margaret Johnson, Bruce Fireman. (United States)

2:00 PM

Analysis of Registry-Based Case-Control Studies With a Joint Exposure and Outcome Model Based on the Reverse Waiting Time Distribution [8]

Henrik Støvring, Anton Pottegård, Jesper Hallas. (Denmark)

2:15 PM

Amiodarone Use and the Risk of Acute Pancreatitis: Influence of Different Exposure Definitions on Risk Estimation [9]

Mirjam Hempenius, Helga Gardarsdottir, Anthonius de Boer, Olaf Klungel, Rolf Groenwold. (Netherlands)

2:30 PM

Estimating Cumulative Risk in the Presence of Competing Events and Dependent Censoring in Pharmacoepidemiology Studies [10]

Sara Levintow, Leah McGrath, M. Alan Brookhart. (United States)

2:45 PM

Diagnostics for Informative Censoring: Application to Antipsychotic Trials With High Dropout Rates [11]

John Jackson. (United States)

Doacs, Doacs... and More Doacs

Panorama Hall

Moderators: Dorothee Bartels, FISPE, & Kristian Filion

1:30 PM

Risk of Major and Clinically Relevant Non-Major (CRNM) Bleeding in Patients Prescribed Rivaroxaban for Stroke Prevention in Non-Valvular AF (SPAF) and the Prevention and/or Treatment of Deep Vein Thrombosis and/or Pulmonary Embolism (DVT/PE) in Primary Care in England [12]

Sandeep Dhanda, Miranda Davies, Debabrata Roy, Lesley Wise, Saad Shakir. (United Kingdom)

1:45 PM

Association Between Proton Pump Inhibitor Use and Gastrointestinal Bleeds in NOAC Treated AF Patients [13]

Joris Komen, Tomas Forslund, Bjorn Wettermark, Paul Hjemdahl, Olaf Klungel, Aukje Mantel - Teeuwisse. (Netherlands)



1:30 PM – 3:00 PM

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Doacs, Doacs... and More Doacs (continued)

Panorama Hall

Moderators: Dorothee Bartels, FISPE, & Kristian Filion

2:00 PM

Frailty and Benefit of Dabigatran versus Warfarin in Older Adults With Atrial Fibrillation [14]

Dae Kim, Robert Glynn, Jerry Avorn, Sara Dejene, Sebastian Schneeweiss. (United States)

2:15 PM

Benefit-Risk Profile of Dabigatran Compared With Vitamin-K Antagonists in Elderly Patients With Non-Valvular Atrial Fibrillation: a Cohort Study in the French Nationwide Claims Database [15]

Patrick Blin, Caroline Dureau-Pournin, Abdelilah Abouelfath, Régis Lassalle, Jacques Bénichou, Yves Cottin, Patrick Mismetti, Cécile Droz-Perroteau, Nicholas Moore. (France)

2:30 PM

Drug Interactions With Oral Anticoagulants in German Nursing Home Residents - a Comparison Between Vitamin K Antagonists (VKA) and Non-VKA Oral Anticoagulants [16]

Kathrin Jobski, Falk Hoffmann, Stefan Herget-Rosenthal, Michael Dörks. (Germany)

2:45 PM

Dabigatran versus Rivaroxaban for Secondary Stroke Prevention in Patients With Atrial Fibrillation Rehabilitated in Skilled Nursing Facilities [17]

Matthew Alcusky, Anne L Hume, Marc Fisher, Jennifer Tjia, Robert J Goldberg, David D McManus, Kate L Lapane. (United States)

Shots Heard 'Round the World

South Hall 1 AB

Moderators: Wan-Ting Huang & Katherine Yih

1:30 PM

National Impact of Prevnar 13[®] Vaccine on Ambulatory Care Visits for Otitis Media in Children Under 5 Years in the United States [18]

Xiaofeng Zhou, Cynthia de Luise, Michael Gaffney, Catharine W Burt, Daniel A Scott, Nicolle Gatto, Kimberly J Center. (United States)

1:45 PM

Safety of Newly Adjuvanted Vaccines Among Older Adults, a Systematic Literature Review and Meta-Analysis [19]

Marc Baay, Kaatje Bollaerts, Thomas Verstraeten. (Belgium)

2:00 PM

Hospital-Diagnosed Adverse Events After HPV Vaccination: a Self-Controlled Case Series Analysis [20]

Sia K Nicolaisen, Reimar W Thomsen, Irene Petersen, Buket Öztürk, Kim Varming, Jørn Olsen, Henrik T Sørensen, Lars Pedersen. (Denmark)

2:15 PM

Advance System Testing: Benefit-Risk Analysis of a Marketed Vaccine Using Cohort Modelling and MCDA Swing Weighting [21]

Kaatje Bollaerts, Eduoard Ledent, Tom De Smedt, Daniel Weibel, Hanne-Dorthe Emborg, Klara Berensci, Ana Correa, Giorgia Danieli, Talita Duarte-Salles, Consuelo Huerta, Elisa Martin, Gino Picelli, Lara Tram, Lina Titievsky, Lina Titievsky, Miriam Sturkenboom, Vincent Bauchau. (Belgium)

2:30 PM

Evidence From a Quasi-Experimental Study for the Effectiveness of the Influenza Vaccination Against Myocardial Infarction in UK Adults Aged at Least 65y [22]

Adam J. Streeter, William E Henley. (United Kingdom)

2:45 PM

Real-World Effectiveness of Influenza Vaccination in Older Adults in the UK From 1997-2012: a Quasi-Experimental Cohort Study [23]

Dr. Henley, Dr. Streeter. (United Kingdom)



1:30 PM – 3:00 PM

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Drugs in Pregnancy - Ondansetron, Opioids, Gabapentin

South Hall 2A

Moderators: Brian Bateman & Vera Ehrenstein

1:30 PM

Gabapentin Use in Pregnancy and the Risk of Maternal and Neonatal Outcomes [24]

Elisabetta Patorno, Sonia Hernández-Díaz, Krista F. Huybrechts, Jacqueline M. Cohen, Rishi J. Desai, Helen Mogun, Brian T Bateman. (United States)

1:45 PM

Infections in Children After Prenatal Exposure to Methadone and Buprenorphine: Nordic Registry Study [25]

Milada Mahic, Sonia Hernandez-Diaz, Mollie Wood, Ingvild Odsbu, Mette Nørgaard, Helle Kieler, Svetlana Skurtveit, Marte Handal. (United States)

2:00 PM

Ondansetron and the Risk of Congenital Malformations [26]

Krista F Huybrechts, Sonia Hernandez-Diaz, Loreen Straub, Kathryn Gray, Elisabetta Patorno, Rishi Desai, Helen Mogun, Brian T Bateman. (United States)

2:15 PM

Rurality and Variability in Opioid Use Among Pregnant Women [27]

Andrew D Wiese, Sarah Osmundson, Marie R Griffin, Jea-Young Min, Ed Mitchel, Carlos G Grijalva. (United States)

2:30 PM

Comparative Safety of Ondansetron Use During Pregnancy [28]

Elizabeth A Suarez, Michele Jonsson Funk. (United States)

2:45 PM

Opioid Dispensing After Vaginal Delivery [29]

Malavika Prabhu, Elizabeth Garry, Sonia Hernandez-Diaz, Sarah C. MacDonald, Krista F. Huybrechts, Brian T. Bateman. (United States)

The Aetion Evidence Platform™ is the only validated real-world evidence platform that enables reproducible, transparent safety and effectiveness analyses at scale.

- 10+ presentations at ICPE 2018 use the Aetion Evidence Platform
- FDA collaborator
- Validated, rapid-cycle analytics™



Visit us at ICPE Booth 10
www.aetion.com / press@aetion.com



1:30 PM – 3:00 PM

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Biologics - Take it or Leave It

South Hall 2B

Moderators: Cristiano Moura & Jaclyn Bosco

1:30 PM

A Real-World Comparison of Effectiveness and Safety Outcomes Between Clinical Trial Eligible and Ineligible Patients in the British Association of Dermatologists Biologic Interventions Register (BADBIR) [30]

Kayleigh J Mason. (United Kingdom)

1:45 PM

The Risk of Keratinocyte Carcinoma (KC) in Psoriasis Patients Receiving Biologic Therapy Compared to Conventional Systemic Therapy: Results From the British Association of Dermatologists Biologic Interventions Register (BADBIR) [31]

Kayleigh J Mason. (United Kingdom)

2:00 PM

Comparative Effectiveness of Tumour Necrosis Factor Inhibitor Therapy Vs. Conventional Synthetic DMARDs on Need for Joint Replacement Among Rheumatoid Arthritis Patients: a Propensity Score Matched Analysis of UK Registry Data [32]

Samuel Hawley, M. Sanni Ali, Rene Cordtz, Lene Dreyer, Christopher J Edwards, Nigel K Arden, Cyrus Cooper, Andrew Judge, Kimme Hyrich, Daniel Prieto-Alhambra. (United Kingdom)

2:15 PM

The Association of Biologic Drug-Levels With Infection Risk: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis [33]

Meghna Jani, William G Dixon, Mark Lunt, Diederik DeCock, John Isaacs, Ann W Morgan, Anthony G Wilson, Kath Watson, Anne Barton, Kimme Hyrich. (United Kingdom)

Pfizer

Working together for a healthier world

Committed to bringing therapies to people that extend and significantly improve their lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Pfizer Epidemiology is proud to support the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management in Prague, Czech Republic.



1:30 PM – 3:00 PM

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Biologics - Take it or Leave It (continued)

South Hall 2B

Moderators: Cristiano Moura & Jaclyn Bosco

2:30 PM

Tumor Necrosis Factor-Alpha Inhibitors and Risk of Non-Hodgkin Lymphoma in a Cohort of Adults With Rheumatologic Conditions [34]

Gregory S Calip, Pritesh R. Patel, Sruthi Adimadhyam, Shan Xing, Zhaoju Wu, Karen Swaiss, Glen T. Schumock, Todd A. Lee, Brian C. Chiu. (United States)

2:45 PM

Methotrexate Use and the Risk for Cardiovascular Disease Among Rheumatoid Patients Initiating Biologic Disease-Modifying Antirheumatic Drugs [35]

Fenglong Xie, Lang Chen, Huifeng Yun, Emily Levitan, Paul Muntner, Jeffrey R Curtis. (United States)

Psychotropics - The More It Changes, The More It's The Same

South Hall 3A

Moderators: Jason C. Hsu & Maribel Salas, FISPE

1:30 PM

Agomelatine and Other Antidepressants and the Risk of Acute Liver Injury (ALI), a Pass in Four European Countries [36]

Manel Pladevall, Jesper Hallas, Tania Schink, Johan Reutfors, Rosa Morros, Beatriz Poblador-Plou, Joan Forn, Maja Hellfritsch, Tammo Reinders, David Hägg, Maria Giner-Soriano, Alexandra Prados-Torres, Miguel Cainzos-Achirica, Anton Pottgård, Bianca Kollhorst, Lena Brandt, Jordi Cortés, Jaume Aguado, Gabriel Perlemuter, Jordi Castellsagué, Emmanuelle Jacquot, Nicolas Deltour, Susana Perez-Gutthann. (Spain)

1:45 PM

Risk of Traumatic Brain Injury in Elderly New Users of Antidepressants [37]

Federica E Pisa, Jonas Reinold, Bianca Kollhorst, Ulrike Haug, Tania Schink. (Germany)

2:00 PM

Zolpidem Use and Suicide Death in South Korea: a Population-Based Case-Control Study [38]

BongKyoo Choi, Hi Gin Sung, Jin Hyun Nam, Ju-Young Shin. (Korea, Republic of)

2:15 PM

Evaluation of Opioid Overutilization Criteria Suggested by Centers for Medicare and Medicaid Services Among Privately Insured Or Medigap Population [327]

Amir Sarayani, Almut G Winterstein, Cheng Chen, Yu-Jung "Jenny" Wei. (United States)

2:30 PM

Degree of Serotonin Reuptake Inhibition of Antidepressants and the Risk of Ischemic Stroke and Myocardial Infarction [40]

Antonios Douros, Sophie Dell'Aniello, Golsa Dehghan, Jean-François Boivin, Christel Renoux. (Canada)

2:45 PM

Risk of Suicide With Concurrent Use of Benzodiazepine, Antidepressant, Opioid Analgesic and Zolpidem: a Population Based Case-Control and Case-Crossover Study [41]

Hi Gin Sung, junqing Li, Jin Hyun Nam, BongKyoo Choi, Ju-Young Shin. (Korea, Republic of)

3:30 PM 5:00 PM

Break/Posters/Exhibits

Congress Foyer 2 & 3ABC





3:30 PM – 5:00 PM

CONCURRENT SESSIONS: SYMPOSIA AND WORKSHOPS

3:30 PM

Sequential and Sequential Design: Tools for Prospective Sequential Medical Product Safety Surveillance [42] Congress Hall
Judith C. Maro, Efe Eworuke, Andreia Leite, Martin Kulldorff. (United States)

3:30 PM

Bringing Patient-Generated Data into Pharmacoepidemiology: The Who, What, Why, Where, When...and How [43] Panorama Hall
William G Dixon, Dorothee Bartels, Jeffrey Curtis, Alison Bourke, David Martin, Kueiyu Joshua Lin. (United Kingdom)
Sponsored by the Digital Epidemiology Special Interest Group

3:30 PM

Time Series Analysis: Where Are We Now, and What Will the Future Bring? [44] South Hall 1 AB
Joris J. Komen, Peter G. Mol, Gisbert W. Selke, Morten Andersen. (Netherlands)

3:30 PM

Implementation Science - the Art Nouveau of Pharmacoepidemiology for Improving Risk Mitigation in Healthcare [45] South Hall 2A
Priya Bahri, Meredith Smith, Bert H.G.M. Leufkens, Elaine H. Morrato. (United Kingdom)

3:30 PM

Advances in the Study of Medication Errors in Computerized Healthcare Databases and Spontaneous Reporting Systems in Europe and North America [46] South Hall 2B
Michael D Nguyen, Jo Wyeth, Kevin Haynes, Lisa Herrinton, Rodrigo Postigo, Adrian Levy. (United States)

5:00 PM – 6:30 PM

CONCURRENT SESSIONS: ORAL PRESENTATIONS

PS I Still Love You

Congress Hall

Moderators: **Olaf Klungel, FISPE, & Jeremy Rassen**

5:00 PM

Propensity Score Matching versus Propensity Score Fine Stratification and Coarsened Exact Matching in Claims Data [47]
John E Ripollone, Krista F Huybrechts, Kenneth J Rothman, Ryan E Ferguson, Jessica M Franklin. (United States)

5:15 PM

Propensity Score Diagnostics: The Challenges We Face When Providing Evidence That a Propensity Based Estimate Is Unbiased [48]
Emily Granger, Jamie C Sergeant, Mark Lunt. (United Kingdom)

5:30 PM

Evaluation of Treatment Effect Modification in Propensity Score Matching: An Empirical Example [49]
M Sanni Ali, Ian J Douglas, Elizabeth Williamson, Daniel Prieto-Alhambra, Liam Smeeth. (United Kingdom)

5:45 PM

Covariate Balance Assessment in Propensity Score Matching After Multiple Imputation With Chained Equations: An Empirical Example [50]
M Sanni Ali, Danielle E Robinson, Sara Khalid, Ian Douglas, Liam Smeeth, Daniel Prieto-Alhambra. (United Kingdom)

6:00 PM

Extension of Disease Risk Score Based Confounding Adjustments for Multiple Outcomes of Interest: An Empirical Evaluation [51]
Rishi J Desai, Richard Wyss, Yinzhu Jin, Justin Bohn, Sengwee Toh, Austin Cosgrove, Adele Kennedy, Jessica Kim, Clara Kim, Rita Ouellet-Hellstrom, Sara Karami, Jacqueline Major, Aaron Niman, Shirley Wang, Joshua Gagne. (United States)

6:15 PM

A Joint Application of Disease Risk Score and Propensity Score to Control for Confounding: a Clinical Example [52]
M Sanni Ali, Ian J Douglas, Elizabeth Williamson, Daniel Prieto-Alhambra, Liam Smeeth. (United Kingdom)



5:00 PM – 6:30 PM

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Methods for Data Far and Wide

Panorama Hall

Moderators: **Stephan Lanes & Nicolle Gatto, FISPE**

5:00 PM

Performance of a Distributed Regression Analysis Software and Workflow [53]

Qoua Her, Yury Vilik, Jessica Young, Zilu Zhang, Jessica Malenfant, Sarah Malek, Sengwee Toh. (United States)

5:15 PM

Performance of Fixed and All-Available Look-Back Approaches in Claims Database Studies: a Plasmode Simulation [54]

Mitchell M Conover, Til Stürmer, Charles Poole, Robert J Glynn, Ross J Simpson, Michele Jonsson Funk. (United States)

5:30 PM

Do Gaps in Enrollment Matter? a Study of the Effect of Strict Enrollment Criteria in US Commercial and Medicaid Databases on Population Representativeness and the Prevalence of COPD and Asthma [55]

Harriet A Dickinson, John Logie. (United Kingdom)

5:45 PM

Assessment of Misclassification Bias Due to Short Look-Back Periods in Epidemiological Studies of Chronic Disease Incidence [56]

Nils Ekström, Michael Törnblom, Lina Titievsky, Viktor Wintzell, James Stark, Mats Rosenlund. (Sweden)

6:00 PM

Privacy-Protecting Analytic Methods Using Only Aggregate-Level Data for Multivariable-Adjusted Analysis in Distributed Data Networks [57]

Xiaojuan Li, Bruce H Fireman, Jeffrey R Curtis, David E Arterburn, David Fisher, Erick Moyneur, Mia Gallagher, Marsha A Raebel, W Benjamin Nowell, Lindsay Lagreid, Sengwee Toh. (United States)

6:15 PM

Multi-Database Multiple Imputation Within a Distributed Data Drug Safety Network: a Simulation Study and Real-World Data Example [58]

Matthew H Secrest, Robert W Platt, Pauline Reynier, Colin R Dormuth, Andrea Benedetti, Kristian B Filion. (United States)

Drugs in Pregnancy: Anti-infectives, Anti-asthmatics, MS drugs, & TNFs

South Hall 1 AB

Moderators: **Jennita Reefhuis, FISPE, & Alison Kawai**

5:00 PM

Oral Fluconazole in Pregnancy and Risk of Stillbirth and Neonatal Death [59]

Björn Pasternak, Viktor Wintzell, Kari Furu, Anders Engeland, Martin Neovius, Olof Stephansson. (Sweden)

5:15 PM

Tnf Inhibitor Treatment During Pregnancy and Risk of Preterm Birth [60]

Gabriella Bröms, Helle Kieler, Anders Ekbohm, Karin Hellgren, Mika Gissler, Anna-Maria Lahesmaa-Korpinen, Lars Pedersen, Marcus Schmitt-Egenolf, Henrik T Sørensen, Fredrik Granath. (Sweden)

5:30 PM

Impact of Maternal Infection and Antibiotic Use in Pregnancy on the Risk of Childhood Obesity: a Study of 203,999 Mother-Child Pairs With Up to 12 Years of Follow-Up [61]

De-Kun Li, Hong Chen, Jeannette R. Ferber, Roxana Odouli. (United States)

5:45 PM

Disparities in Asthma Prevalence, Severity, and Control in Pregnancy. Evidence From Two Healthcare Databases in the United States [62]

Jacqueline M Cohen, Brian T. Bateman, Krista F. Huybrechts, Michael Schatz, Keele E Wurst, Sonia Hernandez-Diaz. (Norway)

6:00 PM

Use of Multiple Sclerosis Drugs Among Live Birth Pregnancies in the United States [63]

Danijela Stojanovic, Mayura Shinde, Nicole Haug, Mohamed Mohamoud, Leyla Sahin, Genna Panucci, Rajani Rajbhandari, Lockwood Taylor. (United States)

6:15 PM

Uncontrolled Maternal Chronic Respiratory Diseases in Pregnancy Increase the Risk of Anorectal Malformations in Offspring [64]

Romy van de Putte, Ivo de Blaauw, Rianne Boenink, Monique H Reijers, Paul M. Broens, Cornelius E. Sloots, Arno F. van Heijst, Marleen M. van Gelder, Nel Roeleveld, Iris A. van Rooij. (Netherlands)



Meet Us at ICPE.

FIND US AT:
booths: #6-9

LEARN MORE:
rtihs.org/ICPE18

The power of knowledge. The value of understanding.

Our expert team of epidemiologists are no strangers to real-world data. We have long-standing research collaborations with over 20 data providers across Europe and North America. You can trust our background and expertise to guide you to the right data and help you answer your pharmacoepidemiology or risk management questions.

Raising the standard in pharmacoepidemiology

For more than 30 years, Analysis Group has worked with prominent clinicians, academics, and industry thought leaders to develop innovative solutions for our clients across North America, Europe, and emerging markets.

Drawing on our expertise in pharmacoepidemiology, we assist our clients with:

- Real-world evidence generation, patient preference research, and engagement strategies for FDA and EMA regulatory processes and medical devices
- Large-scale safety studies for clinical and post-market safety and non-clinical toxicology
 - Observational pharmacoepidemiology studies
 - Propensity score matching analysis
 - Patient reporting
 - Large-scale analyses of adverse drug reactions
- Health economics and cost-effectiveness analysis
 - Health economics studies with randomized, controlled, clinical studies
- Pharmacovigilance and post-market safety analysis for drug safety reports
 - PHARM and PASS methods
- Strategic response to drug safety concerns raised by regulatory agencies
- Design and evaluation of the effectiveness of REMS programs
- Adverse drug reaction causal inference
- Comparative effectiveness research
- Extrapolation of experimental and observational analysis for patient preference studies
- Quality of life instrument development and validation
- Real-time monitoring of drug safety events
- Manufacturing pharmaceutical quality control



ANALYSIS GROUP
ECONOMIC, FINANCIAL and STRATEGY CONSULTANTS
Drug Safety and Epidemiology

For more information, contact Mei Sheng Duh, Sc.D., M.P.H., Managing Principal and Chief Epidemiologist, at meisheng@analysisgroup.com, 617-426-8131 or visit our website at www.analysisgroup.com/multiple



5:00 PM – 6:30 PM

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Heart, Blood, and Bleed

South Hall 2A

Moderators: **Nicholas Moore, FISPE, & Eileen Ming**

5:00 PM

Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparins for Venous Thromboembolism Prevention Following Total Hip Replacement: Comparative Effectiveness and Medical Costs From a French Nationwide Cohort Study of Around 120,000 Patients [65]

Patrick Blin, Charles-Marc Samama, Alain Sautet, Patrick Mismetti, Jacques Benichou, Séverine Lignot-Maleyran, Stéphanie Lamarque, Simon Lorrain, Régis Lassalle, Anne-Françoise Gaudin, François-Emery Cotte, Cécile Droz-Perroteau, Nicholas Moore. (France)

5:15 PM

Serious Bleeding and Use of Warfarin in Combination With Sulfonylureas Or Metformin [66]

Young Hee Nam, Colleen M. Brensinger, Warren B. Bilker, Charles E. Leonard, Xu Han, Sean Hennessy. (United States)

5:30 PM

Sodium-Glucose Co-Transporter-2 Inhibitors and the Risk of Cardiovascular Outcomes and Adverse Events [67]

Jacob Udell, Greg Carney, Michael Paterson, Kristian Filion, Amit Garg, Lorraine Lipscombe, David Juurlink, Muhammad Mamdani, Colin Dormuth. (Canada)

5:45 PM

Benefit-Risk of Rivaroxaban 20 Or 15mg Compared to Vitamin-K Antagonists in Patients With Non-Valvular Atrial Fibrillation: a Cohort Study in the French Nationwide Claims Database [68]

Patrick Blin, Caroline Dureau-Pournin, Marie-Agnès Bernard, Régis Lassalle, Laurent Fauchier, Frédéric Sacher, Jean Dallongeville, Cécile Droz-Perroteau, Nicholas Moore. (France)

6:00 PM

Comparative Effectiveness of Apixaban versus Rivaroxaban for the Prevention of Cardiovascular Diseases and Recurrent Venous Thromboembolism [69]

Ghadeer Dawwas, Haesuk Park. (United States)

6:15 PM

Comparative Effectiveness and Safety of Low-Dose Non-Vitamin K Oral Anticoagulants and Acenocoumarol in Patients With Atrial Fibrillation in Valencia Spain [70]

Yared Santa-Ana-Tellez, Clara L Rodríguez-Bernal, Aníbal García-Sempere, Salvador Peiró, Gabriel Sanfélix-Gimeno. (Spain)

Heart & Limbs

South Hall 2B

Moderators: **Cynthia Girman, FISPE, & Gregory Nichols**

5:00 PM

Association Between Glycaemic Control and Fracture Risk in Diabetic Patients: a Nested Case Control Study [71]

Janina Vavanikunnel, Sarah Charlier, Claudia Becker, Cornelia Schneider, Susan Jick, Christoph R Meier, Christian Meier. (Switzerland)

5:15 PM

Sodium-Glucose Cotransporter-2 Inhibitor Use and Lower-Extremity Amputation Risk Among Commercially-Insured U.S. Patients, 2013-2015 [72]

Jeff Y. Yang, John B. Buse, Emily W. Gower, Virginia Pate, Tiansheng Wang, Til Stürmer. (United States)

5:30 PM

Delays in Anti-Hyperglycemic Treatment Intensification Impacts Risk of Diabetes Complications [73]

Gregory A Nichols, Victoria Romo-LeTourneau, Suma Vupputuri, Sheila Thomas. (United States)

5:45 PM

Risk of Amputations Associated With SGLT2 Inhibitors: a Propensity-Matched Cohort Study [74]

Sruthi Adimadhyam, Todd A. Lee, Gregory S. Calip, Daphne E. Smith Marsh, Brian T. Layden, Glen T. Schumock. (United States)

6:00 PM

A Safety Signal of Venous Thromboembolic Events With the Use of DPP-4 Inhibitors: a Pharmacovigilance Disproportionality Analysis [75]

Amandine Gouverneur, Athénaïs Lair, Mickael Arnaud, Bernard Bégaud, Frantz Thiessard, Antoine Pariente, Francesco Salvo. (France)

6:15 PM

Frailty and Risk of Adverse Events Associated With Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylureas in Older Adults With Type 2 Diabetes [76]

Dae Kim, Janet Sultana, Sebastian Schneeweiss, Robert Glynn, Julie Barberio, Elisabetta Patorno. (United States)



We are committed to therapeutic progress to serve patient needs



4 billion euro turnover
2.8 billion for Servier and
1.2 billion euros for generics

25% of turnover from Servier drugs is invested in R&D
excluding generics

No. 2 pharmaceutical company in France

No. 30 in the world; 3 research centres including 2 in France

5 major R&D areas

Cardiovascular and immune-inflammatory diseases ■ Neuropsychiatric disorders
■ Oncology ■ Diabetes

SERVIER Pharmacoepidemiology
is proud to support the 34th ICPE in Prague, Czech Republic

To learn more, visit us at www.servier.com




TRANSFORMING THE
LANGUAGE OF LIFE
INTO VITAL MEDICINES.

At Amgen, we believe that the answers to medicine's most pressing questions are written in the language of our DNA. As pioneers in biotechnology, we use our deep understanding of that language to create vital medicines that address the unmet needs of patients fighting serious illness—to dramatically improve their lives.

For more information about Amgen, our pioneering science and our vital medicines, please visit www.amgen.com.

Amgen is a proud sponsor of the 34th ICPE. Epidemiologic research at Amgen focuses on patients with grievous illness and advancing pharmacoepidemiologic methods.



© 2012 Amgen Inc. All rights reserved.



5:00 PM – 6:30 PM

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Predicting Adherence and Persistence to Medication

South Hall 3A

Moderators: Sarah-Jo Sinnott & Partick Souverein

5:00 PM

Real-World Persistence for Newly Prescribed HIV-1 Treatment: Single versus Multiple Tablet Regimen Comparison [77]

Joshua Cohen, Anne Beaubrun, Richa Bashyal, Ahong Huang, Teng Huang, Onur Baser. (United States)

5:15 PM

Epidemiology and Predictors of Barriers to Medication Adherence Using Administrative Claims and Electronic Health Record Data [1113]

Julie Lauffenburger, Romit Bhattacharya, Chandrasekar Gopalakrishnan, Jessica Lee, Julie Barberio, Thomas Isaac, Thomas Sequist, Niteesh Choudhry. (United States)

5:30 PM

Predictors of Persistent Prescription Opioid Analgesic Use Among People Without Cancer in Australia: a Retrospective Cohort Study [79]

Samanta Lalic, Natasa Gisev, J Simon Bell, Maarit J Korhonen, Jenni Ilomäki. (Australia)

5:45 PM

Time-Varying Measures of Adherence to Other Medications to Predict Persistence to Statin Treatment [80]

Yaa-Hui Dong, Zhigang Lu, Yinzhu Jin, Moa P. Lee, Gregory Brill, Hiraku Kumamaru, Joshua J. Gagne. (Taiwan)

6:00 PM

The Impact of the Duration of Bisphosphonate Drug Holidays on Hip Fracture Rates [81]

Jeffrey R Curtis, Rui Chen, Li Zixu, Tarun Arora, Kenneth G Saag, Nicole Wright, Shanette Daigle, Meredith Kilgore, Elizabeth Delzell. (United States)

6:15 PM

Adherence Trajectories to Essential Medications After Acute Coronary Syndrome and Their Impact on Clinical Outcomes. a Population-Based Cohort Study [82]

Daniel Bejarano-Quisoboni, Isabel Hurtado, Clara L Rodriguez-Bernal, Anibal García-Sempere, Sofia Bauer-Izquierdo, Julian Librero, Salvador Peiró, Gabriel Sanfélix-Gimeno. (Spain)

6:45 PM – 7:45 PM

Special Interest Group Meetings (Open to all participants.)

Adherence	South Hall 2B
Asian Pharmacoepidemiology Network (AsPEN)	Zoom
Benefits Risk Assessment, Communication and Evaluation (BRACE)	South Hall 3A
Biologics & Biosimilars	South Hall 2A
Comparative Effectiveness Research (CER)	South Hall 1 AB
Database	Panorama Hall
Digital Epidemiology	Club A

Drug Utilization/Health Services Research	South Hall 3B
Medical Devices	Chamber Hall
Medications in Pregnancy	Terrace 2A
Molecular Epidemiology/Biomarkers/ Pharmacogenetics	Dressing Room 222
Oncology	Dressing Room 223
Pediatrics	Terrace 2B
Rare Disease	Dressing Room 224
Vaccines	Club E

7:30 PM – 9:30 PM

PDS Editorial Board (By invitation only.)



7:00 AM – 8:00 AM

Poster Session B & Spotlight Session B Set-up

Congress Foyer 2A (Poster Session)
& Congress Foyer 3A (Spotlight)

7:00 AM – 8:00 AM

Coffee & Tea

Congress Foyer 2 & 3ABC

7:00 AM – 8:00 AM

Meetings

(Open to all participants.)

- ◆ Asian DURG Club C
- ◆ Geriatric Pharmacoepidemiology SIG South Hall 3A

7:00 AM – 5:00 PM

Speaker Ready Room Room 2.1

*Please arrive 24 hours before your presentation start time to upload or check your presentation.

7:00 AM – 6:00 PM

Registration

Congress Foyer 0

8:00 AM – 6:00 PM

Exhibits/Posters Session B

Congress Foyer 2 & 3ABC



Old Town Square and Church of Our Lady

8:00 AM – 9:30 AM

CONCURRENT SESSIONS: ORAL PRESENTATIONS

Diversity in Design: A Mismatch of Methods

Congress Hall

Moderators: Daniel Prieto-Alhambra, FISPE, & Dana Teetsch

8:00 AM

Variation in Risk Estimates From Different Cohort Selection Strategies When Using Recurrent Index Events [362]

Henry T Zhang, Mitchell M Conover, Til Stürmer. (United States)

8:15 AM

Implementation of the Prevalent New User Study Design in the US Medicare Population: Benefit versus Harm [363]

Elizabeth Garry, John B Buse, Mugdha Gokhale, Jennifer L. Lund, Virginia Pate, Til Stürmer. (United States)

8:30 AM

The Case-Crossover Design for Drug Interaction Studies: Interaction Term Model versus a Novel Fully Saturated Model [364]

Katsiaryna Bykov, Robert J. Glynn, Murray A. Mittelman, Sebastian Schneeweiss, Joshua J. Gagne. (United States)

Student Award Recipient – Best Methods Abstract Submitted by a Student/Post-Doc

8:45 AM

Minor Differences, Major Consequences? Lessons Learned From Replication of a Claims-Based Drug Safety Assessment [365]

Ting-Ying Huang, Laura Hou, Laura Shockro, Ella Pestine, Michael Nguyen, Judith C Maro, Rima Izem. (United States)

9:00 AM

Strategies for Selecting Start of Follow-Up in Longitudinal Studies With Multiple Eligible Index Opportunities [366]

Mitchell M Conover, Henry T Zhang, Til Stürmer, Robert J Glynn, Charles Poole, Michele Jonsson Funk. (United States)

9:15 AM

Implementation of the Trend-In-Trend Study Design in a Setting With Cross-Over of Preferred Treatment Choice: An Example of Second-Line Antidiabetics [367]

Phyo T Htoo, John Buse, Virginia Pate, Til Stürmer. (United States)

Advances in Vaccine Safety Monitoring

Panorama Hall

Moderators: Daniel Weibel & Anne Butler

8:00 AM

Effectiveness of Prenatal Tdap in the Prevention of Infant Pertussis in the US [368]

Sylvia Becker-Dreps, Anne M. Butler, Leah J. McGrath, Kim A. Boggess, David J. Weber, Dongmei Li, Michael G. Hudgens, J. Bradley Layton. (United States)

8:15 AM

Advance System Testing: Feasibility of Using a Network of Health Data Bases for Vaccine Safety Studies [369]

Daniel Weibel, Caitlin Dodd, Olivia Mahaux, Francois Haguinet, Tom De Smedt, Talita Duarte-Salles, Gino Picelli, Lara Tramontan, Giorgia Danieli, Ana Correa, Elisa Martin, Consuelo Huerta, Klara Berensci, Benedikt Becker, Hanne-Dorthe Emborg, Myint Tin Tin Htar, Kaatje Bollaerts, Vincent Bauchau, Lina Titievsky, Miriam Sturkenboom. (Netherlands)



8:00 AM – 9:30 AM

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Advances in Vaccine Safety Monitoring (continued)

Panorama Hall

Moderators: Daniel Weibel & Anne M. Butler

8:30 AM

Determining Which of Several Concomitantly Administered Vaccines Increase Risk of An Adverse Event [370]

Shirley V Wang, Kristina Stefanini, Edwin Lewis, Sophia R Newcomer, Bruce Fireman, Matthew F Daley, Jason M Glanz, Martin Kulldorff. (United States)

8:45 AM

Epilepsy in Children Following Pandemic Influenza Vaccination [371]

Siri Eldevik Haberg, Kari M Aaberg, Pål Surèn, Lill Trogstad, Sara Ghaderi, Camilla Stoltenberg, Per Magnus, Inger Johanne Bakken. (Norway)

9:00 AM

Risk Factors of Zoster Vaccine Failure Among Elderly in England [372]

Maria Alexandridou, Thomas Verstraeten, Kaatje Bollaerts. (Belgium)

9:15 AM

HPV Vaccines and Risk of Thyroid Disorders in Young Girls [373]

Cedric Collin, Sara Miranda, Christophe Chaignot, Amelie Poidvin, Paul De-Boissieu, Alain Weill, Mahmoud Zureik, Rosemary Dray-Spira. (France)

DEPARTMENT OF CLINICAL EPIDEMIOLOGY IN AARHUS, DENMARK

Better clinical care through research

VISIT US AT BOOTH # 22-23





8:00 AM – 9:30 AM

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Psychotropics in Pregnancy

South Hall 1AB

Moderators: Jacqueline Cohen & Maqura Shinde

8:00 AM

Maternal Use of Atypical Antipsychotics and Gestational Weight Gain [374]

Yanmin Zhu, Dikea Roussos-Ross, Christian Hampp, Yu-Jung Wei, Babette Brumback, Almut G. Winterstein. (United States)

8:15 AM

Maternal Use of Benzodiazepines and Z-Hypnotics During Pregnancy and Developmental Outcomes in Offspring at 5 Years of Age [375]

Angela Lupattelli, Christina D Chambers, Gretchen Bandoli, Marte Handal, Svetlana Skurtveit, Hedvig Nordeng. (Norway)

8:30 AM

Self-Reported Postnatal Depressive Symptom Severity After Treatment With Antidepressants in Pregnancy: A Cross-Sectional Study in 12 European Countries Using the Edinburgh Postnatal Depression Scale [376]

Angela Lupattelli, Michael J Twigg, Ksenia Zagorodnikova, Myla M Moretti, Mariola Drozd, Alice Panchaud, Andre Rieutord, Romana Gjergja Juraski, Marina Odalovic, Debra Kennedy, Gorazd Rudolf, Herbert Juch, Hedvig Nordeng. (Norway)

8:45 AM

Association of Antidepressant Continuation in Pregnancy With Maternal Gestational Weight Gain and Gestational Diabetes [377]

Paige D Wartko, Noel S. Weiss, Daniel A. Enquobahrie, Beth A. Mueller, Gary K. Chan, Alyssa Stephenson-Famy, Sascha Dublin. (United States)

9:00 AM

Are Associations Between Prenatal Antidepressant Exposure and Toddler Neurodevelopment Mediated by Gestational Age at Birth? [378]

Mollie E Wood, Sonia Hernandez-Diaz, Hedvig M Nordeng. (United States)

9:15 AM

Psychotropic Polytherapy Among Publicly Insured Pregnant Women in the United States [379]

Anna Cantarutti, Brian T. Bateman, Elisabetta Patorno, Rino Bellocco, Stephanie White-Bateman, Sonia Hernández-Díaz, Krista F. Huybrechts. (Italy)

Let It Beat, Let It Beat

South Hall 2A

Moderators: Jason C. Hsu & Patrick Blin

8:00 AM

Fluoroquinolone Use and Risk of Aortic Aneurysm and Dissection: Nationwide Cohort Study in Sweden [380]

Björn Pasternak, Malin Inghammar, Henrik Svanström. (Sweden)

8:15 AM

Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Liver Injury [381]

Antonios Douros, Laurent Azoulay, Hui Yin, Samy Suissa, Christel Renoux. (Canada)
Student Award Recipient - Second-Best Abstract Submitted by a Student/Post-Doc

8:30 AM

Does Comorbidity Interact With Acute Myocardial Infarction to Increase Mortality? [382]

Erzsébet Horváth-Puhó, Morten Schmidt, Anne Gulbech Ording, Hans Erik Bøtker, Timothy L. Lash, Henrik Toft Sørensen. (Denmark)

8:45 AM

Risk Factors for Stroke and Choice of Oral Anticoagulant in Atrial Fibrillation [383]

Lars J Kjerpeseth, Hanne Ellekjær, Randi Selmer, Inger Ariansen, Kari Furu, Eva Skovlund. (Norway)

9:00 AM

Effect of Migraine on Cardiovascular Diseases [384]

Szimonetta Komjáthiné Szépligeti, Kasper Adelborg, Louise Holland-Bill, Vera Ehrenstein, Erzsébet Horváth-Puhó, Victor W Henderson, Henrik Toft Sørensen. (Denmark)

9:15 AM

Long-Term Clinical Outcomes Following a Myocardial Infarction Among the General Population in England [385]

Anna Schultze, Rikisha Shah, Andrew Tershakovec, Tarek A Hammad, Tommi Tervonen, Cathy Anne Pinto, Dimitra Lambrelli. (United Kingdom)



8:00 AM – 9:30 AM

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Diabetes All Mixed Up

South Hall 2B

Moderators: Christian Hamppe, FISPE & Andrea Margulis

8:00 AM

Antidiabetic Medication in Pregnancy: An International Drug Utilization Study [386]

Carolyn E Cesta, Jacqueline M Cohen, Laura Pazzagli, Brian T Bateman, Gabriella Bröms, Kristjana Einarsdóttir, Kari Furu, Mika Gissler, Anna Heino, Sonia Hernandez-Diaz, Krista F Huybrechts, Øystein Karlstad, Jiong Li, Johan Reutfors, Randi Selmer, Yongfu Yu, Helga Zoega, Ingvild Odsbu. (Sweden)

8:15 AM

Clinical Effectiveness of Sitagliptin Compared to Sulphonylureas for Type 2 Diabetes [387]

Manuj Sharma, Irwin Nazareth, Irene Petersen. (United Kingdom)

8:30 AM

Hepatic Safety of Vildagliptin: Multi-Database, Non-Interventional Safety Study [388]

Rachael Williams, Frank de Vries, Wolfgang Kothny, Carmen Serban, Sandra Lopez-Leon, Paivi Paldanius, Raymond Schlienger. (Switzerland)

8:45 AM

Incretin-Based Drugs and the Risk of Cholangiocarcinoma Among Patients With Type 2 Diabetes [389]

Devin Abrahami, Antonios Douros, Hui Yin, Jean-Luc Faillie, Oriana Yu, Nathaniel Bouganim, Robert Platt, Laurent Azoulay. (Canada)

9:00 AM

Time to Treatment Intensification in Patients on Dual Pharmacotherapy for Type 2 Diabetes [390]

Giuseppe Roberto, Francesco Barone-Adesi, Francesco Giorgianni, Valeria Pizzimenti, Claudia Bartolini, Corrado Magnani, Marina Maggini, Roberto Da Cas, Stefania Spila-Alegiani, Carmen Ferrajolo, Paolo Francesconi, Gianluca Trifiro, Elisabetta Poluzzi, Fabio Baccetti, Rosa Gini. (Italy)

9:15 AM

Risk of Uroseptic Hospitalizations Among Patients Initiating Sodium-Glucose Co-Transporter 2 Inhibitors: a Retrospective Cohort Study [391]

Chintan Dave, Sebastian Schneeweiss, Michael Fralick, Dae Kim, Elisabetta Patorno. (United States)

Painful Policy

South Hall 3A

Moderators: Bjorn Wettermark & Gianluca Trifiro

8:00 AM

Estimating the Optimal Duration of Initial Opioid Analgesic Prescriptions in Post-Surgical Populations Using FDA's Sentinel Distributed Database [392]

Mallika L. Mundkur, Tamra Meyer, Talia Menzin, Judy Staffa, Corinne Woods, Judith C. Maro, Justin Bohn. (United States)

8:15 AM

Prescription Opioid Use and Concurrent Psychotropic Drug Use During Pregnancy: a Population-Based Retrospective Cohort Study Utilizing Linked Administrative Data [393]

Dan Chateau, Deepa Singal, Ana Hanlon-Dearman, Chelsea Ruth, Laurence Katz, Marni Brownell. (Canada)

8:30 AM

Identifying Off-Label Pharmaceutical Company Promotion of Opioids for Cancer Pain Management [394]

Shelley A. Jazowski, Stephen Patrick, Stacie B Dusetzina. (United States)

8:45 AM

Using Trajectory Models to Assess Effect of Hydrocodone Up-Scheduling on Chronic Opioid Users [395]

Irene B. Murimi, Hsien-Yen Chang, Christopher M. Jones, Mark Bicket, G. Caleb Alexander. (United States)

9:00 AM

Predictors of Opioid Tapering Success [396]

David H. Smith, Jennifer Kuntz, John F. Dickerson, Xiuhai Yang, Lynn L. DeBar, Lou Ann Thorsness, Jennifer L. Schneider, Allison J. Firemark, Dea Papajorgji-Taylor, Mark D. Sullivan. (United States)

9:15 AM

Assessing Association Between Cash Payment and Potential Opioid Misuse Among Patients on Chronic Opioid Therapy [397]

Hilary A Aroke, Xuerong Wen, Ashley L Buchanan, Stephen S Kogut. (United States)



9:30 AM – 10:00 AM
Break/Posters/Exhibits
Congress Foyer 2 & 3ABC

10:00 AM – 11:30 AM
Plenary Session
Congress Hall

Machine Learning and Artificial Intelligence – Opportunities for Pharmacoepidemiology?

Data science has emerged as a new discipline with growing impact. It has links and overlaps with epidemiology, and there are areas of possible synergy. An important characteristic of data science is its open embrace of novel computational and analytical approaches such as machine learning and artificial intelligence.

The objectives of this session are to illustrate what machine learning and artificial intelligence have recently achieved in other domains, to share experiences of their application in the analysis of real-world evidence, and to discuss barriers and success factors for their use to achieve better patient outcomes

While artificial neural networks have been known and used for decades, recent years have seen a surge in performance following improved computational power and theoretical developments, which have inspired a new class of so-called deep neural networks. These have been found to outperform human reviewers on classification tasks such as image and speech recognition. At the same time, these methods are typically applied in the setting of supervised learning which requires large amounts of reliable training data that will often be hard to come by in our domain, and any use of complex predictive models in a medical context requires extra care.

Speakers

John Rigg, Senior Principal, Predictive Analytics, IQVIA: *The Future of Healthcare – How Machine Learning May Enhance Our Analysis of Real-World Evidence*

Johan Ellenius, Senior Researcher and Team Manager, Uppsala Monitoring Centre: *Barriers and Success Factors for Machine Learning to Improve Patient Outcomes*

11:30 AM – 1:00 PM
Lunch/Poster Session B/Exhibits
Congress Foyer 2 & 3ABC

12:00 PM – 1:00 PM
Committee Meetings
(Open to all participants)

- ◆ Development Club C
- ◆ Global Development Zoom
- ◆ History & Archives Club H
- ◆ Publications & Communications Terrace 2A
- ◆ Public Policy Terrace 2B

12:15 PM – 1:15 AM
Spotlight Poster Session B:

- ◆ Benefit Risk Assessment Communication & Evaluation (BACE)
- ◆ Databases
- ◆ Drug Utilization Research
- ◆ Medical Devices
- ◆ Rare Disease

Congress Foyer 3A

1:00 PM – 2:30 PM

CONCURRENT SESSIONS: ORAL PRESENTATIONS

Oral Bisphosphonates & Osteoporosis

Congress Hall

Moderator: **Charles Leonard & Ursula Kirchmayer**

1:00 PM

Comparative Safety and Effectiveness of Alendronate versus Raloxifene in Women With Osteoporosis [398]

Yuxi Tian, Yeeseuk Kim, Jianxiao Yang, Vojtech Huser, Peng Jin, Christophe Lambert, Hojun Park, Rae Woong Park, Peter Rijnbeek, Mui Van Zandt, Rohit Vashisht, Yonghui Wu, Seng Chan You, Jon Duke, George Hripcsak, David Madigan, Christian Reich, Nigam Shah, Patrick Ryan, Martijn Schuemie, Marc Suchard. (United States)

1:15 PM

The Effect of Oral Bisphosphonates on Acute Kidney Injury, Gastrointestinal Events and Hypocalcaemia in Patients With Chronic Kidney Disease [399]

M Sanni Ali, Danielle E Robinson, Natalia Pallares, Christian Tebe, Cyrus Cooper, Bo Abrahamsen, Fergus Caskey, Yoav Ben-Shlomo, Antonella Delmestri, Andrew Judge, M Kassim Javaid, Adolfo Diez-perez, Daniel Prieto-Alhambra. (United Kingdom)

1:30 PM

Risk of Age-Related Macular Degeneration and Cataract Surgery After Initiation of Denosumab versus Zoledronic Acid for Osteoporosis: a Multi-Database Cohort Study [400]

Yin Zhu Jin, Theodore N Tsacogianis, Miin Roh, Sangshin Park, Nam-Kyong Choi, Seoyoung Kim. (United States)

1:45 PM

Oral Bisphosphonate Use and All-Cause Mortality in Patients With Advanced (stage IIIB+) Chronic Kidney Disease: a Propensity Score Analysis [401]

Dunia Alarkawi, Dana Bliuc, Natalia Pallares, Cristian Tebe, Cyrus Cooper, Fergus Caskey, Yoav Ben-Shlomo, Andrew Judge, Kassim Javaid, Adolfo Diez-Perez, Jacqueline Center, A/Prof. Daniel Prieto-Alhambra. (United Kingdom)

2:00 PM

Oral Bisphosphonate Use and Latent Class Trajectories of Kidney Function: a Cohort Study [402]

Victoria Y Strauss, Danielle E Robinson, M Sanni Ali, Laurie Tomlinson, Cyrus Cooper, Fergus Caskey, Yoav Ben-Shlomo, Antonella Delmestri, Andrew Judge, M Kassim Javaid, Daniel Prieto-Alhambra. (United Kingdom)

2:15 PM

Comparative Cardiovascular Safety of Strontium Ranelate and Bisphosphonates Amongst Patients With No Contraindications: a Multi-Database Study in 5 EU Countries by the EU-ADR Alliance [403]

M Sanni Ali, Klara Berencsi, Karine Marnier, Nicolas Deltour, Lars Pedersen, Peter Rijnbeek, Francesco Lapi, Monica Simonetti, Miriam Sturkenboom, Johan Van der Lei, Johan Van der Lei, Daniel Prieto-Alhambra. (United Kingdom)



CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

1:00 PM – 2:30 PM

Risky Business: Benefit Risk Assessment and Risk Minimization

Panorama Hall

Moderators: Rachel Sobel, FISPE & Rachel DiSantostefano

1:00 PM

Use of Real-World Evidence in Personalized Benefit Risk Assessment: Closing the Knowledge Gap [404]

Cathy Anne Pinto, Tommi Tervonen, Kevin Marsh, Dimitra Lambrelli, Anna Schultze, Andy Tershakovec, Johanna Hyacinthe, Thibaud Prawitz, Tarek Hammad. (United States)

1:15 PM

Quality of Reporting on Risk Minimization Evaluation Studies: a Systematic Review [405]

Andrea M Russell, Rebecca J Mullen, Elaine H Morrato, Meredith Y Smith. (United States)

1:30 PM

Impact of Schedule IV Controlled Substance Classification on the Use of Carisoprodol in the United States [406]

Yan Li, Chris Delcher, Joshua Brown, Gary M. Reisfield, Yu-Jung Wei, Xi Wang, Almut G. Winterstein. (United States)

1:45 PM

Impact of Risk Evaluation and Mitigation Strategies (REMS) on Erythropoiesis Stimulating Agent Use [407]

Mengdong He, Joshua J. Gagne, Aaron S. Kesselheim, Ameet Sarpatwari. (United States)

2:00 PM

Impact of Risk Minimisation Measures on the Use of Strontium Ranelate: a Multi-National Cohort Study in 5 EU Countries by the EU-ADR Alliance [408]

Klara Berencsi, M Sanni Ali, Karine Marinier, Nicolas Deltour, Samuel Hawley, Lars Pedersen, Peter Rijnbeek, Johan Van der Lei, Francesco Lapi, Monica Simonetti, Carlen Reyes, Miriam Sturkenboom, Daniel Prieto-Alhambra. (United Kingdom)

2:15 PM

FDA's Risk Evaluation and Mitigation Strategy (REMS) for Transmucosal Immediate Release Fentanyl (TIRFS) [409]

Jeffrey E. Rollman, James Heyward, G. Caleb Alexander. (United States)

Inflammatory Guidance: Burden, Costs, and Outcomes of Autoimmune Diseases

South Hall 1 AB

Moderators: Helga Gardarsdottir, FISPE, & Stella Blackburn, FISPE

1:00 PM

Prevalence of Systemic Sclerosis in Europe and North-America: Reducing Uncertainty for Improving Decision Making [410]

Laura Perez, Sandro Gsteiger. (Switzerland)

1:15 PM

Moderate and Severe Systemic Lupus Erythematosus Is Associated With Greater Health Care Utilization and Costs: Analysis of the Integrated Optum Claims Data 2011-2015 [411]

Irene B. Murimi, Dora H. Lin, Jonathan C Tierce, Xia Wang, Henk Nab, Barnabas Desta, G. Caleb Alexander, Edward R. Hammond. (United States)

1:30 PM

Prediction of Cardiovascular Events in Rheumatoid Arthritis Patients Using a Multibiomarker of Disease Activity [412]

Fenglong Xie, Lang Chen, Huifeng Yun, Jeffrey R Curtis. (United States)

1:45 PM

Propensity Score Methods: The Study of the Effect of β -Interferon and Glatiramer Acetate on Multiple Sclerosis Disability [413]

Mathilde Lefort, Gilles Edan, Emmanuelle Leray. (France)

2:00 PM

Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients according to Concomitant Glucocorticoid and Methotrexate Use [414]

Jeffrey R Curtis, Fenglong Xie, Lang Chen, Huifeng Yun, Sasha Bernatsky, Kevin Winthrop. (United States)

2:15 PM

Marginal Structure Modeling of Association Between Disease Activity and Hospitalized Infection Among Patients in a Rheumatoid Arthritis Registry [415]

Huifeng Yun, Lang Chen, Jason Roy, Jeffrey D Greenberg, Jeffrey R Curtis. (United States)

SUBMIT YOUR RESEARCH NOW

Patient Related Outcome Measures

www.dovepress.com/patient-related-outcome-measures-journal

Co-Editor-in-Chief: Dr Robert H Hlowland (USA)

Co-Editor-in-Chief: Dr Liana Castel (USA)

Associate Editor: Dr Lynne Nemeth (USA)

Patient Related Outcome Measures is an international, peer reviewed, open access journal focusing on treatment outcomes specifically relevant to patients. All aspects of patient care are addressed within the journal and practitioners from all disciplines are invited to submit their work as well as healthcare researchers and patient support groups.

Patient Related Outcome Measures endorses the COSMIN, STARD, PRISMA and RECORD statements.

The journal is indexed in PubMed, PMC, ESCI, DOAJ, OAlster.



BENEFITS OF PUBLISHING WITH DOVE MEDICAL PRESS

- » Rapid & Responsive Publication
- » On avg 26 business days to first decision
- » Open Access & Peer-Reviewed
- » Indexed
- » International Readership
- » Global readership with over 460,000 visits a month
- » Video Abstracts
- » Article Collections
- » Publication Analytics & Allmetrics
- » Dove Medical Press is part of Taylor & Francis and is affiliated with OASPA, COPE and HINARI

Clinical Epidemiology

www.dovepress.com/clinical-epidemiology-journal

IMPACT
FACTOR
3.799

Editor-in-Chief: Professor Henrik Toll Sørensen (DEN)

Associate Editors: Dr Vera Ehrenstein (DEN), Dr Irene Petersen (UK), Professor Lars Pedersen (DEN)

Clinical Epidemiology is an international, peer reviewed, open access journal, focusing on the application of epidemiological principles and questions relating to patients and clinical care in terms of prevention, diagnosis, prognosis, and treatment. *Clinical Epidemiology* endorses the PRISMA, STROBE and RECORD statements.

The journal is indexed in PubMed, PMC, Embase, Scopus, DOAJ, OAlster, SciSearch, Journal Citation Reports

Dovepress

www.dovepress.com
Part of Taylor & Francis

 facebook.com/DoveMedicalPress

 @Dovepress

 linkedin.com/company/dove-medical-press

Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC. Company registration number: 4067256. Registered in England and Wales. Registered address: 5 Haverhill Place, London, SE11P. Information Number: GB 334 5642 20



1:00 PM – 2:30 PM

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Geriatric Management and Measurements

South Hall 2A

Moderators: Jodi Segal, FISPE & Jennifer Lund

1:00 PM

Cognitive and Other Neuropsychological Assessments Documented in Electronic Health Records Prior to Or at Alzheimer's Disease Diagnosis [416]

Nancy N. Maserejian, Jin Wang, Henry Krzywy, Maneesh Juneja, Judith Jaeger. (United States)

1:15 PM

Improving Claims-Based Frailty Prediction in the Medicare Population Using STOPPFrail Drug Criteria [417]

Sophie E Mayer, Virginia Pate, Laura C Hanson, Michele Jonsson Funk, Keturah R Faurot, Til Stürmer, Jennifer L Lund. (United States)

1:30 PM

Anticholinergic Safety in US Nursing Home Residents With Dementia: Risk of Delirium and Mortality [418]

Izumi Sato, Isao Iwata, Tobias Gerhard, Stephen Crystal, Daniel B Horton, Soko Setoguchi. (United States)

1:45 PM

Can Treatments for Hypertension Be Repurposed for the Treatment of Dementia? [419]

Venexia M Walker, Neil M Davies, Patrick G Kehoe, Richard M Martin. (United Kingdom)

2:00 PM

Effect of Bisphosphonates on Nonvertebral Fracture Among Older Nursing Home Residents [420]

Andrew R Zullo, Yoojin Lee, Tingting Zhang, Kevin W McConeghy, Lori A Daiello, Douglas P. Kiel, Vincent Mor, Sarah D. Berry. (United States)

2:15 PM

Medication Appropriateness for Elderly Nursing Home Residents With a Limited Remaining Life Expectancy: Adjusting the Start/Stop Criteria by Means of a Delphi Consensus Study [421]

C A Pouw, M Smalbrugge, C M Hertogh, R J van Marum, Jacqueline G Hugtenburg. (Netherlands)

Pediatric Potpourri

South Hall 2B

Moderators: Andrea Margulis & Susan dosReis, FISPE

1:00 PM

Association Between Azathioprine Use and Risk of Acute Pancreatitis in Pediatric Inflammatory Bowel Disease: a Nationwide Swedish Cohort Study [422]

Viktor Wintzell, Henrik Svanström, Ola Olén, Mads Melbye, Jonas F Ludvigsson, Björn Pasternak. (Sweden)

1:15 PM

Cost Effectiveness of Early Treatment in Pediatric Patients With Hepatitis C Virus Infection [423]

Joehl T Nguyen, A. Sidney Barritt, Ravi Jhaveri. (United States)

1:30 PM

A Statistical Model of RSV Disease in Neonates and Efficacy Prediction for Maternal Vaccines [424]

Bing Cai, Yili Chen, Meichun Ding, Yasmeen Agositi, Kena A Swanson, Beate Schmoele-Thoma, William C Gruber, Philip R Dormitzer. (United States)

1:45 PM

Association Between Oseltamivir and Suicide Among Children: a Case-Crossover Study [425]

Rachel L Harrington, Sruthi Adimadhyam, Todd A Lee, Glen T Schumock, James W Antoon. (United States)

2:00 PM

Gabapentin Use for Hospitalized Neonates [426]

Hibo Abdi, Nathalie L Maitre, Kristen L Benninger, Jonathan L Slaughter. (United States)

2:15 PM

Relational Patient-Provider Continuity of Care and the Risk of Emergency Department Use Among U.S. Medicaid-Insured Youth With Mental Health Diagnosis [427]

Dinci Pennap, Julie M. Zito, Eberechukwu O. Onukwugha. (United States)



1:00 PM – 2:30 PM

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Your Pills, Your Cancer Risk

South Hall 3A

Moderators: Patrick Blin & Thomas Ahern

1:00 PM

Breast Cancer Risk in Chronic Users of Phthalate-Containing Medications: a Danish Nationwide Cohort Study [428]

Thomas P. Ahern, Deirdre Cronin-Fenton, Anne Broe, Sinna P. Ulrichsen, Bernard F. Cole, Timothy L. Lash, Peer M. Christiansen, Henrik Toft Sørensen, Rulla M. Tamimi, Per Damkier. (United States)

1:15 PM

Use of Vitamin K Antagonists and Prostate Cancer Risk: a Danish Nationwide Study [429]

Kasper Bruun Kristensen, Patricia Hjorslev Jensen, Charlotte Skriver, Søren Friis, Anton Pottegård. (Denmark)

1:30 PM

Use of Valproic Acid and Risk of Skin Cancer [430]

Kasper Bruun Kristensen, Sidsel Arnspang Pedersen, Sigrun Alba Schmidt, Anton Pottegård. (Dominica)

1:45 PM

Testosterone Supplementation in Relation to Prostate Cancer in a US Commercially-Insured Claims Database [431]

Daniel C Beachler, Lauren E Parlett, Stephan Lanes, Robert N Hoover, Michael B Cook. (United States)

2:00 PM

Use of Proton Pump Inhibitors and Risk of Pancreatic Cancer [432]

Blánaid Hicks, Søren Friis, Anton Pottegård. (United Kingdom)

2:15 PM

Development of Predictive Models to Identify Advanced-Stage Cancer Patients in a US Administrative Claims Database [433]

Daina Esposito, Leo Russo, Francois-Xavier Lamy, Ruihua Yin, Vibha Desai, Patrice Verpillat, Jose Peñalvo, Dina Oksen, Stephan Lanes. (United States)

2:35 PM – 3:30 PM

Annual Meeting of ISPE Members & Awards Ceremony

Congress Hall

Annual Meeting

- ◆ Call to Order & Presidential Address
Jesper Hallas, FISPE, President
- ◆ Financial Report
Tobias Gerhard, FISPE, Vice President Finance
- ◆ New Business

Awards Ceremony

- ◆ **The Ronald D. Mann Best Paper Awards for Manuscripts Published in *Pharmacoepidemiology and Drug Safety (PDS)*, 2017, Vol.25**
 - ◆ **Presenters**
Brian Strom, FISPE, Editor-in-Chief
Vincent Lo Re, III, FISPE, Regional Editor for the Americas
Hubert GM Leufkens, FISPE, Regional Editor for Europe
Byung Joo Park, FISPE, Regional Editor for Asia-Pacific & ROW
Leah Webster, Journals Publishing Manager, Health Sciences, Wiley
 - ◆ **Honorable Mentions**
The Effect of Statins on Influenza-Like Illness Morbidity and Mortality
Paul Brassard, Jennifer W. Wu, Pierre Ernst, Sophie Dell'Aniello, Brielan Smiechowski, Samy Suissa
Relative Preferences in the Abuse of Immediate-Release vs. Extended-Release Opioids in A Sample of Treatment-Seeking Opioid Abusers
Theodore J. Cicero, Matthew S. Ellis, Zachary A. Kasper

The Feasibility of Using Multiple Databases to Study Rare Outcomes: The Potential Effect of Long-Acting Beta Agonists With Inhaled Corticosteroid Therapy on Asthma Mortality

Catherine B. Johannes, Lisa J. McQuay, Kirk D. Midkiff, Brian Calingaert, Elizabeth B. Andrews, Patricia Tennis, Jeffrey S. Brown, Carlos A. Camargo, Jr., Rachael L. DiSantostefano, Kenneth J. Rothman, Til Stürmer, Stephan Lanes, Kourtney J. Davis

Impact of an Opioid Risk Reduction Initiative on Motor Vehicle Crash Risk Among Chronic Opioid Therapy Patients

Ryan N. Hansen, Rod L. Walker, Susan M. Shortreed, Sascha Dublin, Kathleen Saunders, Evette J. Ludman, Michael Von Korff

- ◆ **First Prize**
Prevalent New-User Cohort Designs For Comparative Drug Effect Studies
Samy Suissa, Erica E. M. Moodie, Sophie Dell'Aniello

ISPE Awards

- ◆ **Sustained Service Award**
Keith Beard, FISPE Ulf Bergman, FISPE
Stephen JW Evans, FISPE Allen Mitchell, FISPE
- ◆ **Distinguished Service Award**
Yola Moride, FISPE



2:35 PM – 3:30 PM

Annual Meeting of ISPE Members & Awards Ceremony (continued)

Congress Hall

ICPE 2018 Awards

◆ The Andrew McAfee Award

(Best abstract submitted from a researcher or student/post-doc living in a developing country)

Wenchao Lu, Peking University School of Pharmaceutical Sciences, *GLP-1RAs and Risk of Diabetic Retinopathy: Analysis of the FDA Adverse Event Reporting System Database*

◆ The John Snow Award

(Best abstract submitted by a female researcher or student living in a developing country)

Fu Mengyuan, Peking University Health Science Center, *Utilization of Antibiotics for Patients With Acute Upper Respiratory Tract Infections at Community Health Care Institutions in Beijing*

◆ Student Awards

◆ Best Methods Award

Katsiaryna Bykov, Harvard T. H. Chan School of Public Health, *The Case-Crossover Design for Drug Interaction Studies: Interaction Term Model versus a Novel Fully Saturated Model*

◆ Third Best Abstract

Suzanne Landi, UNC-Chapel Hill, *Child Growth and Developmental Outcomes Following In-Utero Exposure to Metformin versus Insulin for Treatment of Gestational Diabetes*

◆ Second Best Abstract

Antonios Douros, McGill University, *Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Liver Injury*

◆ The Stanley A. Edlavitch Award

(Best Abstract Submitted by A Student/Post-Doc)

Maja Hellfritzscht Poulsen, University of Southern Denmark

Short-Term Risk of Bleeding, Ischemic Stroke, and Death in Patients With Atrial Fibrillation Switching Between Oral Anticoagulants: a Case-Crossover Study [434]

Maja Hellfritzscht, Shirley V Wang, Erik L Grove, Joshua J Gagne, Jesper Hallas, Anton Pottegård. (Denmark)

◆ Induction of ISPE Fellows

Dorothee B. Bartels
Bruce Carleton
Susan dosReis
Helga Gardarsdottir
Christian Hampp
Amalia M. Issa

Michele Jonsson-Funk
Olaf Klungel
David Miller
Daniel Prieto-Alhambra
Jodi Beth Segal
Sengwee Darren Toh

ISPE Board Transition

◆ Retiring Board Members & Officers

Morten Andersen
Wan-Ting Huang
Vincent Lo Re, FISPE
Sabine Straus
Tobias Gerhard, FISPE
Kiyoshi Kubota, FISPE

◆ Induction of New Directors

Vera Ehrenstein, Academic (Europe/Africa)
Sengwee Darren Toh, FISPE, Academic (Americas)
Chieko Ishiguro, Government/Regulatory (Asia/Pacific)
Malcolm Maclure, Government/Regulatory (Americas)
Pia Caduff-Janosa, Government/Regulatory (Europe/Africa)


◆ Installation of 2018-2019 Officers

Almut G. Winterstein, FISPE, President Elect
Krista Huybrechts, FISPE, Vice President Finance
Jesper Hallas, FISPE, Immediate Past President
Alison Bourke, FISPE, President

Adjournment of Meeting

**Our mission is clear.
We are pioneers in neuroscience.**

We're proud
to support the
**34th Annual International
Conference of
Pharmacoepidemiology
and Therapeutic Risk
Management**



Caring Deeply. Working Fearlessly. Changing Lives.™

Founded in 1978, Biogen is one of the world's oldest independent biotechnology companies.

www.biogen.com



Big data. Bigger analytics.

Research can be a strenuous task, but finding answers in your data set doesn't have to be. With de-identified, patient-level claims and EMR data for the same patients in one dataset, IBM Watson Health™ can help ease your research burden.

Data + analytics = accelerated discovery

By utilizing our cloud-based analytic platform with the IBM® MarketScan® Explorys® Claims EMR Data Set, you can access the data and search for answers without the need for data intake, software, or programming skills.

Stop by booth #11/12 for a demonstration of how using our newest linked data set along with IBM® MarketScan® Treatment Pathways can help you work faster and smarter. When you're at this booth, ask us about exciting new updates to the IBM® Explorys® EHR Data Set and Treatment Pathways.

Also, learn how our complete suite of life sciences solutions can help you develop an effective strategy and compelling portfolio of research to maximize your product's value.

to schedule a meeting or see a demonstration at ICIPE,
visit ibm.biz/IBMWH_2018ICPE



© Copyright IBM Corp. 2018. IBM, the IBM logo, and Watson are trademarks of IBM Corporation in the United States and other countries. Other trademarks and service marks are the property of their respective owners. 18-17225-0713



3:30 PM 4:00 PM

Break/Posters/Exhibits

Congress Foyer 2 & 3ABC

4:00 PM – 5:30 PM

CONCURRENT SESSIONS: SYMPOSIA AND WORKSHOPS

4:00 PM

Moving From RECORD to CORD - Guidelines for Conducting Research Using Routinely-Collected Health Data [435]

Congress Hall

Sinead Langan, Liam Smeeth, Henrik Sorensen, Eric Benchimol. (United Kingdom)

Sponsored by the Database Special Interest Group

4:00 PM

Pharmacoepidemiology in Eastern Europe - A EuroDURG/SIG-DUR Symposium Dedicated to The Late MUDr. Ludvik Štika [436]

Panorama Hall

Ulf Bergman, Jiri Vlcek, Vera Vlahovic-Palcevski, Jolanta Gulbinovic, Björn Wettermark. (Sweden)

4:00 PM

Ten Years of ENCePP. Time to Celebrate and Move Forward [437]

South Hall 1AB

Alejandro Arana, Xavier Kurz, Susana Pérez-Gutthann, Laura Yates, Gianluca Trifiró, Sebastian Schneeweis, Patrice Verpillat, Jiri Vlcek. (Spain)

4:00 PM

When And Where To Use Blinding In Pragmatic Randomized Clinical Trials [438]

South Hall 2A

Jennifer B Christian, Emily S. Brouwer, Kourtney J. Davis, Dimitri Bennett, Nancy A. Dreyer, Cynthia J. Girman. (United States)

4:00 PM

Patient-Focused Benefit Risk Assessment: Why, When and How Should Epidemiologists Get Involved [439]

South Hall 2B

Rachael L DiSantostefano, Leo Russo, Kevin Marsh, Alison Cave, Brett Hauber, Elizabeth Andrews. (United States)

5:30 PM – 6:30 PM

Council & EuroDURG Meetings (Open to all participants)

Academic Council

Panorama Hall

Government/Regulatory Council

South Hall 1 AB

Industry/Service Providers Council

South Hall 2A

Student Council & Chapter

South Hall 2B

EuroDURG Meeting (Open to all participants.)

South Hall 3A

7:30 PM – 11:30 PM

Social Evening at the Municipal House

Join ISPE members for an evening of food, music, networking and dancing.

Full ICPE registration includes:

- ◆ Admission to the Municipal House by badge or ticket (guests)
- ◆ Food
- ◆ Entertainment
- ◆ Transportation. Buses will shuttle between the Prague Congress Centre and the Municipal House with the first bus departing from Entrance 10 at 7:00pm.

A cash bar will be available.





7:00 AM – 8:00 AM

Poster Session C & Spotlight Session C Set-up

Congress Foyer 2A (Poster Session) & Congress Foyer 3A (Spotlight)

7:00 AM – 8:15 AM

Coffee & Tea

Congress Foyer 2 & 3ABC

7:00 AM – 3:30 PM

Speaker Ready Room Room 2.1

**Please arrive 24 hours before your presentation start time to upload or check your presentation.*

7:00 AM – 4:30 PM

Registration

Congress Foyer 0

8:00 AM – 1:45 PM

Exhibits/Posters Session C

Congress Foyer 2 & 3ABC

8:30 AM – 10:00 AM

CONCURRENT SESSIONS: ORAL PRESENTATIONS

A Methods Stew

Congress Hall

Moderators: Robert Platt & Soko Setoguchi, FISPE

8:30 AM

Statins and All-Cause Mortality Among Patients With Heart Failure: Minimizing Immeasurable Time Bias in the Setting of a Nested Case-Control Study [750]

In-sun Oh, Kristian B. Filion, Ju-young Shin. (Korea, Republic of)

8:45 AM

A Word of Caution: All-Cause Mortality and Residual Confounding in Medicare Claims Data [751]

Xabier García-Albéniz, John Hsu, Miguel A Hernán. (Spain)

9:00 AM

Use of Real-World Evidence in Personalized Benefit-Risk Assessment: Detecting Treatment Patterns Using Gaussian Mixture Models [752]

Tommi Tervonen, Cathy Anne Pinto, Kevin Marsh, Dimitra Lambrelli, Anna Schultze, Thibaud Prawitz, Andrew Tershakovec, Tarek A Hammad. (United Kingdom)

9:15 AM

The Use of Propensity Score Distributions to Gain Understanding on Drug Utilization in Routine Clinical Practice: a Case Study on Newer vs Older Oral Anticoagulants [753]

Clementine Nordon, Lucien Abenhaim, Lamiae Grimaldi-Bensouda. (France)

9:30 AM

Observational Studies on Non-Specific Effects (NSE) of Diphtheria-Tetanus-Pertussis Vaccination (DTP) in Low-Income Countries: Assessing the Impact of Bias and Confounding by Using Meta-Regression [754]

Kaatje Bollaerts, Thomas Verstraeten, Catherine Cohet. (Belgium)

9:45 AM

Quantification of Unmeasured Confounding in a Post-Marketing Drug Monitoring Program [755]

Elisabetta Patorno, Chandrasekar Gopalakrishnan, Kimberly G Brodovicz, Andrea Meyers, Dorothee B Bartels, Julie Barberio, Jun Liu, Sebastian Schneeweiss. (United States)



Figure on Charles Bridge



8:30 AM – 10:00 AM

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Yearning to Dig Deep: Adventures in Data Mining

Panorama Hall

Moderators: Gianluca Trifiro & Daniel Prieto-Alhambra, FISPE

8:30 AM

Deep Learning to Detect Features of a Population of Anti-Osteoporosis Drug Users [756]

Sara Khalid, M Sanni Ali, Peter Rijnbeek, Daniel Prieto-Alhambra. (United Kingdom)

8:45 AM

Does Hyperparameter Tuning Improve the Performance of Super Learning for Predicting When Antidepressants Are Prescribed for Indications Other Than Depression? [757]

Jenna Wong, Travis Manderson, Michal Abrahamowicz, David Buckeridge, Robyn Tamblyn. (United States)

9:00 AM

Signal Detection Using Tree-Temporal Scan Statistics in the Sentinel System [758]

Judith C. Maro, Michael D. Nguyen, Rima Izem, Ya-Hui Hsueh, Inna Dashevsky, Austin Cosgrove, S. Christopher Jones, Jacqueline M. Major, Esther H. Zhou, Elande Baro, Joshua J. Gagne, Shirley V. Wang, Martin Kulldorff. (United States)

9:15 AM

Data Mining for Adverse Drug Events With a Propensity Score Matched Tree-Based Scan Statistic [759]

Shirley V Wang, Judith C Maro, Elande Baro, Rima Izem, Inna Dashevsky, James R Rogers, Michael Nguyen, Joshua J Gagne, Elisabetta Patorno, Krista F Huybrechts, Jacqueline M Major, Esther Zhou, Megan Reidy, Austin Cosgrove, Sebastian Schneeweiss, Martin Kulldorff. (United States)

9:30 AM

Probabilistic Record Linkage to Detect Duplicated Content in Twitter Prior to Pharmacovigilance Analyses [760]

Tomas Bergvall, Lucie Gattepaille, Sara Vidlin, Niklas Norén. (Sweden)

9:45 AM

Time-To-Onset in Statistical Signal Detection of ADRs: a Follow-Up Study [761]

Joep Scholl, Florence van Hunsel, Eelko Hak, Eugène van Puijenbroek. (Netherlands)

Renal Outcomes and Safety

South Hall 1 AB

Moderators: Daniel Mines & Yea-Huei Kao Yang, FISPE

8:30 AM

Risk and Prognosis of Acute Kidney Injury in Bisphosphonate Users Undergoing Hip Fracture Surgery [762]

Christian Fynbo Christiansen, Nisha Shetty, Uffe Heide-Jørgensen, Henrik Toft Sørensen, Vera Ehrenstein, Alma Becic Pedersen. (Denmark)

8:45 AM

Optimal Plasma Potassium Ranges for Mortality Prediction Across Chronic Kidney Disease Stages; the Stockholm Creatinine Measurements (Scream) Project [763]

Hairong Xu, Alessandro Gasparini, Marie Evans, Juan-Jesus Carrero. (United States)

9:00 AM

Influence of Statin Potency on the Risk of Renal Failure - a Nationwide Cohort Study Using Laboratory Data [764]

Anna Citarella, Marie Linder, Simona Cammarota, Anders Sundström, Helle Kieler. (Italy)

9:15 AM

Tacrolimus Pharmacogenetics and Acute Kidney Injury After Lung Transplantation [765]

Todd Miano, Judd Flesch, Joshua Diamond, Jason Christie, Rui Feng, Caitlin Forker, Melanie Brown, Michelle Oyster, Edward Cantu, Mary Porteus, Laurel Kalman, Melanie Rushefski, Russel Localio, Michael Shashaty. (United States)

9:30 AM

Comparative Safety of Calcium-Free Phosphate Binders Vs Calcium-Based Phosphate Binders in Patients With End-Stage Renal Disease Requiring Maintenance Hemodialysis [766]

Julia Spoendlin, Julie M Paik, Theodore Tsacogianis, Seoyoung C Kim, Sebastian Schneeweiss, Rishi J Desai. (United States)

9:45 AM

Lithium Treatment and Risk of Chronic Kidney Disease - a Danish Population-Based Case-Control Study [767]

Daniel P Henriksen, Anton Pottegård, Jesper Hallas, Mads Nybo, Per Damkier. (Denmark)



8:30 AM – 10:00 AM

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Drugs in Pregnancy - Metformin, Vareniclin, OCs, Methods

South Hall 2A

Moderators: Sascha Dublin & Angela Lupattelli

8:30 AM

Metformin versus Insulin for Initial Treatment of Gestational Diabetes: Maternal and Neonatal Outcomes [768]

Suzanne Landi, Sarah Radke, Kim Boggess, Stephanie M Engel, Til Stürmer, Anne S Howe, Michele Jonsson Funk. (United States)

8:45 AM

Child Growth and Developmental Outcomes Following In-Utero Exposure to Metformin versus Insulin for Treatment of Gestational Diabetes [769]

Suzanne N Landi, Sarah Radke, Stephanie M Engel, Til Stürmer, Kim Boggess, Anne S Howe, Michele Jonsson Funk. (United States)

Student Award Recipient – Third Best Abstract Submitted by a Student/Post-Doc

9:00 AM

First Trimester Exposure to Varenicline Was Not Associated With Increased Risk of Major Birth Defects: Findings From the Smoking Mums (Maternal Use of Medications and Safety) Study [770]

Duong T Tran, David B Preen, Kristjana Einarsdottir, Anna Kemp-Casey, Deborah Randall, Stephanie Choi, Louisa R Jorm, Alys Havard. (Australia)

9:15 AM

Algorithms to Estimate the Timing of Pregnancy for Stillbirths in Pregnancy Safety Studies [771]

Anna Cantarutti, Brian T. Bateman, Sonia Hernández-Díaz, Kathryn J. Gray, Elisabetta Patorno, Giovanni Corrao, Rishi J. Desai, Krista Huybrechts. (Italy)

9:30 AM

The Impact of Naive Identification of Pregnancies on Cohort Inclusion and Misclassification of Person-Time in Insurance Claims Data [772]

Dana Y Teltsch, Natalia Petruski-Ivleva, Liza R. Gibbs, Emma R. Payne. (United States)

9:45 AM

Periconceptional Oral Contraceptive Use and Adverse Perinatal Outcomes: The Pride Study [773]

Marleen M. van Gelder, Ibtissam Mokadem, Marc E. Spaanderma, Nel Roeleveld. (Netherlands)

Keep Your Brain Under Control

South Hall 2B

Moderators: David Miller, FISPE, Marina Machado

8:30 AM

The Association Between Treatment With Systemic Prednisolone and Insomnia - a Symmetry Analysis [774]

Daniel P. Henriksen, Jesper Hallas. (Denmark)

8:45 AM

Safety of Baclofen for Alcohol Use Disorders: Comparison With Nalmefene, Acamprosate and Naltrexone in a Cohort Study of 165,334 Patients Between 2009 and 2015 in France [775]

Christophe Chaignot, Mahmoud Zureik, Gregoire Rey, Rosemary Dray-Spira, Joël Coste, Alain Weill. (France)

9:00 AM

Evaluating the Assumptions of the Self-Controlled Case Series Design in Studies Investigating the Risks of Antipsychotic Use in the Older Population [776]

Emmae Ramsay, Nicole Pratt, Anna Moffat, Lisa Kalisch-Ellett, Elizabeth Roughhead. (Australia)

9:15 AM

Comparative Effectiveness of Adjunctive Psychotropic Medications in Schizophrenia [777]

Tobias Gerhard, T. Scott Stroup, Stephen Crystal, Cecilia Huang, Zhiqiang Tan, Melanie A Wall, Chacku Mathai, Mark Olfson. (United States)

9:30 AM

Latent Class Analysis of Anticholinergic and Sedative Medication Use: a National Population Study [778]

Helene van der Meer, Hans Wouters, Martina Teichert, Fabienne Griens, Lisa Pont, Katja Taxis. (Netherlands)

9:45 AM

The Risk of Alzheimer's Disease Associated With Benzodiazepines and Related Drugs: a Nationwide Nested Case-Control Study [779]

Vesa Tapiainen, Heidi Taipale, Antti Tanskanen, Jari Tiihonen, Sirpa Hartikainen, Anna-Maija Tolppanen. (Finland)



8:30 AM – 10:00 AM

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Cancer Treatment, Lessons from Three Continents

South Hall 3A

Moderators: Lesley Wise & Jessica Jalbert

8:30 AM

Treatment for Older Diffuse Large B-Cell Lymphoma Patients With Cognitive Impairment and Dementia [780]

Christopher D. Saffore, Naomi Y. Ko, Holly M. Holmes, Pritesh R. Patel, Karen Sweiss, Sruthi Adimadhyam, Brian C. Chiu, Gregory S. Calip. (United States)

8:45 AM

Understanding Treatment Pathways for HER2-Positive Metastatic Breast Cancer (HER2+MBC) Patients: Analysis Using Group-Based Trajectory Models (GBTM) [781]

Benjamin Daniels, Sallie-Anne Pearson. (Australia)

9:00 AM

Potential for Using External Control Arms Derived From Electronic Health Records to Replace Control Arms From Randomized Controlled Trials [782]

Gillis Carrigan, Samuel Whipple, William B Capra, Michael D Taylor, Michael Lu, Brandon Arnieri, Jeffrey S Brown, Amy P Abernethy, Ryan Copping, Kenneth J Rothman. (United States)

9:15 AM

Using Group Based Trajectory Models and Propensity Score Weighting to Detect Heterogeneous Treatment Effects: The Case Study of Generic Hormonal Therapy for Women With Breast Cancer [783]

Aaron N Winn, Nicole Fergestrom, Joan M Neuner. (United States)

9:30 AM

Characterization of Chronic Lymphocytic Leukemia (CLL) Patients in Real-Life Clinical Practice in Helsinki, Finland 2005-2015 [784]

Vesa Lindström, Juha Mehtälä, Riho Klement, Amy Leval, Tiina Järvinen. (Finland)

9:45 AM

Developing a Model of Theory Based Behavioural Influences on Endocrine Therapy Medication Taking Behaviour in Women With Breast Cancer [785]

Caitriona Cahir, Stephan U Dombrowski, Linda Sharp, Kathleen Bennett. (Ireland)

10:00 AM – 10:30 AM

Break/Posters/Exhibits

Congress Foyer 2 & 3ABC

10:30 AM – 12:00 PM

CONCURRENT SESSIONS: SYMPOSIA AND WORKSHOPS

10:30 AM

Adventures in Replication: Initial Experiences related to the Joint ISPE/ISPOR Guidance [786]

Judith C. Maro, Shirley V. Wang, Robert W. Platt, Ting-Ying Huang, Xavier Kurz. (United States)

10:30 AM

Quantitative Benefit-Risk Assessment: Hands-On Workshop [787]

Quazi S Ataher, Douwe Postmus, Hans L. Hillege, Tommi Tervonen. (United States)

10:30 AM

It Takes a Village Part II: Workshop to Reconsider Core Competencies for New Generations in the Global and Rapidly Changing Community of Pharmacoepidemiology [788]

Soko Setoguchi, Paul Stang, Susana Perez-Gutthann, Frank May, Olaf Klungel, Brian Strom, Leyla Sahin, Pia Caduff, Wei Zhou, Jessica C Young, Chien Chou Su, Laura Hester, Yanmin Zhu, Carolyn Cesta, Mohammed Zabiuddin Ahad, Daniel Horton, Sonia Hernandez-Diaz. (United States)

10:30 AM

Increasing Access to Drug Utilization Data Globally: Developing an Action Plan [789]

Monique Elseviers, Ria Benko, Johanita Burger, Claudia Osorio-de-Castro, Frank May, Robert Vander Stichele, Veronika Wirtz, Katja Taxis, Björn Wettermark. (Belgium)

10:30 AM

Challenges and Potential of Vaccine Post-Licensure Benefit-Risk Assessments in Resource Limited Countries [790]

Daniel Weibel, Patrick Zuber, Alena Khromava, Abraham Oduro, Andy Stergachis, James Stark, Harry Seifert, Miriam Sturkenboom, Steve Black, Andrea Sutherland. (Netherlands)
Sponsored by the Vaccines Special Interest Group



12:00 PM – 1:30 PM

Lunch/Poster Session C/Exhibits

Congress Foyer 2 & 3ABC

12:00 PM – 1:30 PM

ISPE Board of Directors Luncheon

Terrace 2A

Open to ISPE members; members should contact info@pharmacoepi.org if they would like to attend.

12:15 PM – 1:15 PM

Spotlight Poster Session C

- ◆ Medications in Pregnancy & Lactation
- ◆ Molecular Epidemiology/ Biomarkers/Pharmacogenetics
- ◆ Oncology
- ◆ Pediatrics
- ◆ Vaccines

Congress Foyer 3A

1:30 PM – 3:00 PM

CONCURRENT SESSIONS: ORAL PRESENTATIONS

Comparative Effectiveness: Heart & Flow

Congress Hall

Moderators: Emily Brouwer & Annlouise Assaf, FISPE

1:30 PM

Drug-Drug Interaction of Non-Potassium-Sparing Diuretics and Laxatives Is Associated With Cardiovascular Mortality in Hypertension-Treated Subjects [791]

Liesa K Hoppe, Clarissa Muhlack, Hermann Brenner, Ben Schöttker. (Germany)

1:45 PM

The Use of Propensity Score Distributions to Gain Understanding on Drug Utilization in Routine Clinical Practice: a Case Study on Newer vs Older Antiplatelet Agents [792]

Clementine Nordon, Lucien Abenheim, Lamiae Grimaldi-Bensouda. (French Guiana)

2:00 PM

Preadmission Use of Aspirin Or Clopidogrel on Sepsis Outcome a Population-Based Cohort Study [793]

Chien-Chang Lee (Taiwan)

2:15 PM

Utilization and Clinical Outcomes of Ticagrelor in Patients Following Percutaneous Coronary Intervention [794]

Nicholas Belviso, Herbert Aronow, Marilyn Barbour, David Louis, Dhaval Kolte, Michelle Caetano, Xuerong Wen. (United States)

2:30 PM

Comparative Effectiveness of Prasugrel versus Ticagrelor for the Prevention of Cardiovascular Diseases in Patients With Acute Coronary Syndrome [795]

Ghadeer Dawwas, Eric Dietrich, David E Winchester, Almut G Winterstein, Richard Segal, Haesuk Park. (United States)

2:45 PM

Preventive Effects of Single and Dual Anti-Platelets Use on Long Term Survival Among Out Hospital Cardiac Arrest Survivors [796]

Dr. Szu-Ta Chen, Tzu-Chun Hsu, Chien-Chang Lee. (United States)



Powder Tower at Entrance to Old Town Prague



1:30 PM – 3:00 PM

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Drug Utilization Research: Making It Count

Panorama Hall

Moderators: **Katja Taxis & Luciane Lopes**

1:30 PM

Prescribing Antimicrobial Drugs for Urinary Tract Infections in Primary Care in the Netherlands [797]

Marlies Mulder, Esmee Baan, Annelies Verbon, Bruno Stricker, Katia Verhamme. (Netherlands)

1:45 PM

National Estimates for Gabapentin- and Pregabalin-Involved Deaths From 2010 to 2015 Using a Novel Data Resource [798]

Richard Swain, Alex Secora, Yulan Ding, James Trinidad, Jaqueline Puigbo, Jennie Wong, Rajdeep Gill, Cynthia Kornegay, Judy Staffa. (United States)

2:00 PM

Multi-Level Modelling to Investigate Factors Impacting Prescribing Variability [799]

Debabrata Roy, Lesley Wise, Saad Shakir. (United Kingdom)

2:15 PM

The Introduction of New Anticoagulation Therapy in the European Union: The Case of Rivaroxaban [800]

Irene Bezemer, Tania Schink, Luis Alberto García Rodríguez, Leif Friberg, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Pareen Vora, Ana Ruigómez, Ron Herings. (Netherlands)

2:30 PM

The Right-Rx Medication Reconciliation Trial: Impact on Potential Adverse Drug Events [801]

Robyn Tamblyn, Allen R Huang, Aude Motulsky, Ari N Meguerditchian, Nancy E Winslade, David L Buckeridge, Alan Forster, Todd Lee, Andre Bonnici, Isabelle Couture. (Canada)

2:45 PM

Evaluation of Switching Patterns in Fda'S Sentinel System - a New Tool to Assess the Substitutability of Generic Drugs [802]

Dr. Sarah K Dutcher, Jennifer R Popovic, Michael Nguyen, Sukhminder K Sandhu, Patty Greene, Rima Izem, Wenlei Jiang, Zhong Wang, Yueqin Zhao, Andrew B Petrone, Anita K Wagner, Joshua J Gagne. (United States)

To Be or Not To Be: Is It Really Valid?

South Hall 1 AB

Moderators: **Kevin Haynes, FISPE & Katherine Donegan**

1:30 PM

Early Lessons on ICD-10-CM/PCS Transition in Claims-Based Drug Safety Assessments [803]

Ting-Ying Huang, Emily C Welch, Margie Goulding, David J Graham, Rongmei Zhang, Marie Bradley. (United States)

1:45 PM

Intussusception Risk After Pentavalent Rotavirus Vaccination in Finnish Infants: Validity Study Comparing Results From Patient File Verified and Register-Based Data in Finland [804]

Dr. Miia Artama, Tuomo Nieminen, Jukka Jokinen, Tuija Leino, Arto Palmu. (Finland)

2:00 PM

Validation of Transfusion Administrations Among Potential Transfusion-Related Acute Lung Injury (TRALI) Patients Included in the Sentinel Distributed Database [805]

Mayura U Shinde, Meghan A Baker, Caren Spencer-Smith, Lesley H Curtis, Steven A Anderson, Austin Cosgrove, Richard Forshee, Jason Hickok, Adele Kennedy, David J Mohlman, Mikhail Menis, Karla M Miller, Manette Niu, Joyce Obidi, Wendy Paul, Russell

Poland, Robert Rosofsky, Kimberly Smith, Salim Surani, Vinod Easwaran Nambudiri, Craig Zinderman, Azadeh Shoaibi, Candace C Fuller. (United States)

2:15 PM

Validation of the Combined Comorbidity Score in the ICD-10 Era: Application to High-Risk Populations [806]

Justin Bohn, Emily C Welch, Jenny W. Sun, Joshua J. Gagne, Sengwee Toh. (United States)

2:30 PM

Validating Prescription Registry Data on Statins Use by Blood Measurements [807]

Anders Hammerich Riis, Rune Erichsen, Eva B. Ostfeld, Carsten S. Højskov, Ole Thorlacius-Ussing, Mogens Stender, Timothy L. Lash, Holger Jon Møller. (Denmark)

2:45 PM

Documenting Diagnosis: Comparing Mild Cognitive Impairment Diagnosis Rates From ICD Codes vs. Clinical Notes [808]

Aaron W Kamauu, Olga V Patterson, Todd Johnson, Andrew Wilson, John R Holmen, Nicole M Bailey, Patrick R Alba, Benjamin Viernes, Kristine E Lynch, Scott L DuVall. (United States)



1:30 PM – 3:00 PM

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Algorithms: Rarely Pure and Never Simple

South Hall 2A

Moderators: Rosa Gini & Zhiqiang Lu

1:30 PM

Identification of Binge-Eating Disorder Patients in Electronic Health Record Data [809]

Monica L. Bertoia, William M. Spalding, Karen Yee, Judith C. Kando, Cynthia M. Bulik, John D. Seeger. (United States)

1:45 PM

Methods to Detect Dementia in Electronic Health Data: Comparing Cognitive Tests Scores With Algorithms for Dementia [810]

Barbara N Harding, Jeffrey F. Scherrer, James Floyd, Susan A Farr, Sascha Dublin. (United States)

2:00 PM

How Valid Are the Codes Used to Identify Acute Liver Injury (ALI)? a Study in 3 European Data Sources [811]

Joan Forn, Miguel Cainzos-Achirica, Maja Hellfritzsich, Maria Giner-Soriano, Beatriz Poblador-Plou, Jesper Hallas, Rosa Morros, Alexandra Prados-Torres, Anton Pottegård, Jordi Cortés, Jaume Aguado, Jordi Castellsagué, Emmanuelle Jacquot, Nicolas Deltour, Susana Perez-Gutthann, Manel Pladevall. (Spain)

2:15 PM

Algorithm to Classify Patient Immunocompromise Level in Database Studies [812]

Laurie Aukes, Joan Bartlett, Bruce Fireman, John Hansen, Edwin Lewis, Elizabeth Earley, Morgan A. Marks, Nicola P. Klein, Patricia Saddier. (United States)

2:30 PM

Incorporating Time-Varying Clinical Data Into a Machine Learning Algorithm to Detect Atrial Fibrillation and Flutter [813]

Nathan Hill, Daniel Ayoubkhani, Matthew Lumley, Steven Lister, Usman Farooqui, Phil McEwan, Jason Gordon, Mark O'Neil, David Clifton. (United Kingdom)

2:45 PM

Algorithms to Predict Left Ventricular Ejection Fraction Class in Patients With Heart Failure Using Medicare Claims Data [814]

Rishi J Desai, Kueiyu J Lin, Elisabetta Patorno, Julie Barberio, Moa Lee, Raisa Levin, Thomas Evers, Shirley Wang, Sebastian Schneeweiss. (United States)

What's Harm Got To Do With It?

South Hall 2B

Moderators: Bjorn Wettermark & Jason C. Hsu

1:30 PM

A Novel Claims-Based Algorithm to Predict Opioid Overdose in the US [815]

Jenny W Sun, Jessica M Franklin, Kathryn Rough, Rishi J Desai, Sonia Hernandez-Diaz, Krista F Huybrechts, Brian T Bateman. (United States)

1:45 PM

Long-Acting Opioid Selection and the Risk of Serious Infections [816]

Andrew D Wiese, Marie R Griffin, C. Michael Stein, William Schaffner, Robert Greevy, Ed Mitchel, Carlos G Grijalva. (United States)

2:00 PM

Geographic Variation of High-Risk Opioid Use and Risk of Overdose Among Disabled Medicare Beneficiaries in the US From 2011 to 2015 [817]

Weihuan Lo-Ciganic, Walid Gellad, Lili Zhou, Julie Donohue, Anne Roubal, Lisa Hines, Jeremiah Lindemann, Daniel Malone, Sandipan Bhattacharjee, C. Kent Kwok. (United States)

2:15 PM

Incident Opioid Use and Risk of Hip Fracture Among Persons With Alzheimer's Disease, a Nationwide Matched Cohort Study [818]

Heidi Taipale, Aleksi Hamina, Niina Karttunen, Marjaana Koponen, Antti Tanskanen, Jari Tiihonen, Sirpa Hartikainen, Anna-Maija Tolppanen. (Finland)

2:30 PM

Comparative Safety of Commonly-Used Opioids and Fracture Hospitalizations in United States Nursing Homes [819]

Jacob Hunnicutt, Shao-Hsien Liu, Christine Ulbricht, Anne Hume, Kate Lapane. (United States)

2:45 PM

Prevalence and Incidence Trends of Opioid Use Disorder and Prior Prescription Opioid Utilization, 2005-2015 [820]

Yu-Jung Jenny Wei, Cheng Chen, Amir Sarayani, Almut G Winterstein. (United States)



1:30 PM – 3:00 PM

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Safety in Numbers: Assessing Interventions and Outcomes

South Hall 3A

Moderators: J. Bradley Layton & Christian Hampp, FISPE

1:30 PM

Prevalence of Thrombocytopenia Upon Acute Hospital Admission: a Study in Denmark [821]

Guillaume Moulis, Christian Fynbo Christiansen, Bianka Darvalics, Henrik Toft Sørensen, Mette Nørgaard. (Denmark)

1:45 PM

Association Between Fluoroquinolone Use and Anterior Cruciate Ligament Injury in the United States [822]

Mackenzie M Herzog, Jennifer L Lund, Virginia Pate, Jeffrey T Spang, Stephen W Marshall. (United States)

2:00 PM

The Impact of An In-Hospital Multifaceted Clinical Pharmacist Intervention on the Risk of Readmission: a Randomized Clinical Trial [823]

Lene Vestergaard Ravn-Nielsen, Marie-Louise Duckert, Mia Lolk Lund, Jolene Pilegaard Henriksen, Michelle Lyndgaard Nielsen, Christina Skovsende Eriksen, Thomas Croft Buck, Anton Pottegård, Morten Rix Hansen, Jesper Hallas. (Denmark)

2:15 PM

Impact of the New Reimbursement Limitations of Palivizumab Prophylaxis in Italy [824]

Valeria Belleudi, Francesco Trotta, Silvia Narduzzi, Luigi Pinnarelli, Marina Davoli, Antonio Addis. (Italy)

2:30 PM

Systematic Review of the Applicability to Real-World Populations of Randomised Controlled Trial Evidence of Treatments for Physical Health Conditions [825]

Daniel R Morales, Davy He, Bruce Guthrie. (United Kingdom)

2:45 PM

Comparative Effectiveness of Antibiotic Therapy for the Treatment of Urinary Tract Infections [826]

Anne M. Butler, Matthew R. Keller, Michael J. Durkin, Vikas R. Dharnidharka, Margaret A. Olsen. (United States)

3:00 PM 3:15 PM

Break/Posters

Congress Foyer 2 & 3ABC



Old Town Prague from Charles Bridge



3:15 PM – 4:45 PM

Hot Topics Session: *New Versus Prevalent User Designs in PE: Time to Get Principled About When We Can be Pragmatic*

Congress Hall

Since Feinstein's 1971 paper on "Sources of 'chronology bias' in cohort statistics", epidemiologists have discussed the potential pitfalls of defining cohorts by past exposures. Pharmacoepidemiologists have made key contributions to highlighting the importance of new user designs from Kramer et al., in 1987, to Ray et al., in 2003, and Hernan et al., in 2008. New user designs have since become the widely accepted standard in pharmacoepidemiology. Recently, however, the supremacy of the new user design has been questioned. In a point-counterpoint published in the *American Journal of Epidemiology* 2015, Vandenbroucke and Pearce asked whether limiting studies to new users damages epidemiology and in 2017, Suissa et al., proposed prevalent new-user cohort designs when comparing new drugs with older drugs.

In this hot topic session, we propose to have two speakers presenting the importance of the new user design and the importance of the inclusion of prevalent users in 20 minutes each. These talks will be followed by a 20-minute talk identifying the implicit assumptions needed for including prevalent users in pharmacoepidemiologic studies and the plausibility of these

assumptions in selected settings. The remaining 30 minutes will include a moderated discussion with the audience. The goal of the moderator will be to lead the discussion with the audience to go beyond an exchange of arguments towards a broader understanding of the underlying assumptions, areas of common ground, and identification of next steps in the research agenda. We therefore do not propose a podium discussion with the previous speakers. Instead, the objective of the proposed hot topic session is to generate discussion and ultimately guidance that can be used by all pharmacoepidemiologists when making decisions on whether their studies need to be principled and when they might consider being more pragmatic.

Speakers

- ◆ **Sonia Hernandez-Diaz, FISPE**, Harvard School of Public Health, *New User*
- ◆ **Jan Vandenbroucke**, Leiden University Medical Center, *Prevalent User*
- ◆ **Til Sturmer, FISPE**, Gillings School of Global Public Health, University of North Carolina-Chapel Hill, *Assumptions*
- ◆ **Jesper Hallas, FISPE**, University of Southern Denmark, *Discussion Moderator*

4:45 PM – 5:15 PM

The Final Word

Congress Hall

34th ICPE Awards

Olaf Klungel, FISPE, Chair, 2018 Scientific Program Committee

- ◆ **Charles Leonard**, Newcomer Track
- ◆ **Ian Douglas**, Newcomer Track
- ◆ **J. Bradley Layton**, Spotlight Poster Sessions
- ◆ **Mary Ritchey**, Moderator Subcommittee
- ◆ **Krista Huybrechts, FISPE**, Moderator Subcommittee

Spotlight Poster Awards

J. Bradley Layton, Chair, Spotlight Poster Sessions

2019 Meetings

Mid-Year Meeting – Rome

- ◆ **Ursula Kirchmayer**, Co-Chair, Program Planning Committee
- ◆ **Gianluca Trifirò**, Co-Chair, Program Planning Committee

35th ICPE – Philadelphia

- ◆ **Vin Lo Re, III, FISPE**, Chair, 2019 Scientific Program Committee
- ◆ **Daniel Horton**, Chair, 2019 Local Host Committee
Drawing for complimentary registrations to ICPE 2019 – *must be present to win*

Adjournment of the ICPE 2018

Olaf Klungel, FISPE, Chair, 2018 Scientific Program Committee

5:45 PM – 6:30 PM

2019 ICPE Scientific Program Committee Meeting *(Open to ISPE members)*

Terrace 2A

▶ PHARMALEX

Leading specialist provider of:

- ▶ **Pharmacovigilance, Epidemiology & Risk Management**
- ▶ **Development Consulting Services**
- ▶ **Regulatory Affairs**
- ▶ **Quality Management & Compliance**



**KNOWLEDGE.
ACCELERATED.**
confidence beyond compliance

PharmaLex has extensive global expertise in patient-level datasets for medical products epidemiology and provides strategic responses regarding drug safety commitments to regulatory agencies.

www.pharmalex.com

Visit booth 32 to learn more

The Search Engine for Healthcare Databases



- **Explore standardized resource with 300+ population database profiles worldwide**
- **Review accurate profiles with 75 data fields including verified contact information**
- **Compare data elements across multiple profiles**
- **Access specialized glossary of international coding systems**

www.bridgetodata.org

B.R.I.D.G.E. TO DATA® is an online service provided by DGI, LLC. Schedule a demo today!



THE
BEST DATA
 GIVES YOU MILLIONS MORE
 REASONS TO USE THE WORD
"AHA"

As a health services and innovation company, Optum is tackling the biggest challenges in health care by partnering across the entire system. We use our industry-leading data and analytics with your extensive research and expertise to develop the right formula for market success.

Transforming data into actionable insights is how we get it done.

Visit us at booths 4 and 5
optum.com/epidemiology



syneoshealth.com

**SHORTENING THE DISTANCE
 FROM LAB TO LIFE.**

KC Research and Inventiv Health have become Syneos Health™, the only fully integrated biopharmaceutical solutions organization with a unique approach. At Syneos Health, all the disciplines involved in bringing new therapies to market, from clinical to commercial, work together with a singular goal — greatly increasing the likelihood of customer success. We call our business model Biopharmaceutical Acceleration. You can call it the future.





OVERVIEW

Poster sessions are designed to give presenters an opportunity to discuss informally their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, to present sufficient information for viewers to understand the methods, results, and significance of the research, and to promote conversations and networking among conference participants.

NOTE
Neither ISPE nor the Prague Congress Centre will be responsible for any poster that is left on display overnight or is lost or damaged.

POSTER SESSIONS

Spotlight Session Posters will be displayed in Congress Foyer 3A; all other posters (Sessions A, B & C) will be displayed in Congress Foyer 2A. Each day will have a distinct Spotlight Session and Poster Session. All posters for a specific day's session must be removed by the end of that day.

- ◆ Friday, August 24, Poster Session A and Spotlight Session A
- ◆ Saturday, August 25, Poster Session B and Spotlight Session B
- ◆ Sunday, August 26, Poster Session C and Spotlight Session C

1. SET UP

7:00am-8:00am; all posters must be in place by 8:00am. The poster area (including floor) must remain clear and clean of tubes.

2. HOURS

Posters will be displayed from 8:00am-6:00pm on Friday and Saturday, and 8:00am-1:45pm on Sunday.

3. DISCUSSION TIME

Poster Sessions: Presenters should be at their posters between 12:15-1:15pm on Friday (A) and Sunday (C); and between 11:45-12:45pm on Saturday (B)

Spotlight Sessions: Organized by the ISPE Special Interest Groups (SIGs). Presenters should be at their posters between 12:15-1:15pm on Friday (A) and Sunday (C); and between 11:45-12:45pm on Saturday (B)

The Spotlight Sessions offer pre-selected presenters the opportunity to share their work and to discuss their results with an audience. When the spotlight session chair and audience stop at your poster, please give a brief, 3-minute, presentation and to answer questions about your research.

FRIDAY

- ◆ Asian Pharmacoepidemiology Network (AsPEN)
- ◆ Adherence
- ◆ Biologics & Biosimilars
- ◆ Comparative Effectiveness Research (CER)
- ◆ Digital Epidemiology

SATURDAY

- ◆ Benefit Risk Assessment, Communication & Evaluation (BRACE)
- ◆ Databases
- ◆ Drug Utilization Research
- ◆ Medical Devices
- ◆ Rare Disease

SUNDAY

- ◆ Medications in Pregnancy & Lactation
- ◆ Molecular Epidemiology/Biomarkers/Pharmacogenetics
- ◆ Oncology
- ◆ Pediatrics
- ◆ Vaccines

4. TAKE DOWN

All posters must be taken down by 6:30pm on Friday and Saturday, and by 5:00pm on Sunday.

SPOTLIGHT SESSION PRIZES

A group of judges will select the best poster from each Spotlight Session. The best presenters will receive an invitation to display their poster for the duration of the ICPE. The winners will be announced during The Final Word session on Sunday afternoon, August 26.

NUMBERING SYSTEM

Each poster board will be numbered. Presenters should attach their posters to the board number corresponding to the number assigned to their poster listed in the **Final Program**. The **POSTER BOARD NUMBER OR LETTER** is the first number listed. The **PUBLICATION NUMBER**, for use in locating abstracts in the **Final Program**, is listed after the abstract title.

Example

97 **Characteristics of Patients with Depression Who Initiate Antidepressant and Benzodiazepine Therapy Simultaneously, Compared with Antidepressant Monotherapy [176]**

Greta A Bushnell, Alice White, Til Stürmer, Bradley N Gaynes, Virginia Pate, Deborah Azrael, Matthew Miller. (United States)

KEY **97** or **J** Poster Board Number or Letter
176 Publication Number

CALL4POSTERS

Posters ordered through Call4Posters can be picked up at Exhibit Booth 27 at the times below.

Poster Pick Up Schedule

Thursday, August 23	Noon-5:00pm
Friday, August 24	7:00am-3:00pm
Saturday, August 25	7:00am-3:00pm
Sunday, August 26	7:00am-Noon





Spotlight Session: Asian Pharmacoevidence Network (AsPEN)

- A** **Detection of Fluoroquinolone Use and the Risk of Rhegmatogenous Retinal Detachment: Sequence Symmetry Analysis Using Nationwide South Korea Healthcare Database Between 2004 and 2015 [83]**
Yeon-Hee Baek, Sang Jun Park, Sohyun Jeong, Ju-Young Shin. (Korea, Republic of)
- B** **Renin-Angiotensin-Aldosterone System Inhibition and Outcome of Sepsis [84]**
Wan-Ting Hsu, Brandon Galm, Gregory Schrank, Wan-Chien Lee, Tzu-Chun Hsu, Chien-Chang Lee, Tobias Kurth. (United States)
- C** **The Cardiovascular Risk of Febuxostat Among Patients With Hyperuricemia Or Gout Compared With Allopurinol: A Population-Based Study in Taiwan [85]**
Chien-Huei Huang, Chien-Chou Su, Pheng-Ying Yeh Liu, Yea-Huei Kao Yang, Ching-Lan Cheng. (Taiwan)
- D** **Mortality Risk Associated With Haloperidol Use Compared to Other Antipsychotics: An 11-Year Population-Based Propensity-Score-Matched Cohort Study [86]**
Kim Shijian Lao, Angel YS Wong, Ian CK Wong, Frank MC Besag, Esther W Chan. (Hong Kong)
- E** **Comparative Physical Morbidity and Mortality Risk of Antipsychotics in Patients With Parkinson's Disease [87]**
Ms. Hsun-Yin Liang, Mr. Chien-Chou Su, Mr. Cheng-Yang Hsieh, Ms. Yea-Huei Kao Yang, Mr. Edward Chia-Cheng Lai. (Taiwan)
- F** **Analysis on Reasons for Discontinuations of Sodium Glucose Co-Transporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus in Real-World Practices in Taiwan [88]**
Yi-Han Lin, Shih-Chieh Shao, Yuk-Ying Chan, Hui-Yu Chen, Yea-Huei Kao Yang, Edward Chia-Cheng Lai. (Taiwan)

- G** **Beliefs About Medicines and Nonadherence in Patients With Coronary Heart Disease, Hypertension, Type 2 Diabetes Mellitus: A Cross-Sectional Online Survey in China [89]**
Bo Nie, Sarah C.E. Chapman, Li Wei. (United Kingdom)

Spotlight Session - Adherence

- H** **Randomized Controlled Trial to Test the Effectiveness of a Patient Tailored Intervention Programme to Enhance Adherence to Antihypertensive Medication [90]**
Danielle van der Laan, Petra Elders, Giel Nijpels, Liset van Dijk, Christel L Boons, Jacqueline G Hugtenburg. (Netherlands)
- I** **Abstract Withdrawn [91]**
- J** **Abstract Withdrawn [92]**
- K** **Mediation by Patient-Reported Outcomes of the Association Between Film-Coated Or Dispersible Formulations of Deferasirox and Serum Ferritin Reduction: A Post Hoc Analysis of the Eclipse Trial [93]**
Ali T Taher, Raffaella Origa, Silverio Perrotta, Alexandra Kouraklis, Vicky Huang, Jackie Han, Andreas Bruederle, Priyanka J Bobbili, Wendy Y Cheng, Mei Sheng Duh, John B Porter. (United States)
- L** **Mobile Health Intervention Increases Inhaled Corticosteroid Adherence in Adolescents With Asthma [94]**
Richelle C. Kosse, Marcel L. Bouvy, Tjalling W. de Vries, Ellen S. Koster. (Netherlands)
- M** **The Association Between Adherence to Antihypertensive Medications and Subsequent Healthcare Utilisation in the Ageing Community Dwelling Adults: Results From Wave One of the Irish Longitudinal Study on Ageing (TILDA) [95]**
Caroline A Walsh, Caitriona Cahir, Kathleen E Bennett. (Ireland)

- N** **Variation in Medicines Use by Ethnicity: A Comparison Between 2006/7 and 2012/13 [96]**
Kebede Beyene, Scott Metcalfe, Rhys Jones, Jude Ulrich, A'tene Andrews, Catherine Proffitt, Jeff Harrison. (New Zealand)
- O** **Comparison of Adherence and Discontinuation of Hypoglycemic Agents Among Patients With Asthma and Diabetes: A Retrospective Analysis From 2005-2015 [97]**
Yasser Albogami, Almut Winterstein. (United States)

Spotlight Session - Biologics and Biosimilars

- P** **Characterization of Patients With Ulcerative Colitis in a Postauthorization Safety Study of Golimumab Based in the Spanish Eneida Registry [98]**
Joan Fortuny, Lawrence Rasouliyan, Daniel Mines, Anita Tormos, Elizabeth Earley, Susana Pérez-Gutthann, Eugeni Domènech, Javier P. Gisbert. (Spain)
- Q** **Tocilizumab and the Risk for Cardiovascular Disease Events Among Rheumatoid Arthritis Patients: A Direct Comparison in Real World Setting [99]**
Fenglong Xie, Huifeng Yun, Emily Levitan, Paul Muntner, Jeffrey R Curtis. (United States)
- R** **Dose Escalation, Switching and Discontinuation of Biologic Disease Modifying Drugs in Patients With Rheumatoid Arthritis: A Comparison of Concomitant versus Non-Concomitant Users of Methotrexate [100]**
Colin Dormuth, Anat Fisher, Robert Platt. (Canada)
- S** **Development and Internal Validation of a Multivariate Prognostic Model for Serious Infection in Patients With Psoriasis on Systemic Therapies [101]**
Zenas Yiu, Mark Lunt, Darren Ashcroft, Christopher Griffiths, Richard Warren. (United Kingdom)



- T A Propensity-Score Weighting Approach to Compare Registry and Trial Populations of Patients With Psoriasis on Biologic Therapies [102]**
Zenas Yiu, Kayleigh Mason, Jonathan Barker, Philip Hampton, Kathleen McElhone, Catherine Smith, Richard Warren, Christopher Griffiths, Mark Lunt, David Burden. (United Kingdom)
- U Impact of Rheumatoid Arthritis Patient Eligibility for Tumour Necrosis Factor Therapy (As Per Nice Guidance Concerning Disease Activity) on Need for Joint Replacement: A Regression Discontinuity Study [103]**
Samuel Hawley, M. Sanni Ali, Christopher J Edwards, Irene Petersen, Kimme Hyrich, Daniel Prieto-Alhambra. (United Kingdom)
- V Exploring the Association Between Monoclonal Antibodies and Depression and Suicidal Ideation and Behaviour: A Vigibase Study [104]**
Lotte A Minnema, Thijs J Giezen, Patrick C Souverein, Toine C Egberts, Hubert G Leufkens, Helga Gardarsdottir. (Netherlands)
- W Timing of the Last Dose of Biologic Therapy and Risk of Post-Surgical Infections in Patients With Psoriasis [105]**
Zenas Yiu, Darren Ashcroft, Ian Evans, Kathleen McElhone, Shernaz Walton, Mark Lunt, Christopher Griffiths, Richard Warren. (United Kingdom)

Spotlight Session - CER

- X Three-Group Extension of Propensity Score Trimming Rules: A Simulation Study [106]**
Kazuki Yoshida, Daniel H Solomon, Sebastien Haneuse, Seoyoung C Kim, Elisabetta Paterno, Sara K Tedeschi, Houchen Lyn, Sonia Hernandez-Diaz, Robert J Glynn. (United States)
- Y Comparative Effectiveness of Two-Drug Therapy versus Monotherapy As Initial Regimen in Hypertension: A Propensity Score Matched Cohort Study in CPRD [107]**
Karine Marinier, Pauline Macouillard, Martine De Champvallins, Nicolas Deltour, Neil Poulter, Giuseppe Mancia. (France)

- Z Comparative Safety of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Risk of Hospitalization and Cardiovascular Events in Patients With Type 2 Diabetes [108]**
Omar Mansour, Hsien-Yen Chang, G Caleb Alexander, Sonal Singh. (United States)
- AA Baseline Information From a Post-Marketing Monitoring Program on Empagliflozin: Implications for Study Validity and Exposure Accrual [109]**
Elisabetta Paterno, Ajinkya Pawar, Jessica Franklin, Anouk Déruaz-Luyet, Kimberly Brodovicz, Dorothee Bartels, Martin Kulldorff, Sebastian Schneeweiss. (United States)
- BB Comparison of Propensity Score (PS) Weighting and Trimming Strategies to Reduce Variance and Bias of Treatment Effect Estimates: A Simulation Study [110]**
Til Stürmer, Kenneth J. Rothman, Alan R. Ellis, Richard Wyss, Mitchell Conover, Mark Lunt, Robert J. Glynn. (United States)
- CC Comparative Safety of Atypical Antipsychotics Used in the Treatment of Neuropsychiatric Symptoms of Dementia: A Mixed Treatment Comparison [111]**
Ismaeel Yunusa, Adnan Alsumali, Asabe E Garba, Tewodros Eguale. (United States)
- DD SGLT2 Inhibitors and Mycotic Infections: A Prescription Sequence Symmetry Analysis [112]**
Sruthi Adimadhyam, Todd A. Lee, Gregory S. Calip, Daphne E. Smith Marsh, Brian T. Layden, Glen T. Schumock. (United States)
- EE Comparative Effectiveness of P2Y12 Antiplatelet Switching Strategies [113]**
Nicholas J Belviso, Herbert Aronow, Michelle Caetano, David Louis, Dhaval Kolte, Marilyn Barbour, Xuerong Wen. (United States)

Spotlight Session - Digital Epidemiology

- FF Assessing Disease Activity With Promis Measures Using Smartphone Technology Among Patients With Rheumatic Diseases [114]**
Huifeng Yun, Shuo Yang, Benjamin W Nowell, Cooper Filby, Lang Chen, Jeffrey R Curtis. (United States)
- GG Assessment of Medication Use During Pregnancy by Web-Based Questionnaires, Pharmacy Records, and Biological Monitoring in Blood [115]**
Marleen M. van Gelder, Lutea A. de Jong, Bernke te Winkel, Erik J. Olyslager, Saskia Vorstenbosch, Eugène P. van Puijenbroek, Nel Roeleveld. (Netherlands)
- HH Patients' Perceptions of Unmet Medical Need in Rheumatoid Arthritis [116]**
Jeffrey Curtis, Mark Genovese, Christine Radawski, Brett Hauber, W. Benjamin Nowell, Kelly Hollis, Carol Gaich, Amy DeLozier, Kelly Gavigan, Anabela Cardoso. (United States)
- II Using Social Media to Collect Patient Perspectives on Quality of Life: A Feasibility Study [117]**
Amr Makady, Rachel Kalf, Bettina Ryll, Gilliosa Spurrier, Anthonius de Boer, Hans Hillege, Olaf Klungel, Wim Goettsch. (Netherlands)
- JJ Designing and Evaluating a Web-Based App As a Digital Risk Minimization Tool: Practical Considerations [118]**
Meredith Y. Smith, Carmit Strauss, Tamara Lindberg. (United States)



Adherence

- 1 Monitoring and Managing Medication Adherence in Community Pharmacies [119]**
Rébecca Fénélon-Dimanche, Geneviève Lalonde, Marie-France Beauchesne, Johanne Collin, Line Guénette, Lucie Blais. (Canada)
- 2 Association Between Daily versus Evening/Bedtime Statin Dosing and Medication Adherence [120]**
Zachary Marcum, Claire Huang, Robert Romanelli. (United States)
- 3 Too Many Cooks in the Kitchen: The Association of Medication Adherence and Diabetes Control With Number and Type of Prescribing Physicians [121]**
Matthew L Maciejewski, Bradley G Hammill, Elizabeth A Bayliss, Lesley H Curtis, Virginia Wang. (United States)
- 4 Variability of Chronic Disease Medication Adherence Measures—A Systematic Review [122]**
Asieh Golozar, Jenny Lee, Kevin Lee. (Germany)
- 5 Influence of Race/Ethnicity on Medication Nonadherence Among Us Adults With Diabetes Or Hypertension - a Systematic Review [123]**
Jenny Lee, Kevin Lee, Asieh Golozar. (Germany)
- 6 Oral Antidiabetic Drugs Adherence and Glycemic Control Among Patients With Type 2 Diabetes Mellitus [124]**
Bander Balkhi, Tariq Alhawassi, Thamer Alshammari, Nasser AlQahtani, Mansour Almetwazi, Mansour Mahmoud, Sondus Ata, Mada Basyoni, Monira Alwhaibi. (Saudi Arabia)
- 7 Real-World Adherence to Warfarin, Dabigatran, Rivaroxaban and Apixaban Among Patient With Nonvalvular Atrial Fibrillation: 2010-2015 [125]**
Phuong N. Pham, Joshua D. Brown. (United States)

Analytical Methods

- 8 Tree-Temporal Scan Analyses for Detecting Safety Signals in Clinical Development of Vaccines: A Simulation Study [126]**
Francois Haguinet, Lionel Van Holle, Pascale Schrauben, Vincent Bauchau. (Belgium)
- 9 Estimation of the Effect of Discontinuing a Preventive Therapy in Older Adults Using Healthcare Databases: An Exploration of the Use of Marginal Structural Models on the Example of Statins [127]**
Anke Neumann, Philippe Giral, Alain Weill, Joël Coste. (France)
- 10 A Comparison of Methodological Approaches on the Association Between De Novo Vitamin D Supplement Use Post-Diagnosis and Breast Cancer Mortality [128]**
Jamie Madden, Lina Zgaga, Finbarr Leacy, Kathleen Bennett. (Ireland)
- 11 Statistical Inference in An Updated Network Meta-Analysis: A Comparison of Likelihood Ratio Meta-Analysis and Conventional Meta-Analysis [129]**
Colin Dormuth, Anat Fisher, Robert Platt. (Canada)
- 12 Overcoming Temporal Confounding in the Assessment of Therapeutic Equivalence of Brand and Generic Drugs [130]**
Lamar Hunt, Irene Murimi, Daniel Scharfstein, Ramin Mojtabai, Ravi Varadhan, Jodi Segal. (United States)
- 13 Trends of Insulin-Like Growth Factor 1, Growth Hormone, and Biochemical Control of Patients With Acromegaly in Italy: A Longitudinal Retrospective Chart Review Study [131]**
Annamaria Colao, Ludovica Grasso, Marialuisa Di Cera, Wendy Y Cheng, Philippe Thompson-Leduc, Hoi Ching Cheung, Mei Sheng Duh, Maureen P Neary, Alberto M Pedroncelli, Ricardo Maamari, Rosario Pivonello. (Canada)
- 14 Comparison of Case Definitions for Harmonized Health Outcome Assessments [132]**
Johanna Urban, Mike Zoglowek, Jorgen Bauwens, Nadia G. Tornieporth, Jan Bonhoeffer. (Germany)
- 15 Performance Indicators of the Brighton Collaboration Case Definition 'Neonatal Infections' [133]**
Mike Zoglowek, Johanna Urban, Jorgen Bauwens, Nadia Tornieporth, Jan Bonhoeffer. (Germany)
- 16 Targeted Estimation of Background Rates With Existing Data via Odds-Weights Computed From Simulated Data of Target Referents [134]**
Anthony P Nunes, Stephen M Ezzy, Robert V Gately, David D Dore. (United States)
- 17 Dealing With Time-Varying Confounding by Marginal Structural Model in Observational Study: An Application in Parkinson's Disease [135]**
Shih-Wei Chiu, Takuhiro Yamaguchi. (Japan)
- 18 Adjusting for Multiple Use of Patients When Matching With Replacement: A Simulation [136]**
Sarah A Short, David J Pasta. (United States)
- 19 Causal Estimation in Observational Data Subject to Missing by a Machine Learning Approach [137]**
Jinghua He, Xiaochun Li, Zuoyi Zhang, Shaun Grannis, Changyu Shen, Changyu Shen. (United States)
- 20 Computational Algorithms for SAS-Based Distributed Regression Software Applications for Cox and GLMs [138]**
Qoua Her, Yury Vilik, Jessica Young, Zilu Zhang, Jessica Malenfant, Sarah Malek, Sengwee Toh. (United States)
- 21 Process Mining for Exploring Treatment Patterns in Chronic Lymphocytic Leukemia in a Real World Oncology Database [139]**
James A Black, Felipe Castro, Linda Lundberg, Michael Marino, Rudi Niks, Anne Rozinat. (Switzerland)
- 22 Misclassification of Time-At-Risk Due to Free Sample Drug Use: A Simulation Study [140]**
Zilu Zhang, Efe Eworuke, Margie R. Goulding, Michael D. Nguyen, Bruce Fireman, Judith C. Maro. (United States)



- 23 Effects of Time-Varying Stress-Ulcer Prophylaxis Strategies on Risk of Ventilator Associated Events [141]**
Xiaojuan Li, Michael Klompas, Jessica G Young. (United States)

Burden of Disease - Alimentary and Metabolism

- 24 Racial Heterogeneity in the Association of Proton Pump Inhibitors and Cardiovascular Disease [142]**
Elizabeth J. Bell, Jennifer L. St. Sauver, Aaron F. Folsom, Nicholas B. Larson, Paul Y. Takahashi, Suzette J. Bielinski. (United States)
- 25 Platelet Aggregation Inhibitors Use and Risk of Recurrent Diverticular Bleeding Among Patients With a Prior Episode of Diverticular Bleeding [143]**
Ravy K. Vajravelu, Frank I. Scott, Ronac Mamtani, James D. Lewis. (United States)
- 26 Self-Reported Comorbidity, Functional Dependence and Healthcare Resource Utilization of Chronic Hepatitis C Virus Infection Patients [144]**
Phyo Htoo, Ning (Jackie) Zhang, Jinghua He. (United States)
- 27 Incidence and Episodes of Hypoglycaemia in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Observational Studies [145]**
Hassan H Alwafi, Alaa Alsharif, Li Wei, Abdallah Y Naser, Mansour Al Metwazi, J. Simon Bell, Jenni Ilomaki, Gang Fang, Ian C Wong. (United Kingdom)
- 28 Age- and Sex-Specific Incidence of Non-Traumatic Lower Limb Amputation in Patients With Type 1 Diabetes Mellitus in a U.S. Claims Database [146]**
Sampada Gandhi, Chuntao Wu, Zoran Doder, Xinyu Li, Juhaeri Juhaeri. (United States)
- 29 Systematic Review of Breast Cancer and Subsequent Risk of Hypothyroidism [147]**
Dr. Anne Mette Falstie-Jensen, Ebbe Lorenzen, Jeanette D. Jensen, Marianne Ewertz, Kristin V. Reinertsen, Kristin V. Reinertsen, Olaf M. Dekkers, Deirdre P. Cronin-Fenton. (Denmark)

- 30 Racial and Ethnic Disparities in Lower Extremity Amputation Among Medicare Beneficiaries With Diabetic Foot Ulceration and Infection in the United States [148]**
Ching-Yuan Chang, Tze-Woei Tan, Weihsuan Lo-Ciganic. (United States)

Burden of Disease - Cancer

- 31 Allergic Rhinitis and Subsequent Risk of Cancer Among US Elderly Adults [149]**
Monica E D'Arcy, Donna Rivera, Andrew Grothen, Eric Engels. (United States)
- 32 Proton Pump Inhibitors Prescriptions and Colorectal Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study [150]**
Veronika Fedirko, Deirdre Cronin-Fenton, Anders Hammerich Riis, Henrik Toft Sørensen, Claus Lindbjerg Andersen, Ole Thorlacius-Ussing, Timothy Lash. (United States)
- 33 Identifying Patients With Metastatic Castration-Resistant Prostate Cancers (mCRPC) in the Snds Database: Camerra Study [151]**
Nicolas Thurin, Patrick Blin, Magali Rouyer, Jérémy Jové, Marine Gross-Goupil, Thibaud Haaser, Xavier Rébillard, Michel Soulié, Camille Capone, Cécile Droz-Perroteau, Nicholas Moore. (France)
- 34 Global Burden of Cancer: International Comparison of Cancer Epidemic From Geographic and Economic Perspectives [152]**
Jason C. Hsu, Illich Chua, Sheng-Mao Chang, Joanne Lo, Yu-Chi Tseng, Peng-Chan Lin, Hone-Jay Chu. (Taiwan)
- 35 Assessing Predicted Mesothelioma Incidence Trends in the United States [153]**
Martin Lavallee, Rong Liu, David Vizcaya. (Spain)
- 36 Estimating the Incidence Rate of Advanced Colorectal Cancer in Germany Based on Claims Data [154]**
Katja Anita Oppelt, Ulrike Haug. (Germany)
- 37 International Comparison of 10 Common Cancers' Incidence and Mortality Between 12 Asian Countries [155]**
Joanne Lo, Jason C. Hsu, Sheng-Mao Chang, Yu-Chi Tseng, Peng-Chan Lin, Hone-Jay Chu. (Taiwan)
- 38 Incidence of Marrow Neoplasms in Breast Cancer Survivors: A National Population-Based Cohort Study [156]**
Marie Joelle Jabagi, Norbert Vey, Anthony Goncalves, Thien Le Tri, Mahmoud Zureik, Rosemary Dray-Spira. (France)
- 39 Recording of Colorectal Cancer in the United Kingdom and Comparison of Cancer Registrations With Diagnoses in Other Routinely Collected Data Sources - a Systematic Review of the Literature [157]**
Sarah Irvin, Pareen Vora, Montse Soriano Gabarro. (United States)
- 40 Prevalence of Co-Existing Chronic Health Conditions Among Cancer Patients [158]**
Monira Alwahaibi, Bander Balkhi, Thamir Alshammari, Sondus Ata, Mada Basyoni, Mansour Almetwazi, Nasser AlQahtani, Mansour Mahmoud, Tariq Alhawassi. (Saudi Arabia)
- 41 Chemoradiotherapy Treatment Patterns and 1-Year Survival Rate Among Patients With Unresectable, Stage III Non-Small Cell Lung Cancer: Time Trends From 2009 - 2014 [159]**
Priyanka J Bobbili, Kellie Ryan, Mei Sheng Duh, Ancilla Fernandez, Maral DerSarkissian, Akanksha Dua, Melissa Pavilack, Jorge E Gomez. (United States)
- 42 Disease Burden of Patients With Advanced Renal Cell Carcinoma in Korea [160]**
Sola Han, Siin Kim, Hae Sun Suh. (Korea, Republic of)
- 43 Insight Into the Role of the General Practitioner in the Management of Colorectal Cancer: Record Linkage of the Netherlands Cancer Registry and the General Practitioner Database of the Pharm Database Network [161]**
Josephina G. Kuiper, Myrthe P Van Herk-Sukel, Valery E Lemmens, Ron C Herings. (Netherlands)



- 44 Incidence of Nonmelanoma Skin Cancer and Related Procedures - An Analysis of a U.S. Medical Claims Database, 2012-2014 [162]**
Laura Governale, Tongsheng Wang, Maria Paris, Steve Niemcryk. (United States)
- 45 Non-Aspirin NSAID Use and Contralateral Breast Cancer Risk [163]**
Annet Bens, Deirdre Cronin-Fenton, Christian Dehlandorff, Maj-Britt Jensen, Bent Ejlersen, Niels Kroman, Søren Friis, Lene Mellemkjær. (Denmark)

Burden of Disease - Cardiovascular

- 46 The Association Between Statins Initiated After a Colorectal Cancer Diagnosis, and Mortality in a Cohort With Stage I-III Colorectal Cancer [164]**
Amelia Smith, Lina Zgaga, Kathleen Bennett. (Ireland)
- 47 Lower Gastrointestinal Bleeding and Risk of Colorectal Cancer in Users and Non-Users of Low-Dose Aspirin [165]**
Frederikke Schønfeldt Troelsen, Dóra Körmendiné Farkas, Anne Gulbech Ording, Søren Friis, Rune Erichsen, Henrik Toft Sørensen. (Denmark)
- 48 Statin Use Is Associated With Elevated Levels of Fasting Serum Insulin and Insulin Resistance, and Increased Risk of Type 2 Diabetes [166]**
Fariba Ahmadizar, Taulant Muka, Bruno Stricker, Carolina OchoaRosales, Marija Glisic, Oscar Franco. (Netherlands)
- 49 Risk of Age-Related Macular Degeneration in Aspirin Users [167]**
Wanju Annabelle Lee, Ching-Lan Cheng, Yea-Huei Kao Yang. (Taiwan)
- 50 Plasma Potassium and the Risk of Mortality: A Time-Dependent Analysis From the Stockholm Creatinine Measurements (SCREAM) Project [168]**
Hairong Xu, Marco Trevisan, Marie Evans, Juan-Jesus Carrero. (United States)
- 51 Distribution of CHA₂DS₂-VASC Scores in Patients With Atrial Fibrillation Treated With Rivaroxaban in Primary vs. Secondary Care Settings [169]**
Miranda Davies, Lesley Wise, Saad Shakir. (United Kingdom)
- 52 Characteristics of Patients Initiated on Statin Therapy by General Practitioners in Quebec Canada: The Obstet Cohort [170]**
Sarasa Johnson, Manon Choinière, Michèle Bally, Marie-Pierre Dubé, Jean-Claude Tardif, Jacques Leloir. (Canada)
- 53 Body Mass Index and the Risk of Cardiovascular Disease and All-Cause Mortality in European Primary Care Databases [171]**
Myriam Alexander, Nafeesa N Dhalwani, Peter Rijnbeek, Mees Mosseveld, Johan van der Lei, Talita Duarte-Salles, Daniel Prieto-Alhambra, David Ansell, Alessandro Pasqua, Francesco Lapi, Paul Avillach, Peter Egger, Usha Gungabissoon, Stuart Kendrick, William Alazawi, Dawn Waterworth, Katrina Loomis, Naveed Sattar. (United Kingdom)
- 54 Primary Care Recorded NAFLD and the Risk of Incident MI and Stroke: Findings From Analyses of 18 Million Patients in the UK, the Netherlands, Spain and Italy [172]**
Myriam Alexander, Katrina A Loomis, Johan van der Lei, Talita Duarte-Salles, Daniel Prieto-Alhambra, David Ansell, Alessandro Pasqua, Francesco Lapi, Peter Rijnbeek, Mees Mosseveld, Paul Avillach, Peter Egger, Nafeesa N Dhalwani, Stuart Kendrick, Dawn M Waterworth, William Alazawi, Naveed Sattar. (United Kingdom)
- 55 Predictors of Outpatient Cardiac Rehabilitation Referral Among Hospitalized Heart Failure Patients: The Atherosclerosis Risk in Communities (ARIC) Study [173]**
Sydney T Thai, Wayne D Rosamond, Anthony J Viera, Patricia P Chang, Salim S Virani, M Alan Brookhart, Montika Bush, Laura R Loehr, June Stevens, Anna Kucharska-Newton. (United States)
- 56 Cardiovascular Outcomes and Mortality in Type 2 Diabetes With Comorbid Cardio-Renal-Metabolic Conditions in the UK [174]**
Sharon MacLachlan, Hungta Chen, Phillip Hunt, Enrico Repetto, Jiten Vora. (United States)
- 57 Long-Term Incidence and Risk Factors of Cardiovascular Events in Asianpopulations: Systematic Review and Meta-Analysis of Population-Based Cohort Studies [175]**
Sylvi Irawati, Riswandy Wasir, Amand Floriaan Schmidt, Atiqul Islam, Talitha Feenstra, Erik Buskens, Bob Wilffert, Eelko Hak. (Netherlands)
- 58 A Cohort Study of Hypotension Among Incident Heart Failure Patients Using the UK Thin Database [176]**
Mar Martín-Pérez, Alexander Michel, Mark Ma, Luis A. García Rodríguez. (Spain)
- 59 Chronic Kidney Disease (CKD) in US Adults With Type 2 Diabetes (T2D) and/or Cardiovascular Diseases (CVD): A National Estimate of Prevalence by KDIGO 2012 Classification [177]**
Tongtong Wang, Yuzhi Xi, Robert Lubwama, Carol Koro. (United States)
- 60 Cardiovascular and Bleeding Outcomes in a Nordic Cohort of Adult Patients With Chronic Immune Thrombocytopenia (cITP) [178]**
Dr. Kasper Adelborg, Nickolaj Risbo Kristensen, Mette Nørgaard, Shahram Bahmanyar, Waleed Ghanima, Karynsa Cetin, Henrik Toft Sørensen, Christian Fynbo Christiansen. (Denmark)

Data Linkage

- 61 Using Existing NHS Datasets to Determine Outcomes of Cancer Medicines: A Feasibility Study [179]**
Kelly Baillie, Tanja Mueller, Jiafeng Pan, Christine Crearie, Jennifer Laskey, Robert Jones, Marion Bennie. (United Kingdom)
- 62 Using the Seer-Medicare Linked Databases to Identify Novel Prostate Cancer Risk Factors [180]**
Monica E D'Arcy, Neal Freedman, Ruth Pfeiffer, Michael Cook, Eric A Engels. (United States)



- 63 Electronic Health Records (EHR) vs Medicare Claims Data: Comparing the Relative Completeness of Non-Fatal Outcomes in a Linked Cohort [181]**
Sudha R Raman, Christopher Bush, Melissa Greiner, Michelle M Smerek, Lesley H Curtis. (United States)
- 64 Agreement Between Electronic Health Records and Administrative Claims Data for Patients With Multiple Myeloma [182]**
Leah J. McGrath, Rohini K. Hernandez, Ying Yu, Robert A. Overman, Diane Reams, Alexander Liede, M. Alan Brookhart. (United States)
- 65 Developing a Multiphase Claims-Based Algorithm for Non-Live Pregnancy Outcomes Research [183]**
Matthew Secrest, Syd Phillips, Sophie W Shen, Kimberley J Woodcroft, Susan A Oliveria, Teresa A Simon. (United States)
- 66 Can Patients Accurately Report Their Drugs? - a Comparison of Self-Reported Medication With a National Register in Denmark in a Subset of the Protect Pregnancy Cohort [184]**
Alison Bourke, Maja Laursen, Nancy Dreyer, Christine Erikstrup Hallgreen, Stella Blackburn. (United Kingdom)
- 67 Linking Electronic Health Data in Pharmacoepidemiology: Guidance for Assessing Appropriateness and Feasibility [185]**
Donna R Rivera, Mugdha N Gokhale, Matthew W Reynolds, Elizabeth B Andrews, Danielle Chun, Kevin Haynes, Michele L Jonsson-Funk, Kristine E Lynch, Jennifer L Lund, Helen Strongman, Sudha R Raman. (United States)
- 68 Concordance of Hospitalized Endpoints Within the Linked Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES) Databases Among Patients Treated With Oral Antidiabetic Therapies [186]**
M. Elle Saine, Dena M Carbonari, Craig W Newcomb, Jason A Roy, Arlene M Gallagher, Serena Cardillo, Sean Hennessy, Brian L Strom, Vincent Lo Re. (United States)
- 69 Including Primary Care Data From Multiple Software Systems in a Data Linkage Programme: Results From Expanding the Clinical Practice Research Datalink (CPRD) [187]**
Rebecca E Ghosh, Shivani Padmanabhan, Rachael Williams, Puja Myles. (United Kingdom)
- 70 Linking Randomized Control Trials and Electronic Databases Assessing Feasibility in 41 Countries [188]**
Mehdi Najafzadeh, Emma Payne, Margaret Okobi, Jeremy A Rassen. (United States)
- 71 A Comparison of Record Linkage Software and Algorithms Using Real-World Data [189]**
Suzanne L West, Alan Karr, Matthew T Taylor, Soko Setoguchi, Doug Kou, Tobias Gerhard, Daniel B. Horton. (United States)
- 72 Using Italian Administrative Healthcare Data Sources to Study Infusive Antineoplastic Utilization in Clinical Practice: A Validation Study [190]**
Claudia Bartolini, Giuseppe Roberto, Valentino Moscatelli, Andrea Spini, Alessandro Barchielli, Davide Paoletti, Silvano Giorgi, Sandra Donnini, Marina Ziche, Maria Cristina Monti, Rosa Gini. (Italy)
- 73 Assessment of UK Biobank Phenotype Data [191]**
Oksana Kirichuk, Samantha St. Laurent, Julia DiBello, Margaret Ehm, Mathias Chiano, Chi Truong, Dawn Waterworth. (United Kingdom)
- 74 Using Real-World Data (RWD) in Health Technology Assessment (HTA) Practice: A Comparative Study of 5 HTA Agencies [192]**
Amr Makady, Ard van Veelen, Pall Jonsson, Owen Moseley, Anne D'Andon, Anthonius de Boer, Hans Hillege, Olaf Klungel, Wim Goettsch. (Netherlands)
- 75 Outcomes of Cetuximab in First Line Therapy for Metastatic Colorectal Cancer According to Tumor RAS-BRAF Mutation Status From An Update of EREBUS Cohort [193]**
Magali Rouyer, Pernelle Noize, Denis Smith, Eric François, Antonio Sa Cunha, Alain Monnereau, Edwige Yon, Emmanuelle Bignon, Cécile Droz-Perroteau, Nicholas Moore, Annie Fourrier-Réglat. (France)
- 76 Evaluation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer With Real-Life Use, Effectiveness, Safety, and Quality of Life in the Fuji Cohort [194]**
Magali Rouyer, Annie Fourrier-Réglat, Florence Tubach, Stéphane Oudard, Karim Fizazi, Florence Joly, Stéphanie Lamarque, Estelle Guiard, Aurélie Balestra, Clémentine Lacueille, Jérémy Jové, Cécile Droz-Perroteau, Nicholas Moore. (France)
- 77 Direct Oral Anticoagulants versus Low-Molecular-Weight Heparins for Venous Thromboembolism Prevention Following Total Knee Replacement: Comparative Effectiveness and Medical Costs From a French Nationwide Cohort Study of Around 50,000 Patients [195]**
Patrick Blin, Charles-Marc Samama, Alain Sautet, Patrick Mismetti, Jacques Benichou, Séverine Lignot-Maleyran, Stéphanie Lamarque, Simon Lorrain, Régis Lassalle, Anne-Françoise Gaudin, François-Ermy Cotte, Cécile Droz-Perroteau, Nicholas Moore. (France)
- 78 Antihistamine Use and Risk of Ovarian Cancer: A Population-Based Case-Control Study [196]**
Freija Verdoodt, Anton Pottegård, Christian Dehlendorff, Marja Jäätelä, Jesper Hallas, Søren Friis, Susanne K. Kjaer. (Denmark)
- 79 Non-Aspirin NSAID Use and Survival After Ovarian Cancer [197]**
Freija Verdoodt, Christian Dehlendorff, Susanne K. Kjaer, Søren Friis. (Denmark)
- 80 Statin Use and Progression in Men With Advanced Prostate Cancer Treated With Androgen Deprivation Therapy [198]**
Yu-Hsuan Shao, Su-Chen Fang, Szu-Yuan Wu. (Taiwan)

Drug Effectiveness - Cancer



Drug Effectiveness - Infections

- 81 Receipt and Virologic Outcomes of HCV Direct-Acting Antivirals by Alcohol Use and HIV Status [199]**
Christopher T. Rentsch, Denise A. Esserman, Emily J. Cartwright, Janet P. Tate, David A. Fiellin, Amy C. Justice, Vincent Lo Re. (United Kingdom)
- 82 Hospitalization After Oral Antibiotic Initiation in Finnish Community Dwellers With and Without Alzheimer's Disease [200]**
Heli Järvinen, Heidi Taipale, Marjaana Koponen, Antti Tanskanen, Jari Tiihonen, Anna-Maija Tolppanen, Sirpa Hartikainen. (Finland)
- 83 Monthly Intramuscular Clindamycin Served As a Prophylactic Antibiotic for Recurrent Cellulitis: An Accessible Alternative to Penicillin Regimen [201]**
Yu-Fen Huang, Hung-Jen Tang, Hui-Chen Su. (Taiwan)
- 84 Comparative Effectiveness of Teicoplanin versus Vancomycin in Patients With Methicillin-Resistant Staphylococcus Aureus (MRSA) Bacteremia [202]**
Hsing-Chun Hsieh, Edward Chia-Cheng Lai. (Taiwan)
- 85 The Antiretroviral Therapy Effectiveness in the Viral Load Trend: A 10-Year Analysis of People Living With HIV in Minas Gerais State, Brazil [203]**
Cassia C. Mendicino Mrs, Letícia P. Braga Mrs, Cristiane A. Menezes de Pádua PhD. (Brazil)
- 86 Macrolide Empiric Therapy Is Not Associated With Early Clinical Improvement in Hospitalized Patients With Pneumonia [204]**
Evangeline J Pierce, Julio A Ramirez, Timothy L Wiemken. (United States)
- 87 Consumption of Reserve Group Antibiotics in Europe [205]**
Reka Bordas, Maria Matuz, Reka Viola, Edit Hajdu, Gyongyver Soos, Zoltan Peto, Peter Doro, Ria Benko. (Hungary)

- 88 Trends, Disparities and Geographical Variation in Outpatient Antibiotic Consumption - a Population-Based Prevalence Study [206]**
Pia K Kristensen, Soeren P Johnsen, Reimar W Thomsen. (Denmark)
- 89 Non-Visit-Based Antibiotic Use in a United States Medicaid Cohort [207]**
Michael A Fischer, Mufaddal Mahesri, Joyce Lii, Tiffany Brown, Jeffrey A Linder. (United States)
- 90 The Effect of Antimicrobial Drug Use on the Composition of the Urinary Microbiota in An Elderly Population [208]**
Marlies Mulder, Djawad Radjabzadeh, Robert-Jan Hassing, Jan Heeringa, Andre Uitterlinden, Robert Kraaij, Bruno Stricker, Annelies Verbon. (Netherlands)

Drug Effectiveness - Nervous System

- 91 20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia [209]**
Jari Tiihonen, Antti Tanskanen, Heidi Taipale. (Finland)
- 92 'Real World' Effectiveness of Methylphenidate in Improving Academic Achievement of Attention Deficit Hyperactivity Disorder (ADHD) Students - a Systematic Review [210]**
Joyce C Faria, Lilian A Ferreira, Lívia J Duarte, Vivian T Anicio, Cristiane A Menezes de Pádua, Edson Perini. (Brazil)
- 93 Efficacy and Safety of Naltrexone for Amphetamine and Methamphetamine Use Disorder: A Systematic Review of Randomized Controlled Trials [211]**
Lam Lam, Shweta Anand, Xue Li, Man Li Tse, Jia Xi Zhao, Esther WY Chan. (Hong Kong)

- 94 Varenicline Is More Effective Than Nicotine Replacement Therapy During Pregnancy: Findings From the Smoking Mums (Maternal Use of Medications and Safety) Study [212]**
Stephanie K Choi, Duong T Tran, David B Preen, Deborah Randall, Anna Kemp-Casey, Kristjana Einarsdottir, Louisa R Jorm, Alys Havard. (Australia)

- 95 Abstract Withdrawn [213]**

Drug Utilization - Cancer

- 96 Use of Electronic Healthcare Data to Study the Real-World Utilization of Antineoplastic Drugs for the Treatment of Lung Cancer: A Systematic Review [214]**
Francesco Pellicano, Andrea Spini, Sandra Donnini, Silvano Giorgi, Claudia Bartolini, Rosa Gini, Marina Ziche, Giuseppe Roberto. (Italy)
- 97 Overall Survival and Treatment Patterns Among Real-World Patients With Metastatic Non-Small Cell Lung Cancer Not Previously Treated With Systemic Therapy for Advanced Cancer [215]**
Jason C. Simeone, Beth L. Nordstrom, Ketan Patel, Alyssa B. Klein. (United States)
- 98 Overall Survival and Treatment Patterns Among Real-World Patients With Metastatic Urothelial Carcinoma Treated With First-Line Therapy [216]**
Jason C. Simeone, Beth L. Nordstrom, Ketan Patel, Alyssa B Klein, Laura Horne. (United States)
- 99 Chronic Myeloid Leukemia Among Veterans From 2006-2015: Trends in Utilization of Tyrosine Kinase Inhibitors [217]**
Catherine Chanfreau, Kristine E Lynch, Ji won Chang, Daniel J Becker, Daphne R Friedman, Donna R Rivera, Scott L DuVall, Julie A Lynch. (United States)
- 100 Impact of Psychotropic Polypharmacy on Health Care Resource Utilization Among Newly Diagnosed Non-Metastatic Cancer Patients in the United States [218]**
Hilary A. Aroke, Ami M Vyas, Ashley L Buchanan, Stephen S Kogut. (United States)



- 101 5- α -Reductase Inhibitors Prescribing Patterns for Benign Prostatic Hyperplasia: Evaluation and Cost-Effectiveness Analysis in An Italian Local Healthcare System [219]**

Dr. Grazia Mingolla, Dr. Paola Digiorgio. (Italy)

- 102 Drug Utilization Before and After a Diagnosis With Sarcoidosis [220]**

Daniel P Henriksen, Martin T Ernst, Christian B Laursen, Jesper R Davidsen, Anton Pottegård. (Denmark)

- 103 Predictors of Tyrosine Kinase Inhibitor Treatment for Chronic Myeloid Leukemia [221]**

Ashley L Cole, William A Wood, Benyam Muluneh, Jennifer L Lund, Jennifer Elston Lafata, Stacie B Dusetzina. (United States)

- 104 Use of Prescription Drugs Among Ovarian Cancer Patients in Denmark [222]**

Anton Pottegård, Søren Friis, Søren Friis, Freija Verdoodt, Christian Dehlendorff, Jesper Hallas, Susanne K Kjær. (Denmark)

- 105 Adherence to Adjuvant Endocrine Therapy for Breast Cancer Patients: Impact of a Recently Implemented Outreach Program [223]**

Laurel Habel, Catherine Lee, Devon Check, Ninah Achacoso, Leslie Manace, Lou Fehrenbacher, Charles Quesenberry. (United States)

Drug Utilization - Cardiovascular

- 106 Adherence to Oral Anticoagulants in Patients With Atrial Fibrillation [224]**

Lamia Grimaldi-Bensouda, Jean-Yves Le Heuzey, Lucien Abenheim. (France)

- 107 Rituximab Use in Medicare Patients With Immune Thrombocytopenia (ITP) [225]**

Shuling Li, Julia Molony, Anne Sexter, Karynsa Cetin, Ivy Altomare, Jeffrey Wasser. (United States)

- 108 A Systematic Review of Adherence to Preventative Low Dose Aspirin Therapy and Its Effects on Ischemic Vascular Outcomes [226]**

Sarah Irvin, Montse Soriano-Gabarro, Párean Vora. (United States)

- 109 Factors Influencing Non-Persistence With Antiplatelet Medications and Statins in Patients After An Ischemic Stroke [227]**

Martin Wawruch, Dusan Zatko, Gejza Wimmer Jr, Jan Luha, Jan Murin, Tomas Tesar. (Slovakia)

- 110 Oral Anticoagulants Initiations in Atrial Fibrillation Patients in France in 2015-2016: Do Prescribing Patterns Have a Rationale? [228]**

Géric Maura, Cécile Billionnet, Jérôme Drouin, Antoine Pariente. (France)

- 111 Selection Bias in Studies of Non-Vitamin K Antagonist Oral Anticoagulant Users With Atrial Fibrillation [229]**

Maja Hellfritsch, Erik L Grove, Simone B Haastrup, Lotte Rasmussen, Anton Pottegård. (Denmark)

- 112 Use of Non-Vitamin K Antagonist Oral Anticoagulants During 2008-2016: A Danish Nationwide Drug Utilization Study [230]**

Simone B Haastrup, Maja Hellfritsch, Lotte Rasmussen, Anton Pottegård, Erik L Grove. (Denmark)

- 113 Trends in Concomitant Clopidogrel and Proton Pump Inhibitor Treatment Among ACS Inpatients, 2000-2016 [231]**

Nawal Farhat, Nisrine Haddad, James Crispo, Doug McNair, Franco Momoli, Shi Wu Wen, Don Mattison, Nick Birkett, Dan Krewski. (Canada)

- 114 The Association Between Statin Medication Adherence and Subsequent Healthcare Utilisation in Ageing Community Dwelling Adults: Results From the Irish Longitudinal Study on Ageing (TILDA) [232]**

Caroline A Walsh, Caitriona Cahir, Kathleen E Bennett. (Ireland)

- 115 Twenty Five Year Trends in Antihypertensive Medicine Usage in the State Sector of Sri Lanka: 1992 to 2016 [233]**

A. D. M Gunasekara, B.M.R Fernandopulle, L Panapitiya, B.V.S.H Beneragama, E.D Weeraratne, S Sri Ranganathan. (Sri Lanka)

- 116 When Prescriptions Fall Short: Using CPT Codes to Augment Warfarin Prescriptions in Claims [234]**

Michael A Webster-Clark, Jennifer Lund, Virginia Pate. (United States)

- 117 Trends in Use of Rivaroxaban for Prophylaxis and Treatment in General Practice in the United Kingdom Between 2012 -2015 [235]**

Ana Ruigomez, Gunnar Brobert, Párean Vora, Kiliana Suzart-Woischnik, Yanina Balabanova, Luis-Alberto Garcia Rodriguez. (Spain)

- 118 Database Analysis of Venous Thromboembolism Treatment Patterns in Inpatient vs Outpatient Settings [236]**

Kimberley Woodcroft, Syd Phillips, Giancarlo Maranzano, Harjeet Caberwal. (United States)

Informatics

- 119 Feasibility Analysis and Data Visualization to Identify a Complex Group of Cancer in the Simulacrum [237]**

Ali Abbasi, Shubham Tayal, Deborah Layton, Toby Gosden. (United Kingdom)

- 120 An Application of Machine Learning for the Refinement of An EHR-Derived Cohort [238]**

Sarah R Hoffman, Emily R Pfaff, Wanda K Nicholson. (United States)

- 121 Validation of Adaptable Computable Phenotype As Run on Health Plan Common Data Model [239]**

Ezra I. Fishman, John Barron, Kevin Haynes. (United States)

- 122 Use Chang Gung Research Database for Traditional Chinese Medicine Studies in Taiwan: Patient Characteristics and Data Representativeness [240]**

Shih-Chieh Shao, Yuk-Ying Chan, Hui-Yu Chen, Yea-Huei Kao Yang, Edward Chia-Cheng Lai. (Taiwan)

- 123 Development of a Mobile Application for Genetic Diagnostic (GDx) Testing Return of Results in the Department of Veterans Affairs [241]**

Julie A Lynch, Scott L DuVall, Catherine C Chanfreau-Coffinier, Olga Efimova, Kristine E Lynch, Michael Icardi. (United States)



- 124 A Data-Driven Automatic Method to Detect Irrational Drug Use Prescriptions: A Pilot Study [242]**

Lin Zhuo, Shanshan Wu, Yu Yang, Shuang Tang, Siyan Zhan. (China)

- 125 The InGef Research Database - a Data Source for Pharmacoepidemiological Studies in Germany [243]**

Niklas Schmedt, Frank Andersohn, Jochen Walker. (Germany)

Medical Devices

- 126 Predicting Patient Anti-Arrhythmic Drug Cessation After Catheter Ablation for Atrial Fibrillation [244]**

Amer Ghanem, Rahul Khanna, Andrew Yoo. (United States)

- 127 Risk of Endometriosis Is Greatly Increased in White Women With IUD Removal vs. Insertion [245]**

Ashley Sier, Yasameen Azarbaijani, Hind Baydoun, Yelizaveta Torosyan. (United States)

- 128 Analysis of Autoimmune Comorbidities Among Discharges With Iud Removals vs. Insertions Suggests Increased Iud-Related Risk Which Is Further Modified by Race [246]**

Yasameen Azarbaijani, Ashley Sier, Hind Baydoun, Yelizaveta Torosyan. (United States)

- 129 Characterizing the Procedural Utilization of Mechanical Stapler Buttress Technology in the Premier Healthcare Database [247]**

Andrew Yoo, Gary Chung, Heather Strang, Christine Lim. (United States)

- 130 Analysis of Cerebro/Cardio-Vascular Comorbidities Among Discharges With Iud Removals Vs. Insertions Suggests Increased Iud-Related Risk Which Is Further Modified by Race [248]**

Yasameen Azarbaijani, Ashley Sier, Hind Baydoun, Yelizaveta Torosyan. (United States)

- 131 How to Quantify Predictive Model Performance: A Case Study in Predicting Repeat Incisional Hernia Surgery in Insurance Claims [249]**

Gary Chung, Andrew Yoo. (United States)

Methods - Validation Studies

- 132 Prospective Validation of a Risk Prediction Model to Identify High-Risk Patients for Medication Errors at Hospital Admission [250]**

Ms. Marieke M. Ebbens, Sylvia A. van Laar, Elsbeth J. Wesselink, Kim B. Gombert-Handoko, Patricia M. van den Bemt. (Netherlands)

- 133 Recording of Hospital Bleeding Events in UK Primary Care: A Linked Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES) Study [251]**

Laura McDonald, Cormac Sammon, Mihail Samnaliev, Sreeram V Ramagopalan. (United Kingdom)

- 134 Assessment of Obesity Prevalence and Validity of Obesity Diagnoses Coded in Administrative Claims Data for Selected Surgical Populations [252]**

Eric M Ammann, Iftekhar Kalsekar, Andrew Yoo, Chia-Wen Hsiao, Robin Scamuffa, Stephen S Johnston. (United States)

- 135 A Case Study Assessing the Impact of the New U.S. ICD-10-CM Coding System on Pharmacoepidemiologic Studies—An Application Between Angiotensin-Converting Enzyme Inhibitors and Angioedema [253]**

Catherine A Panozzo, Emily C Welch, Tiffany S Woodworth, Ting-Ying Huang, Qoua L Her, Joshua J Gagne, Jenny W Sun, Catherine Rogers, Talia J Menzin, Max Ehrmann, Katherine E Freitas, Nicole R Haug, Sengwee Toh. (United States)

- 136 Adjudicating Serious Liver Injury/ Disease and Interstitial Lung Disease in Electronic Health Records Or Claims Data [254]**

Arlene K Tave, Earl Goehring, Vibha Desai, Chuntao Wu, Rhonda Bohn, Nawar Shara, Sally Tamayo, Nicholas Sicignano, Juhaeri Juhaeri, Judith K. Jones. (United States)

- 137 A Systematic Review of Measures for Calculating Adherence and Persistence to Multiple Medication From Prescription Data [255]**

Sofa Dewi Alfian, Ivan Surya Pradipta, Eelko Hak, Petra Denig. (Netherlands)

- 138 Using a Simple Prescription Gap to Determine Warfarin Discontinuation Can Lead to Substantial Misclassification [256]**

Kueiyu Joshua Lin, Joshua J Gagne, Sebastian Schneeweiss. (United States)

- 139 Challenges of Using Electronic Health Record (EHR) Data for Medication Exposure and Comparison With Claims Data [257]**

Lauren Stevens, Raymond Schlienger, Ron Parambi, Heather Norman, Cheryl Enger. (United States)

- 140 Measurement Error in the Assessment of Oral Glucocorticoid Exposure Using UK Primary Care Electronic Health Records [258]**

Rebecca M Joseph, Tjeerd P van Staa, Mark Lunt, Michal Abrahamowicz, William G Dixon. (United Kingdom)

- 141 Methods for Handling Missing Ethnicity Data and Their Impacts on the Association Between Ethnicity and Type 2 Diabetes Diagnoses in UK Primary Care [259]**

Tra My Pham, James R Carpenter, Tim P Morris, Irene Petersen. (United Kingdom)

- 142 Feasibility of Assessing Breastfeeding Status in Electronic Health Records [260]**

Mary S. Anthony, Darios Getahun, Amy L. Alabaster, David Cronkite, Jennifer Gatz, Maqdooda Merchant, Vicki Y. Chiu, Mary Anne Armstrong, Mary E. Ritchey, Michael Fassett, Juliane Schoendorf, Alex Asimwe. (United States)

- 143 Are You Really Dead? Validation of Death and Date of Death in Patients With COPD in CPRD [261]**

Elena Rivero-Ferrer, Jordi Castellsague, Jaume Aguado, Estel Plana, Nuria Saigi, Esther Garcia-Gil, Susana Perez-Gutthann, Cristina Rebordosa. (Spain)

- 144 Identifying Multiple Inhaler Triple Therapy (MITT) Prescribing in COPD Patients: An Algorithm for UK Primary Care Data [262]**

Wilhelmine H Meeraus, Dave J Webb, Hana Mullerova. (United Kingdom)



- 145 To Pile Or Not to Pile: How to Define Episodes of Use of COPD Medications in the CPRD [263]**
Estel Plana, Cristina Rebordosa, Jaume Aguado, Nuria Saigí, Esther Garcia, Jordi Castellsagué, Susana Perez-Gutthann. (Spain)
- 146 A Flexible Approach to Evaluating the Validity of Commonly Used Claims-Based Cancer Algorithms [264]**
Monica D'Arcy, Til Stürmer, Jennifer L Lund. (United States)
- 147 Assessing the Performance and Possibility of Overfitting of Different Algorithm Development Methods Used to Define Advanced Stage ER+/HER2- Breast Cancer [265]**
Daniel C Beachler, Ruihua Yin, Stephan Lanes, Kelsey Gangemi, Daina Esposito, Cynthia de Luise. (United States)
- 148 Identification of Incident Pancreatic Cancer in Administrative Health Data: A Validation Study by the Canadian Network for Observational Drug Effect Studies (CNODES) [266]**
Jennifer W. Wu, Laurent Azoulay, Anjie Huang, J. Michael Paterson, Fangyun Wu, Matthew H. Secrest, Kristian B Filion. (Canada)
- 149 Diagnostic Accuracy of the International Classification of Disease 10th Revision Codes of Heart Failure in Administrative Database [267]**
Pauline Bosco-Levy, Stéphanie Duret, François Picard, Etienne Puymirat, Véronique Gilleron, Patrick Blin, Gilles Chatellier, Vincent Looten, Nicholas Moore. (France)
- 150 Endpoint Adjudication in Pharmacoepidemiological Research [268]**
Robert W Flynn, Amy Rogers, Kerr Grieve, Filippo Pigazzani, Isla S Mackenzie, Thomas MacDonald. (United Kingdom)
- 151 A Systematic Review of Validated Suicide Outcome Classification in Electronic Healthcare Database Studies [269]**
Richard Swain, Lockwood Taylor, Elisa Braver, Wei Liu, Simone Pinheiro, Andrew Mosholder. (United States)
- 152 Use of Patient Profiles to Enhance the Interpretation of the Risk of Acute Pancreatitis Among Patients on Multidrug Antidiabetic Therapy [270]**
Donnie Funch, Kathleen Mortimer, Ling Li, Heather Norman, David Dore, Atheline Major-Pedersen, Heidrun Bosch-Traberg, Helge Gydesen. (United States)
- 153 Identifying IBD Patients in Claims Database: A Comparison of Validated Algorithms [271]**
Yizhou Ye, Sudhakar Manne, Dimitri Bennett. (United States)
- 154 Validation of Uterine Perforation and Intrauterine Device Expulsion in Electronic Health Records [272]**
Catherine W Saltus, Mary S Anthony, Mary Anne Armstrong, Debbie Postlethwaite, Darios Getahun, Fagen Xie, Jennifer Gatz, Jane Grafton, Maqdooda Merchant, Laura Ichikawa, Michael Fassett, Renate Schulze-Rath, Alex Asiimwe. (United States)
- 155 Validating Updated Claims-Based Algorithms to Identify Incident Fragility Fractures [273]**
Nicole C. Wright, Shanette G. Daigle, Akhila Balasubramanian, Tarun Arora, Elizabeth S. Delzell, Jeffrey R. Curtis. (United States)
- 156 Assessing the Impact of Missing Deaths on Survival Analyses Conducted in An Oncology Electronic Health Record (EHR) Database [274]**
Gillis Carrigan, Samuel Whipple, Michael D Taylor, Aracelis Z Torres, Anala Gossai, Brandon Arnieri, Melissa Tucker, Philip P Hofmeister, Peter Lambert, Sandra D Griffith, William B Capra. (United States)
- 157 Addressing Variability of the Estimated Incidence of Acute Myocardial Infarction Across Heterogeneous European Healthcare Data Sources: A Strategy From the EMIF Project [275]**
Giuseppe Roberto, Maria Garcia-Gil, Talita Duarte-Salles, Paul Avillach, Rients vanWijngaarden, Sulev Reisberg, Alessandro Pasqua, Lars Pedersen, Lara Tramontan, Miguel Angel Mayer, Ron Herings, Miriam Sturkenboom, Johan van der Lei, Martijn Schuemie, Peter Rijnbeek, Rosa Gini. (Italy)
- 158 Predicting Out-Of-Hospital Death Using Insurance Claims Data [276]**
Jessica C Young, Debra E Irwin, Ashley L Cole, Virginia Pate, Michele Jonsson Funk. (United States)
- 159 Validation of An Algorithm to Identify Opioid Overdose Among US Commercially Insured Individuals [277]**
Daniel C Beachler, Siting Zhou, Kelsey Gangemi, Stephan Lanes, Alexander M Walker, Rachelle Rodriguez, Paul Coplan. (United States)
- 160 Validation of Electronic Health Record Derived COPD Exacerbations Using Randomised Clinical Trial Data [278]**
Matthew Sperrin, David J Webb, Pinal Patel, Kourtney J Davis, Susan Collier, Alexander Pate, Dave Leather, Jeanne M Pimenta. (United Kingdom)
- 161 Impact of the Definition of Osteoarthritis and of the Timing of Its Onset on the Association Between Type 2 Diabetes Mellitus and Osteoarthritis: Clinical Practice Research Datalink [279]**
Yannick Nielen, Pieter C. Dagnelie, Annelies Boonen, Olaf Klungel, Bart van den Bemt, Frank de Vries. (Netherlands)
- 162 Determining Infant Age From Administrative Claims Data Without Birth Date: A Validation Study [280]**
Julia B Ward, Casey Pierce, John Lim, Brian R Matlaga, Lydia Feinstein. (United States)
- 163 Impact of Look-Back Time on the Measurement of Prevalence and Incidence in Healthcare Databases [281]**
Jeremy A Rassen, Amanda Patrick, Dorothee B Bartels, Sebastian Schneeweiss, William Murk. (United States)
- 164 Varying Numerator and Denominator Population Definitions in Annual Prevalence Proportions Estimated From Administrative Claims Data [282]**
Laura L. Hester, James A. Weaver, David M. Kern, Christopher A. Knoll, Patrick B. Ryan. (United States)



165 Algorithms for Cardiovascular Death in Administrative Claims Databases: A Systematic Review [283]

Sonal Singh, Kathryn Anzuoni, Leah Goldman, Jea Y Min, Carlos Grijalva, Marie R Griffin, Christine Whitmore, James S Morrow, Charles E Leonard, Mano Selvan, Vinit Nair, Yunping Zhao, Sengwee Toh, Andrew Petrone, James Williams, Elnara Fazio-Eynullayeva, Hassan Fouyazi, Richard Swain, Tyler Cole, Susan Andrade. (United States)

166 Comparison of Dispensed Medications and Forensic-Toxicological Findings to Assess Pharmacotherapy in the Swedish Population 2006-2013 [284]

Antti Tanskanen, Jonas Forsman, Heidi Taipale, Thomas Masterman, Jari Tiihonen. (Sweden)

167 Review of Claims Profiles to Develop and Refine Study Cohort and Outcome Definitions [285]

Veena Hoffman, Kathleen M Mortimer, Nancy D Lin, John D Seeger. (United States)

168 Cleaning Multiple Prescription Data in General Practice Datasets [286]

Jim Slattery, Xavier Kurz. (United Kingdom)

169 Validation Study With Stratified Sampling [287]

Kiyoshi Kubota, Masao Iwagami, Takuhiro Yamaguchi. (Japan)

170 The Impact of Increasing Allowable Inpatient Diagnoses in Medicare Claims Data [288]

John G Connolly, Joshua J Gagne, Kueiyu J Lin. (United States)

171 Abstract Withdrawn [289]

Novel Data Collection Tools

172 Abstract Withdrawn [290]

173 First Insight to National Database on Electronic Prescriptions in Finland [291]

Emma Aarnio, Maarit J Korhonen. (Finland)

174 Feasibility Assessment for Conducting a Multi-Country Post-Marketing Safety Oncology Study Using Secondary Data Sources in Europe [292]

Karen E Wells, Rui Jiang, Jerzy E Tyczynski, Matthew Secrest, Susan A Oliveria. (United States)

175 Abstract Withdrawn [293]

176 Identification of a Hereditary Angioedema Cohort in a US Ambulatory EMR Database [294]

Emily S Brouwer, Emily W Bratton, Aimee Near, Kathy Lang, Christina D Mack. (United States)

177 Validation of Clinical vs Algorithmic Definition of Line of Therapy in Multiple Myeloma [295]

James A Black, Uzor Ogbu, Elisabeth Wassner Fritsch, John Byon, Mike Lu, Jingbo Yi. (Switzerland)

178 Utilization of Pharmacogenetic Testing Within the Department of Veterans Affairs [296]

Leland E. Hull, Scott L Duvall, Olga V. Efimova, Catherine C. Chanfreau-Coffinier, Gregorio Coronado, Julie A Lynch. (United States)

179 Information on the Expected Delivery Date in German Claims Data: Assessing its Potential to Estimate the Beginning of Pregnancy [297]

Nadine Wentzell, Ulrike Haug, Katarina Dathe, Marlies Onken, Tania Schink. (Germany)

180 Replicating Sentinel Initiative's Cohort Identification and Descriptive Analysis (CIDA) Program Core Functionalities Using a Novel Analytics Platform [298]

Catherine Richards, Erick Moynour, Valerie Carter, Matthew Guthrie, Jordan A Menzin, Joseph Menzin. (United States)

Pediatric Pharmacoepidemiology

181 How Much Reliable Is to Explore Postmarketing Antibiotic Use in Pediatric Population Through Italian Claims Databases? [299]

Carmen Ferrajolo, Valentina Ientile, Valeria Pizzimenti, Cosimo Gennari, Maurizio Maggini, Francesco Rossi, Annalisa Capuano, Gianluca Trifiro'. (Italy)

182 Advances in Epidemiological Methods and Utilisation of Large Databases: A Methodological Review of Observational Studies on Psychotropic Drug Use in Pregnancy and Central Nervous System Outcomes in Children [300]

Zixuan Wang, Kenneth K Man, Phoebe W Ho, Michael T Choy, Ian C Wong. (United Kingdom)

183 Increase in Diagnosis of Depressive Disorders Contributes to the Increase in Antidepressant Use in Adolescents [301]

Svetlana Skurteveit, Jørgen Bramness, Vidar Hjellvik, Ingeborg Hartz, Ragnar Nesvåg, Lars Hauge, Marte Handal. (Norway)

184 Paediatric Use of Melatonin and Other Sleeping Agents- a Register Linkage Study in Sweden [302]

Elin Kimland, Carola Bardage, Anastasia Nyman, Anders Järleborg. (Sweden)

185 The Role of Mental Disorders in Teenage Pregnancy [303]

Nakyung Jeon, Regina Bussing, Stephan Schmidt, Yasser Albogami, Almut Winterstein. (United States)

186 Utilisation of Neonatal Medication Error Prevention Strategies: A Clinical Practice Survey of Australian and New Zealand Neonatal Units [304]

Nadine Matti, Minh-Nha R Nguyen, Cassandra Mosel, Luke E Grzeskowiak. (Australia)

187 Locations Where Medication Changes Occur for Neurologically Impaired Children [305]

James A Feinstein, Jacob Thomas, Diane Fairclough, Robert Valuck, Allison Kempe, Chris Feudtner. (United States)

188 Pomme 1 and 2: New Cohorts to Evaluate Long Term Consequences of Prenatal Drug Exposure [306]

Dr. Justine Benevent, Caroline Hurault-Delarue, Mélanie Araujo, Jean-Louis Montastruc, Isabelle Lacroix, Christine Damase-Michel. (France)



189 The Effects of Pneumococcal Pneumonia Vaccination Program for Children: An Interrupted Time-Series Analysis [307]

Ju-Ling Chen, Ching-Fen Shen, Yea-Huei Kao Yang, Ching-Lan Cheng. (Taiwan)

190 Severity of Adverse Drug Reactions in Crimean Children in 2011-2016. Analysis of Spontaneous Reports [308]

Aleksandr V Matveev, Anatoliy Ye Krashennnikov, Elena A Egorova. (Russian Federation)

Pharmacovigilance - Cancer

191 The Usability of Commercial Healthcare Claims Data in Japanese Pharmacovigilance: A Comparison With a Prospective Postmarketing Study [309]

Yukinori Sakata, Hiroko Tsukamoto, Toshiyuki Matsuoka, Satoshi Ohashi, Tadashi Koga, Tetsumi Toyoda, Mika Ishii. (Japan)

192 Effect of Aggressive Drug Safety Measures in Reducing Adverse Drug Reactions: Post-Hoc Analysis of Data From All-Case Surveillance of Igaratimod Using Generalized Estimating Equations [310]

Mr. Kai Shibata, Ms. Akiko Yoshimura, Mr. Satoshi Ikeuchi, Ms. Mika Ishii. (Japan)

193 Use of Antipsychotics and the Risk of Colorectal Cancer: A Case-Control Study Using Data From the Linked Netherlands Cancer Registry and Pharmo Database Network Population [311]

Josephina G Kuiper, Myrthe P van Herk-Sukel, Valery E Lemmens, Ron C Herings. (Netherlands)

194 Long Term Heart-Specific Mortality Among 347,476 Breast Cancer Patients Treated With Radiotherapy Or Chemotherapy: A Registry-Based Cohort Study [312]

Janick Weberpals, Lina Jansen, Oliver Müller, Hermann Brenner. (Germany)

195 Risk of Neurological Adverse Events During Tumour Necrosis Factor Inhibitor Treatment for Arthritis: A Population-Based Cohort Study From Danbio and the Danish National Patient Registry [313]

Ms. Tine I Kopp, Rikke K Jacobsen, Melinda Magyari, Else H Ibfelt, Henning Loch, Finn T Sellebjerg, Dorte Vendelbo, René Cordtz, Lene Dreyer. (Denmark)

196 Glucocorticoids and the Risk of Peptic Ulcer Bleeding: Case-Control Analysis Based on Swiss Claims Data [314]

Daphne Reinau, Matthias Schwenkglenks, Mathias Frueh, Andri Signorell, Eva Blozik, Christoph R Meier. (Switzerland)

197 Factors Associated With Arthritis and Carpal Tunnel Syndrome After Aromatase Inhibitors Among Female Breast Cancer Population: A Nationwide Claims Data Analysis [315]

Hsu-Chih Sophia Chien. (United States)

198 Risk of Breast Cancer in Women Initiating Insulin Glargine Compared With Insulin Detemir Or NPH Insulin [316]

Marie C Bradley, Yoganand Chillarige, Hana Lee, Xiyuan Wu, Patricia Bright, Shruti Parulekar, Michael Wernecke, Mat Soukup, Jeffrey A Kelman, David J Graham. (United States)

199 Exposure to Phthalate-Containing Prescription Drugs and the Risk of Colorectal Adenocarcinoma: A Danish Nationwide Case-Control Study [317]

Zandra N. Ennis, Anton Pottegård, Jesper Hallas, Thomas P. Ahern, Per Damkier. (Denmark)

200 Androgen Deprivation Therapy for Prostate Cancer and the Incidence of Rheumatoid Arthritis [318]

Christina M Santella, Adi Klil-Drori, Koray Tascilar, Hui Yin, Armen Aprikian, Laurent Azoulay. (Canada)

Trials

201 Diuretic Use and Serum Urate Levels in the Febuxostat versus Allopurinol Streamlined Trial (FAST) [319]

Robert W Flynn, Thomas MacDonald, Ian Ford, George Nuki, on behalf of the FAST steering committee. (United Kingdom)

202 Administrative Claims Data to Support Pragmatic Clinical Trial Outcome Ascertainment Using PCORnet Adaptable Trial As An Example [320]

Qinli Ma, Kevin Haynes, Haechung Chung, Sonali Shambhu, Matthew Roe, William S Jones. (United States)

203 Can Cluster Randomisation of Prescribing Policy Be Used to Efficiently Generate Drug Safety and Effectiveness Data? Pilot Phase of the Evidence Study [321]

Robert W Flynn, Amy Rogers, Angela Flynn, Thomas MacDonald, Isla Mackenzie, Alexander Doney. (United Kingdom)

204 Using a Single Non-Inferiority Margin Or a Single Preserved Fraction for An Entire Pharmacological Class May Be Invalid for the Analysis of Non-Inferiority: A Case Study of Statin Non-Inferiority Trials [322]

Turki Althunian, Anthonius de Boer, Rolf H Groenwold, Olaf H Klungel. (Netherlands)

205 Regulatory Challenges in the Design of Non-Inferiority Trials: Evaluating Scientific Advice Letters From the European Medicines Agency (EMA) [323]

Mr Turki Althunian, Anthonius de Boer, Aukje K Mantel-Teeuwisse, Rolf H Groenwold, Christine C Gispens-De Wied, Hubert G Leufkens, Andre Elferink, Olaf H Klungel. (Netherlands)

206 The Landscape of Clinical Trials for Testosterone: Potential Indications [324]

Pernilla J. Bjerkeli, Juan Merlo, Carola Tilgmann. (Sweden)

207 A Precision Medicine Trial to Study Heterogeneity in Paediatric Asthma: Design of the Puffin Trial [325]

Elise M Slob. (Netherlands)



Burden of Disease - Nervous System

- 208 Relationship Between Migraine Trigger Factors and Auras [326]**
Bernadette Louwrens, Ilse Truter. (South Africa)
- 210 Multiple Source of Information to Characterize the Clinical, Therapeutic Management and Economic Burden of Patients With Multiple Sclerosis in France [328]**
Jonathan Epstein, Bruno Detournay, Francis Guillemin, Mathias Cousin, Bertrand Tehard, Teresa Garot, Laurence Bitoun, Marc Soudant, Paul-Henri Depoortere, David Pau. (France)
- 211 Treatment Resistant Depression As a Risk Factor for Substance Use Disorders - a National Register-Based Cohort Study [329]**
Philip Brenner, David Hägg, Allitia DiBernardo, Gang Li, Robert Bodén, Lena Brandt, Johan Reutfors. (Sweden)
- 212 Alcohol-Specific Mortality in People With Epilepsy: Population-Based Matched Cohort Study [330]**
Hayley C Gorton, Roger T Webb, Matthew J Carr, Rosa Parisi, Marcos DelPozo-Banos, Kieran J Moriarty, Owen Pickrell, Ann John, Darren M Ashcroft. (United Kingdom)
- 213 Substance Use Disorders Are Risk Factors for Treatment Resistant Depression [331]**
Philip Brenner, Lena Brandt, David Hägg, Gang Li, Allitia DiBernardo, Robert Bodén, Johan Reutfors. (Sweden)
- 214 Prevalence and Predictors of Dementia in Older Adults With Employer-Sponsored Health Insurance [332]**
Ashley I. Martinez, Daniela C. Moga. (United States)
- 215 Abstract Withdrawn [333]**
- 216 Epidemiologic Temporal Trends of Neuromyelitis Optic Spectrum Disorder in the United States From 2000 to 2015 [334]**
Mellissa Williamson, Matthew McEnany, Stefanie Maxion-Bergemann, Rose Ong. (United States)

- 217 Comparison of Characteristics and Management of Embolic Strokes of Different Sources [335]**
Lamia Grimaldi-bensouda, Jean-Yves Le Heuzey, Lucien Abenheim. (France)
- 218 Part 1 Descriptive Characteristics of Incident Dementia Patients in Four Electronic Health Record Databases in Europe [336]**
Glen James, Estelle Collin, Marcus Lawrance, Achim Mueller, Liliiana Zarembo-Pechmann, Jana Podhorna, Peter Rijnbeek, Johan van der Lei, Lars Pedersen, David Ansell, Alessandro Pasqua, Myriam Alexander, Usha Gungabissoon, Peter Egger, Jerry Novak, Mark Gordon. (United Kingdom)
- 219 Comorbid Conditions and Medication Utilization Among Patients With Major Depressive Disorder in the United States [337]**
Ankita Shah, Gary Bloomgren, Amy O'Sullivan, Madé Wenten. (United States)
- 220 Depression and Anxiety and Health Related Quality of Life (HRQL) Among Cancer Patients [338]**
Muneera Mansor Alwhaibi, Bushra Ahmed AlKhalifah, Lamyaa Alnaim. (Saudi Arabia)

Drug Utilization - Diabetes

- 221 Diabetes Treatment in Brazil: Affordable Choices and Good Coverage [339]**
Andréia T. Fontanella, Sotero S. Mengue, Rogério B. Borges. (Brazil)
- 222 Real-World Use of Dulaglutide in Europe: A Multi-Country Drug Utilization Study [340]**
Ayad K. Ali, Massoud Toussi, Syd Phillips, Montserrat Roset. (United States)
- 223 Comparison of Diabetic Patients' Baseline Characteristics in Clinical Trials versus Real-World Settings [341]**
Birgit Ehlken, Emile Schokker, Karel Kostev. (Germany)
- 224 The Treatment Patterns of Patients With Type 2 Diabetes in Urban China [342]**
Yuzhuo Wang, Chaowei Fu, Weibing Wang, Qi Zhao, Na Wang, Biao Xu. (China)
- 225 Changes in Diabetes Medication Adherence in Older Cancer Patients versus Matched Cancer-Free Cohorts: A Difference-In-Difference Analysis [343]**
Jennifer L Lund, Ke Meng, Benjamin Y Urick, Joel F Farley, Krutika Amin, Stephanie B Wheeler, Katherine E Reeder-Hayes, Justin G Trogon. (United States)
- 226 Federal Provision of Insulin in Brazil: Volumes and Expenditures 2009-2015 [344]**
Leticia L Dias, Maria Angelica Borges dos Santos, Claudia G Osorio-de-Castro. (Brazil)
- 227 Prescription Pattern of Anti-Diabetics Agents in the Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus: A National Database From Taiwan [345]**
Kai-Cheng Chang, Huang-Tz Ou, Chien-Huei Huang, Yuk-Ying Chan. (Taiwan)
- 228 Mining Treatment Patterns of Glucose-Lowering Medications for Type 2 Diabetes in the Netherlands [346]**
Jan M Van Den Heuvel, Fariba Ahmadizar. (Netherlands)
- 229 Utilization of New Antidiabetic Drugs Between 2008 and 2017 in Hungary [347]**
Marta Csatornai, Ria Benkő, Peter Doro. (Hungary)
- 230 Description of the Utilization Patterns of SGLT-2 Inhibitors in Type 2 Diabetic Patients in Korea [348]**
Hyeonjeong Kim, Ayeong Seo, Bong Gi Kim, Eun Jin Kim, Eunsun Noh, Soo Youn Chung. (Korea, Republic of)



Methods to Avoid Bias and Confounding

231 Methodological Approaches to Reduce Immeasurable Time Bias: The Case of Beta-Blockers and the Risk of Mortality in Patients With Heart Failure [349]

Ju-Young Shin, In-sun Oh, Kristian B. Filion. (Korea, Republic of)

232 Healthy User Bias in Comparative Safety Studies for Brand versus Generic Products; the Example of Warfarin [350]

Steven T Bird, Stephaeno Brereton, Yueqin Zhao, Steven Kozlowski, Stephen McKean, Rima Izem, Michael Wernecke, Jeffrey A Kelman, David J Graham. (United States)

233 Negative Control Time Window to Identify Residual Confounding in Comparative Effectiveness Study: An Example of Bisphosphonate Use and Risk of Fracture [351]

Danielle E Robinson, M Sanni Ali, Antonella Delmestri, Daniel Prieto-Alhambra. (United Kingdom)

234 Adherence to Statin Therapy and the Traumatic Injury: An Investigation Using Claims Database in Japan [352]

Tsugumichi Sato, Motoyoshi Akiyama, Kiyoshi Kubota. (Japan)

235 Methods for Estimating Treatment Episodes - Dosage Assumptions versus Real Prescribed Dosage Accounting for Treatment Gaps and Overlaps [353]

Dr. Laura Pazzagli, Lena Brandt, Marie Linder, Anders Sundström, Emese Vago, David Myers, Morten Andersen, Panagiotis Mavros, Shahram Bahmanyar. (Sweden)

236 Quantifying the Impact of Mortality Underreporting on Analyses of Overall Survival [354]

Michael T Bretscher, Thibaut Sanglier. (Switzerland)

237 How Is Outcome Misclassification Addressed in Pharmacoepidemiology Database Studies? [355]

Rosa Gini, Stephan Lanes, Vinay Mehta, Xiaofeng Zhou, Germano Ferreira, Matt Reynolds, Gillian C Hall. (Italy)

238 Conditioning on Calendar Time in Studies of Newly Marketed Drugs [356]

Justin Bohn, Sengwee Toh, Robert J. Glynn, Sebastian Schneeweiss, Joshua J. Gagne. (United States)

239 Do Regression Models With Better Goodness of Fit Ensure Less Biased Treatment Effect Estimates? [357]

Pengxiang Li, Jalpa Doshi. (United States)

240 Sample Size Needed to Achieve Covariate Balance [358]

Joshua J Gagne, Rishi J Desai, Shirley V Wang. (United States)

241 Maternal ADHD Medication Use During Pregnancy and the Risk of ADHD in Children [359]

Maxim Lemelin, Odile Sheehy, Anick Béard. (Canada)

242 Multiple Imputation of Clinical Variables in FFS Medicare Population [360]

Tiansheng Wang, Emily W Gower, Jennifer L Lund, Michele Jonsson Funk, Virginia Pate, John B Buse, Til Sturmer. (United States)

243 Assessing Residual Confounding of Comparative Mortality Risk of Antipsychotics Use in Elderly Patients With Ischemic Stroke [361]

Chien-Chou Su, Edward Chia-Cheng Lai, Cheng-Yang Hsieh, Hao-Wen Chan, Chih-Hung Chen, Huey-Juan Lin, Sheng-Feng Sung, Yu-Wei Chen, Yea-Huei Kao Yang. (Taiwan)

End Poster Session A



Spotlight Session - Benefit Risk Assessment, Communication and Evaluation (BRACE)

A A Novel Approach to Correlate Soft and Hard Outcomes: Effectiveness of Abatacept (Orencia®) Patient Alert Cards in Rheumatoid Arthritis Patients [440]

Esther Artime, Randip Kahlon, Nawab Qizilbash, Ignacio Méndez, Tzuyung Kou. (Spain)

B The Effect of Risk Evaluation and Mitigation Strategies on Healthcare Provider's Awareness of Drug Risks [441]

Shelly L. Harris, Cynthia LaCivita, Doris Auth, Claudia Manzo. (United States)

C The Use of Real World Evidence in European Medicines Regulation [442]

Jeremy P Brown, Kevin Wing, Stephen Evans, Krishnan Bhaskaran, Liam Smeeth, Ian Douglas. (United Kingdom)

D Mapping Benefit-Risk Decision-Making Processes and Identifying Decision Points With the Potential to Include Patient Preference Information Throughout the Medical Product Lifecycle [443]

Chiara Whichello, Karin Schölin Bywall, Jonathan Mauer, Stephen J Watt, Irina Cleemput, Cathy Anne Pinto, Eline van Overbeeke, Isabelle Huys, Rosanne Janssens, Richard Hermann, Jorien Veldwijk. (Netherlands)

E Trends in US Emergency Department Visits for Zolpidem-Related Adverse Events Before and After FDA Drug Safety Communications, 2010-2016 [444]

Andrew I Geller, Daniel S Budnitz, Esther H Zhou, Maribeth C Lovegrove, Gerald J Dal Pan. (United States)

F Consistency of Drug Labels for Therapeutically Equivalent Medications [445]

Zippora Kiptanui, Paul Dowell, Bethany Ogbenna, Karishma Desai, Dodi Zenilman, Ilene Harris, Jingjing Qian, Richard Hansen. (United States)

G Evaluation of Physician Knowledge of Safety and Safe Use Information for Afibercept [446]

Laurie Zografos, Elizabeth Andrews, Brian Calingaert, Eric Davenport, Dan Wolin, Zdravko Vassilev. (United States)

H Acceptance of Uncertainties at Marketing Authorisation and the Fate of Medicines in the European Union [447]

Lourens T Bloem, Mariana Karomi, Jarno Hoekman, Hubert G Leufkens, Olaf H Klungel, Aukje K Mantel-Teeuwisse. (Netherlands)

Spotlight Session - Databases

I Utilization of ICD10 Codes Indicating Weeks of Gestation in Routine Clinical Care of Pregnant Women in the US [448]

Kelesitse Phiri MS, ScD, Robin C. Clifford BS, MS, Robert V. Gately MS, Michael C. Doherty MS, John D. Seeger PharmD, DrPH. (United States)

J Linkage of Mother and Child Pairs in the Information System for Research in Primary Care (SIDIAP) in Catalonia [449]

Dr. Talita Duarte-Salles, Leonardo Méndez-Boo, Yesika Díaz, Eduardo Hermsilla, Maria Aragón, Francesc Fina, Daniel Prieto-Alhambra, Manuel Medina-Peralta, Bonaventura Bolívar, Maria Garcia-Gil. (Spain)

K Impact of Validation of Major Bleeding Events Diagnosis Recorded in a Primary Care Database [450]

Ana Ruigomez, Gunnar Brobert, Kiliana Suzart-Woischnik, Luis A Rodriguez. (Spain)

L Effect of Coding System on the Consistency of Prevalence Estimates in Databases [451]

Dana Teltsch, Caitlin Curnyn, William Murk, Jeremy A. Rassen. (United States)

M Prognostic Impact of Various Comorbidity Measures on 1-Year Mortality [452]

Morten Madsen, Anne G Ording, Vera Ehrenstein. (Denmark)

N Development of a Dynamic Pregnancy Database Within the Optum Research Database [453]

Kelesitse Phiri MS, ScD, Robin C. Clifford BS, MS, Robert V. Gately MS, Michael C. Doherty MS, John D. Seeger PharmD, DrPH. (United States)

O Intravitreal Antivegf Drugs Use in Italy in the Years 2010-2016: A Multi-Regional Study on Claims Databases, Enriched With Prospective Data Collection [454]

Dr. Giulia Scondotto. (Italy)

P The Missing Puff: Results of Multiple Imputation of PPFEV1 in CPRD [455]

Jaume Aguado, Estel Plana, Nuria Saigi, Esther Garcia, Jordi Castellsagué, Susana Perez-Gutthann, Cristina Rebordosa. (Spain)

Spotlight Session - Drug Utilization Research

Q Dispensing of Specialist HIV Drugs in Community Pharmacies-Evaluation of Effects on Access and Satisfaction [456]

Miguel Gouveia, Margarida Borges, João Costa, Francesca Fiorentino, Gonçalo Jesus, António Teixeira Rodrigues, Maria Cary, José Guerreiro, Peter Heudtlass, Suzete Costa, António Vaz Carneiro. (Portugal)

R Part 2 Treatment Pathway Analysis of Incident Dementia Patients in Four Electronic Health Record Databases in Europe [457]

Glen James, Estelle Collin, Marcus Lawrance, Achim Mueller, Liliana Zarembo-Pechmann, Jana Podhorna, Peter Rijnbeek, Johan van der Lei, Lars Pedersen, David Ansell, Alessandro Pasqua, Myriam Alexander, Usha Gungabissoon, Peter Egger, Jerry Novak, Mark Gordon. (United Kingdom)

S Prevalence and Determinants of ADHD Medication Use in Quebec Children Between 1998 and 2015 [458]

Takoua Boukhris, Maxim Lemelin, Odile Sheehy, Anick Berard. (Canada)

T Seventeen-Year Nationwide Trends in Use of Long-Acting Bronchodilators and Inhaled Corticosteroids Among Adults: A Danish Drug Utilization Study [459]

Mette Reilev, Anton Pottgård, Jesper Rømhild Davidsen, Lotte Rasmussen, Jens Søndergaard, Christian B Laursen, Daniel Pilsgaard Henriksen. (Denmark)

U Recent Trend of Antidiabetic Medications Use and Hypoglycemia Among T2DM in the U.S. Commercially Insured Population [460]

Gang Fang, Izabela E Annis. (United States)



- V Impact of New Drugs and Treatment Recommendations on Drug Utilization in Multiple Sclerosis [461]**
Irene Eriksson, Joris Komen, Fredrik Piehl, Rickard E Malmström, Björn Wettermark, Mia von Euler. (Sweden)
- W Post-Surgical Opioid Prescriptions and Risk of Long-Term Use in the US [462]**
Jessica C Young, Nabarun Dasgupta, Brooke A Chidgey, Michele Jonsson Funk. (United States)
- X Adherence of Prescribers to Recommendations to Reduce Medication Related Hospitalizations [463]**
Christina E Hoeve, Fouzia Lghoul-Oulad Saïd, Margaretha F Warlé-van Herwaarden, Patricia M van den Bemt, Miriam C Sturkenboom, Martina Teichert, Peter A de Smet. (Netherlands)

Spotlight Session - Medical Devices

- Y Risks of Ischemic and Bleeding Events of Drug-Eluting Stents: A Nationwide Population-Based Cohort Study [464]**
Emmanuelle Schapiro-Dufour, Aurore Tricotel, Thien Le Tri, Pierre Ducimetière, Claude Sichel, Michel Slama, Albert Trinh-Duc, Hubert Galmiche, Rosemary Dray-Spira, Mahmoud Zureik. (France)
- Z Safety Evaluation of the Levonorgestrel Intrauterine Device Mirena® From the French Nationwide Claims and Hospitalization Database [465]**
Pauline Bosco-Levy, Amandine Gouverneur, Claire Langlade, Ghada Miremont, Antoine Pariente. (France)
- AA Investigation of Psychiatric Adverse Events Following Exposure to Levonorgestrel Containing IUDs [466]**
Jim Slattery, Daniel Morales, Luis Pinheiro, Xavier Kurz. (United Kingdom)

- BB Information Delivery Affects Patients' Preference to Implantable Devices or Surgeries More Than Toward Medicines to Treat Heart Failure [467]**
Lauren Williams, Matthew Taylor, Xiaojuan Mi, Edward Lai, Soko Setoguchi. (United States)
- CC Utilizing Natural Language Processing to Identify Intraoperative Medical Device Failures and Subsequent Surgeon Mitigation [468]**
Amer Ghanem, Andrew Yoo. (United States)
- DD Analysis of the Likelihood of Hypertension Among Discharges With Iud Removal vs. Insertion Suggests IUD-Related Risk Increase Mostly in Non-White Women [469]**
Ashley Sier, Yasameen Azarbaijani, Hind Baydoun, Yelizaveta Torosyan. (United States)
- EE Analysis of Allergic/Inflammatory Skin Conditions Among Discharges With IUD Removals vs. Insertions Suggests IUD-Related Risk Increase Which Is Modified by Race [470]**
Yasameen Azarbaijani, Ashley Sier, Hind Baydoun, Yelizaveta Torosyan. (United States)
- FF Can Electronic Health Records Be Used to Identify Medical Procedure-Related Events Indicative of Difficult Insertion of Intrauterine Devices? [471]**
Mary E Ritchey, Debbie Postlethwaite, Susan D Reed, Darios T Getahun, Jennifer Gatz, Richard Lynen, Catherine W Saltus, Amy L Alabaster, Theresa M Im, Harpreet S Takhar, Alex Asimwe. (United States)

Spotlight Session - Rare Disease

- GG Hydroxyurea Adherence and Cumulative Dose Associated With Hospital Readmission in Sickle Cell Disease [472]**
Jifang Zhou, Jin Han, Edith A. Nutescu, Victor R. Gordeuk, Santosh L. Saraf, Gregory S. Calip. (United States)

- HH Entacapone and Prostate Cancer in Parkinson's Disease Patients: A Large Veterans Health Administration Study [473]**
Jacqueline M Major, Diane Dong, Francesca Cunningham, Kunthel By, Kwan Hur, David C Shih, Rong Jiang, Gerald D Podskalny, Simone Pinheiro, Steven T Bird, Stephine Keeton, David J Graham. (United States)
- II Viral Kinetic Correlates of Cytomegalovirus Disease and Death After Hematopoietic Cell Transplant [474]**
Elizabeth Duke, Peter Gilbert, Terry Stevens-Ayers, Johnathan Golob, Nicole Cossrow, Morgan Marks, Hong Wan, T. Christopher Mast, Meei-Li Huang, Keith R Jerome, Lawrence Corey, Joshua T Schiffer, Michael Boeckh. (United States)
- JJ Demographic Characteristics and Treatment Patterns Among Patients Treated for Hereditary Angioedema in a U.S. Cohort, 2006-2015 [475]**
Raffi Tachdjian, Karin E. Johnson, Deborah Casso, Susan A. Oliveria, Giovanna Devercelli, Gagan Jain. (United States)
- KK Burden of Illness in Patients With Duchenne Muscular Dystrophy in the United States [476]**
Rose C Ong, Amale El Ghachi, Marco Castillo. (Switzerland)
- LL Acute Generalized Exanthematous Pustulosis: Results of the German Registry Over a 10-Year Period [477]**
Dr. Maren Paulmann, Dr. Peggy Sekula, Prof. Maja Mockenhaupt. (Germany)
- MM Efficacy of Enzyme Replacement Therapy for Hunter Syndrome [478]**
Mrs. Livia Lovato Pires Lemos, Paulo Henrique Ribeiro Fernandes Almeida, Juliana Álvares, Francisco de Assis Acurcio, Augusto Afonso Guerra. (Brazil)
- NN Safety of Enzyme Replacement Therapy for Mucopolysaccharidosis II [479]**
Paulo H. Almeida, Livia L. de Lemos, Juliana Álvares, Brian Godman, Marion Bennie, Francisco de A. Acúrcio, Augusto A. Guerra Junior. (Brazil)



Study Design and Bias

- 1 Comparative Performance of a Modified Landmark Approach to Avoid Immortal Time Bias When No Time to Treatment Data Are Available Within Oncological Databases [480]**
Janick Weberpals, Lina Jansen, Geert Silversmit, Julie Verbeeck, Lydia van der Geest, Pauline A Vissers, Vesna Zadnik, Hermann Brenner. (Germany)
- 2 Assumptions About Grace Period in Exposure Definition May Impact Comparative Estimates on Risk of Gastrointestinal Bleeding Between Oral Anticoagulants [481]**
Liliya Sinyavskaya, Madeleine Durand. (Canada)
- 3 Defining Exposure Measures for Inferring the Association Between Prescription Opioid Use and Bone Fracture [482]**
Emily Peach, Harmony Otete, Li-Chia Chen, Andrew Cooper, Roger Knaggs. (United Kingdom)
- 4 The Effect of Anti-Acid Therapy on Survival in Idiopathic Pulmonary Fibrosis: A Methodological Review of Observational Studies [483]**
Tanja Tran, Samy Suissa. (Canada)
- 5 Variation of the Exposure Measures for Evaluating Long-Term Opioid Utilisation in Chronic Non-Cancer Pain [484]**
Hsin-Te Lin, Teng-Chou Chen, Li-Chia Chen. (United Kingdom)
- 6 Impact of Recruitment Approach on Response Rate to An Online Survey Assessing Behavior Related to the Misuse and Abuse of Prescription Opioids [485]**
Judith J Stephenson, Daina B Esposito, Kelsey Gangemi, Ruihua Yin, Jie Zhang, David M Kern, M Soledad Cepeda. (United States)
- 7 Application of the Prevalent New-User Design Among Commercially-Insured US Patients (Marketscan 2006-2015) [486]**
Arti Virkud, Jeff Yang, Virginia Pate, Til Stürmer. (United States)
- 8 Evaluation of the Quality of Interim Analyses in Observational Safety Studies - Literature Review [487]**
Jie Li, Onyekachukwu Illoh, Wei Liu. (United States)

- 9 The Drug Interaction Outcomes Surveillance Study: Simulations Comparing Self-Controlled Designs [488]**
Katsiaryna Bykov, Jessica M. Franklin, Hu Li, Jill Chappell, Joshua J. Gagne. (United States)
- 10 The Use of Case Crossover and Self-Controlled Case Series Studies in Pharmacoepidemiology: A Literature Review [489]**
Brian Buysse, Jayashri Desai, Susan Sinclair, Julie Duncan, Jessica Albano. (United Kingdom)
- 11 Persistent User Bias in Unidirectional, Not Bidirectional, Self-Controlled Crossover Observational Pharmacoepidemiology (SCOPE) Studies [490]**
Malcolm Maclure, Jesper Hallas, Heather Whitaker, Joseph A Delaney, Suzanne Cadarette. (Canada)
- 12 Selection Bias in Observational Studies: Impact of Identifying "New Users" With Open Data Sources [491]**
Tomomi Tomomi, James van Schyndle, Alan Fan, Satoshi Uno, Daisuke Kato. (Japan)
- 13 The Discover Study: Diversity of Sites, Physicians and Patients [492]**
Wolfgang Rathmann, Jesús Medina, Mikhail Kosiborod, Antonio Nicolucci, Javier Cid-Ruzafa, Peter Fenici, Niklas Hammar, Filip Surmont, Kamlesh Khunti. (Germany)
- 14 Estimating Influenza Vaccine Effectiveness Using An Active Comparator Reduces Bias Due to Confounding by Frailty [493]**
Anne M. Butler, J. Bradley Layton, Whitney S. Krueger, Abhijit V. Kshirsagar, Leah J. McGrath. (United States)

Pregnancy and Lactation

- 15 Medication Use During Pregnancy in the Netherlands: A Population-Based Study [494]**
E. Houben, I.D. Bezemer, C.W. Hukkelhoven, E.A.P. Steegers, R.M.C. Herings. (Netherlands)

- 16 Evaluation of Spontaneous Adverse Event Reports for Congenital and Neonatal Birth Problems Attributed to Ondansetron Within the FDA Adverse Events Reporting System (FAERS) [495]**
Mohamed A Mekkawy, Ola F Khedr, Hala Shokr, Yasmin H Elsobky. (Egypt)
- 17 Glyburide versus Insulin for the Treatment of Women With Gestational Diabetes in Kaiser Permanente Northern California [496]**
Monique M Hedderson, Fei Xu, Romain Neugebauer, Assiamira Ferrara. (United States)
- 18 Pregnancy Trends and Antiretroviral Exposure During Pregnancy Among HIV-Negative and HIV-Positive Women in a Large United States Claims Database [497]**
Cassandra Nan, Shan Zheng, Marianne Cunnington, Vani Vannappagari. (United Kingdom)
- 19 Paternal Exposure to Methotrexate and the Risk of Miscarriage - a Registerbased Nationwide Cohort Study [498]**
Jon Andersen, Bjarke Askaa, Kasper Broedbaek. (Denmark)
- 20 Pregnancy Outcome After First Trimester Exposure to Bisoprolol: An Observational Cohort Study [499]**
Maria Hoeltzenbein, Anne-Katrin Fietz, Angela Kayser, Sandra Zinke, Reinhard Meister, Corinna Weber-Schoendorfer, Christof Schaefer. (Germany)
- 21 The Pregnancy Rate in Women of Childbearing Age With Psoriasis [500]**
Huifang Liang, Dongmu Zhang, Gweneth Levy, Michael C Snabes, Arsalan Shabbir, Dianlin Guo, Syed S Islam. (United States)
- 22 The Epidemiology of Pre-Existing Chronic Kidney Disease in a Cohort of Pregnant Women in the US [501]**
Julia Spoendlin, Julie Paik, Helen Mogun, Sonia Hernandez-Diaz, Elisabetta Patorno, Kathryn Gray, Brian Bateman, Krista Huybrechts, Rishi J Desai. (United States)
- 23 Abstract Withdrawn [502]**



- 24 Hospitalization of Children After Prenatal Exposure to Methadone and Buprenorphine: National Registry Studies From Czech Republic [503]**
Marte Handal, Blanka Nechanská, Svetlana Skurtveit, Milada Mahic, Viktor Mravčík, Roman Gabrhelík. (Norway)
- 25 Late Gestation Use of Serotonin Reuptake Inhibitor Antidepressants is Not Associated With an Increased Risk for Low Milk Supply in Mothers of Preterm Infants [504]**
Luke E Grzeskowiak, Catherine Leggett, Lynn Costi, Claire T Roberts, Lisa H Amir. (Australia)
- 26 Antiepileptic Drugs in Pregnancy, and Duration of Pregnancy, Birth Weight, Length and Head Circumference [505]**
Andrea V Margulis, Brian D'Onofrio, Catarina Almqvist, Thomas McElrath, Anna Sara Oberg, Estel Plana, Kenneth J Rothman, Sonia Hernandez-Diaz. (Spain)
- 27 Use of Antiepileptic Drugs in Pregnancy: A Multinational Register-Based Study [506]**
Jacqueline M Cohen, Carolyn E Cesta, Kari Furu, Kristjana Einarsdóttir, Mika Gissler, Anna Heino, Vidar Hjellvik, Jiong Li, Johan Reutfors, Randi Selmer, Yongfu Yu, Helga Zoega, Øystein Karlstad. (Norway)
- 28 Antipsychotic Drug Use in Pregnancy: A Multinational Database Study [507]**
Johan Reutfors, Helga Zoega, Carolyn Cesta, Brian T Bateman, Anna Cantarutti, Jacqueline Cohen, Giovanni Corrao, Kristjana Einarsdóttir, Anders Engeland, Kari Furu, Alys Havard, Sonia Hernandez-Diaz, Krista F Huybrechts, Pär Karlsson, Oystein Karlstad, Jiong Li, Andrea Schaffer, Yongfu Yu, Gabriella Bröms. (Sweden)
- 29 Patterns and Predictors for Prescription of Psychotropics and Mood-Stabilizing Anti-Epileptics During Pregnancy in Denmark From 2000-2016 [508]**
Per Damkier, Louise S Christensen, Anne Broe. (Denmark)
- 30 Development and Evaluation of Health Education Materials for Women With Gestational Diabetes Mellitus [509]**
Radiana Staynova, Stanislav Gueorguiev, Elina Petkova, Emanuela Vasileva, Vesselina Ianatchkova. (Bulgaria)
- 31 No Increase in Serious Or Opportunistic Infections in Infants Prenatally Exposed to Biologics [510]**
Christina Chambers, Kenneth L Jones, Diana L Johnson, Ronghui Xu, Yunjun Luo. (United States)
- 32 Medically Assisted Reproduction and the Risk of Preterm Birth [511]**
Jessica Gorgui, Odile Sheehy, Jacquetta Trasler, William Fraser, Anick Berard. (Canada)
- 33 Individual Benzodiazepine Exposure During Early Pregnancy and the Risk of Spontaneous Abortion [512]**
Jin-Ping Zhao, Odile Sheehy, Anick Bérard. (Canada)
- 34 First Trimester Exposure to Gadolinium Contrast; a Utilization Study of 4.4 Million Live-Birth Pregnancies [513]**
Steven T Bird, Elnara Fazio-Eynullayeva, Corinne Woods, Patty Greene, Kate Gelperin, Ira Krefting, Leyla Sahin, Erica Radden, Mayura Shinde. (United States)
- 35 Opioid Dispensing Patterns After Oocyte Retrieval [514]**
Pietro Bortoletto, Elizabeth Garry, Krista F. Huybrechts, Raymond M. Anchan, Brian T. Bateman. (United States)
- 36 Asthma Associated With Infertility - But Not Among Women Taking Regular Asthma Preventers: Evidence From the International Scope Study [515]**
Luke E Grzeskowiak, Lisa G Smithers, Jessica A Grieger, Tina Bianco-Miotto, Shalem Y Leemaqz, Vicki L Clifton, Lucilla Poston, Lesley M McCowan, Louise C Kenny, Jenny Myers, James J Walker, Robert J Norman, Gus A Dekker, Claire T Roberts. (Australia)
- 37 Abstract Withdrawn [516]**
- 38 Using Supervised Machine Learning Methods to Develop a List of Medications of Greatest Concern During Pregnancy [517]**
Elizabeth Ailes, John Zimmerman, Jennifer Lind, Fanghui Fan, Kun Shi, Jennita Reefhuis, Cheryl Broussard, Meghan Frey, Janet Cragan, Emily Petersen, Kara Polen, Margaret Honein, Suzanne Gilboa. (United States)
- 39 The Impact of Technology on the Prevalence of Congenital Malformations [518]**
Loreen Straub, Krista F Huybrechts, Brian T Bateman, Helen Mogun, Sonia Hernandez-Diaz. (United States)
- 40 Evaluating Pregnancy Registries: Opportunities for Improving Post Marketing Surveillance Methods in Pregnancy [519]**
Sonia Roldan Munoz, Virginia Rasi, Corinne de Vries. (United Kingdom)
- 41 In-Utero SSRI and SNRI Exposure and the Risk of Neurodevelopmental Outcomes in Children: A Population-Based Retrospective Cohort Study Utilizing Linked Administrative Data [520]**
Deepa Singal, Dan Chateau, Matthew Dahl, Laurence Katz, Chelsea Ruth, Elizabeth Wall-Wieler, Ana Hanlon-Dearman, Marni Brownell. (Canada)
- 42 Opioid Prescribing After Vaginal and Cesarean Delivery and Risk of Persistent Use [521]**
Sarah S Osmundson, Andrew D Wiese, Marie R Griffin, Jae Young Min, Carlos G Grijalva. (United States)
- 43 Do ICPE Pregnancy Abstracts Make it to Term? [522]**
Elena Rivero-Ferrer, David Martinez, Lawrence Rasouliyan, Mary S Anthony, Andrea V Margulis, Susana Perez-Gutthann. (Spain)
- 44 Medication Use During Pregnancy and Lactation in Mainland China: Based on a National Health Insurance Database in 2015 [523]**
Jingyuan Zhang, Xiaodong Guan, Luwen Shi. (China)



- 45 Pharmacological Treatment Utilization and Discontinuation Before and During Pregnancy in Women With Inflammatory Bowel Disease [524]**
Xi Wang, Chao Chen, Ellen M Zimmermann, Joshua M Brown, Hong Xiao, Almut Winterstein. (United States)
- 46 The Top 10 Most Commonly Dispensed Medications During Pregnancy From 2005 to 2015 [525]**
Xi Wang, Yanmin Zhu, Yan Li, Hong Xiao, Almut Winterstein. (United States)
- 47 A Multiphase Claims-Based Algorithm for Live Pregnancy Outcomes Research [526]**
Syd Phillips, Matthew Secrest, Karin Johnson, Sophie W Shen, Kimberley J Woodcroft, Susan A Oliveria, Teresa A Simon. (United States)
- 48 A Comparison of Pregnancy and Lactation Product Labeling Based on FDA and EMA Requirements [527]**
Jayashri Desai, Susan Sinclair, Brian Buysse, Jessica Albano. (United States)
- 49 Healthcare Provider Counseling About Prescription Medication Use During Pregnancy Among Women of Reproductive Age [528]**
Michelle Vu, Jennifer N. Lind, Elizabeth C. Ailes, Cheryl S. Broussard, Kayla N. Anderson, Gitangali Baroi, Suzanne M. Gilboa. (United States)
- 50 Generation of a New Zealand Pregnancy Cohort for Medicine Utilisation and Safety Studies [529]**
Sarah Donald, Dave Barson, Lianne Parkin, Simon Horsburgh, Katrina Sharples. (New Zealand)
- 51 Awareness Strategies, Referral Sources, and Impact on Enrollment in Pregnancy and Lactation Studies [530]**
Deborah Covington, Nicole Hurst, Tammy Moore. (United States)
- 52 Trends in FDA Post-Marketing Commitment Requirements for Pregnancy Registries [531]**
Deborah Covington, Bronwen Mabe, Rebecca Buus. (United States)

- 53 Maternal Use of Thyroid Hormone Replacement Therapy: Group-Based Trajectory Modelling of Adherence and Agreement Between Self-Reporting and Prescription Records During Pregnancy [532]**
Anna-Simone Frank, Angela Lupattelli, David S. Matteson, Hedvig Nordeng. (Norway)
- 54 Exposure to Mycophenolate Before and During Pregnancy in France: A Nationwide Cohort Study [533]**
Sara Miranda, Cedric Collin, Hanane Laouar, Annie Rudnichi, Rosemary Dray-Spira. (France)

Pharmacovigilance - Methods/ Data

- 55 Identifying Adverse Drug Effects From Granular Longitudinal Inpatient Data [534]**
James Flory, Ying Taur. (United States)
- 56 Characteristics of Medical Information Database Network (MID-NET®) of 23 Hospitals on Drug Safety Assessment [535]**
Takashi Ando, Chieko Ishiguro, Yoshiaki Fujimura, Michio Kimura, Koichiro Murata, Naoki Nakashima, Masaharu Nakayama, Kazuhiko Ohe, Takao Orii, Eizaburo Sueoka, Takahiro Suzuki, Hideto Yokoi, Mitsune Yamaguchi, Yoshiaki Uyama. (Japan)
- 57 Drug-Drug Interactions in Nursing Homes: A Systematic Review and Meta-Analysis of 136357 Residents [536]**
Pajaree Mongkhon, Darren M Ashcroft, Chuenjid Kongkaew. (Thailand)
- 58 The Association Between Potentially Inappropriate Medication Use and Health-Related Outcomes Among Nursing Home Residents: A Systematic Review and Meta-Analysis [537]**
Pajaree Mongkhon, Rattima Jeenapongsa, Tanasin Tanasombat, Chuenjid Kongkaew. (Thailand)
- 59 Signals in Types of Adverse Event Reporting of Concurrent Use of Botanical Dietary Supplements and Anticancer Prescriptions in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) [538]**
Jingjing Qian, Shahariar Mohammed Fahim, Ahmed Ullah Mishuk, Angela Calderón, Richard Hansen. (United States)
- 60 Development and Pilot Testing of a Process for Postmarketing Surveillance to Comparatively Assess and Monitor for Brand vs. Generic Safety and Effectiveness [539]**
Richard Hansen, Peggy Peissig, Richard Berg, James Linneman, David Page, Jingjing Qian, Md Motiur Rahman. (United States)
- 61 A Comparison of Two Algorithms to Identify Sudden Cardiac Deaths [540]**
Jea Young Min, Carlos G Grijalva, Tony Morrow, Christine C Whitmore, Marie R Griffin. (United States)
- 62 Outpatient Adverse Drug Reactions As Reason of Emergency Department Visit [541]**
Matias F. Martinez, Ana Muñoz, Camila Chavez, Luis Herrada, Marcela Jiron. (Chile)
- 63 Understanding the Views of Patients Using Health Unlocked, a Social Network for Health, About the Monitoring of the Safety of Medicines [542]**
Alexander Bulcock, Ruth Costello, Phill Tregunno, Goran Nenadic, William Dixon. (United Kingdom)
- 64 Use of Patient-Reported Data to Detect Medication Errors [543]**
Meaghan Zisk, Rhiannon Leutner, Sonja Brajovic, Stephanie Eaneff, Andrew Thompson, Gabrielle Farhadi Jones, Sally Okun, Marni Hall, Carol Pamer. (United States)
- 65 Signal Detection in Vaers and Eudravigilance Using Disproportionality and Time to Onset Method and Their Combination [544]**
Caitlin Dodd, Lionel van Holle, Maria de Ridder, Daniel Weibel, Miriam Sturkenboom. (Netherlands)



- 66 Pilot of a Pharmacoepidemiology Capacity Building Electronic Survey for the Latin American and African Regions [545]**
Maribel Salas, Wendy Camelo Castillo, Lucia D Juarez, Chengchen Zhang, Ariel Arias, Kwame Appenteng, Macarius Donneyong, Nicolas Thurin, Luciane C Lopes, Diana Gomez Galicia, Johanita Burger, Daniel Ankrah, Olayinka Ogunleye, Joseph Fadare, Juan David Rueda, Martie Lubbe, Aida Kuzucan, Chioma S Ejekam, Miriam del Carmen Garcia Estrada, Jorgelina Bernet, Luis Alesso, Raquel Herrera Comoglio, Lisa Pont, Norma Angelica Rodriguez, Ilse Truter. (United States)
- 67 Patient Reporting of Adverse Drug Events in Rural Uganda - What Do They Know, Their Attitude and Practices Toward Reporting [546]**
Helen Ndagije, Edward Galiwango, Victoria Nambasa, Dan Kajungu. (Uganda)
- 68 Pharmacovigilance Analysis of Product Confusion Errors and Issues [547]**
Genaro Castillon, Zsuzsanna Gesztesi, Yola Moride. (Canada)
- 69 Adverse Drug Events: Validating Post Marketed Safety Signals With Pooled Clinical Trial Results [548]**
Rose Petrie, Rianna Barton, Brian Overstreet, James Davis, Robert Kyle. (United States)
- 70 Medication Errors, Impact of Work-Shifts, and Associated Contributing Factors: A Cross Sectional Study in a Developing Country Scenario [549]**
Sri Harsha Chalasani, Madhan Ramesh. (India)
- 71 Assessing the Quality of the Individual Case Safety Reports Received at the Pharmacovigilance Center of Peru Using Vigigrade [550]**
Yesenia Rodriguez, Yanet Condori, Maria Hernandez. (Peru)
- 72 Adverse Drug Events in Hospital Settings: Reporting & Fate at a Tertiary Academic Hospital: Cross-Sectional Study [551]**
Mansour Almetwazi, Mohammed Alqasem, Tariq AlHadlaq, Ali Aljumayd, Faisal Alreshedi, Wael Mancy, Nasser Alqahtani, Ghadah Alhuwyail, Tariq Alhawassi. (Saudi Arabia)
- 73 Subset Disproportionality Analysis Within a Global Database to Uncover Adverse Drug Reactions in Risk Groups [552]**
Lovisa Sandberg, Yasunori Aoki, Rebecca Chandler, Henric Taavola, Niklas Norén. (Sweden)
- 74 Drug Shortages May Compromise Patient Safety: Results of a Survey of the Reference Pharmacies of the Drug Commission of German Pharmacists [553]**
André Said, Ralf Goebel, Matthias Ganso, Petra Zagermann-Muncke, Martin Schulz. (Germany)
- 75 Gender Differences in Drug - Adverse Drug Reaction Combinations Reported to the National Pharmacovigilance Centre in the Netherlands [554]**
Sieta T. de Vries, Petra Denig, Corine Ekhart, Peter G Mol, Eugene P van Puijenbroek. (Netherlands)
- 76 Assessment of Medication Errors in the Surgery Department in a Developing Country's Tertiary Care Teaching Hospital [555]**
Chalasani Sri Harsha, Madhan Ramesh. (India)
- 77 Interest in a Mobile App for Two-Way Risk Communication - a Survey Study Among European Healthcare Professionals and Patients [556]**
Sieta T de Vries, Petra Denig, Peter G Mol, on behalf of IMI Web-RADR work package 3b consortium. (Netherlands)
- 78 Assessment of Patient-Initiated Adverse Event Reports Received by the Food and Drug Administration From Patients Like Me [557]**
Sonja Brajovic, Sally Okun, Sanjay Sahoo, Marni Hall, Carol Pamer. (United States)
- 79 Current Practices of Pharmacovigilance in Middle East: A Quantitative Study Among Arab Countries [558]**
Thamir M Alshammari, Nasser M Alqahtani, Khalidah A Alenzi. (Saudi Arabia)
- 80 Detecting Adverse Drug Events in Spontaneous Reporting Data: A Systematic Comparison [559]**
Louis Dijkstra, Marco Garling, Ronja Foraita, Iris Pigeot. (Germany)
- 81 First Year Results of Using a New Prediction Model-Based Algorithm for Computer-Assisted Database Screening of Adverse Drug Reactions in the Netherlands [560]**
Florence Hunsel, Joep Scholl, Eugene Puijenbroek. (Netherlands)
- 82 A Model for Data Monitoring Committees for Retrospective Study Designs in the Real World Setting [561]**
Atheline Major-Pedersen, Mary Kate McCullen, Mary Beth Sabol, Omolara Adetunji, Joseph Massaro, Alfred Neugut, Julie Ann Sosa, Anthony Hollenberg. (Denmark)
- 83 Factors Distinguishing Identified Risks From Potential Risks: Analysis of Safety Specification of Japan and EU Risk Management Plan [562]**
Saeko Hirota, Takuhiro Yamaguchi. (Japan)
- 84 A Comparative Analysis of Safety Advisories in Australia, Canada, the United States, and the United Kingdom [563]**
Lucy T Perry, Alice Bhasale, Alice Fabbri, Joel Lexchin, Lorri Puil, Maisah Joarder, Barbara Mintzes. (Australia)
- 85 Is Signal Detection Method Based on Time-To-Onset Useful for Drugs Other Than Vaccines? [564]**
Tsugumichi Sato, Kosuke Kumano, Yukari Kamijima, Kiyoshi Kubota. (Japan)



86 Web-Based Signal Detect ION Using Medical Forums World Wide From 2005-2015 [565]

Marie-Laure Kürzinger, Natalie Gavrielov-Yusim, Chihiro Nishikawa, Chunshen Pan, Julie Pouget, Limor Epstein, Dorit Dekel-Rotman, Stéphanie Tcherny-Lessenot, Stephen Lin, Bernard Hamelin, Juhaeri Juhaeri. (France)

87 Impact of the Intensified Reporting Requirements on Reporting of Suspected Side Effects of New Pharmacological Products in Denmark [566]

Christine E Hallgreen, Reema Al-bader, Rahat Nazmi, Espen Jimenez-Solem. (Denmark)

88 Validation of Algorithms to Identify Pancreatic Cancer and Thyroid Neoplasms From Health Insurance Claims Data in a 10-Year Follow-Up Study [567]

Caihua Liang, Monica L. Bertoia, C. Robin Clifford, Yan Ding, Qing Qiao, Joshua J. Gagne, David D. Dore. (United States)

89 Validity of Hospital ICD-10-GM Codes to Identify Acute Liver Injury [568]

Antje Timmer, Sanny Kappen, Dominik de Sordi, Manel Pladevall, Susana Perez-Gutthann, Emmanuelle Jacquot, Nicola Deltour, Tania Schink. (Germany)

90 A Prospective Cross Sectional Study of Prescribing Errors Prevalence and Nature in Emergency Department [569]

Mona Bin Anzan, Tariq Alhawassi, Monira Alwehaibi, Khalid Alburikan, Mansour Almetwazi, Salma Alkhani. (Saudi Arabia)

91 Analysis of Drug Information Centre Enquires Between 1994 and 2016 [570]

Katerina Mala-Ladova, Petra Thomson, Natalia Cikovska, Barbora Chmelikova, Josef Maly, Eva Zimcikova, Martin Dosedel, Petra Matoulikova, Jiri Vlcek. (Czech Republic)

Pharmacovigilance - Musculo-Skeletal

92 Cyclooxygenase Selectivity and Chemical Subgroup of Non-Steroidal Anti-Inflammatory Drugs and Frequency of Spontaneous Reporting of Hypersensitivity Reactions: A Case/Non-Case Study in Vigibase [571]

Mohammad Bakhriansyah, Ronald H Meyboom, Patrick C Souverein, Anthonius de Boer, Olaf H Klungel. (Netherlands)

93 Eperisone Related Adverse Drug Reactions Including Anaphylaxis: A Study on 242 Korean Patients [572]

Dr. Kyung Hee Park, Sang Chul Lee, Jae-Hyun Lee, Jung-Won Park. (Korea, Republic of)

94 Abstract Withdrawn [573]

95 Signals of Increased Risk of Serotonin Syndrome Associated With Drug Interaction With Tramadol in Spontaneous Adverse Event Reporting Database [574]

Sun-Young Jung, Jong-Mi Seong. (Korea, Republic of)

96 Hypocalcemia and Denosumab: A Comparative Study With Hypocalcemic Drugs [575]

Thierry Trenque, Aurore Morel, Agathe Trenque, Emmanuelle Herlem, Yohan Talineau, Brahim Azzouz. (France)

97 Use of Parenteral Glucocorticoids and the Risk of New Onset Type 2 Diabetes Mellitus: A Case-Control Study [576]

Ala Keyany, Yannick Nielen, Patrick C Souverein, Frank de Vries, Bart van den Bemt. (Netherlands)

98 Risk of Diabetes Mellitus Among Rheumatoid Arthritis Patients Taking Non-Biologic DMARDs: A Population-Based Study [577]

Elham Rahme, Louis Bessette, Hacene Nedjar, Francisco de Assis Acurcio. (Canada)

99 Risk of Diabetes Mellitus Among Rheumatoid Arthritis Patients Taking TNF Inhibitors With Or Without Non-Biologic DMARDs and Corticosteroid: A Population-Based Cohort Study [578]

Elham Rahme, Louis Bessette, Hacene Nedjar, Francisco de Assis Acurcio. (Canada)

100 Comparative Safety of Flavocoxid (Limbrel) versus Nsaids Among Osteoarthritis Patients [579]

Fenglong Xie, Justin K Owensby, Jeffrey R Curtis. (United States)

101 Analyzing Factors Influencing the Risk of Falls - Pilot Project Results [580]

Jan Vosatka, Josef Maly, Martin Dosedel, Iva Brabcova, Hana Hajduchova, Sylva Bartlova, Ales Kubena, Jozef Kolar, Jiri Vlcek, Valerie Tothova. (Czech Republic)

Pharmacovigilance - Nervous System

102 Abstract Withdrawn [581]

103 Neuroleptic Drug Use and Neurodegeneration [582]

Stephen K Van Den Eeden, Kathleen B. Albers, Charles P. Quesenberry. (United States)

104 A Novel Approach for Active Surveillance of Pregnancy Safety in Multiple Sclerosis [583]

Eva-Maria Didden, Elizabeth B Andrews, Kerstin Hellwig, Sonia Hernandez-Diaz, Melinda Magyari, Andrea V Margulis, Elena Rivero-Ferrer, Silvia Bader-Weder, David Wormser. (Switzerland)

105 Association of Ischaemic Colitis With Triptans Treatment - a Nested Case Control Study in the United Kingdom Using the Health Improvement Network Primary Care Data [584]

Alexandra Pacurariu, Reynold D Francisca, Swabra Nakato, Maria de Ridder, Sabine Straus, Miriam Sturkenboom. (Netherlands)

106 The Risk of Brain Hemorrhage With the Use of Antidepressant Drugs [585]

Seonji Kim. (Korea, Republic of)

107 Reported Adverse Drug Reactions in Children and Adolescents Using Antipsychotics: Data From Vigibase [586]

Lenneke Minjon, Patrick C. Souverein, Emma de Jong, Toine C. Egberts, Eibert R. Heerding. (Netherlands)



- 108 Use of Pharmacoepidemiological Approach in Evaluating Drug Effect on Driving Impairment: A Systematic Literature Review [587]**
Hu Li, Ellen Dennehy, Xiong (Sean) Liu, JiHyun Miller, Ana Vaz. (United States)
- 109 Do Antipsychotics Increase the Risk of Fractures? [588]**
Hongliu Ding, Danijela Stojanović, Allen Brinker, Ida-Lina Diak, Cindy Lortepeter, Robert L Levin, Lookwood Taylor. (United States)
- 110 Initial Patterns of Prescription Opioid Use and Risk of Mortality Among Adult Patients With Non-Cancer Pain Conditions in the United States [589]**
Hilary A Aroke, Ashley L Buchanan, Jeffrey Bratberg, Joseph Hogan, Josiah Rich, Xuerong Wen, Stephen S Kogut. (United States)
- 111 Trends in Carbamazepine Use, Severe Cutaneous Adverse Reactions, and HLA-B*15:02 Screening: A Nationwide Study in Taiwan [590]**
Chih-Wan Lin, Wei-I Huang, Pi-Hui Chao, Wei-Ming Ke, Wen-Wen Chen, Fei-Yuan Hsiao. (Taiwan)
- 112 Guideline Adherence for Laboratory Monitoring of Ambulatory Patients Treated With Lithium: A Retrospective Follow-Up Study in the Netherlands [591]**
Mariëtte Nederlof, Toine C Egberts, Liesbeth van Londen, Maurits C de Rotte, Patrick C Souverein, Ron C Herings, Eibert R Heerdink. (Netherlands)
- 113 Utilisation and Safety of Asenapine in Primary Care in England: Results From a PASS [592]**
Sandeep Dhanda, Flavien Coukan, Lesley Wise, Saad Shakir. (United Kingdom)
- 114 Utilisation and Safety of Asenapine in Secondary Care in the UK: Results From the Observational Safety Evaluation of Asenapine (OBSERVA) Study [593]**
Sandeep Dhanda, Jan Slade, Vicki Osborne, Lesley Wise, Saad Shakir. (United Kingdom)
- 115 Antiepileptic Drug Use and the Risk of Stroke Among Community-Dwelling Persons With Alzheimer's Disease: A Matched Cohort Study [594]**
Dr. Sirpa Hartikainen. (Finland)
- 116 Self-Harm in People With Epilepsy: Population-Based Cohort and Nested Case-Control Studies [595]**
Hayley C Gorton, Roger T Webb, W O Pickrell, Matthew J Carr, Darren M Ashcroft. (United Kingdom)
- 117 Use of High H1 Receptor Affinity Antidepressants and Risk of Type 2 Diabetes Mellitus [596]**
Francesco Barone-Adesi, Virginio Salvi, Roberta Picariello, Tiziana Cena, Corrado Magnani, Claudio Mencacci, Roberto Gnani, Giuseppe Costa. (Italy)
- 118 Safety and Tolerability of Antipsychotic Medication Use in Individuals With Autism Spectrum Disorder: A Systematic Review and Meta-Analysis [597]**
Basmah H Alfageh, Zixuan Wang, Pajaree Mongkhon, Frank Besag, Tariq M Alhawassi, Ruth Brauer, Ian C Wong. (United Kingdom)
- 119 Antiepileptic Drug Use Is Associated With An Increased Risk of Pneumonia Among Community-Dwelling Persons With Alzheimer's Disease, a Nationwide Matched Cohort Study [598]**
Heidi Taipale, Pasi Lampela, Marjaana Koponen, Antti Tanskanen, Jari Tiihonen, Sirpa Hartikainen, Anna-Maija Tolppanen. (Finland)
- 120 Use of Antipsychotics and Risk of Acute Respiratory Failure Among Adults: A Population-Based Nested Case-Control Study [599]**
Meng-Ting Wang, Yun-Han Wang, Chen-Wei Lin, Chen-Liang Tsai, Jyun-Heng Lai, Yu-Juei Hsu, Chin-Bin Yeh. (Taiwan)
- 121 Neurological Adverse Events With Baclofen Among Clinical Sub-Populations With and Without Alcohol Use Disorders, HIV, and HCV [600]**
Christopher T. Rentsch, David A. Fiellin, Kendall J. Bryant, Amy C. Justice, Janet P. Tate. (United Kingdom)
- 122 The Efficacy and Safety of Psychotropic Drug Treatment in Adolescents With Anorexia Nervosa: A Systematic Review [601]**
Maedeh Y Beykloo, Abdallah Y Naser, Dasha Nicholls, Mima Simic, Ruth Brauer, Ian CK Wong. (United Kingdom)
- 123 Prevalence of CYP3A4 Inhibitor Use in Patients With Dementia: A Cross-Sectional Study in the United States [602]**
Shreya Dave, Sudhakar Manne. (United States)
- 124 Risk of Self-Harm Associated With Individual Antiepileptic Drugs: A Propensity Score Analysis [603]**
Hayley C Gorton, Roger T Webb, Marcos DelPozo-Banos, Mark Lunt, Ann John, Darren M Ashcroft. (United Kingdom)

Pharmacovigilance - Other

- 125 Assessment of Risk of Variant Creutzfeldt-Jakob Disease (VCJD) From Use of Bovine Heparin [604]**
Hong Yang, Yin Huang, David Keire, Sau Lee, Luisa Gregori, David Asher, Cyrus Bett, Brian Niland, Scott Brubaker, Richard Forshee. (United States)
- 126 Risk of Tympanic Membrane Perforation After Quinolone Ear Drops for Acute Otitis Externa: A Retrospective Cohort Study [605]**
Xi Wang, Patrick J Antonelli, Adel Alrwan, Almut Winterstein. (United States)
- 127 Medication-Related Adverse Events Among Older Adults: A Nationwide Readmission Study [606]**
James A. Crispo, Dylan P. Thibault, Allison W. Willis. (Canada)



- 128 Assessment of Transfusion-Related Acute Lung Injury (TRALI) After Blood Transfusion [607]**
Candace C Fuller, Craig Zinderman, Caren Spencer-Smith, Kimberly Smith, Steven A Anderson, Lesley H Curtis, Richard Forshee, Jason Hickok, Stacey Honda, Richard Max Kaufman, Adele Kennedy, Mikhail Menis, Karla M Miller, Manette Niu, Joyce Obidi, Wendy Paul, Russell Poland, Robert Rosofsky, Robert Jin, Rong Tilney, Mayura U Shinde, Azadeh Shoaibi, Fang Zhang, Lauren Zichittella, Meghan A Baker. (United States)
- 129 Reports of Adverse Events With Levonorgestrel IUD Mirena in France Before and After the 2017 Media Intense Coverage [608]**
Claire Langlade, Amandine Gouverneur, Pauline Bosco-Lévy, Aurore Gouraud, Marie-Christine Pérault-Pochat, Johana Béné, Ghada Miremout-Salamé, Antoine Pariente. (France)
- 130 Insertion- and Removal-Related Events Associated With the Nexplanon Contraceptive Implant: Results From the Nexplanon Observational Risk Assessment (NORA) Study [609]**
Suzanne Reed, Carol Koro, Klaas Heinemann. (Germany)
- 131 Risk of Hypertension in Patients Treated With Mirabegron Compared to Tolterodine: A Nationwide Cohort Study [610]**
Anna Citarella, Marie Linder, Simona Cammarota, Helle Kieler. (Italy)
- 132 Opioid-Related Factors Affecting Mortality in Indiana, USA [611]**
Sariya Udayachalerm, David R. Foster PharmD FCCP, Michael D. Murray PharmD MPH FCCP. (United States)
- 133 Association Between Persistent Opioid Prescribing and Opioid-Related Deaths in the United Kingdom [612]**
Teng-Chou Chen, Li-Chia Chen, Roger David Knaggs. (United Kingdom)
- 134 Identifying Opioid Overdose Deaths and All-Cause Mortality in Administrative Claims Data and the National Death Index [613]**
Vibha Ca Desai, Daniel C Beachler, Daina B Esposito, Kelsey Gangemi, Stephan Lanes. (United States)
- 135 Analysis of the Risks Associated With Using Dietary Supplements by Patients in the Pre-Operative Period [614]**
Julie Straznicka, Anna Faltysova, Jitka Pokladnikova, Ludek Jahodar. (Czech Republic)
- 136 Occurrence of Safety Outcomes Among Golimumab Initiators in Routine Care [615]**
Najat Ziyadeh, Anja Geldhof, Wim Noël, John Seeger. (United States)
- 137 Occurrence of Safety Outcomes Among Ustekinumab Initiators in Routine Care [616]**
Najat Ziyadeh, Anja Geldhof, Wim Noël, John Seeger. (United States)
- 138 Differences in Diagnostic and Treatment of Endometriosis in Europe: Comparative Data From the Vipos Study [617]**
Klaas Heinemann, Sabine Moehner, Kerstin Becker. (Germany)
- 139 Drug Exposure and Risk of Acute Liver Failure Leading to Registration for Liver Transplantation (ALFT): Results of the Salt III Study in Adults in France [618]**
Régis Lassalle, Séverine Lignot-Maleyran, Sophie Micon, Simon Lorrain, Jérémy Jove, Dominique Larrey, Lucy Meunier, Georges-Philippe Pageaux, Cécile Droz-Perroteau, Nicholas Moore. (France)
- 140 Comparative Risk of Respiratory Depression in Patients Treated With Opioids for Non-Malignant Pain [619]**
Meghna Jani, Kamilla Kopec-Harding, Mark Lunt, William G Dixon. (United Kingdom)
- 141 Prevalence of Hospital Admissions Related to Medication in the Netherlands Between 2008 and 2013 [620]**
Fouzia Lghoul - Oulad Saïd, Karin Hek, Ron M Herings, Margaretha F Warlé - van Herwaarden, Sandra de Bie, Vera E Valkhoff, Jelmer Alsmas, Mees Mosseveld, Ann M Vanrolleghem, Bruno H Stricker, Miriam C Sturkenboom, Peter A de Smet, Patricia M van den Bemt. (Netherlands)
- 142 Trends in U.S. Emergency Dept. Visits for Zolpidem-Related Adverse Events Before and After FDA Drug Safety Communications, 2010-2016 [621]**
Andrew MD, Andrew MD. (United States)
-
- ### Pharmacovigilance - Respiratory
- 143 Predisposing Factors, Incidence and Severity Assessment of Antibiotic-Induced Hypersensitivity reactions in Inpatients of a Tertiary Care Hospital in India [622]**
Shilpa Palaksha, R. Chaithra, Gurumurthy Parthasarathi, Madhan Ramesh, P A Mahesh. (India)
- 144 Risk of Cardiovascular Events Among COPD Patients Using Roflumilast [623]**
Inyoung Lee, Patrick M Zueger, Todd A Lee. (United States)
- 145 The Effect of Inhaled Corticosteroids on Hair Cortisol [624]**
Esmé J Baan, Erica L Van Den Akker, Yolanda B De Rijke, Johan C De Jongste, Miriam Sturkenboom, Katia M Verhamme, Marjolein Engelkes, Hettie M Janssens. (Netherlands)
- 146 Occurrence of Infections Associated With Long-Term Add-On Therapy of Oral Corticosteroids in Elderly Patients With Severe Asthma: A Retrospective Cohort Study [625]**
Sola Han, Jin Seon Son, Hyungtae Kim, Siin Kim, Hae Sun Suh. (Korea, Republic of)
- 147 The Effect of Inhaler Switching on Asthma and COPD Patients [626]**
Chloe Bloom, Ian Douglas, Liam Smeeth, Jennifer Quint. (United Kingdom)
-
- ### Geriatric Pharmacoeconomics
- 148 Treatment Patterns and Survival Among Elderly Patients With Selected Lymphomas - Findings From Medicare Claims Data [627]**
Joseph Menzin, Lauren Johns, Echo Li-Eng. (United States)



- 149 Antiepileptic Drug Use and Dementia Risk - Analyses of Finnish Health Register and German Health Insurance Data [628]**
Heidi Taipale, Willy Gomm, Karl Broich, Wolfgang Maier, Anna-Maija Tolppanen, Antti Tanskanen, Jari Tiihonen, Sirpa Hartikainen, Britta Haenisch. (Germany)
- 150 Preadmission Antithrombotic Therapy and Risk of Blood Transfusion and 30-Days Mortality Following Hip Fracture Surgery: A Danish Nationwide Cohort Study [629]**
Cecilie Daugaard, Nickolaj R Kristensen, Alma B Pedersen, Søren P Johnsen. (Denmark)
- 151 Examining the Risk of Major Gastrointestinal Bleeding Events in Older People Using Antithrombotics: A Nationwide Study Using a Self-Controlled Case-Series Design [630]**
Te-yuan David Chyou, Prasad Shiva Nishtala. (New Zealand)
- 152 Association of Statins With Functioning, Rehospitalization, and Mortality in Frail Older Adults [631]**
Andrew R Zullo, Richard Ofori-Asenso, Michael A Steinman. (United States)
- 153 Long-Term Thiazide Use and Risk of Fractures Among Persons With Alzheimer's Disease -Nested Case-Control Study [632]**
Heidi Taipale, Jaana Rysä, Janne Hukkanen, Marjaana Koponen, Antti Tanskanen, Jari Tiihonen, Sirpa Hartikainen, Anna-Maija Tolppanen. (Finland)
- 154 The Impact of Cyp2d6 Mediated Drug-Drug Interaction in Elderly: Co-Prescription of Metoprolol and Paroxetine/Fluoxetine [633]**
Muh. Akbar Bahar, Yuanyuan Wang, Jens H.J. Bos, Bob Wilffert, Eelko Hak. (Netherlands)
- 155 Potential Omissions of Angiotensin Inhibition Treatment Among Older US Adults After An Acute Myocardial Infarction [634]**
Marcela Jiron, Virginia Pate, Laura C Hanson, Jennifer Lund, Michele Jonsson Funk, Til Stürmer. (Chile)
- 156 Potential Omissions of Oral Anticoagulant Among Older US Adults With Newly Diagnosed Atrial Fibrillation [635]**
Marcela Jiron, Virginia Pate, Laura C Hanson, Jennifer Lund, Michele Jonsson Funk, Til Stürmer. (Chile)
- 157 Concomitant Sedative and Opioid Use: A Dose Response Analysis [636]**
Tham Thi Le, Siyeon Park, Michelle Choi, Linda Simoni-Wastila. (United States)
- 158 Selective Serotonin Reuptake Inhibitor Use and Adverse Outcomes and Quality of Care in Hip Fracture Patients [637]**
Stine B Bruun, Irene Petersen, Nickolaj R Kristensen, Deirdre Cronin-Fenton, Alma B Pedersen. (Denmark)
- 159 Antiepileptic Drugs and Accumulation of Hospital Days Among Persons With Alzheimer's Disease [638]**
Pii Lavikainen, Heidi Taipale, Antti Tanskanen, Marjaana Koponen, Jari Tiihonen, Sirpa Hartikainen, Anna-Maija Tolppanen. (Finland)
- 160 Impact of Drug Burden Index on Adverse Health Outcomes in Irish Community-Dwelling Older People: A Cohort Study [639]**
Catherine Byrne, Caroline Walsh, Caitriona Cahir, Kathleen Bennett. (Ireland)
- 161 Psychotropic Drug Use and Psychotropic Polypharmacy Among Persons With Alzheimer's Disease [640]**
Kim Orsel, Heidi Taipale, Anna-Maija Tolppanen, Marjaana Koponen, Antti Tanskanen, Jari Tiihonen, Helga Gardarsdottir, Sirpa Hartikainen. (Finland)
- 162 Potentially Inappropriate Medication Use and Incident Dementia in Privately-Insured Older Adults [641]**
Ashley I. Martinez, Gregory A. Jicha, Daniela C. Moga. (United States)
- 163 Potentially Inappropriate Medication Use and Emergency Department Visits in Older Women Diagnosed With Breast Cancer Initiating Chemotherapy [642]**
Danielle S Chun, Sharon Peacock-Hinton, Jennifer L Lund. (United States)
- 164 Comparative Mortality Risks of Antipsychotic Augmentation in Treatment-Resistant Depression Patients [643]**
Hsueh-I Mou, Chien-Chou Su, Wei-Hung Chang, Yea-Huei Kao Yang, Edward Chia-Cheng Lai. (Taiwan)
- 165 Polypharmacy and Frailty in a Longitudinal Community-Based Cohort Study [644]**
Shahar Shmuel, Jennifer L Lund, Carolina Alvarez, Christine D Hsu, Priya Palta, Anna M Kucharska-Newton, Amanda E Nelson, Yvonne M Golightly. (United States)
- 166 Beyond Opioids: Pharmacologic Intensification of Pain Management in Nursing Home Residents With Cancer [645]**
Shao-Hsien Liu, Jacob N. Hunnicutt, Christine M. Ulbricht, Deborah Mack, Bill M. Jesdale, Catherine E. Dubé, Anne L. Hume, Kate L. Lapane. (United States)
- 167 Improving Population-Level PIM Exposure Metrics Using Medicare Claims Data [646]**
Jennifer L Lund, Virginia Pate, Marcela Jiron, Laura C Hanson, Shahar Shmuel, Michael A Webster-Clark, Joel F Farley, Til Sturmer. (United States)
- 168 Anticholinergic and Sedative Drug Burden in Irish Community-Dwelling Older People: A Cross-Sectional National Database Study [647]**
Catherine Byrne, Caroline Walsh, Caitriona Cahir, Cristin Ryan, David Williams, Kathleen Bennett. (Ireland)
- 169 Validating the Latent Construct of Problematic Opioid Use Among Medicare Beneficiaries [648]**
Tham T Le, Aida Kuzucan, Linda Simoni-Wastila. (United States)
- 170 The Association Between Physical Functioning and Healthcare Utilization in Older Adults: A Retrospective Longitudinal Cohort Study [649]**
Yue Cheng, Joshua Brown. (United States)



171 Potential Inappropriate Medications Among Inpatient Older Adults in a Teaching Hospital Chile [650]

Ms. Tamara Sandoval, Carlos Silva, Iván Maturana, Marcela Jirón. (Chile)

172 Potentially Inappropriate Medications Use: Prevalence and Predictors in Saudi Arabia [651]

Tariq Alhawassi, Wafa Alatawi, Monira Alwhaibi. (Saudi Arabia)

173 What Is the Impact of Dementia Diagnosis on Patterns of Medication Use Among Older Adults? [652]

Danijela Gnjidic, George Agogo, Christine M Ramsey, Daniela C Moga, Heather G Allore. (Australia)

174 Mean Number of Drugs and Prevalence of Polypharmacy Among Community-Dwelling Persons With and Without Alzheimer's Disease [653]

Heidi Taipale, Marjaana Koponen, Anna-Maija Tolppanen, Jari Tiihonen, Sirpa Hartikainen, Antti Tanskanen. (Finland)

175 Potential Drug-Drug Interactions Among Older Emergency Department Patients in Chile [654]

Marcela Jiron, Luis Herrada, Andres Lueiza, Matias Martinez, Tamara Sandoval. (Chile)

176 Health Care Professionals' Attitudes Towards Deprescribing in Patients Nearing the End of Their Life: A Systematic Review [655]

Carina Lundby Olesen, Trine Graabæk, Dorte Nielsen, Jesper Ryg, Jens Søndergaard, Anton Potttegård. (Denmark)

177 Adherence, Self-Management and Beliefs About Immunosuppressives in Kidney Transplant Outpatients [656]

Barbora Vankova, Josef Maly, Katerina Mala-Ladova, Ales Kubena, Pavel Navratil, Sylvie Dusilova-Sulkova. (Czech Republic)

Health Economics / Outcomes Research

178 Ledipasvir-Sofosbuvir (Harvoni) Response and Treatment Duration in a Hepatitis C Virus Genotype 1 Cohort: A Claims Data Analysis From a Health Plan Perspective [657]

Liana D Castel, Gary Henshaw, Aran Canes, Thom Stambaugh. (United States)

179 Assessing the Direct Medical Cost of Treating Patients With Cancer in Kenya: A Pilot Study- Findings and Implications for the Future [658]

Omondi Atieno, Sylvia Opanga, Amanj Kurdi, Antony Martin, Brian Godman. (United Kingdom)

180 Direct Medical Cost of Metastatic Colorectal Cancer (mCRC) Treatment in Indonesia [659]

Erna Kristin, Dwi Endarti, Rizaldy Taslim Pinzon, Dwi Aris Nugrahaningsih, Alfi Yasmina. (Indonesia)

181 Validation Study of a Novel Method for Predicting the Budget Impact of New Innovative Medicines [660]

Joost W. Geenen, Svetlana V. Belitser, Rick A. Vreman, Martijn Bloois, van, Olaf H. Klungel, Cornelis Boersma, Anke M. Hövels. (Netherlands)

182 Abstract Withdrawn [661]

183 Cost Analysis of Anti-Osteoporotic Drugs in Real-World Clinical Practice [662]

Valentina Orlando, Valeria Marina Monetti, Francesca Guerriero, Antonella Piscitelli, Veronica Russo, Raffaele Piscitelli, Enrica Menditto, Matteo Ruggeri. (Italy)

184 Clinical Features, Outcome, and Hospital Volume of Pediatric Brain Tumor Resection Surgery in Japan [663]

Daisuke Shinjo, Kimikazu Matsumoto, Keita Terashima, Tetsuya Takimoto, Takashi Noguchi, Kiyohide Fushimi. (Japan)

185 Psychosocial Factors in Promoting Patient Safety Culture: A Structural Equation Modelling Analysis [664]

Alan M Oliveira, Marcus T Silva, Taís F Galvão, Luciane C Lopes. (Brazil)

186 A Systematic Review of the Methodological Quality of Economic Studies Evaluating Ophthalmic Drugs [665]

Inês Ribeiro, Francisco Batel Marques, Carlos Alves. (Portugal)

187 Measuring Enhanced MTM Services: Literature Review and Quality Indicator Development [666]

Christine Gill, Zippora Kiptanui, Corey Triebwasser, Lanlan Xu, Evan Perlman, Karin Johnson, Ilene Harris. (United States)

188 Blood Eosinophilia, Use of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality [667]

Olorunfemi A Oshagbemi, Frits Franssen, Dionne Braeken, Yvonne Henskens, Emiel Wouters, Andrea M. Burden, Frank de Vries. (Netherlands)

189 Deep Molecular Response in Chronic Phase - Chronic Myeloid Leukemia Patients Treated With Second-Line Nilotinib Or Dasatinib: A Multi-Country Retrospective Chart Review Study [668]

Jorge Cortes, MD, Lynn Huynh, MPH, MBA, DrPH, Estella Mendelson, BSRN, MBA, Patricia Brandt, PhD, Darshan Dalal, MPH, MD, PhD, Maral DerSarkissian, PhD, Diego Cortina, MD, MSc, Sahil Narkhede, BA, Mei Sheng Duh, MPH, ScD. (United States)

190 Real-World Analysis of Treatment Patterns and Long-Term Effectiveness Among Patients With Advanced Neuroendocrine Tumors of Lung Origin: A Multicenter Study [669]

Lynn Huynh, Todor Totev, Arvind Dasari, Emily K Bergsland, Al B Benson, Beilei Cai, Jesse Shea, Mei Sheng Duh, Maureen P Neary, Matthew H Kulke. (United States)

191 Healthcare Quality Measures Among Diabetics Using Linked Insurance Claims-EMR Data [670]

Brenna L. Brady, Debra E. Irwin. (United States)



- 192 Real-World Study of Comorbidities and Complications in Relapsed/Refractory Acute Myeloid Leukemia Patients Identified Using a Claims-Based Algorithm [671]**
Shahed Iqbal, Aimee Near, Neil Dhopeswarkar, Huan Huang, Maribel Salas, Kathy Lang. (United States)
- 193 Healthcare Resource Burden Among Patients With Severe Aplastic Anemia Who Have Had Insufficient Response to Immunosuppressive Therapy: A Retrospective Chart Review Study [672]**
Lynn Huynh, Jasmina I Ivanova, Todor Totev, Mehmet Bilginsoy, Joseph Antin, Anuja Roy, Mei Sheng Duh, Régis Peffault de Latour. (United States)
- 194 Risk Factors Associated With 7-Day versus 30-Day Readmission Among Patients With Heart Failure Using Nationwide Readmission Database [673]**
Phuong N Pham, Xiao Hong, Amir Sarayani, Ming Chen, Joshua D. Brown. (United States)
- 195 Healthcare Resource Utilization of Conjunctivitis in the General Population and in Patients With Prior Antibiotic-Resistant Infection: A Retrospective US Claims-Based Analysis [674]**
Wendy Cheng, Nora McCormick, Mei Sheng Duh, Hoi Ching Cheung, Priyanka Bobbili, Corey Joseph, Sujata Sarda. (United States)
- 196 Predicting 30-Day Mortality Or Risk of Re-Hospitalization in Medicare Patients Discharged to Skilled Nursing Facilities After Hospitalization for Heart Failure [675]**
Lin Li, Jonggyu Baek, Bill M. Jesdale, Anne Hume, Giovanni Gambassi, Robert J. Goldberg, Kate L. Lapane. (United States)
- 197 Access to Patient-Centered Medical Home Care Among Adults With Chronic Conditions: Findings From the Medical Expenditures Panel Survey [676]**
Ziyad Almalki. (Saudi Arabia)
- 198 The Impact of Patient Centered Medical Home on Hypertension-Associated Health Care Utilization and Cost [677]**
Ziyad S Almalki. (Saudi Arabia)
- 199 Health Care Costs and Utilization Associated With High Risk Prescription Opioid Use [678]**
Hsien-Yen Chang, Hadi Kharrazi, Dave Bodycombe, Jonathan P. Weiner, G. Caleb Alexander. (United States)
- 200 Coverage and Out-Of-Pocket Spending on Brand versus Generic/Biosimilar Specialty Drugs in Medicare Part D [679]**
Stacie B. Dusetzina, Shelley A. Jazowski, Ashley L. Cole, Joehl Nguyen. (United States)
- 201 Disinvestment of Health Technologies by the Brazilian National Health Technology Incorporation Committee, 2012-2016 [680]**
Rosângela Caetano, Ricardo E Steffen, Rondineli M Silva, Aline N Biz, Ione A Oliveira, Claudia G Osorio-de-Castro, Pamela K Santana. (Brazil)
- 202 Trends in Coverage for Disease Modifying Therapies for Multiple Sclerosis in Medicare Part D [681]**
Daniel M Hartung, Kirbee Johnston, Adrienne Irwin, Dennis Bourdette. (United States)
- 203 The Economic Burden of Preventable Adverse Drug Reactions. A Systematic Review [682]**
Dario Formica, Paola M Cutroneo, Janet Sultana, Ylenia Ingrassiotta, Francesco Salvo, Edoardo Spina, Gianluca Trifirò. (Italy)
- 204 Comparison of Outcome and Cost Between the Open, Laparoscopic, and Robotic Surgical Treatments for Colon Cancer: A Propensity Score-Matched Analysis Using Nationwide Hospital Record Database [683]**
Chong-Chi Chiu, James J Choi, Tzu-Chun Hsu, Brandon Galm, Chien-Chang Lee. (Taiwan)
- 205 Comorbidity and Treatment Burden Among HIV-Infected Patients in a US Medicaid Population [684]**
Maral DerSarkissian, Rachel Bhak, Alan Oglesby, Julie Priest, Emily Gao, Monica Machecha, Camara Sharperson, Francois Laliberte, Mei S Duh. (United States)
- 206 Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the FDA, 2015-2016 [685]**
Thomas J. Moore, Hanzhe Zhang, Gerard Anderson, G. Caleb Alexander. (United States)
- 207 Predictors of Drug Shortages and Association With Generic Drug Prices: A Retrospective Cohort Study [686]**
Chintan Dave, Ajinkya Pawar, Erin Fox, Gregory Brill, Aaron Kesselheim. (United States)
- 208 Patients' Needs and Wishes Regarding Pharmaceutical Care Provided by the Pharmacist for Women Treated With Adjuvant Endocrine Therapy for Breast Cancer [687]**
Selma En-nasery, Vashti N Tromp, Marjan J Westerman, Lonneke Timmers, Christel L Boons, Inge Konings, Jacqueline G Hugtenburg. (Netherlands)
- 209 Impact of the Interaction Between Tizanidine and Ciprofloxacin on Healthcare Utilisation in Swiss Claims Data [688]**
Annika M Jödicke, Ivanka Curkovic, Urs Zellweger, Ivan T Tomka, Thomas Neuer, Gerd A Kullak-Ublick, Malgorzata Roos, Marco Egbring. (Switzerland)
- 210 Improving the Use of All-Oral Direct Acting Antivirals in Hepatitis C Virus Infected Patients With Substance Use Disorder [689]**
Xinyi Jiang, Wei Wang, Haesuk Park. (United States)
- 211 Outcome and Economic Comparison for Type B Aortic Dissection Patients Receiving Open Surgery, Thoracic Endovascular Aortic Repair, and Medical Treatment [690]**
Ronan Wenhan Hsieh, Tzu-Chun Hsu, Wan-Ting Hsu, Chien-Chang Lee. (Taiwan)



- 212 Association Between Use of Phthalate-Containing Medication and Semen Quality Among Men in Couples Referred for Assisted Reproduction [691]**
Anne Broe, Anton Pottegård, Jesper Hallas, Thomas P Ahern, Jens Fedder, Per Damkier. (Denmark)

Drug Utilization - Nervous System

- 213 Abstract Withdrawn [692]**
- 214 Prescribing Patterns of Benzodiazepine in Malaysia From 2014 to 2016 [693]**
Norny Syafinaz Ab Rahman, Fatin Azzyati Pakururazi, Che Suraya Zin, Helina Abd Halim. (Malaysia)
- 215 Comorbidities and Treatment Initiation in Patients With Parkinson's Disease: A Retrospective Cohort Study Using a US Insurance Claims Database [694]**
Richard Houghton, Frank Boess, Lynne Verselis, Yingjie Ding, Rita Freitas, Niculae Constantinovici, Rose Ong. (Switzerland)
- 216 Treatment Patterns Among Patients With Multiple Sclerosis Initiating Glatopa Therapy: A Descriptive Analysis Using a Large US Claims Database Linked With Electronic Medical Records [695]**
Kristen Bibeau, Sigal Melamed-Gal, Ying Wu, Jessica K Alexander, Kathryn Starzyk. (United States)
- 217 Utilisation of Antiepileptic Drugs in Girls and Women of Childbearing Potential in Three European Countries [696]**
Caroline Hurault-Delarue, Rachel Charlton, Rosa Gini, Maria Loane, Anna Pierini, Aurora Puccini, Amanda Neville, Julia Snowball, Christine Damase-Michel, Joan Morris. (France)
- 218 Impact of New Oral Disease-Modifying Therapies on the Prescription of Injectable and Off-Label Drugs in Multiple Sclerosis in France Over 2011-2015 Using National Administrative Databases [697]**
Jonathan Roux, Alice Guilleux, Emmanuelle Leray. (France)

- 219 Prescribing Valproate to Girls and Women of Childbearing Age in Germany: Analysis of Trends Based on Claims Data [698]**
Nadine Wentzell, Ulrike Haug, Tania Schink, Susanne Engel, Judith Liebenraut, Roland Linder, Marlies Onken, Christof Schaefer, Katarina Dathe. (Germany)
- 220 Disease Modifying Therapy Dispensing During Pregnancy: A Multidatabase Pregnancy Cohort of Women With Multiple Sclerosis [699]**
Sarah C MacDonald, Krista F Huybrechts, Brian T Bateman, Rishi J Desai, Thomas F McElrath, Sonia Hernández-Díaz. (United States)
- 221 Use of Analgesics in France, Following Dextropropoxyphene Withdrawal [700]**
Eric Van Ganse, Manon Belhassen, Marine Ginoux, Emilie Chrétien, Catherine Cornu, Claude Ecoffey, Frédéric Aubrun. (France)
- 222 Abstract Withdrawn [701]**
- 223 Initiation of Long-Acting Injectable Antipsychotics in the Canadian Province of Manitoba [702]**
Donica Janzen, I fan Kuo, Christine Leong, James Bolton, Silvia Alessi-Severini. (Canada)
- 224 Trends in Opioid and Analgesic Utilisation in Ireland From 2000 to 2015 [703]**
Frank Moriarty, Kathleen Bennett, Tom Fahey. (Ireland)
- 225 Identifying Pain Medications for Trigeminal Neuralgia Patients in a US Claims Database [704]**
Lisa Vinikoor-Imler, Nasha Wang, Anne Dilley, Susan Eaton, Nancy Maserejian. (United States)
- 226 Recent Pharmacoepidemiology of Tic Disorders in Korea: A Nationwide Population-Based Study [705]**
Hankil Lee, Hye-Young Kang. (Korea, Republic of)
- 227 Benzodiazepines and Z-Drug Use in Canadian Adults - Drug Utilization Study(2001-2016) [706]**
Jaden Brandt, Christine Leong. (Canada)

Drug Utilization - Opioids

- 228 Non-Prescription Use of Opioids Among University Students [707]**
Raissa C Cândido, Cristiane A Menezes de Pádua, Edson Perini, Daniela R Junqueira. (Brazil)
- 229 Trends in Prescription Opioid Use Among Hemodialysis Patients in the United States, 2007-2014 [708]**
Matthew Daubresse, G. Caleb Alexander, Deidra Candice Crews, Dorry Segev, Mara McAdams DeMarco. (United States)
- 230 Opioid Prescription Patterns in UK Primary Care Patients With Knee Osteoarthritis: A Population Based Study [709]**
Aqila Taqi, Harmony Otete, Roger Knaggs. (United Kingdom)
- 231 Chronic Opioid Use After Surgery: A Meta-Analysis of Observational Studies [710]**
Amala Murthy, Hilary Aroke, Nicholas Belviso, Xuerong Wen. (United States)
- 232 Chronic Use of Opioids Before and After Hysterectomy: Patterns and Predictors [711]**
Xuerong Wen, Kristen A. Matteson, Hilary Aroke, Stephen Kogut, Teresa Shireman. (United States)
- 233 Patterns of Opioid Utilization in the 90-Days Post Hospital Discharge and Risk of Re-Admissions and Emergency Department Visits [712]**
Siyana Kurteva, Daniale Weir, Alexandra Schmidt, Todd Lee, Robyn Tamblyn. (Canada)
- 234 Prevalence and Predictors of Opioid Use During Pregnancy Over 15 Years in the Quebec Pregnancy Cohort [713]**
Odile Sheehy, Christelle Berthod, Anick Bérard. (Canada)
- 235 Unpacking the Association Between Mental Health Disorders and Opioid Prescribing [714]**
Matthew T Taylor, Daniel B Horton, Theresa Juliano, Tobias Gerhard. (United States)
- 236 Patterns and Predictors of Long-Term Opioid Use in Older Adults [715]**
GYeon Oh, Erin L. Abner, David W. Fardo, Patricia R. Freeman, Daniela C. Moga. (United States)



- 237 Comparing the Patterns and Predictors of Opioid Use in Older Adults With Different Cognitive Status [716]**
GYeon Oh, Erin L. Abner, David W. Fardo, Patricia R. Freeman, Daniela C. Moga. (United States)
- 238 Trends and Patterns of Analgesic Utilization in Malaysia From 2010 to 2016: Preference for Tramadol [717]**
Che Suraya Zin, Nor Ilyani Nazar, Norny Syafinaz Rahman, Nor Elina Alias, Wan Rohaidah Ahmad, Nurul Sahida Rani, Ng Kim Swan, Felicia Loh Ye. (Malaysia)
- 239 Opioid Analgesic Utilization, Poisonings and Deaths: The Impact of Hydrocodone Rescheduling [718]**
Sara Karami, Jacqueline M Major, Yulan Ding, Jennie Wong, Rajdeep Gill, Tamra Meyer, Alex Secora, Adebola Ajao, Jana McAninch, Grace P Chai, Judy A Staffa. (United States)
- 240 Opioid Use After Hip Fracture Surgery [719]**
Amalie H Simoni, Lone Nikolajsen, Anne E Olesen, Christian F Christiansen, Alma B Pedersen. (Denmark)

Burden of Disease - Other

- 241 EHR-Driven Evidence for Health and Wellness Research: Lessons From the NBA [720]**
Christina Mack, Mackenzie Herzog, Eva Oakkar, Kristin Shiue, Peter Meisel, Nancy Dreyer, John DiFiori. (United States)
- 242 Long-Term Use of High-Dose Opioid Analgesics in Kentucky From 2012 to 2016 [721]**
Huong Luu, Svetla Slavova. (United States)
- 243 A Retrospective Analysis on Pattern of Poisoning and Its Treatment Outcome [722]**
Eswaran Maheswari, P Sri Aishwarya, Aruna C Ramesh. (India)
- 244 Treatment Characteristics of Patients With Binge-Eating Disorder [723]**
Monica L. Bertoia, William M. Spalding, Karen Yee, Judith C. Kando, Cynthia M. Bulik, John D. Seeger. (United States)

- 245 The Incidence of Glaucoma in the United Kingdom, 2000-2015 [724]**
Luis Velez-Nandayapa, Claudia Becker, Laura Eggenschwiler, Susan S Jick, Christoph R Meier. (Switzerland)
- 246 Organ Damage in Systemic Lupus Erythematosus (SLE) is Consistently Associated With Increased Mortality: A Meta-Analysis [725]**
Edward R. Hammond, Irene B. Murimi, Dora H. Lin, Henk Nab, Hong Kan, Oluwadamilola Onasanya, Jonothan C. Tierce, Xia Wang, Barnabas Desta, G. Caleb Alexander. (United States)
- 247 Organ Damage and Health-Related Quality of Life (HRQOL) in Systemic Lupus Erythematosus (SLE): A Systematic Review [726]**
Edward R. Hammond, Dora H. Lin, Irene B. Murimi, Henk Nab, Hong Kan, Oluwadamilola Onasanya, Jonothan C. Tierce, Xia Wang, Barnabas Desta, G. Caleb Alexander. (United States)
- 248 Epidemiology and Burden of Illness in Systemic Lupus Erythematosus: Analysis Using the Japanese Health Insurance Claims Database and Disease Blogs on the Internet [727]**
Shinichi Matsuda, Takumi Ohtomo, Shiho Tomizawa, Shinichi Watanabe, Terumi Nakayama, Yuki Miyano, Miwako Mogi, Hiroshi Kuriki, Yoichiro Takahashi. (Japan)
- 249 Economic Burden in Patients With Primary Dysmenorrhea: A Cross-Sectional Survey [728]**
Sola Han, Kyoung Sun Park, Hae Sun Suh, Jin Moo Lee. (Korea, Republic of)
- 250 Prevalence and Disease Characteristics of Lupus Patients Across Markets [729]**
Carey Strader, Anne LaPrade, Nikoletta Sternbach. (United States)
- 251 Greater Severity of Atopic Dermatitis (AD) Is Associated With Poorer Patient-Reported Outcomes Among Adults With Moderate-To-Severe AD [730]**
Fredrik Nyberg, Jes B Hansen, Line Andersen. (Sweden)
- 252 Assessing the Use of Complex Case Definitions on Measures of Incidence in a US Claims Database [731]**
John W Logie, Harriet Dickinson, Sarah Rabhi. (United Kingdom)

Burden of Disease - Respiratory

- 253 Changing Causes of Mortality for People With Chronic Respiratory Diseases in England, 2005-2015 [732]**
Alicia Gayle, Eleanor Axson, Chloe Bloom, Vidya Navaratnam, Jennifer Quint. (United Kingdom)
- 254 Clinical and Economic Burden of Community-Acquired Pneumonia Among Adults Low-Risk Inpatient: A Retrospective Analysis of Nationwide Registry Data in Japan [733]**
Sayuri Shimizu, Keiko Konomura, Shunya Ikeda, Kiyohide Fushimi. (Japan)
- 255 Persistent Severe Asthma: Healthcare Resource Utilization and Costs for Patients Receiving Multiple Controller Medications [734]**
Jianbin Mao, Jill Davis, Jeffrey T McPheeters, Xiao Xu, Trung N Tran. (United States)
- 256 Characterization of Elderly Patients With Idiopathic Pulmonary Fibrosis Within a United States Administrative Claims Database [735]**
Kathleen M. Mortimer, Nadine Hartmann, Christine Chan, Heather Norman, Laura Wallace, Cheryl Enger. (United States)
- 257 Comparison of CT-Scan and Chest X-ray Recording in Chronic Obstructive Pulmonary Disease Patients in a Large UK Primary and Secondary Care Setting (Clinical Practice Research Datalink and Hospital Episode Statistics) [736]**
Hannah R Whittaker, Olivia Connell, Jennifer Campbell, Jennifer K Quint. (United Kingdom)
- 258 Asthma Treatment in Real Life [737]**
Esmé J Baan, Leila Karimi, Astrid Heeremans, Guy G Brusselle, Miriam Sturkenboom, Hettie M Janssens, Lies Lahousse, Katia M Verhamme. (Netherlands)



Pharmacovigilance - Infections

259 Abstract Withdrawn [738]

260 Association Between Systemic Fluoroquinolone Exposure and Peripheral Neuropathy: Population-Based Nested Case-Control Study [739]

Daniel R Morales, Jim Slattery, Alexandra Pacurariu, Luis Pinheiro, Xavier Kurz. (United Kingdom)

261 Profiling the Safety of Antituberculosis Medicines in Ugandan Patients [740]

Victoria P Nambasa. (Uganda)

262 Prevalence and Determinants of Antibiotic Related Adverse Drug Reactions in Kenya: Spontaneously Reported Cases at the Pharmacy and Poisons Board Database [741]

Miriam Njoroge, Margaret Oluka, George Osanjo, Sylvia Opanga, Brian Godman, Amanj Kurdi. (United Kingdom)

263 Association Between Systemic Fluoroquinolone Exposure and Tendon Rupture: Population-Based Nested Case-Control Study [742]

Daniel R Morales, Jim Slattery, Alexandra Pacurariu, Patricia McGettigan, Xavier Kurz. (United Kingdom)

264 Passive Enhanced Safety Surveillance in Children Receiving Fluenz[®] Tetra Vaccination in England During the Early 2017-2018 Influenza Season [743]

Lorna Hazell, Saad Shakir, Jacky Dentith, Edward Hammond, Dennis Brooks. (United Kingdom)

265 Adverse Drug Reactions Reported to the Western Cape Programmatic Pharmacovigilance Programme in South Africa: 2005 to 2017 [744]

Karen Cohen, Jackie Jones, Annemie Stewart, Jacqueline Voget, Tracey Naledi, Andrew Boule, Ushma Mehta, Marc Blockman. (South Africa)

266 Adverse Reactions to Bedaquiline in South African Patients [745]

Karen Cohen, Jackie Jones, Vanessa Mudaly, Jacqueline Voget, Tracey Naledi, Gary Maartens. (South Africa)

267 A Safety Profile and Characterization of Antiretroviral Drugs - An Analysis of the Uganda National Pharmacovigilance Centre Spontaneous Reporting System [746]

Victoria Nambasa, Helen Ndagije, Dan Kajungu. (Uganda)

268 Oral Fluoroquinolone and the Risk of Aortic Dissection: A Population-Based Case-Crossover Study [747]

Chien-Chang Lee, Meng-tse Lee, Ronan W Hsieh, Lorenzo Porta. (Taiwan)

269 Fluoroquinolone Use and Risk of Arterial Aneurysm Or Dissection [748]

Sandy Maumus-Robert, Xavier Bérard, Yohann Mansiaux, Pascale Tubert-Bitter, Stéphanie Debette, Antoine Pariente. (France)

270 Quantification of the Association Between Ciprofloxacin Use and Observed Ciprofloxacin Resistance [749]

Rolinda D van Gaalen, Wieke Altorf - van der Kuil, Annelot Schoffelen, Marjolijn C Wegdam-Blans, Jacco Wallinga, Sabine de Greeff. (Netherlands)

End Poster Session B



Spotlight Session - Medications in Pregnancy and Lactation

- A Antidepressants Use During Pregnancy and the Risk of Gestational Diabetes Mellitus [827]**
Maëlle Dandjinou, Odile Sheehy, Anick Bérard. (Canada)
- B Prenatal Paracetamol Exposure and Child Neurodevelopment at 5 Years [828]**
Johanne Naper Troennes, Angela Lupattelli, Mollie Wood, Eivind Ystrom, Hedvig Nordeng. (Norway)
- C In-Utero SSRI and SNRI Exposure and the Risk of Long Term Adverse Mental and Educational Outcomes in Children: A Population-Based Retrospective Cohort Study Utilizing Linked Administrative Data [829]**
Marni Brownell, Deepa Singal, Matthew Dahl, Laurence Katz, Chelsea Ruth, Elizabeth Wall-Wieler, Ana Hanlon-Deerman. (Canada)
- D Risk of Early Neurodevelopmental Disorders Associated With Prenatal Exposure to Valproate: A Nationwide Cohort Study Based on the French Healthcare Databases [830]**
Pierre-Olivier Blotiere, Sara Miranda, Alain Weill, Mahmoud Zureik, Joël Coste, Rosemary Dray-Spira. (France)
- E Trivalent Inactivated Influenza Vaccine (TIV) During Pregnancy and Risk for adverse Infant Neurodevelopment [831]**
Lyndsay A Avalos, Jeannette Ferber, Ousseny Zerbo, Allison Naleway, Roxana Odouli, Tia Kauffman, Joanna Bulkley, De-Kun Li. (United States)
- F Abstract Withdrawn [832]**
- G In Utero Drug Exposure and Hearing Disorders in 2-Year-Old Children: A Case-Control Study Using the Efemeris Database [833]**
Caroline Foch, Mélanie Araujo, Alexandra Weckel, Christine Damase-Michel, Caroline Hurault-Delarue, Jean-Louis Montastruc, Justine Benevent, Geneviève Durrieu, Isabelle Lacroix. (France)

- H Utilising the CPRD Pregnancy Register to Examine the Pattern of Antiepileptic Drug Use During Pregnancy in the UK [834]**
Stephanie O Dellicour, Jennifer Campbell, Sonia Cotton, Katherine Donegan. (United Kingdom)

Spotlight Session - Molecular Epidemiology, Biomarkers and Pharmacogenetics

- I Genome-Wide Association Study of Asthma Symptoms Despite Inhaled Corticosteroids Use in Dutch Children [835]**
Niloufar Farzan, Susanne J Vijverberg, Natalia Hernandez-Pacheco, Maria Pino-Yanes, Anke H Maitland-van der Zee. (Netherlands)
- J A Pharmacoeconomic Decision Analytic Model of Multigene Molecular Diagnostics for Colorectal Cancer Precision Medicine [836]**
Amalia M. Issa, Vivek S Chaudhari. (United States)
- K Pharmacogenomics of HIV in East Africa: Characterizing Drug Resistant Mutations (DRMS) in the Cross-Border Integrated Health Study, 2016 [837]**
Arti V Virkud, Jessie Edwards, Grace Mulholland, Milissa Markiewicz, Peter Arimi. (United States)
- L Multi-Drug Resistance Protein 2 (MRP2) Expression, Adjuvant Tamoxifen Treatment and the Risk of Breast Cancer Recurrence in a Danish Population-Based Nested Case-Control Study [838]**
Cathrine F Hjorth, Anja N Schulz, Henrik T Sørensen, Timothy Lash, Per Damkier, Stephen Hamilton-Dutoit, Deirdre Cronin-Fenton. (Denmark)
- M Drug Repurposing: Calcium Channel Blockers in Psychiatric Disorders? [839]**
Christiane Gasse, Xiaoqin Liu, Katja Glejsted Ingstrup, David A. Collier. (Denmark)

- N PD-L1 Expression, EGFR Mutations (EGFRm) & KRAS Mutations (KRASm) in Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) Patients [840]**
Deirdre Cronin-Fenton, Tapashi Dalvi, Elizabeth Hedgeman, Mette Norgaard, Lars Pedersen, Hanh Hansen, Jon Fryzek, Jill Walker, Anders Mellemgaard, Torben R. Rasmussen, Norah Shire, James Rigas, Danielle Potter, Stephen Hamilton-Dutoit, Henrik T Sørensen. (Denmark)
- O The Use of Antimicrobial Drugs Has Long-Term Impact on the Human Stool Microbiota [841]**
Marlies Mulder, Djawad Radjabzadeh, Andre Uitterlinden, Rob Kraaij, Bruno Stricker, Annelies Verbon. (Netherlands)
- P The Use of Genetic Risk Scores in Pharmacogenetics Studies- a Simulation Study [842]**
Md Jamal Uddin, Merete Nordentoft, Claus Thorn Ekstrøm. (Denmark)

Spotlight Session - Oncology

- Q Myelodysplastic Syndrome and Acute Myeloid Leukemia Following Use of Chemo-Immunotherapy and Granulocyte Colony-Stimulating Factors Among Elderly Non-Hodgkin Lymphoma Patients [843]**
Kellyn M. Moran, Zhaoju Wu, Sruthi Adimadhyam, Todd A. Lee, Brian C. H. Chiu, Gregory S. Calip. (United States)
- R Abstract Withdrawn [844]**
- S Prognostic Role of Neutrophil-Lymphocyte Ratio in Localized and Metastatic Renal Cell Carcinoma. a Population-Based Cohort Study [845]**
Maria M Pedersen, Frede Donskov, Lars Pedersen, Mette Nørgaard. (Denmark)
- T Association of Exogenous Hormone Use With Breast Cancer Subtype Defined by Oncotype DX Recurrence Score [846]**
Halei Benefield, Katherine Reeder-Hayes, Stephanie Wheeler, Lisa Carey, Andrew Olshan, Melissa Troester. (United States)



U Use of Antipsychotics and Risk of Breast Cancer: A Danish Nationwide Case-Control Study [847]

Anton Pottegård, Timothy L Lash, Deidre Cronin-Fenton, Thomas P Ahern, Per Damkier. (Denmark)

V Direct-Acting Antivirals Reduce the Risk of Non-Hepatic Cancers Among Hepatitis C Virus Infected Patients [848]

Wei Wang, Vincent Lo Re III, Hong Xiao, Joshua Brown, Yi Guo, Haesuk Park. (United States)

W Incidence of Hypothyroidism in Women With Breast Cancer -A Danish Population-Based Matched Cohort Study [849]

Dr. Anne Mette Falstie-Jensen, Anders Kjærsgaard, Dr. Marianne Ewertz, Ebbe Lorenzen, Jeanette D. Jensen, Kristin V. Reinertsen, Olaf D. Dekkers, Deirdre P. Cronin-Fenton.

X Hydrochlorothiazide Use and Risk of Merkel Cell Carcinoma and Malignant Adnexal Skin Tumours [850]

Sidsel Arnsparng Pedersen, Sigrun Alba Johannesdottir Schmidt, Lisbet Rosenkrantz Hølmich, Søren Friis, Anton Pottegård, David Gaist. (Denmark)

Spotlight Session - Pediatrics

Y Identifying Targets for Pharmacovigilance in US Children Using a Big Data “Market Basket” Analysis (The a Priori Algorithm) [851]

James A Feinstein, Chris Feudtner, Allison Kempe, Robert Valuck, Elaine Morrato. (United States)

Z Antipsychotic Use Among US Commercially-Insured Youth Following Implementation of State Prior Authorization Monitoring Policies [852]

O’Mareen C Spence, Susan dosReis. (United States)

AA Predictors for Pharmacological and Psychotherapeutic Treatment in Children Newly Diagnosed With ADHD [853]

Oliver Scholle, Jörg M Fegert, Bianca Kollhorst, Eyyub E Öztürk, Oliver Riedel, Michael Kölch. (Germany)

BB Off-Label Systemic Drug Utilization in a Large Us Pediatric Population [854]

Daniel B Horton, Divya Hoon, Matthew T. Taylor, Tobias Gerhard, Brian L Strom. (United States)

CC Adverse Drug Reactions of Statins in a Paediatric Population: A Descriptive Analysis of Individual Case Safety Reports From Vigibase [855]

Cécile Conte, Charlotte Vert, Vanessa Rousseau, Leyla Chebane, Jean Louis Montastruc, Genevieve Durrieu, Pascale Olivier. (France)

DD Quantifying Prevalence and Mortality Associated With Neonatal Enteroviral Sepsis (NES) Using Inpatient Data in FDA’s Sentinel System [856]

Marie C Bradley, Mayura SHINDE, Yodit Belew, Jason Hickok, Russell Poland, Karla M Miller, Austin Cosgrove, Crystal Garcia, Rong Tilney, Candace Fuller. (United States)

EE Factors Associated With Antibiotic Prescribing for Common Childhood Diseases: A Population-Based Study [857]

Naima Ahmed Tamanna, Md. Mehedi Hasan, Md. Jamal Uddin, A.T.M. Mijanur Rahman. (Bangladesh)

Spotlight Session - Vaccines

FF Clinical Effectiveness of High-Dose versus Standard-Dose Influenza Vaccination Among Veterans Health Administration Patients: A Crossover Study [858]

Yinong Young-Xu, Julia Snider, Salaheddin Mahmud, Robertus van Aalst, Edward W Thommes, Jason K Lee, Ayman Chit. (United States)

GG Advance System Testing: Vaccine Benefit Studies Using Multi-Country Electronic Health Data: An Example on Pertussis Vaccination [859]

Myint Tin Tin Htar, Maria de Ridder, Toon Braeye, Ana Correa, Talita Duarte-Salles, Consuelo Huerta, Elisa Martin, Lara Tramontan, Giorgia Danieli, Gino Picelli, Noline van der Maas, Klara Berensci, Lisen Arnheim-Dahlstrom, Ulrich Heining, Hanne-Dorthe Emborg, Daniel Weibel, Kaat Bollaerts, Lina Titievsky, Vincent Bauchau, Miriam Sturkenboom. (France)

HH Physicians’ Intention to Prescribe the HPV Vaccination Later Than Recommended: A Systematic Review and Meta-Analysis [860]

Nicole M. Bailey, Camelia Graham, Aaron W. Kamau, Andrew R. Wilson. (United States)

II Varicella Vaccine Safety Surveillance Using a Tree-Based Scan Statistic [861]

Chia-Hung Liu, Yi-Chen Juan, Yen-Yum Yang, Wan-Ting Huang, K Arnold Chan. (Taiwan)

JJ Where Do People Get Vaccinated? Trends in Influenza Immunization by Provider Setting [862]

Xuerong Wen, Zack Babcock, Katherine Orr, Steven Cohen, Aisling Caffrey. (United States)

KK Developing the Infrastructure to Assess Pregnancy Outcomes Following Vaccination: Influenza Vaccines and Spontaneous Abortion As a Use Case [863]

Alison Tse Kawai, Megan Reidy, Lauren Zichittella, Colleen Stockdale, Erin Longley, Cheryl Walraven, Chunfu Liu, Azadeh Shoabi, Sandra Feibelmann, Grace Lee. (United States)

LL Post-Authorization Safety Study (PASS): Cohort Event Monitoring for CYD-TDV Dengue Vaccine [864]

Carine Cohen, Lydie Marcelon, Thais N Moreira, Julius Lecciones, Mary Ann Bunyi, Heloisa I Gamberardino, Anna Skipetrova, Joshua Nealon, Elsa Sarti, Esteban Puentes-Rosas, Annick Moureau, Céline Zocchetti, Alena Khromava, on behalf of the study team (France)

MM Near Real-Time Safety Surveillance of Three Seasonal Influenza Vaccines in Europe During Influenza Season 2017/18 [865]

Sonja Banga, Anne-Laure Chabanon, Cecile Eymin, Tim Caroe, Karina Butler, Annick Moureau. (Canada)



Drug Effectiveness - Cardiovascular

- 1 Anticoagulant Treatment in Combination With Antiplatelet Therapy in Patients With Coronary Artery Disease and Atrial Fibrillation: A Comparative Effectiveness and Safety Study in Valencia, Spain [866]**
Yared Santa-Ana-Tellez, Clara L Rodríguez-Bernal, Aníbal García-Sempere, Salvador Peiró, Gabriel Sanfélix-Gimeno. (Spain)
- 2 Statin Use at the Time of Intra-Abdominal Surgery is Associated With Reduced Risk of Post-Operative Adhesion-Related Complications [867]**
Frank I Scott, Ravy K Vajravelu, Ronac Mamtani, Najjia N Mahmoud, James D Lewis. (United States)
- 3 Clinical Events After Discontinuation of β -Blockers in Patients Without Heart Failure Optimally Treated After Acute Myocardial Infarction. a Cohort Study on the French Healthcare Databases [868]**
Anke Neumann, Géric Maura, Alain Weill, François Alla, Nicolas Danchin. (France)
- 4 Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Overall Mortality and Major Cardiovascular Diseases in Primary Prevention: Population-Based Nationwide Cohort Study Based on French Health Insurance Data (SNIIRAM) [869]**
Emmanuel Oger, Lucie-Marie Scailteux, Sandrine Kerbrat, Pierre-Yves Scarabin, André Happe, François Paillard, Emmanuel Nowak. (France)
- 5 Anticoagulants in Patients With Atrial Fibrillation After Intracranial Hemorrhage [870]**
Sylvie Perreault, Robert Côté, Brian White-Guay. (Canada)
- 6 Statins for the Primary Prevention of Cardiovascular Disease in Low Cardiovascular Risk Koreans [871]**
JuYoung Kim, InSun Ryou, Hwa Yeon Park, Sohee Oh, JeongHyun Kim. (Korea, Republic of)
- 7 Comparative Effectiveness of Statin and Renin-Angiotensin-Aldosterone System Blocker Combination Therapy in Patients With Coronary Heart Disease: A Nationwide Population-Based Cohort Study [872]**
Jimin Lee, Sukhyang Lee. (Korea, Republic of)
- 8 Comparative Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants and Acenocoumarol in Patients With Atrial Fibrillation: A Propensity-Weighted Cohort Study [873]**
Clara Rodríguez-Bernal, Yared Santa-Ana Téllez, Anibal García-Sempere, Isabel Hurtado, Salvador Peiró, Gabriel Sanfélix-Gimeno. (Spain)
- 9 Reductions in Death, Stroke and Myocardial Infarction: The Comparative Effectiveness of 4th Line Antihypertensive Drugs in Resistant Hypertension [874]**
Sarah-Jo Sinnott, Liam Smeeth, Elizabeth Williamson, Pablo Perel, Dorothea Nitsch, Laurie Tomlinson, Ian Douglas. (United Kingdom)
- 10 Effect of Evidence-Based Combination Pharmacotherapy for the Secondary Prevention of Cardiovascular Disease: Systematic Review and Meta-Analysis [875]**
Tian-Tian Ma, Ian CK Wong, Kenneth KC Man, Yang Chen, Ling-Qing Ding, Zi-Xuan Zhang, Lin Zhang, Li Wei. (United Kingdom)
- 11 The Effect of Indapamide versus Bendroflumethiazide for Primary Hypertension - a Systematic Review [876]**
Tatiana V Macfarlane, Filippo Pigazzani, Robert W Flynn, Tom M Macdonald. (United Kingdom)
- 12 Incidence of Effectiveness and Safety Outcomes in Hemodialysis Patients With Atrial Fibrillation on Warfarin [877]**
Ms. Sapna Rao, Abhijit Kshirsagar, M Alan Brookhart. (United States)
- 13 Comparative Effect of Statins on the Risk of Incident Alzheimer's Disease [878]**
Paul Brassard, Liliya Sinyavskaya, Christel Renoux, Sophie Dell'Aniello, Serge Gauthier, Samy Suissa. (Canada)
- 14 Detection of Drug Interaction Between Warfarin and Antimicrobial Agents Based on Administration Routes and Antimicrobial Susceptibility To *Bacteroides Fragilis* [879]**
Tatsuya Yagi, Takafumi Naito, Ayami Kato, Kensho Hirao, Katsuhito Hori, Junichi Kawakami. (Japan)
- 15 Preventive Effect of Statins, Metformin, Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Age-Related Macular Degeneration in the Elderly: A Nested Case-Control Study [880]**
Hyesung Lee, Ha-Lim Jeon, Ju-Young Shin. (Korea, Republic of)
- 16 Comparative Outcomes of Treatment Initiation With Brand-Name versus Generic Warfarin: A Medicare Cohort Study [881]**
Rishi J Desai, Chandrasekar Gopalakrishnan, Sara Dejene, Ameet Sarpatwari, Raisa Levin, Sarah Dutcher, Zhong Wang, Sara Wittayanukorn, Jessica M Franklin, Joshua Gagne. (United States)
- 17 Effectiveness of Statins According to Cardiovascular Risk in the Elderly [882]**
Julien Bezin, Nicholas Moore, Yohann Mansiaux, Philippe Gabriel Steg, Antoine Pariente. (France)
- 18 Clinical Effectiveness and Safety of Clopidogrel Co-Administered With Statins and Proton Pump Inhibitors in Patients Undergoing Percutaneous Coronary Intervention [883]**
Mi-Sook Kim, Hong Ji Song, Joongyub Lee, Bo Ram Yang, Nam-Kyong Choi, Byung-Joo Park. (Korea, Republic of)
- 19 Comparative Effectiveness of Statins in Cardiovascular Secondary Prevention [884]**
Mr. Jordan Guillot, Pr. Nicholas Moore, Pr. Antoine Pariente, Dr. Julien Bezin. (France)
- 20 Postponement of Death by Heart Failure Treatment: A Meta-Analysis of Randomized Clinical Trials [885]**
Morten Rix Hansen. (Denmark)



- 21 Association Between Adherence to Renin-Angiotensin-Aldosterone-System (RAAS) Inhibitors and Renal Function Among Patients With Type 2 Diabetes: A Population Based Study Using Real World Data [886]**
E Smits, J A Overbeek, E Houben, R M Herings, M P van Herk-Sukel, M Teichert, P A de Smet. (Netherlands)

Drug Effectiveness - Other

- 22 Bone Marker CTX-1 As An Indicator of Osteoporosis Treatment Initiation and Adherence in Clinical Practice [887]**
Andréa Senay, Sylvie Perreault, Josée Delisle, Suzanne N Morin, Andreea Banica, G Yves Laflamme, Stéphane Leduc, Jean-Marc MacThiong, Pierre Ranger, Dominique Rouleau, Julio C Fernandes. (Canada)
- 23 Risk of Osteoporotic Fractures in New Users of Denosumab Compared With New Users of Alendronate: A Danish Population-Based Cohort Study [888]**
Alma B Pedersen, Uffe Heide-Jørgensen, Henrik T Sørensen, Daniel Prieto-Alhambra, Vera Ehrenstein. (Denmark)
- 24 Factors Influencing Treatment Maintenance of SC and IV Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Real Life [889]**
Tiphaine Vauléon, David Pau, Jean Darloy, René-Marc Flipo, Nicolas Segaud, Jean-Paul Eschard, Samuel Gally, Ralph Niarra, Isabelle Idier, Guy Baudens. (France)
- 25 Acute Pharmacological Management After Spinal Cord Injury: A Secondary Analysis of Clinical Trial Data [890]**
Catherine Jutzeler, Bobo Tong, Jacquelyn Cragg, Fred Geisler, John Kramer. (Canada)
- 26 Real-World Persistence and Effectiveness of Conventional Systemic Therapies in the Treatment of Psoriasis: A Systematic Review [891]**
Sophie Williams, Kayleigh J. Mason, Zenas Yiu, Kathleen McElhone, Richard B. Warren, Christopher E. Griffiths. (United Kingdom)

- 27 Creation of a Real-World Cohort of Hyperkalemia Patients Using Danish Healthcare Data to Simulate the Control Population of a Single Arm Clinical Intervention Trial [892]**
Reimar W Thomsen, Lotte B Christensen, Sia K Nicolaisen, Kim Kun, Pål Hasvold, Eirini Palaka. (Denmark)

- 28 Clinical Outcomes of Adding Xanthines to ICS and LABA Combination in Patients With Chronic Obstructive Pulmonary Disease [893]**
Yueh-Hsin Wang, Hung-Wei Lin, Jung-Yien Chien, Fang-Ju Lin. (Taiwan)
- 29 Effectiveness of Ranibizumab Intravitreal Injections in Visual Impairment Due to Macular Edema Secondary to Retinal Vein Occlusion: Final Results at 24 Months From the French Boreal Cohort [894]**
Patrick Blin, Cecile Delcourt, Agnès Glacet-Bernard, Catherine Cruzot-Garcher, Franck Fajnkuchen, Jean François Girmens, Pierre Jean Guillausseau, Laurent Kodjikian, Pascale Massin, Merseleh Mahe, Regis Lassalle, Marie-Agnès Bernard, Anais Chartier, Hélène Maizi, Cécile Droz-Perroteau, Adeline Grolleau, Angela Grelaud, Nicholas Moore. (France)

- 30 What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews [895]**
Amr Makady, Anthonius de Boer, Hans Hillege, Olaf Klungel, Wim Goettsch. (Netherlands)
- 31 "Real-World" Evidence for Drugs and Devices: 2017 Literature Reviewed [896]**
Mary E Ritchey, Patrick M Buck, Colleen Castro, Maria Fernandez, Kelly Hollis, Margaret Mordin. (United States)

Drug Utilization - Other

- 32 Discontinuation of First Biologic Drug for Rheumatoid Arthritis: What Happens Next? A Descriptive Drug Utilization Study in Tuscany, Italy [897]**
Giuseppe Roberto, Claudia Bartolini, Nicoletta Luciano, Marta Mosca, Rosa Gini. (Italy)

- 33 Pain Relief Medicines: Availability for Outpatients [898]**
Anahit Amirkhanyan, Anahit Sevikyan, Irina Kazaryan. (Armenia)
- 34 Identification of Medication Discrepancies on Medication Reconciliation During Hospital Admission [899]**
Mei-Wen Wang, Hsun-Yin Liang, Huang-Tz Ou, Pheng-Ying Yeh. (Taiwan)

- 35 Characteristics of Women Initiating Conjugated Estrogens/ Bazedoxifene [900]**
Vibha Ca Desai, Ruihua Yin, Daina B Esposito, Stephan Lanes, Kelsey Gangemi, Leo J Russo. (United States)
- 36 A Data-Driven Methodology to Define and Visualise Line of Therapy for Real-World Data Epidemiology of Cancers [901]**
Ali Abbasi, Ruben Hermans, Dony Patel, Fiona Grimson, Peter McMahon, Joseph Kim, Eric S Groves, Deborah Layton. (United Kingdom)

- 37 Tramadol Use in Norway: A Register-Based Population Study [902]**
Hanne Birke, Ola Ekholm, Per Sjøgren, Olav Fredheim, Thomas Clausen, Svetlana Skurtveit. (Denmark)

- 38 Challenges and Issues in Drug Utilization Research Identified From the Latin American and African Regions [903]**
Maribel Salas, Luciane C Lopes, Brian Godman, Ilse Truter, Abraham G Hartzema, Joseph Fadare, Johanita Burger, Kwame Appenteng, Macarius Donneyong, Ariel Arias, Daniel Ankrah, Olayinka O Ogunleye, Diana Gomez Galicia, Miriam del Carmen Garcia Estrada, Margaret N Oluka, Amos Masseur, Luis Alessio, Raquel Herrera Comoglio, Jorgelina Bernet, Carmen Vilaseca, Martie S Lubbe, Laura Horne, Ulf Bergman. (United States)

- 39 Prevalence and Correlates of Pharmacy Closures in the United States, 2009-2015 [904]**
Jenny Guadamuz, Caleb Alexander, Shannon Zenk, Dima Qato. (United States)

- 40 Physicians As a Source of Medicine Information for Patients [905]**
Anahit Sevikyan, Irina Kazaryan, Anahit Amirkhanyan. (Armenia)



- 41 A Population-Based Description of Chronic Polypharmacy by Sex and Age [906]**
Mr. Jordan Guillot, Dr. Sandy Maumus - Robert, Pr. Antoine Pariente, Dr. Julien Bezin. (France)
- 42 Self-Management of Medication Use by the Brazilian Population: Results From the National Survey on Access, Use and Promotion of Rational Use of Medicines (PNAUM) [907]**
Emilia S Pons, Daniela R Knauth, Sotero S Mengue. (Brazil)
- 43 Utilization of Prescribed Topical Antipsoriatics in Denmark: A Nationwide Study [908]**
Martin T. Ernst, Mathias T. Svendsen, Klaus E. Andersen, Anton Pottegård. (Denmark)
- 44 Patterns of Hormonal Contraceptive Use in the Self Cohort [909]**
Sarah R Hoffman, Jennifer S Smith, Donna D Baird, Quaker E Harmon. (United States)
- 45 Time Trends Among New Users of Osteoporosis Drugs Over 20 Years: Considerations for Pharmacoepidemiologic Study Design [910]**
Kaleen N. Hayes, Joann K. Ban, Andrea M. Burden, Suzanne M. Cadarette. (Canada)
- 46 Over 63,700 Ontario Seniors Have Initiated Denosumab: User Characteristics and Persistence With Therapy [911]**
Joann K Ban, Boyd Hao, Lisa McCarthy, Sara J Guilcher, Suzanne M Cadarette. (Canada)
- 47 Prevalence and Duration of Skeletal Muscle Relaxant Treatment Among Commercially Insured Adults in the United States: 2005 to 2015 [912]**
Yan Li, Gary M. Reisfield, Almut G. Winterstein. (United States)
- 48 Prescribing Variation in English Primary Care Following a Regulatory Safety Warning on Mirabegron [913]**
Frank Moriarty, Shegufta Razzaque, Ronald McDowell, Tom Fahey. (Ireland)
- 49 Patterns of Drug Utilization and Spontaneous Adverse Drug Reactions Reporting of Oral Anticoagulants in the Czech Republic Between 2007-2016 [914]**
Simona Dvořáčková, Eva Zimciková, Katerina Mala-Ladova, Jozef Kolar, Eva Jirsova, Josef Maly. (Czech Republic)
- 50 Characteristics and Treatment Patterns of New Users of Fluticasone Furoate/Vilanterol: A Cohort Study Set in UK Primary Care [915]**
Rebecca E Ghosh, Sonia J Cotton, Dan Dedman, Wilhelmine Meeraus, Courtney Crim, Catherine Harvey, Justyn Amelio, Sarah H Landis. (United Kingdom)
- 51 Use of Bisphosphonates Before and After Hip Fracture Surgery: A Danish Population-Based Prevalence Study, 2005-2015 [916]**
Pia K Kristensen, Nisha Shetty, Vera Ehrenstein, Alma B Pedersen. (Denmark)
- 52 Drug Use Among Canadian Seniors [917]**
Jordan Hunt, Jeff Proulx, Sara Grimwood, Sara Allin, Jocelyn Rioux, Junior Chuang. (Canada)
- 53 Availability of Essential Medicines for Newborns in Healthcare Institutions of Bangladesh [918]**
Muhammad Abdul Baker Chowdhury, Jakia Rahman, Md Iqbal Hossain, Md Jamal Uddin. (United States)
- 54 Use of Prescription Medications With Boxed Warnings in the U.S., 2003-2014 [919]**
Jenny S Guadamuz, Dima M Qato. (United States)
- 55 A Comparison of Drug Utilization Metrics for Six Drug Classes With Nationally Projected Sales and Patient-Level Data From the Sentinel Database [920]**
Mohamed Mohamoud, Yanmin Zhu, Steven Bird, Rima Izem, Nicole Haug, Anita K Wagner, Judith C Maro, Efe Eworuke. (United States)
- 56 Trends and Drivers of Immunosuppressants' Expenditure in Brazil [921]**
Tatiana Luz, Jessica Castro Alves, Claudia Osorio de Castro, Bjorn Wettermark. (Brazil)
- 57 Overall Decreasing Trend in Polypharmacy Over 12 Years, But Still Unresolved in Pediatric Patients in South Korea [922]**
Yeon-Hee Baek, Ju-Young Shin. (Korea, Republic of)
- 58 Factors Related to Intentional Non-Initiation of Bisphosphonate Treatment in Osteoporosis Patients in Primary Care [923]**
K M Swart, M van Vilsteren, W van Hout, E Draak, B C van der Zwaard, H E van der Horst, Jacqueline Hugtenburg, Petra J Elders. (Netherlands)
- 59 Incident Use of Proton Pump Inhibitors in France, 2015 [924]**
Marion Lassalle, Thien Le Tri, Marc Bardou, Michel Biour, Julien Kirchgesner, Franck Rouby, Nathalie Dumarcet, Mahmoud Zureik, Rosemary Dray-Spira. (France)

Drug Utilization - Policy

- 60 Supply of Drugs for the Treatment of Psoriatic Arthritis in the Brazilian Public Health System [925]**
Michael Ruberson da Silva, Jessica Barreto dos Santos, Alessandra Maciel Almeida, Juliana Alvares, Francisco de Assis Acurcio. (Brazil)
- 61 Depression Treatment in Primary Care: Do Prescribers Account for Weight Modulating Effects of Antidepressants? [926]**
Svetlana Puzhko, David Barber, Gillian Bartlett-Esquilant. (Canada)
- 62 Estimating Probability of Refills After Initial Opioid Analgesic Prescriptions for Acute Pain in Primary Care Settings [927]**
Mallika L. Mundkur, Jessica Franklin, Krista Huybrechts, Elisabetta Patorno, Joshua J Gagne, Tamra Meyer, Judy Staffa, Brian T Bateman. (United States)
- 63 Prescription Drug Coverage for Treatment of Low Back Pain Among U.S. Medicaid, Medicare Advantage and Commercial Insurers [928]**
Dora H. Lin, Christopher M. Jones, Wilson M. Compton, James Heyward, Jan L. Losby, Irene B. Murimi, Grant T. Baldwin, Jeromie M. Ballreich, David A. Thomas, Mark Bicket, Linda Porter, Jonothan C. Tierce, G. Caleb Alexander. (United States)



- 64 Coverage of Non-Pharmacologic Treatments for Lower Back Pain Among Public and Private Insurers in the United States [929]**
James Heyward, Christopher M. Jones, Wilson M. Compton, Dora H. Lin, Jan L. Losby, Irene B. Murimi, Grant T. Baldwin, Jeromie M. Ballreich, David A. Thomas, Mark Bicket, Linda Porter, Jonathan C. Tierce, G. Caleb Alexander. (United States)
- 65 Impact of Florida's Prescription Drug Monitoring Program and Pill Mill Law on High-Risk Patients - A Comparative Interrupted Time Series Analysis [930]**
Hsien-Yen Chang, Irene B. Murimi, Mark Faul, Laine Rutkow, G. Caleb Alexander. (United States)
- 66 Evaluating the Impact of Delisting High Strength Opioids on Opioid Use in Ontario [931]**
Qi Guan, Wayne Khuu, Diana Martins, Mina Tadrous, Minh T. Do, Maria Chiu, Tara Gomes. (Canada)
- 67 Opioid Prescriptions in Older Medicare Beneficiaries Following the 2014 Hydrocodone Rescheduling [932]**
Yong-Fang Kuo, Mukaila A Raji, Victor Liaw, Jacques Baillargeon, James S Goodwin. (United States)
- 68 Incorporation of Unlicensed Medicines by the Brazilian Unified Health System, 2012-2016 [933]**
Erica M Pedro, Cristiane R Teodoro, Rondineli M Silva, Ricardo E Steffen, Claudia G Osorio-de-Castro, Rosângela Caetano. (Brazil)
- 69 Challenges in Development, Market Authorisation and Commercialisation of Advanced Therapy Medicinal Products in Europe: A Cohort Study [934]**
Renske M ten Ham, Jarno Hoekman, Anke M Hövels, Andre W Broekmans, Hubert G Leufkens, Olaf H Klungel. (Netherlands)
- 70 Survey of Regulations Related to the Use of Dietary Supplements in Hospitalized Patients in the Czech Republic and New Zealand: Pilot Study [935]**
Jitka Pokladnikova, Julie Straznicka, James Green. (Czech Republic)

- 71 Representative Survey on Czech Physicians Awareness of Generic Drugs and Substitution [936]**
Josef Maly, Eva Zimcikova, Petra Thomson, Jan Babica, Jan Kostriba, Katerina Mala-Ladova. (Czech Republic)
- 72 Availability of Pharmacies Participating in the 340B Drug Pricing Program, 2016 [937]**
Jenny S. Guadamuz, Dima M Qato. (United States)
- 73 Recent Initiatives in Scotland to Improve the Quality and Efficiency of Prescribing: Findings and Implications [938]**
Brian Godman, Amanj Kurdi, Sean MacBride-Stewart, Simon Hurding, Holly McCabe, Alec Morton.

Drug Utilization - Quality of Use of Medicines

- 74 Abstract Withdrawn [939]**
- 75 Point Prevalence Survey of Antibiotic Use and Resistance at the Biggest National Referral Hospital in Kenya: Findings and Implications [940]**
Caleb Okoth, Sylvia Opanga, Faith Okalebo, Margaret Oluka, Amanj Kurdi, Brian Godman. (United Kingdom)
- 76 Comparison of Zidovudine and Tenofovir Based Regimens With Regard to Quality of Life and Prevalence of Symptoms in HIV Patients in a Kenya [941]**
Jilian Etenyi, Faith Okalebo, Sylvia Opanga, Kipruto Sinei, George Osanjo, Amanj Kurdi, Brian Godman. (United Kingdom)
- 77 Mapping Antibiotic Use in a Newly Founded Emergency Department [942]**
Ria Benko, Maria Matuz, Reka Bordas, Reka Viola, Edit Hajdu, Peter Erdelyi, Gyongyver Soos, Zoltan Peto. (Hungary)
- 78 Pattern and Predictors of Antibiotics Use Among Adults in the Rural and Urban Communities, Oyo State, Nigeria [943]**
Waheed A Adedeji, Magbagbeola D Dairo, Akin Oyemakinde, Patrick Nguku, Fatai A Fehintola. (Nigeria)
- 79 Utilisation of Medicines for Treatment of Multiple Myeloma in Australia [944]**
Svetla Gadzhanova, Elizabeth Roughhead, Louise Bartlett. (Australia)
- 80 Appropriateness of Use of Low-Molecular-Weight Heparins Prescribed in Patients Discharged From Emergency Departments: A Drug Utilization Study Based on Administrative Health Databases [945]**
Andrealuna Ucciero, Tiziana Cena, Alessia Pisterna, Corrado Magnani, Francesco Barone-Adesi. (Italy)
- 81 Quality of Anticoagulation Control in Patients With Atrial Fibrillation in Valencia, Spain: A Real-World, Population-Based Study [946]**
Anibal Garcia-Sempere, Isabel Hurtado, Daniel Bejarano-Quisoboni, Clara Rodriguez-Bernal, Yared Santa-Ana, Salvador Peiro, Gabriel Sanfelix-Gimeno. (Spain)
- 82 Use of Preoperative Aspirin in Patients Undergoing Elective Isolated CABG in Japanese Nationwide Registry [947]**
Hiraku Kumamaru, Shun Kohsaka, Noboru Motomura, Hiroaki Miyata. (Japan)
- 83 Evaluating a Risk Evaluation and Mitigation Strategy Designed to Prevent Use of Dronedarone in Patients With Permanent Atrial Fibrillation [948]**
Chuntao Wu, Andrew Koren, Matthew Dormarunno, Heather Schiappacasse, Annette Stemhagen, Rachelle Willette, Stephen Lin, Juhaeri Juhaeri. (United States)
- 84 Evaluating Statin Utilisation in Clinical Practice in Scotland: Impact of Statin Intensity on Adherence and Persistence to Therapy [949]**
Tanja Mueller, Renata C Macedo do Nascimento, Marion Bennie, Brian Godman, Simon Hurding, Sean MacBride Stewart, Augusto A Guerra Junior, Francisco de Assis Acurio, Alec Morton, Amanj Kurdi. (United Kingdom)
- 85 Migraine Cocktails Sold by Pharmacies in South Africa [950]**
Bernadette Louwrens, Ilse Truter. (South Africa)



- 86 Prescribing Patterns of Oxycodone in a Private Healthcare Setting in South Africa [951]**
Ilse Truter. (South Africa)
- 87 Disparities in the Appropriateness of Anticholinergic Drug Use: Analysis of the Regards Study [952]**
Md Motiur Rahman, George Howard, Jingjing Qian, Richard Hansen. (United States)
- 88 The Prevalence of Chronic Antidepressant Drugs Prescriptions in the Province of Bologna, Italy [953]**
Carlotta Lunghi, Pasquale Roberge, Emanuele Forcesi, Sofia Burato, Elisa Sangiorgi, Marco Menchetti, Ippazio C. Antonazzo, Elisabetta Poluzzi. (Canada)
- 89 Claims Database Study of Utilization Patterns of Dimethyl Fumarate in Germany [954]**
Nicholas J. Everage, Jerome Hanna, Rajiv Das, Andreas Simon, Bernd Schweikert. (United States)
- 90 The Safety of Fentanyl Patch Initiation in Australian Clinical Practice: A Population-Based Study [955]**
Natasa Gisev, Sallie Pearson, Briony Larence, Sarah Larney, Bianca Blanch, Louisa Degenhardt. (Australia)
- 91 A Database Study of Antipsychotic Polypharmacy in the Treatment of Schizophrenia in China and Japan [956]**
Minfu He, Hong Qiu, Yongjing Zhang, Huaning Wang, Wentian Dong. (China)
- 92 Generic Substitution Patterns of Levothyroxine and Escitalopram in Subgroups of U.S. Medicare Beneficiaries [957]**
Jingjing Qian, Chao Li, Nan Huo, Ahmed Ullah Mishuk, Li Chen, Richard Hansen, Ilene Harris, Zippora Kiptanui. (United States)
- 93 The Impact of Potentially Inappropriate Medication Use on Mortality and Hospitalization in Nursing Home Residents [958]**
Ivana Ivanova, Monique Elseviers, Robert Vander Stichele, Tine Dilles, Thierry Christiaens. (Belgium)
- 94 Evaluation of Level of Adherence and Deviation From the Standard Hospital Antibiotic Policy: A Cross-Sectional Study [959]**
Meenakshi S, Swathi P, Sujeet K, Sonal Sekhar M. (India)
- 95 Pharmacoepidemiological Study on Over-The-Counter (OTC) Medicines' Use From People in Alexandroupolis [960]**
Vasiliki Gougoula, Ilias Haligiannis, Rafael-Efraim Papadopoulos, Asteria Mantziari, Spyros Polyzois, Anastasios Terzis, Christos Kontogiorgis, Theodoros Constantinidis, George Kolios. (Greece)
- 96 A Description of the National Claims Database in Ghana [961]**
Daniel Ankrah, Jesper Hallas, James Odei, Francis Asenso-Boadi, Macarius Donneyong. (United States)
- 97 Clinical Experience With Oxytocin Quality Used by Healthcare Providers in Lagos, South-West Nigeria: A Cross Sectional Study [962]**
Chioma S Ejekam, Ifeoma P Okafor, Chimezie A Anyakora, Jude I Nwokike, Ebenezer Ozomata, Kehinde Okunade, Sofela E Oridota. (Nigeria)
- 98 Adherence to Inhaled Corticosteroids Before and After An Asthma-Related Hospitalisation: Distinct Trajectories [963]**
Manon Belhassen, Maeva Nolin, Marine Ginoux, Eric Van Ganse. (France)
- 99 Deciphering Patterns of Respiratory Medication Use in Ireland to Target Interventions Appropriately: A Focus on COPD [964]**
Eimir M Hurley, Maire O'Connor, Timothy McDonnell, Charles Normand. (Ireland)
- 100 Real Life Data on COPD Treatment [965]**
Leila Karimi, Esmé J Baan, Tiana Geeraerd, Johan Van Der Lei, Bruno H Stricker, Guy G Brusselle, Lies Lahousse, Katia M Verhamme. (Netherlands)
- 101 Utilization of Antibiotics for Patients With Acute Upper Respiratory Tract Infections at Community Health Care Institutions in Beijing [966]**
Ms. Fu Mengyuan, Mr. Guan Xiaodong. (China)
Recipient of John Snow Award
- 102 Treatment Guidelines: Adherence and Use Among Type 2 Diabetes Mellitus Providers and Their Patients [967]**
Kelly Olsson, Madhura Chitnis, Rachel Huelin. (United States)
- 103 Medical Home Enrollment and Quality of Care: Population Estimates From the U.S. Medical Expenditure Panel Survey [968]**
Joel F. Farley, Arun Kumar, Benjamin Y Urick, Marisa E Domino. (United States)
- 104 Inappropriate Medication Prescribing Among Elderly Patients in Italy [969]**
Elena Olmastroni, Federica Galimberti, Manuela Casula, Veronica Russo, Valentina Orlando, Antonella Piscitelli, Enrica Menditto, Elena Tragni, Alberico L Catapano. (Italy)
- 105 Medicines for Malaria: An Exploration of Practices at Retail Medicines Outlets in Urban and Rural Ghana [970]**
Daniel K Arhinful, Carine Baxerres. (Ghana)
- 106 Self-Medication Practices and Associated Factors Among Undergraduate Medical Students in St Paul Hospital Millennium Medical College [971]**
Samrawit Ethiopia, Amen Bekele, M Sanni Ali. (Ethiopia)
- 107 Medication Prescribing Practices of Eating Disorder Consultants for the Treatment of Young People With Anorexia Nervosa: A Questionnaire Study [972]**
Maedeh Y Beykloo, Dasha Nicholls, Mima Simic, Ruth Brauer, Ian CK Wong. (United Kingdom)
- 108 Use of Medicines in Adults With Autism Spectrum Disorder [973]**
Lisa Kalisch Ellett, Anna Moffat, Alycia Eaton, Robyn Young. (Australia)



- 109 Risk of Drug-Drug Interactions in Out-Hospital Drug Dispensings in France: Results From the Drug-Drug Interaction Prevalence Study (Drug-Dips) [974]**
Louis Letinier, Sebastien Cossin, Yohann Mansiaux, Julien Bezin, Antoine Pariente. (France)
- 110 Monitoring of Italian Pharmaceutical Administrative Databases: An Assessment of Prescriptive Performance [975]**
Veronica Russo, Federica Galimberti, Valentina Orlando, Antonella Piscitelli, Manuela Casula, Elena Olmastroni, Elena Tragni, Enrica Menditto. (Italy)
- 111 Feasibility of Using Point Prevalence Surveys to Assess Antimicrobial Utilisation in Public Hospitals in South Africa; a Pilot Study and Implications [976]**
Brian Godman, Nokuthula Dlamini, Natalie Schellack, Johanna Meyer, Danie Kruger, Amanj Kurdi. (United Kingdom)
- 112 Use of ADHD Medication, Antipsychotics, Antidepressants, and Melatonin in Children and Adolescents With Autism Spectrum Disorder: A Danish Drug Utilization Study [977]**
Lotte Rasmussen, Niels Bilenberg, Anton Pottegård. (Denmark)
- 113 Slow Adoption of New Evidence Into Clinical Practice and Associated Factors: The Case of Duplicate Therapy With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers [978]**
Ryan P Hickson, James Terenyi, Ross J Simpson, Izabela E Annis, Keiko Bury, Gang Fang. (United States)
- Pharmacovigilance - Alimentary Tract and Metabolism**
- 114 The Association of Domperidone Use and Ventricular Arrhythmia in the Elderly [979]**
Bo Ram Yang, Mi-Sook Kim, Byung-Joo Park, Joongyub Lee. (Korea, Republic of)
- 115 Intensive Monitoring (IM) of New Glucose Lowering Drugs (GLD): Results From An Inception Cohort Study in Portugal Using Patients As a Source of Information [980]**
Carla Torre, Jose Guerreiro, Patricia Longo, Joao Filipe Raposo, Hubert Leufkens, Ana Paula Martins. (Portugal)
- 116 GLP-1RAs and Risk of Diabetic Retinopathy: Analysis of the FDA Adverse Event Reporting System Database [981]**
Wenchao Lu, Huilin Tang, Luwen Shi, Tiansheng Wang. (China)
Recipient of the McAfee Award
- 117 Sitagliptin and the Risk of Heart Failure Hospitalization: Comparisons of Different Designs of Case-Only Studies [982]**
Yaa-Hui Dong, Li-Chiu Wu, Chia-Hsuin Chang. (Taiwan)
- 118 Cardiovascular (CV) Safety of Phentermine and Topiramate in a United States Claims Database [983]**
Mary E Ritchey, Shannon Hunter, Craig Peterson, Lan Nguyen, Steven Thomas, Abenah Harding, Elizabeth Andrews, Kenneth J Rothman, Miguel Cainzos, Mary Anthony. (United States)
- 119 Association Between PPI Use and Risk of Cardiovascular Events [984]**
Federica Galimberti, Manuela Casula, Lorenza Scotti, Francesco Mozzanica, Elena Tragni, Giovanni Corrao, Alberico L Catapano. (Italy)
- 120 The Effect of Proton Pump Inhibitors on Cognition and Brain Volume in the Rhineland Study [985]**
Dianna F de Vries, Natascha Merten, Julia C Stingl, Monique M Breteler. (Germany)
- 121 Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy [986]**
Antonios Douros, Kristian B Fillion, Hui Yin, Oriana H Yu, Mahyar Etminan, Jacob A Udell, Laurent Azoulay. (Canada)
- 122 Safety of Colonoscopy Bowel Cleansers When Combined With the Stimulant Laxative, Bisacodyl: A Cnodes Multi-Centre, Population-Based Cohort Study [987]**
Colin Dormuth, Matthew Weir, Richard Morrow, Dan Chateau, Matthew Dahl, Jordan Hunt, Kathy Lee, Fangyun Wu, Michael Paterson. (Canada)
- 123 Time Between Laboratory Tests and Acute Liver and Kidney Injury Diagnosis Codes in CPRD: Are We Doing it Right? [988]**
Anita Tormos, Cristina Rebordosa, Steven Thomas, Estel Plana, Lawrence Rasouliyan, Manel Pladevall-Vila, Soulmaz Fazeli Farsani, Anouk Deruaz-Luyet, Kimberly G Brodovicz, Susana Pérez-Gutthann. (Spain)
- 124 Proton Pump Inhibitor Use and Risk of Hip Fractures Among Community-Dwelling Persons With Alzheimer's Disease - a Nested Case-Control Study [989]**
Sanna Torvinen-Kiiskinen, Anna-Maija Tolppanen, Marjaana Koponen, Antti Tansakanen, Jari Tiihonen, Sirpa Hartikainen, Heidi Taipale. (Finland)
- 125 Use of Proton Pump Inhibitors and Risk of Acute Kidney Injury Among Patients With Rheumatoid Arthritis [990]**
Henrik Svanström, Marie Lund, Mads Melbye, Björn Pasternak. (Denmark)
- 126 The Use of Multiple Antidiabetic Medications and Its Association With Hypoglycaemic Event: A Case-Crossover Study [991]**
Abdallah Y Naser, Ian C Wong, Maedeh Y Beykloo, Kenneth KC Man, Wallis CY Lau, Dana A Hyassat, Li Wei. (United Kingdom)
- 127 Sodium-Glucose Co-Transporter-2 Inhibitors and the Risk of Fractures in Patients With Type 2 Diabetes [992]**
Niklas Schmedt, Frank Andersohn, Jochen Walker, Edeltraut Garbe. (Germany)
- 128 Proton Pump Inhibitor (PPI) Prescriptions and Breast Cancer Recurrence: A Danish Nationwide Prospective Cohort Study [993]**
Hanne V Nielsen, Rikke N Pedersen, Mette Nørgaard, Timothy L Lash, Bent Ejlersen, Peer Christiansen, Henrik T Sørensen, Deirdre C Fenton. (Denmark)



- 129 Metformin Use and Risk of Dementia: A Meta-Analysis of Observational Studies [994]**Md Salman Hussain, Ambrish Singh, Abul Kalam Najmi. (India)
- 130 The Rate of Hypoglycaemic Events in Individuals With Type 1 Diabetes; Systematic Review and Meta-Analysis of Observational Studies [995]**Alaa A Alsharif, Hassan H Alwafi, Mansour Almetwazi, Li Wei, Abdallah Y Naser, J. Simon Bell, Jenni Ilomaki, Gang Fang, Ian C Wong. (United Kingdom)

Pharmacovigilance - Cardiovascular

- 131 Rivaroxaban and Severe Cutaneous Adverse Reaction Using Case-Crossover Analysis [996]**Young-Jin Ko, Seonji Kim, Kyoungsoon Park, Byung-Joo Park. (Korea, Republic of)
- 132 Sequential Pattern Mining to Predict Prescribed Medications Following Hospitalisation for Heart Failure [997]**Prasad Nishtala, Te-yuan Chyou. (New Zealand)
- 133 Dynamics of the QTc-Interval During Use of Intravenous Ciprofloxacin in ICU Patients [998]**Florine A Berger, I H Sijs, N M Groot, N G Hunfeld, J J Bunge, P M Bemt, T Gelder. (Netherlands)
- 134 Incidence of Major and Clinically Relevant Non-Major (CRNM) Bleeding in Patients Prescribed Rivaroxaban in Secondary Care: Results From the Rivaroxaban Observational Safety Evaluation (ROSE) Study [999]**Alison Evans, Miranda Davies, Lesley Wise, Saad Shakir. (United Kingdom)
- 135 Outcomes and Predictors of Low Anticoagulation Control in New Users of Warfarin [1000]**Sylvie Perreault, Robert Côté, Marie-Pierre Dubé, Simon de Denus, Jean-Claude Tardif. (Canada)
- 136 Respiratory Effect of Angiotensin-Converting Enzyme Inhibitors in People With Asthma: A Nested Case Control Study [1001]**Daniel R Morales, Brian Lipworth, Peter Donnan, Huan Wang. (United Kingdom)
- 137 Psoriasis During Angiotensin Conversion Enzyme Inhibitor Exposure: A Case/Non-Case Study Using the French Pharmacovigilance Database [1002]**Brahim Azzouz, Aurore Morel, Yohann Talineau, Thierry Trenque. (France)
- 138 Characteristics of Patients Initiated on a Reduced Dose of Rivaroxaban for Atrial Fibrillation (AF) - Results From the ROSE (Rivaroxaban Observational Safety Evaluation) Study [1003]**Miranda Davies, Alison Evans, Flavien Coukan, Lesley Wise, Saad Shakir. (United Kingdom)
- 139 Assessment of Initiation Dose in Patients Prescribed Rivaroxaban for Stroke Prevention in Non-Valvular AF (SPAF) and Chronic Kidney Disease - Results From the ROSE (Rivaroxaban Observational Safety Evaluation) Study [1004]**Miranda Davies, Alison Evans, Flavien Coukan, Lesley Wise, Saad Shakir. (United Kingdom)
- 140 Serious Hypoglycemia and Use of Warfarin in Combination With Sulfonylureas Or Metformin [1005]**Young Hee Nam, Colleen M. Brensinger, Warren B. Bilker, Charles E. Leonard, Xu Han, Sean Hennessy. (United States)
- 141 Comparative Safety of Co-Prescribed Calcium Channel Blockers and Oral Anticoagulants for Adverse Bleeding Events in Atrial Fibrillation [1006]**Phuong N. Pham, Stephan Schmidt, Joshua Brown. (United States)
- 142 Benefit-Risk Profile of Dabigatran 110mg versus Vitamin-K Antagonists in Patients With Non-Valvular Atrial Fibrillation: A Cohort Study in the French Nationwide Claims Database [1007]**Patrick Blin, Caroline Dureau-Pournin, Abdelilah Abouelfath, Régis Lassalle, Jacques Bénichou, Yves Cottin, Patrick Mismetti, Cécile Droz-Perroteau, Nicholas Moore. (France)
- 143 Benefit-Risk Profile of Dabigatran 150mg versus Vitamin-K Antagonists in Patients With Non-Valvular Atrial Fibrillation: Results From a Matched Cohort Study in the French Nationwide Claims Database [1008]**Patrick Blin, Caroline Dureau-Pournin, Abdelilah Abouelfath, Régis Lassalle, Jacques Bénichou, Yves Cottin, Patrick Mismetti, Cécile Droz-Perroteau, Nicholas Moore. (France)
- 144 Public Health Surveillance Reveals An Increase in Health Care Utilization for Generic vs. Brand-Name Warfarin Users [1009]**Jacinte Leclerc, Claudia Blais, Louis Rochette, Denis Hamel, Line Guénette, Paul Poirier. (Canada)
- 145 Non-Bleeding Adverse Events Associated With Direct Oral Anticoagulants: A Sequence Symmetry Analysis Using the French Healthcare Databases Between 2013 and 2015 [1010]**Géric Maura, Cécile Billionnet, Joël Coste, Alain Weill, Anke Neumann, Antoine Pariente. (France)
- 146 Calcium Channel Blockers and the Risk for Lung Cancer: A Population-Based Nested Case-Control Study [1011]**Victoria Rotshild, Azoulay Laurent, Ilan Feldhamer, Amichai Perlman, Mendel Glazer, Mordechai Muszkat, Ilan Matok. (Israel)
- 147 Pre-Diagnostic Use of Low-Dose Aspirin and Risk of Incident Metastasis and Mortality in Patients With Colorectal Cancer [1012]**Julie Rouette, Giovanni Giorli, Hui Yin, Francesco Lapi, Monica Simonetti, Claudio Cricelli, Michael Pollak, Laurent Azoulay. (Canada)
- 148 Angiotensin Converting Enzyme Inhibitors and the Risk of Lung Cancer [1013]**Blánaid Hicks, Kristan B Filion, Hui Yin, Lama Sakr, Jacob A Udell, Laurent Azoulay. (United Kingdom)



- 149 Gender Differences in Efficacy and Safety of Direct Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Network Meta-Analysis [1014]**
Bruria Raccach, Amichai Perlman, Donna R Zwas, Sarit Hochberg Klein, Mordechai Muszkat, Ilan Matok. (Israel)
- 150 Automatically Identifying Prescribing Cascades in Clinical Notes Using Natural Language Processing [1015]**
Richeek Pradhan, Weisong Liu, Jerry Gurwitz, Hong Yu. (United States)
- 151 Use of Spontaneous Reporting Systems to Detect Host-Medication Interaction in Drug-Induced Adverse Events [1016]**
Dr. Shi-Heng Wang, Wei J. Chen, Le-Yin Hsu, Kuo-Liong Chien, Chi-Shin Wu. (Taiwan)
- 152 Statin Use and the Risk of Intracerebral Hemorrhage: A Population-Based Cohort Study Using Korean National Health Insurance Claims Database [1017]**
Minji Jung, Sukhyang Lee. (Korea, Republic of)
- 153 Statins and New-Onset Diabetes [1018]**
Julien Bezin, Ana Jarne, Bernard Bégaud, Antoine Pariente. (France)
- 154 Concurrent Use of DOACs and Pharmacodynamic Interacting Drugs Is Associated With An Increased Risk of Major Bleeding Compared to Patients Using DOACs Alone: Nested Case-Control Study in UK CPRD [1019]**
Yumao Zhang, Anthonius de Boer, Helga Gardarsdottir, Hendrika A. van den Ham, A. H. Maitland-van der Zee, Patrick C. Souverein. (Netherlands)
- 155 Abstract Withdrawn [1020]**
- 156 The Impact of Antihypertensive Drugs on Serum Potassium and Sodium Levels in Patients Electively Admitted to a Tertiary Hospital [1021]**
Pieter Cornu, Fawaz Alharbi, Mark De Groot, Alain Dupont, Joost Weyler, Olaf Klungel. (Netherlands)
- 157 The Impact of Sex on the Associations Between ACE Inhibitors and Cough and Angioedema: A Systematic Review and Meta-Analysis [1022]**
Fawaz Alharbi, Anzhelika Kholod, Anthonius Anthonius de Boer, Olaf Klungel. (Netherlands)
- 158 Risk of Mouth Ulcer Associated With the Use of Nicorandil in Korea [1023]**
Hyeonjeong Kim, Ayeong Seo, Bong Gi Kim, Eun Jin Kim, Eunsun Noh, Soo Youn Chung. (Korea, Republic of)
- 159 Risk of Major Cardiovascular Events in Adult Patients With Psoriasis Treated With Biologic Therapies Or Methotrexate: Cohort Study in the British Association of Dermatologists Biologic Interventions Register (BADBIR) [1024]**
Watcharee Rungapiromnan, Kayleigh J. Mason, Mark Lunt, Kathleen McElhone, Martin K. Rutter, Richard B. Warren, Christopher E. Griffiths, Darren M. Ashcroft, . BADBIR Study Group. (United Kingdom)
- 160 Comparison of Smoking Cessation Pharmacotherapy Safety During a Government Sponsored Reimbursement Program: A Population-Based Retrospective Cohort Study [1025]**
Greg Carney, Malcolm Maclure, Ken Bassett, Suzanne Taylor, Colin Dormuth. (Canada)
- 161 Short Term Hdl Cholesterol (HDL-C) Decrease and Incidence of Cardiovascular (CV) Events [1026]**
Gema Requena, Julia DiBello, Liyuan Ma, Til Stürmer, Bradley Layton. (United Kingdom)
- 162 Intraparenchymal Hemorrhage Following Novel Oral Anticoagulant (NOAC) Or Vitamin K Antagonist (VKA) Therapy: A Systematic Review and Meta-Analysis of Clinical Outcomes [1027]**
Ismaeel Yunusa, Aislyn C DiRisio, Maya Harary, Ivo S Muskens, William B Gormley, Linda S Aglio, Timothy R Smith, Jean M Connors, Rania A Mekary, Marike L Broekman. (United States)
- 163 Aromatase Inhibitors and Risk of Myocardial Infarction in Post-Menopausal Women With Breast Cancer [1028]**
Farzin Khosrow-Khavar, Kristian B. Fillion, Nathaniel Bouganim, Samy Suissa, Laurent Azoulay. (Canada)
- 164 Cardiovascular Comorbidities and Risk Factors in Accordance With Pharmacogenetics in Rheumatoid Arthritis Patients Treatment With Methotrexate - Preliminary Data [1029]**
Karel Hloch, Martin Dosedel, Tomas Soukup, Erik Jurjen Duintjer Tebbens, Lenka Zaloudkova, Petr Pavek. (Czech Republic)

Biologics/Biosimilars

- 165 Adverse Events With Recombinant G-CSF for Neutropenia in Cancer [1030]**
Brenna L. Brady, Debra E. Irwin. (United States)
- 166 Abstract Withdrawn [1031]**
- 167 Use of Systemic Immunomodulating Medications in Children With Atopic Dermatitis [1032]**
Mia Schneeweiss, Joseph F. Merola. (United States)
- 168 Persistence on Tofacitinib Therapy in Rheumatoid Arthritis [1033]**
Anat Fisher, Colin Dormuth, Marie Hudson. (Canada)
- 169 Incidence Rate of Serious Infections in Patients Receiving Biologic Anti-Inflammatory Agents for Treatment of Rheumatologic, Dermatologic, and Gastrointestinal Conditions [1034]**
Jie (Sophie) Zhang, Gayathri Sridhar, Charles E Barr, Bernadette Eichelberger, BBCIC Anti-inflammatory Research Team, Kevin Haynes. (United States)
- 170 The Longitudinal Population-Based PHARMO-IBD Cohort: Insights Into Treatment Effects and Disease Course [1035]**
Josephina G Kuiper, Marina Bakker, Fernie J Penning-van Beest, Ron C Herings. (Netherlands)



- 171 Evaluation of Health Direct Costs Associated With the Use of Biosimilar and Originator Erythropoiesis Stimulating Agents (Esas): An Italian, Multi-Regional, Population-Based Study [1036]**
Ylenia Ingrassiotta, Dario Formica, Francesco Giorgianni, Valentina Ientile, Alessandro Chinellato, Daniele Ugo Tari, Rosa Gini, Maurizio Pastorello, Salvatore Scondotto, Pasquale Cananzi, Giuseppe Traversa, Armando Genazzani, Gianluca Trifirò. (Italy)
- 172 Exposure- and Dose-Response Analyses in Dose Selection and Labeling of FDA-Approved Biologics [1037]**
Ken Ogasawara, Christopher D. Breder, Dora H. Lin, G. Caleb Alexander. (United States)
- 173 Characteristics of Golimumab Initiators in Routine Care [1038]**
Najat Ziyadeh, Anja Geldhof, Wim Noël, John Seeger. (United States)
- 174 Characteristics of Ustekinumab Initiators in Routine Care [1039]**
Najat Ziyadeh, Anja Geldhof, Wim Noël, John Seeger. (United States)
- 175 Use, Safety and Effectiveness of Targeted Therapies in Colorectal Cancer According to Age and Frailty [1040]**
Amandine Gouverneur, Juliette Coutureau, Jérémy Jové, Magali Rouyer, Angela Grelaud, Sophie Duc, Stéphane Gérard, Denis Smith, Alain Ravaud, Cécile Droz, Marie-Agnès Bernard, Régis Lassalle, Annie Fourrier-Réglat, Pernelle Noize, On behalf the ETNA study group and the EREBUS stud. (France)
- 176 Real-Life Treatment and Survival in Metastatic Colorectal Cancer Elderly Patients: A Population-Based Study [1041]**
Amandine Gouverneur, Julien Bezin, Jérémy Jové, Pauline Bosco-Lévy, Annie Fourrier-Réglat, Pernelle Noize. (France)

- 177 Use of Biological Anti-Inflammatory Drugs in Dermatology, Gastroenterology, and Rheumatology in the Capital Region of Denmark [1042]**
Thomas B Jensen, Jon Trærup Andersen, Rikke Cortes, Kasper Meidahl Petersen, Tonny Studsgaard Petersen, Jakob Kjellberg, Hanne Rølhed Christensen, Espen Jimenez-Solem. (Denmark)
- 178 Clinical Development of Biologics Approved by the U.S. Food and Drug Administration, 2003-2016 [1043]**
G. Caleb Alexander, Ken Ogasawara, Dana Wiegand, Dora H. Lin, Christopher D. Breder. (United States)
- 179 Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease [1044]**
Marni Stott-Miller, Joanne Brady, George Mu, Sue Perera. (United Kingdom)

Burden of Disease - Infections

- 180 Incidence and Treatment Characteristics of Urinary Tract Infections - On-Line Survey [1045]**
Mária Matuz, Nikolett Herédi, Réka Bordás, Márta Csatornai, Réka Viola, Gyöngyvér Soós, Ria Benkő. (Hungary)
- 181 Development and Validation of a Prediction Model for Poor Outcome of Tuberculosis Treatment: A Nationwide, Register-Based Retrospective Cohort Study From the Netherlands [1046]**
Ivan Surya Pradipta, Natasha van't Boveneind-Vrubleuskaya, Onno W Akkerman, Jan-Willem Alffenaar, Eelko Hak. (Netherlands)
- 182 Estimating the Prevalence of HIV Among Liver Transplant Candidates in the United States [1047]**
Ashton A. Shaffer, Alvin G. Thomas, Allan B. Massie, Sally Gustafson, Jon Snyder, Brittany Shelton, Rhiannon Reed, Jayme E Locke, Dorry L Segev. (United States)
- 183 Developing and Validating the Personal Risk of Oncogenic Human Papillomavirus (PRO-HPV) Infection Score in US Women [1048]**
Thuy Thai, Thanh Bui, Mark Ebell. (United States)
- 184 The Economic Burden of Human Immunodeficiency Virus in the US [1049]**
Eric E Chinaeke, Kevin Z Lu. (United States)
- 185 Incidence of Pediatric Acute Bacterial Skin and Skin Structure Infection (ABSSSI) From 2005-2015 [1050]**
Neika Vendetti, Vinay Mehta, Pamela Sears, Carisa De Anda, T. Christopher Mast. (United States)
- 186 Incidence of Herpes Zoster Among Rheumatoid Arthritis Patients in Japan From 2013 to 2016: The Results Using JDM-PV Web Tool [1051]**
Tomoko Kobayashi, Eiko Yoshinaga, Atsushi Nishikawa, Rei Maeda. (Japan)
- 187 Barriers and Facilitators to Initiating and Completing Direct-Acting Antiviral Therapy for Chronic Hepatitis C Infection [1052]**
M. Elle Saine, Frances K. Barg, Dena M. Carbonari, Robert Gross, Vincent Lo Re. (United States)
- 188 Associations Between Use of Anti-Infective Medications and Genital Human Papillomavirus Infections in the US Population [1053]**
Thuy Thai, Thanh Bui, Hong Xiao. (United States)

Burden of Disease - Musculoskeletal

- 189 Osteoporosis-Related Fracture Events [1054]**
Benjamin Chastek, Kevin Sundquist, Setareh A Williams, Deane Leader, Richard Weiss, Yamei Wang, Jeffrey R Curtis. (United States)



190 Determination of Incidence of Hepatitis B Virus Reactivation During Immunosuppressive Therapies for Rheumatoid Arthritis Using a Validated Administrative Data [1055]

Shinobu Imai, Hayato Yamana, Manabu Akazawa, Kiyohide Fushimi, Kiyoshi Migita, Hiroshi Yatsuhashi. (Japan)

191 Association of Body Mass Index With Osteoarthritis Prevalence and Prescription Analgesic Utilization in Overweight Or Obese Patients With Osteoarthritis [1056]

Stephen S Johnston, Eric M Ammann, Robin Scamuffa, Jonathan Samuels, Andrew Stokes, Elliott Fegelman, Chia-Wen Hsiao. (United States)

192 Secular Trends in Major Osteoporotic Fractures Among 50+ Adults in Denmark Between 1995 and 2010 [1057]

Shahab Abtahi. (Netherlands)

193 Increasing Risk of Post-Surgery Infections Among Hip Fracture Patients: A Nationwide Study 2005-2016 [1058]

Kaja Eriksrud Kjoerholt, Søren P. Johnsen, Nickolaj R. Kristensen, Daniel Prieto-Alhambra, Alma B. Pedersen. (Denmark)

194 Long-Term Risperidone Exposure Does Not Increase the Risk of Osteoporosis-Related Fractures [1059]

Becky Shih-Pei Shen, Yan Fang Liu, Hong Qiu, Kuan-Yi Tsai, Hung-Chi Wu, Wen-Miin Liang, Frank Huang-Chih Chou. (Taiwan)

195 A Retrospective Study to Assess the Risk of Falls Due to Prescribed Drugs in Inpatients [1060]

Mr. Hideaki Yashima, Takuya Araki, Taku Shibamiya, Yasuhiro Komatsu, Koujirou Yamamoto. (Japan)

196 Defining Readmissions in a Claims Database Among Patients Receiving Open Reduction Internal Fixation for Femur, Tibia Or Fibula [1061]

Abhishek Chitnis, Theresa Amoloja, Jill Ruppenkamp, Mollie Vanderkarr, Chantal Holy. (United States)

Drug Effectiveness - Diabetes

197 Risk of Cardiovascular Events in Type 2 Diabetes Patients Initiating Second Line Therapy With Glucose Lowering Drugs: A Population-Based Analysis [1062]

Cristiano S Moura, Malik Elharram, Michal Abrahamowicz, Sasha Bernatsky, Hassan Behlouli, Valeria Raparelli, Louise Pilote. (Canada)

198 The Clinical and Economic Effects of Switching US Medicare Beneficiaries With Type 2 Diabetes From Analog to Human Insulin [1063]

Jing Luo, Nazleen Khan, Thomas Manetti, James Rose, Ani Kaloghlian, Balu Gadhe, Sachin H. Jain, Joshua Gagne, Aaron Kesselheim. (United States)

199 Association Between Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and Lower Extremity Amputation: A Retrospective Cohort Study [1064]

Hsien-Yen Chang, Sonal Singh, Omar Mansour, Sheriza Baksh, G. Caleb Alexander. (United States)

200 Rates of Kidney Function Decline and Urinary Tract Infection for Sulfonylureas, DPP4is and SGLT2is: A New-User Cohort Study [1065]

Samantha Wilkinson, Heide Stirnadel-Farrant, Liam Smeeth, Laurie Tomlinson, Ian Douglas. (United Kingdom)

201 Evaluation of Weight Change and Hypoglycemia As Potential Mediators in the Association Between Insulin Use and Death [1066]

Jea Young Min, Amber J Hackstadt, Marie R Griffin, Robert A Greevy, Jonathan Chipman, Carlos G Grijalva, Adriana M Hung, Christianne L Roumie. (United States)

202 Assessing Interactions Between Metformin and Exercise on HbA_{1c}, Functional Capacity, Lipid Profile, Quality of Life and Weight [1067]

Sherif Eltonsy, Monique Dufour Doiron, Patrice Simard, Caroline Jose, Martin Sénéchal, Danielle R. Bouchard, Rémi LeBlanc, Mathieu Bélanger. (Canada)

203 Differences Between Randomized Clinical Trial Patients and Real-World Initiators of Liraglutide [1068]

Jakob S Knudsen, Reimar W Thomsen¹, Anton Pottegård, Lisbeth M Baggesen¹, Filip Knop, Henrik T Sørensen. (Czech Republic)

Propensity Scores

204 Balance of Unmeasured Variables After Propensity Score Matching in Claims-Based Studies of Anticoagulants: A Validation Study Linking Claims Data to Electronic Health Records [1069]

Chandrasekar Gopalakrishnan, Krista F Huybrechts, Adrian Santiago Ortiz, Kristina Zint, Lionel Riou Franca, Dorothee B Bartels, Sebastian Schneeweiss. (United States)

205 Propensity Scores Balance Individual Covariates and Also Combinations of Covariates (Phenotypes) [1070]

Kandace L Amend, Bruce Turnbull, Li Zhou, John D Seeger. (United States)

206 Standard Propensity Score Weighting Did Not Result in Balanced Cohorts, Now What? [1071]

Pamela Landsman-Blumberg, Tasneem Lokhandwala, Bonnie Dean, Agathe Le Lay, Dana Stafkey-Mailey. (United States)

207 Propensity Score (PS) Matched Approaches to Estimate the Association Between Liraglutide Use and Thyroid Cancer (TC) [1072]

Kathleen Mortimer, Donnie Funch, Li Zhou, Eva Ng, Atheline Major-Pedersen, Heidrun Bosch-Traberg, Helge Gydesen, David Dore. (United States)

208 Incremental Utility of Additional Clinical Information and Propensity Score Methods in Controlling for Severe Confounding by Indication [1073]

Hiraku Kumamaru, Jessica J Jalbert, Soko Setoguchi. (Japan)



Quality of Life

- 209 Cost-Utility of Screening for Renal Dysfunction to Detect the Onset and Progression of Chronic Kidney Disease Among Elderly Patients Treated With Proton-Pump Inhibitors [1074]**
Jeff Y. Yang, Emily H. Chang, Stephanie B. Wheeler, Evan S. Dellon. (United States)
- 210 Health-Related Quality of Life in Type 2 Diabetes Mellitus (T2DM) Patients Starting With New Glucose Lowering Drugs (GLD): An Inception Cohort Study in Portugal [1075]**
Carla Torre, Jose Guerreiro, Patricia Longo, Joao Filipe Raposo, Hubert Leufkens, Ana Paula Martins. (Portugal)
- 211 Change of Health Related Quality of Life Tuberculosis Patients After Receiving Treatment: A Longitudinal Study [1076]**
J Atthobari. (Indonesia)

Vaccines

- 212 A Systematic Review of Models Used in Quantitative Benefit-Risk Assessment of Rotavirus Vaccination [1077]**
Hugo Arlegui, Gaelle Nachbaur, Bernard Begaud, Nicolas Praet. (France)
- 213 Impact of Rotavirus Vaccination in Taiwan: An Interrupted Time-Series Analysis [1078]**
Yi-Chen Juan, Chia-Hung Liu, K Arnold Chan, Wan-Ting Huang. (Taiwan)
- 214 Unspecific ICD-10 Hospital Discharge Diagnoses After HPV Vaccination: A Nationwide Matched Cohort and Time Series Study [1079]**
Reimar W Thomsen, Buket Öztürk, Lars Pedersen, Sia K Nicolaisen, Irene Petersen, Kim Varming, Jørn Olsen, Henrik T Sørensen. (Denmark)
- 215 Adverse Events Following DT-IPV and MMR Vaccines in 9-Year-Old Children Primed With Whole-Cell Or a Cellular Pertussing-Containing Vaccines [1080]**
Jeanet M Kemmeren, Nicoline A van der Maas, Hester E de Melker. (Netherlands)
- 216 Serosurvey and Its Impact on National Immunization Strategy in the Czech Republic [1081]**
Roman Prymula. (Czech Republic)
- 217 Estimating Incidence of Adverse Events Following Vaccination in Observational Databases When Exposure Information Is Unavailable: A Contribution From the Advance Project [1082]**
Caitlin Dodd, Kaat Bollaerts, Maria de Ridder, Olivia Mahaux, Francois Haguinet, Tom de Smedt, Ana Correa, Talita Duarte-Salles, Hanne Dorthe Emborg, Consuelo Huerta, Elisa Martin, Gino Picelli, Klara Berencsi, Giorgia Danieli, Miriam Sturkenboom, Daniel Weibel. (Netherlands)
- 218 Characteristics of Vaccination Errors Reported to the European Adverse Event Database Eudravigilance [1083]**
Christina E Hoeve, Anja van Haren, Miriam C Sturkenboom, Sabine M Straus. (Netherlands)
- 219 Pilot Study to Assess Research Capacity for Malaria Vaccine Pharmacovigilance in Ghana and Kenya [1084]**
Eve Wool, James H Stark, Mehreen Arif, Fabiola Catulle, Kiely Flynn, Shela Fobella, Mary C Hiott, Elyse Morris, Deborah Onakomaiya, Magali Romero, Morghann Sims, Rashida Talib, George Wak, Daniel Weibel, Emily Goldmann. (United States)
- 220 Lessons Learned on Enhanced Passive Safety Surveillance of Influenza Vaccines [1085]**
Natasha Khalife, Mariana Almas, Margot Stam Morago, Filipa Negreiro, Lucia Costa, Sara Proietto. (United Kingdom)
- 221 Knowledge and Attitudes Regarding Cervical Cancer and Human Papillomavirus Vaccination in Czech Secondary School Students [1086]**
Eva Zimcikova, Veronika Regnerova, Ales Kubena, Katerina Mala-Ladova. (Czech Republic)

Drug Utilization - Infections

- 222 Real-World Data on the Effect of Doxycycline Plus Prednisone/Prednisolone on COPD Exacerbations Compared With Prednisone/Prednisolone Alone: A Retrospective Cohort Study Among COPD Outpatients [1087]**
Yuanyuan Wang, Jens H. Bos, Catharina C. Schuling-Veninga, Bob Wilffert, Eelko Hak. (Netherlands)
- 223 Emtricitabine/Tenofovir (Truvada®) Fixed-Dose Combination in Pre-Exposure Prophylaxis of Human Immunodeficiency Virus: An Observational Drug Utilization Study Using the French National Health Insurance Database [1088]**
Sophie Billioti de Gage, Fanny Raguideau, Annie Rudnichi, Rosemary Dray-Spira. (France)
- 224 Prescribing of Oral Fluoroquinolones in Canada for Treatment of Acute Bacterial Sinusitis: A Retrospective Cohort Study [1089]**
Shawn C. Bugden, Dan Chateau, Nick Daneman, Jianguo Zhang, Fawziah Lalji, Ingrid Sketris, Mikhael Laskine, Jacqueline Quail, Matthew Dahl, Pierre Ernst. (Canada)
- 225 Prescribing of Oral Fluoroquinolones in Canada for Treatment of Uncomplicated Urinary Tract Infection: A Retrospective Cohort Study [1090]**
Shawn C. Bugden, Dan Chateau, Nick Daneman, Jianguo Zhang, Fawziah Lalji, Ingrid Sketris, Mikhael Laskine, Jacqueline Quail, Matthew Dahl, Pierre Ernst. (Canada)
- 226 Antibiotic Prescription in Southern Italian Outpatients: Real-World Data Analysis of Prevalence, Socioeconomic and Sociodemographic Variables and Geographic Variability [1091]**
Veronica Russo, Valeria Marina Monetti, Ugo Trama, Antonella Guida, Enrica Menditto, Valentina Orlando. (Italy)
- 227 Misuse Among the Most Frequently Prescribed Antibiotics to Outpatients in Mexico City [1092]**
Ramiro Sánchez-Huesca, Claudia Lerma. (Mexico)



- 228 Therapy Completion of Direct-Acting Antivirals for Hepatitis C [1093]**
Marina A Machado, Cristiano S Moura, Marina Klein, Bruce Carleton, Kevin Winthrop, Michal Abrahamowicz, Jordan Feld, Jeffrey R Curtis, Sasha Bernatsky. (Canada)
- 229 Outpatient Antimicrobial Prescriptions to Japanese Children [1094]**
Tomokazu Shoji, Keiko Konomura, Manabu Akazawa. (Japan)
- 230 Linezolid Use in Pediatric Patients [1095]**
Neika Vendetti, Vinay Mehta, T. Christopher Mast. (United States)
- 231 Antimicrobial Stewardship Program: An Adventure From Erratic Towards Utopia [1096]**
Zabiuddin Ahad Mohammed, Vandana Kalwaje Eshwara, Muralidhar Varma, Sonal Sekhar, Chiranjay Mukhopadhyay. (India)
- 232 The Trend of Inpatient Utilization of Colistin in Taiwan From 2006-2013: A Cross-Sectional Study [1097]**
Ms. Nai-Yu Chen, Mr. Chien-Chou Su, Ms. Yea-Huei Kao Yang, Ms. Ching-Lan Cheng. (Taiwan)
- Drug Utilization - Interventions and implementations**
- 233 Reducing Inappropriate Supply of Opioids at Hospital Discharge [1098]**
Alice V Gilbert, Mel Morrow, Jac H Crofton, Tristen L Pogue, Bhavini K Patel. (Australia)
- 234 Evaluation of Antimicrobial Stewardship Programs Implementation and Outcomes Using Quasi Experimental Study Design, in a Selected Hospital at Makkah, Kingdom of Saudi Arabia [1099]**
Abdul Haseeb, Hani Saleh Faidah, Zikria Saleem, Mohamed Fadaq, Dr. Turki Mohammad Noor Al-Sulaimani, Mohamed Azmi Ahmad Hassali. (Saudi Arabia)
- 235 Pharmacy Closures and Adherence to Cardiovascular Medications Among Older Adults in the United States [1100]**
Dima M Qato, Caleb Alexander, Apurba Chakraborty, Jenny Guadamuz, John Jackson. (United States)
- 236 Abstract Withdrawn [1101]**
- 237 Hormonal Contraceptive Use in Norway, 2004-2016: A Nationwide Register-Based Study [1102]**
Ellen B Aares, Øystein Karlstad, Kari Furu. (Norway)
- 238 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Prescriptions From the 6th Month of Pregnancy: Impact of Health Authorities' Advice [1103]**
Mélanie Araujo, Caroline Hurault-Delarue, Claire Bouilhac, Dominique Petiot, Christophe Vayssière, Sabine Vidal, Jean-Louis Montastruc, Christine Damase-Michel, Justine Benevent, Isabelle Lacroix. (France)
- 239 A Descriptive Study of Switching Patterns Among MS Patients Who Started on Glatopa[®] Therapy: A Claims Database Analysis [1104]**
Erin Hulbert, Ying Wu, Djibril Liassou, Kristen B. Bibeau, Jessica K. Alexander, Sigal Melamed-Gal. (United States)
- 240 The Effect of a Regulatory Action to Prevent Therapeutic Duplication of Respiratory Drugs in Korea [1105]**
Hyesung Lee, Inmyung Song, Eui-Kyung Lee, Ju-Young Shin. (Korea, Republic of)
- 241 Reducing the Drug Burden Index - A Post Hoc Analysis of a Randomised Controlled Trial Using Machine Learning [1106]**
Katja Taxis, Jasper De Boer, Heleen G van der Meer, Michael Biehl. (Netherlands)
- 242 Drug Utilisation Patterns in Older Patients Admitted to Geriatric Wards in Norway. Using Network Analysis to Shed Light on the Changes in Patterns [1107]**
Kristian Svendsen, Kjell H Halvorsen, Beate H Garcia. (Norway)
- 243 Preventing a Rise in Anticholinergic and Sedative Medication Load: Feasibility of An Innovative Pharmacist-Led Intervention [1108]**
Helene van der Meer, Hans Wouters, Martina Teichert, Fabienne Griens, Caroline van de Steeg, Jugoslav Pavlovic, Lisa Pont, Katja Taxis. (Netherlands)
- 244 Prescriber Agreement With Pharmacists' Recommendations to Reduce Anticholinergic/Sedative Load [1109]**
Helene van der Meer, Hans Wouters, Martina Teichert, Fabienne Griens, Caroline van de Steeg, Jugoslav Pavlovic, Lisa Pont, Katja Taxis. (Netherlands)
- 245 Efficient Selection of Older Patients for Medication Review: Development and Validation of a Selection Algorithm [1110]**
Stijn Crutzen, Katja Taxis, Petra Denig, On behalf of the ESOM group. (Netherlands)
- 246 Implications of Medicare Part D Cost-Sharing on Disease-Modifying Therapy Initiation Among Individuals With Multiple Sclerosis [1111]**
Daniel M Hartung, Kirbee Johnston, Dennis Bourdette. (United States)
- 247 Tobacco Cessation Treatment Utilization by Kentucky Medicaid Recipients Before and After Medicaid Expansion and Mandated Tobacco Treatment Coverage: 2013-2015 [1112]**
Amie Goodin, Jeffery Talbert, Patricia Freeman, Ellen Hahn, Amanda Fallin-Bennett. (United States)
- 249 The Emergency Department Pharmacist for Improvement of Under- and Overtreatment With Medication: An Interim Analysis [1114]**
Rehana N. Rahman, Bojan Nikolic, Stephanie C Klein Nagelvoort - Schuit, Marjo J. Janssen, Fatma Karapinar-Carkit, Patricia M. van den Bemt. (Netherlands)



Benefit-Risk Assessment, Communication, and Evaluation (BRACE)

- 250 Community Pharmacists' Knowledge and Practice Toward Non-Prescription Products Used for Weight Control: A Cross Sectional Study [1115]**
Sarah I Alamer, Yasir Ibrahim, Mohammad Zaitoun. (Saudi Arabia)
- 251 Pharmacists' Involvement in Rationalization of Valganciclovir Use in Cytomegalovirus Prophylaxis for Renal Transplant Patients: A Pilot Single Center Study [1116]**
Mohammad Zaitoun, As'ad Taha, Huda AlQahtani, Nada Sakr, Abdullah Hadram, Khalid Al-Alsheikh. (Saudi Arabia)
- 252 The Re-Aim Framework and REVLIMID REMS Program: A Methodology for REMS Assessment Using ISPE Recommendations [1117]**
May L. Chan-Liston, Jennifer L. Bourke, Paul Sheehan, Steven Niemcryk, Michael Peng, Robert Bwire, John Freeman, Jay T. Backstrom, Russell Glasgow. (United States)
- 253 Impact of the Erythropoiesis-Stimulating Agents (ESAS) Risk Evaluation and Mitigation Strategy (REMS) on ESA Administration and Red Blood Cell (RBC) Transfusion for Chemotherapy (CT) Induced Anemia (CIA) [1118]**
Amarilys Vega, Rongmei Zhang, Michael Alexander, Hui-Lee Wong, Yuhui Feng, An-Chi Lo, Qin Ryan, Rima Izem, Michael Wernecke, Jeffrey A Kelman, David J Graham. (United States)
- 254 Evaluation for Disparities in Erythropoiesis-Stimulating Agents (ESAS) Administration in Patients With Cancer [1119]**
Hui-Lee Wong, Rongmei Zhang, Michael Alexander, Yuhui Feng, An-Chi Lo, Qin Ryan, Rima Izem, Michael Wernecke, Amarilys Vega, Jeffrey A Kelman, David J. Graham. (United States)
- 255 Qualitative Research: Another Method to Consider in the Ongoing Assessment of Benefit-Risk [1120]**
Teresa A Simon, Chen Zhang, Brian Shakley, David McDonald, Andres Gomez. (United States)
- 256 Do People Understand Benefits and Risks? Even Ineffective Treatments for Delaying Alzheimer's Disease Are Preferable to 'Doing Nothing' for Many Older Adults [1121]**
Rachael DiSantostefano, Shelby Reed, Jui-Chen Yang, Bennett Levitan, F. Reed Johnson. (United States)
- 257 Measuring the Impact of Pharmacovigilance Activities on Public Health; Practical Example of 3 Signals [1122]**
Florence Hunsel, Laura Peters, Helga Gardarsdottir, Agnes Kant. (Netherlands)
- 258 Patient-Centered Benefit-Risk Decision-Making and the Role of Educational Tools and Psychological Instruments in Preference Elicitation- Year 1 of IMI Prefer [1123]**
Ulrik Kihlblom, Selena Russo, Dario Monzani, Geert Vander Stichele, Sarah Verscheuren, Cathy Anne Pinto. (United States)
- 259 Optimizing Rems Counseling Tools for Prescribers and Patients [1124]**
Hilda W Chan, Andrea M Russel, Meredith Y Smith. (United States)
- 260 Patient Factors Affecting Clinician Work Intensity During Opioid Use Discussions [1125]**
Dave Smith, Jennifer Kuntz, Katherine Reese, Lou Ann Thorsness, Ronnie Horner. (United States)
- 261 Primary Care Physician, Oncologist, and Psychiatrist Comfort Levels With Prescriptions Written by Themselves and Peers for Cancer Comorbidities [1126]**
Chiahung Chou, Natalie S Hohmann, Tessa Hastings, Chao Li, Joel Farley, Matthew Maciejewski, Marisa Domino, Richard Hansen. (United States)
- 262 A New Analytic Tool Developed in the Sentinel System to Assess Adherence to FDA's Safe Use Recommendations [1127]**
Noelle M. Cocoros, Anita Wagner, Kevin Haynes, Andrew B. Petrone, Elnara Fazio-Eynullayeva, Yulan Ding, Rima Izem, Joo-Yeon Lee, Jacqueline M. Major, Michael Nguyen, Jing Ju. (United States)
- 263 Redesigning Prioritization Methods Using High Risk Medicines for Clinical Pharmacists [1128]**
Alice V Gilbert, Mel Morrow, John Shanks, Bhavini K Patel. (Australia)
- 264 Limitations in Reporting "Benefit-Risk" Across Therapeutic Areas in Medical Device Literature [1129]**
Whitney S. Krueger, Jessica C. Young, Kelly Hollis, A. Brett Hauber, Alicia Gilsenan, Mary E. Ritchey. (United States)
- 265 Sources of Evidence Supporting Post-Marketing Pharmacovigilance Regulatory Actions Since 2012 [1130]**
Samantha Lane, Elizabeth Lynn, Saad A Shakir. (United Kingdom)
- 266 Impact of the 2012 Pharmacovigilance Legislation on the Harmonisation of DHPCS in the EU [1131]**
Gudlaug Olafsdottir, Sif M Bukhave, Georges Kalligeros, Christine E Hallgreen, Marie L De Bruin. (Denmark)
- 267 Pre/Post Effectiveness Evaluation of the Myozyme (Alglucosidase Alfa) Safety Information Packet [1132]**
Esther Artime, Irene Shui, Stephanie Tcherny-Lessenot, Pierre D'Arbigny, Ignacio Méndez, Nawab Qizilbash. (Spain)
- 268 Benefit Risk Assessment for Fibrinogen Concentrate in the Setting of Complex Cardiac Surgery: Lessons Learned Using the CIRS-BRAT Framework [1133]**
Ulla M Forssen, Andres Brainsky, Jian Ye, Thomas Chung, Douglas J Watson. (United States)



- 269 A Decade of Marketing Approval of Gene and Cell Based Therapies in the United States, European Union, and Japan: A Regulatory Decision-Making Evaluation [1134]**
Delphi G Coppens, Sofieke de Wilde, Henk J Guchelaar, Marie L De Bruin, Hubert G Leufkens, Pauline Meij, Jarno Hoekman. (Netherlands)
- 270 Compendium of Methods for Measuring Patient Preferences in Medical Treatment [1135]**
Chiara Whichello, Vikas Soekhai, Bennett Levitan, Jorien Veldwijk, Tarek Hammad, Ulrik Kihlbom, Eline van Overbeeke, Selena Russo, Ateesha Mohammed, Richard Hermann, Isabelle Huys, Vaishali Patadia, Juhaeri Juhaeri, Esther de Bekker-Grob. (Netherlands)
- 271 Conditions and Factors Influencing Application of Patient Preferences in Benefit-Risk and Other Assessments [1136]**
Eline van Overbeeke, Chaira L Whichello, Rosanne Janssens, Esther de Bekker-Grob, Jorien Veldwijk, Bennett Levitan, Jürgen Kübler, Selena Russo, Karin Schölin Bywall, Irina Cleemput, Alina Comanescu, Paolo Guidi, Ketti Mazzocco, Laura Vergani, Giulia Marton, Jenny Sharpe, Nikoletta Nikolenko, Berkeley Phillips, Rachael DiSantostefano, Axel Hueber, Matthias Englbrecht, Meredith Smith, Richard Hermann, Juhaeri Juhaeri, Isabelle Huys. (Belgium)
- 272 Stakeholder Perspectives on the Integration of Patient Preferences in the Medical Product Life Cycle [1137]**
Rosanne Janssens, Selena Russo, Eline van Overbeeke, Chiara L Whichello, Karin Schölin Bywall, Jürgen Kübler, Sarah Harding, Juhaeri Juhaeri, Bennett Levitan, Irina Cleemput, Alina Comanescu, Rachael L DiSantostefano, Axel Hueber, Matthias Englbrecht, Meredith Y Smith, Richard Hermann, Gabriella Pravettoni, Esther de Bekker-Grob, Jorien Veldwijk, Isabelle Huys. (Belgium)
- 273 Healthcare Professional Survey to Assess the Effectiveness of Abatacept (Orencia®) Patient Alert Cards in Rheumatoid Arthritis Patients [1138]**
Esther Arttime, Randip Kahlon, Nawab Qizilbash, Ignacio Méndez, Tzuyung Kou. (Spain)
- 274 Development of An Evidence-Based Implementation Strategy for Digital Risk Minimization Measures [1139]**
Carmit Strauss, Jasmine C Roddey, Tammy Lindberg, Meredith Y Smith. (United States)
- 275 Quantitative Analysis of Survey Studies Assessing the Effectiveness of Risk Minimisation Measures: State of the Art [1140]**
Esther Arttime, Preen Vora, Alex Asiiimwe, Montse Soriano-Gabarro, Nawab Qizilbash. (Spain)
- 276 Evaluation of Patient Knowledge of Safety and Safe Use Information for Aflibercept [1141]**
Laurie Zografos, Elizabeth Andrews, Brian Calingaert, Eric Davenport, Dan Wolin, Zdravko Vassilev. (United States)
- 277 Risk Management of Medication Errors in the EU [1142]**
Christina E Hoeve, Reynold D Francisca, Miriam C Sturkenboom, Sabine M Straus. (Netherlands)

End Poster Session C



ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
FRIDAY, AUGUST 24, 2018				
Applied Sensitivity Analyses in Pharmacoepidemiology Database Studies				
1		10:30 AM	Congress Hall	Workshop
Employing Longitudinal Trajectories To Model Exposure In Perinatal Pharmacoepidemiology Research				
2		10:30 AM	Panorama Hall	Symposia
Methodologic Considerations for Non-Interventional Studies Evaluating Outcomes of Originator-To-Biosimilar Switching				
3		10:30 AM	South Hall 1A&B	Symposia
Long Live the "Medical Data Janitors": International Data Quality Assurance Practices in Distributed Data Networks				
4		10:30 AM	South Hall 2A	Symposia
Rare Disease Development Programs: An Update				
5		10:30 AM	South Hall 2B	Symposia
Methods: It's About Time				
6		1:30 PM	Congress Hall	Oral
7		1:45 PM	Congress Hall	Oral
8		2:00 PM	Congress Hall	Oral
9		2:15 PM	Congress Hall	Oral
10		2:30 PM	Congress Hall	Oral
11		2:45 PM	Congress Hall	Oral
Doacs, Doacs... and More Doacs				
12		1:30 PM	Panorama Hall	Oral
13		1:45 PM	Panorama Hall	Oral
14		2:00 PM	Panorama Hall	Oral
15		2:15 PM	Panorama Hall	Oral
16		2:30 PM	Panorama Hall	Oral
17		2:45 PM	Panorama Hall	Oral
Shots Heard 'Round the World				
18		1:30 PM	South Hall 1A&B	Oral
19		1:45 PM	South Hall 1A&B	Oral
20		2:00 PM	South Hall 1A&B	Oral
21		2:15 PM	South Hall 1A&B	Oral
22		2:30 PM	South Hall 1A&B	Oral
23		2:45 PM	South Hall 1A&B	Oral
Drugs in Pregnancy - Ondansetron, Opioids, Gabapentin				
24		1:30 PM	South Hall 2A	Oral
25		1:45 PM	South Hall 2A	Oral
26		2:00 PM	South Hall 2A	Oral
27		2:15 PM	South Hall 2A	Oral
28		2:30 PM	South Hall 2A	Oral
29		2:45 PM	South Hall 2A	Oral

Pub. #	Poster #	Presentation Time	Room	Format
Biologics - Take it or Leave It				
30		1:30 PM	South Hall 2B	Oral
31		1:45 PM	South Hall 2B	Oral
32		2:00 PM	South Hall 2B	Oral
33		2:15 PM	South Hall 2B	Oral
34		2:30 PM	South Hall 2B	Oral
35		2:45 PM	South Hall 2B	Oral
Psychotropics - The More It Changes, The More It's The Same				
36		1:30 PM	South Hall 3A	Oral
37		1:45 PM	South Hall 3A	Oral
38		2:00 PM	South Hall 3A	Oral
327		2:15 PM	South Hall 3A	Oral
40		2:30 PM	South Hall 3A	Oral
41		2:45 PM	South Hall 3A	Oral
Sequential and Sequential Design: Tools for Prospective Sequential Medical Product Safety Surveillance				
42		3:30 PM	Congress Hall	Workshop
Bringing Patient-Generated Data into Pharmacoepidemiology: The Who, What, Why, Where, When... and How				
43		3:30 PM	Panorama Hall	Symposia
Time Series Analysis: Where Are We Now, and What Will the Future Bring?				
44		3:30 PM	South Hall 1A&B	Symposia
Implementation Science - the Art Nouveau of Pharmacoepidemiology for Improving Risk Mitigation in Healthcare				
45		3:30 PM	South Hall 2A	Symposia
Advances in the Study of Medication Errors in Computerized Healthcare Databases and Spontaneous Reporting Systems in Europe and North America				
46		3:30 PM	South Hall 2B	Symposia
PS I Still Love You				
47		5:00 PM	Congress Hall	Oral
48		5:15 PM	Congress Hall	Oral
49		5:30 PM	Congress Hall	Oral
51		6:00 PM	Congress Hall	Oral
52		6:15 PM	Congress Hall	Oral



Pub. #	Poster #	Presentation Time	Room	Format
FRIDAY, AUGUST 24, 2018 Continued				
Methods for Data Far and Wide				
53		5:00 PM	Panorama Hall	Oral
54		5:15 PM	Panorama Hall	Oral
55		5:30 PM	Panorama Hall	Oral
56		5:45 PM	Panorama Hall	Oral
57		6:00 PM	Panorama Hall	Oral
58		6:15 PM	Panorama Hall	Oral
Drugs in Pregnancy: Anti-infectives, Anti-asthmatics, MS drugs, & TNFs				
59		5:00 PM	South Hall 1 A&B	Oral
60		5:15 PM	South Hall 1 A&B	Oral
61		5:30 PM	South Hall 1 A&B	Oral
62		5:45 PM	South Hall 1 A&B	Oral
63		6:00 PM	South Hall 1 A&B	Oral
64		6:15 PM	South Hall 1 A&B	Oral
Heart, Blood, and Bleed				
65		5:00 PM	South Hall 2A	Oral
66		5:15 PM	South Hall 2A	Oral
67		5:30 PM	South Hall 2A	Oral
68		5:45 PM	South Hall 2A	Oral
69		6:00 PM	South Hall 2A	Oral
70		6:15 PM	South Hall 2A	Oral
Heart & Limbs				
71		5:00 PM	South Hall 2B	Oral
72		5:15 PM	South Hall 2B	Oral
73		5:30 PM	South Hall 2B	Oral
74		5:45 PM	South Hall 2B	Oral
75		6:00 PM	South Hall 2B	Oral
76		6:15 PM	South Hall 2B	Oral
Predicting Adherence and Persistence to Medication				
77		5:00 PM	South Hall 3A	Oral
1113		5:15 PM	South Hall 3A	Oral
79		5:30 PM	South Hall 3A	Oral
80		5:45 PM	South Hall 3A	Oral
81		6:00 PM	South Hall 3A	Oral
82		6:15 PM	South Hall 3A	Oral

Pub. #	Poster #	Presentation Time	Room	Format
Poster Session A: Spotlight Session – AsPEN				
83	A	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
84	B	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
85	C	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
86	D	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
87	E	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
88	F	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
89	G	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
Poster Session A: Spotlight Session – Adherence				
90	H	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
91	I	12:15 PM – 1:15 PM	WITHDRAWN	
92	J	12:15 PM – 1:15 PM	WITHDRAWN	
93	K	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
94	L	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
95	M	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
96	N	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
97	O	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
Poster Session A: Spotlight Session – Biologistics and Biosimilars				
98	P	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
99	Q	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
100	R	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
101	S	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
102	T	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
103	U	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
104	V	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
105	W	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster



ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

FRIDAY, AUGUST 24, 2018 *Continued*

106	X	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
107	Y	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
108	Z	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
109	AA	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
110	BB	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
111	CC	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
112	DD	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
113	EE	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster

Poster Session A: Spotlight Session – Digital Epidemiology

114	FF	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
115	GG	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
116	HH	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
117	II	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
118	JJ	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster

Poster Session A: Adherence

119	1	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
120	2	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
121	3	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
122	4	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
123	5	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
124	6	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
125	7	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster

Poster Session A: Analytical Methods

126	8	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
127	9	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

128	10	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
129	11	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
130	12	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
131	13	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
132	14	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
133	15	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
134	16	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
135	17	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
136	18	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
137	19	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
138	20	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
139	21	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
140	22	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
141	23	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster

Poster Session A: Burden of Disease - Alimentary and Metabolism

142	24	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
143	25	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
144	26	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
145	27	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
146	28	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
147	29	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
148	30	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster

Poster Session A: Burden of Disease - Cancer

149	31	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
150	32	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
151	33	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster



Pub. #	Poster #	Presentation Time	Room	Format
FRIDAY, AUGUST 24, 2018 <i>Continued</i>				
152	34	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
153	35	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
154	36	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
155	37	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
156	38	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
157	39	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
158	40	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
159	41	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
160	42	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
161	43	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
162	44	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
163	45	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
Poster Session A: Burden of Disease - Cardiovascular				
164	46	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
165	47	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
166	48	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
167	49	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
168	50	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
169	51	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
170	52	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
171	53	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
172	54	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
173	55	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
174	56	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
175	57	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
176	58	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
177	59	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
178	60	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
Poster Session A: Data Linkage				
179	61	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
180	62	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
181	63	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
182	64	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
183	65	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
184	66	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
185	67	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
186	68	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
187	69	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
188	70	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
189	71	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
190	72	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
191	73	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
Poster Session A: Drug Effectiveness - Cancer				
192	74	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
193	75	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
194	76	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
195	77	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
196	78	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
197	79	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
198	80	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster



ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
FRIDAY, AUGUST 24, 2018 Continued				
Poster Session A: Drug Effectiveness - Infections				
199	81	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
200	82	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
201	83	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
202	84	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
203	85	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
204	86	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
205	87	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
206	88	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
207	89	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
208	90	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
Poster Session A: Drug Effectiveness - Nervous System				
209	91	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
210	92	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
211	93	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
212	94	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
213	95	8:00 AM – 6:00 PM	WITHDRAWN	
Poster Session A: Drug Utilization - Cancer				
214	96	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
215	97	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
216	98	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
217	99	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
218	100	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
219	101	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
220	102	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
221	103	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
222	104	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
223	105	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
Poster Session A: Drug Utilization - Cardiovascular				
224	106	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
225	107	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
226	108	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
227	109	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
228	110	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
229	111	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
230	112	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
231	113	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
232	114	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
233	115	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
234	116	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
235	117	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
236	118	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
Poster Session A: Informatics				
237	119	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
238	120	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
239	121	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
240	122	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
241	123	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
242	124	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
243	125	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster



Pub. #	Poster #	Presentation Time	Room	Format
FRIDAY, AUGUST 24, 2018 Continued				
Poster Session A: Medical Devices				
244	126	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
245	127	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
246	128	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
247	129	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
248	130	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
249	131	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
Poster Session A: Methods - Validation Studies				
250	132	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
251	133	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
252	134	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
253	135	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
254	136	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
255	137	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
256	138	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
257	139	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
258	140	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
259	141	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
260	142	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
261	143	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
262	144	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
263	145	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
264	146	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
265	147	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
266	148	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
267	149	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
268	150	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
269	151	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
270	152	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
271	153	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
272	154	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
273	155	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
274	156	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
275	157	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
276	158	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
277	159	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
278	160	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
279	161	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
280	162	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
281	163	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
282	164	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
283	165	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
284	166	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
285	167	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
286	168	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
287	169	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
288	170	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
289	171	8:00 AM – 6:00 PM	WITHDRAWN	
Poster Session A: Novel Data Collection Tools				
290	172	8:00 AM – 6:00 PM	WITHDRAWN	
291	173	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster



ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
FRIDAY, AUGUST 24, 2018 <i>Continued</i>				
292	174	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
293	175	8:00 AM – 6:00 PM	WITHDRAWN	
294	176	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
295	177	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
296	178	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
297	179	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
298	180	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
Poster Session A: Pediatric Pharmacoepidemiology				
299	181	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
300	182	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
301	183	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
302	184	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
303	185	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
304	186	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
305	187	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
306	188	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
307	189	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
308	190	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
Poster Session A: Pharmacovigilance - Cancer				
309	191	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
310	192	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
311	193	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
312	194	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
313	195	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
314	196	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
315	197	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
316	198	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
317	199	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
318	200	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
Poster Session A: Trials				
319	201	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
320	202	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
321	203	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
322	204	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
323	205	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
324	206	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
325	207	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
Poster Session A: Burden of Disease - Nervous System				
326	208	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
328	210	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
329	211	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
330	212	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
331	213	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
332	214	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
333	215	8:00 AM – 6:00 PM	WITHDRAWN	
334	216	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
335	217	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
336	218	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
337	219	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
338	220	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster



Pub. #	Poster #	Presentation Time	Room	Format
FRIDAY, AUGUST 24, 2018 Continued				
Poster Session A: Drug Utilization - Diabetes				
339	221	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
340	222	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
341	223	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
342	224	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
343	225	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
344	226	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
345	227	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
347	229	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
348	230	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
Poster Session A: Methods to Avoid Bias and Confounding				
349	231	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
350	232	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
351	233	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
352	234	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
353	235	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
354	236	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
355	237	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
356	238	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
357	239	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
358	240	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
359	241	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
360	242	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster
361	243	8:00 AM – 6:00 PM	Congress Foyer 3A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
SATURDAY, AUGUST 25, 2018				
Diversity in Design: A Mismatch of Methods				
362		8:00 AM	Congress Hall	Oral
363		8:15 AM	Congress Hall	Oral
364		8:30 AM	Congress Hall	Oral
365		8:45 AM	Congress Hall	Oral
366		9:00 AM	Congress Hall	Oral
367		9:15 AM	Congress Hall	Oral
Advances in Vaccine Safety Monitoring				
368		8:00 AM	Panorama Hall	Oral
369		8:15 AM	Panorama Hall	Oral
370		8:30 AM	Panorama Hall	Oral
371		8:45 AM	Panorama Hall	Oral
372		9:00 AM	Panorama Hall	Oral
373		9:15 AM	Panorama Hall	Oral
Psychotropics in Pregnancy				
374		8:00 AM	South Hall 1 A&B	Oral
375		8:15 AM	South Hall 1 A&B	Oral
376		8:30 AM	South Hall 1 A&B	Oral
377		8:45 AM	South Hall 1 A&B	Oral
378		9:00 AM	South Hall 1 A&B	Oral
379		9:15 AM	South Hall 1 A&B	Oral
Let It Beat, Let It Beat				
380		8:00 AM	South Hall 2A	Oral
381		8:15 AM	South Hall 2A	Oral
382		8:30 AM	South Hall 2A	Oral
383		8:45 AM	South Hall 2A	Oral
384		9:00 AM	South Hall 2A	Oral
385		9:15 AM	South Hall 2A	Oral
Diabetes All Mixed Up				
386		8:00 AM	South Hall 2B	Oral
387		8:15 AM	South Hall 2B	Oral
388		8:30 AM	South Hall 2B	Oral
389		8:45 AM	South Hall 2B	Oral
390		9:00 AM	South Hall 2B	Oral
391		9:15 AM	South Hall 2B	Oral
Painful Policy				
392		8:00 AM	South Hall 3A	Oral
393		8:15 AM	South Hall 3A	Oral
394		8:30 AM	South Hall 3A	Oral
395		8:45 AM	South Hall 3A	Oral
396		9:00 AM	South Hall 3A	Oral
397		9:15 AM	South Hall 3A	Oral



ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
SATURDAY, AUGUST 25, 2018 <i>Continued</i>				
Oral Bisphosphonates & Osteoporosis				
398		1:00 PM	Congress Hall	Oral
399		1:15 PM	Congress Hall	Oral
400		1:30 PM	Congress Hall	Oral
401		1:45 PM	Congress Hall	Oral
402		2:00 PM	Congress Hall	Oral
403		2:15 PM	Congress Hall	Oral
Risky Business: Benefit Risk Assessment and Risk Minimization				
404		1:00 PM	Panorama Hall	Oral
405		1:15 PM	Panorama Hall	Oral
406		1:30 PM	Panorama Hall	Oral
407		1:45 PM	Panorama Hall	Oral
408		2:00 PM	Panorama Hall	Oral
409		2:15 PM	Panorama Hall	Oral
Inflammatory Guidance: Burden, Costs, and Outcomes of Autoimmune Diseases				
410		1:00 PM	South Hall 1 A&B	Oral
411		1:15 PM	South Hall 1 A&B	Oral
412		1:30 PM	South Hall 1 A&B	Oral
413		1:45 PM	South Hall 1 A&B	Oral
414		2:00 PM	South Hall 1 A&B	Oral
415		2:15 PM	South Hall 1 A&B	Oral
Geriatric Management and Measurements				
416		1:00 PM	South Hall 2A	Oral
417		1:15 PM	South Hall 2A	Oral
418		1:30 PM	South Hall 2A	Oral
419		1:45 PM	South Hall 2A	Oral
420		2:00 PM	South Hall 2A	Oral
421		2:15 PM	South Hall 2A	Oral
Pediatric Potpourri				
422		1:00 PM	South Hall 2B	Oral
423		1:15 PM	South Hall 2B	Oral
424		1:30 PM	South Hall 2B	Oral
425		1:45 PM	South Hall 2B	Oral
426		2:00 PM	South Hall 2B	Oral
427		2:15 PM	South Hall 2B	Oral

Pub. #	Poster #	Presentation Time	Room	Format
Your Pills, Your Cancer Risk				
428		1:00 PM	South Hall 3A	Oral
429		1:15 PM	South Hall 3A	Oral
430		1:30 PM	South Hall 3A	Oral
431		1:45 PM	South Hall 3A	Oral
432		2:00 PM	South Hall 3A	Oral
433		2:15 PM	South Hall 3A	Oral
Annual Meeting of ISPE Members & Awards Ceremony				
434		2:30 PM	Congress Hall	Award
Moving From RECORD to CORD - Guidelines for Conducting Research Using Routinely-Collected Health Data				
435		4:00 PM	Congress Hall	Symposia
Pharmacoepidemiology in Eastern Europe - a EuroDURG/SIG-DUR Symposium Dedicated to the Late MUDr. Ludvík Štika				
436		4:00 PM	Panorama Hall	Symposia
Ten Years of ENCePP. Time to Celebrate and Move Forward				
437		4:00 PM	South Hall 1A&B	Workshop
When And Where To Use Blinding In Pragmatic Randomized Clinical Trials				
438		4:00 PM	South Hall 2A	Symposia
Patient-Focused Benefit Risk Assessment: Why, When and How Should Epidemiologists Get Involved				
439		4:00 PM	South Hall 2B	Symposia
Poster Session B: Spotlight Session – BRACE				
440	A	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
441	B	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
442	C	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
443	D	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
444	E	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
445	F	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
446	G	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
447	H	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster



Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

SATURDAY, AUGUST 25, 2018 *Continued*

Poster Session B: Spotlight Session – Databases

448	I	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
449	J	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
450	K	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
451	L	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
452	M	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
453	N	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
454	O	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
455	P	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster

Poster Session B: Spotlight Session – DUR/HSR

456	Q	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
457	R	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
458	S	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
459	T	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
460	U	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
461	V	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
462	W	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
463	X	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster

Poster Session B: Spotlight Session – Medical Devices

464	Y	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
465	Z	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
466	AA	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
467	BB	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
468	CC	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
469	DD	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

470	EE	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
471	FF	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster

Poster Session B: Spotlight Session – Rare Disease

472	GG	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
473	HH	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
474	II	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
475	JJ	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
476	KK	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
477	LL	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
478	MM	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster
479	NN	11:45 AM – 12:45 PM	Congress Foyer 3A	Poster

Poster Session B: Study Design and Bias

480	1	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
481	2	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
482	3	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
483	4	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
484	5	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
485	6	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
486	7	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
487	8	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
488	9	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
489	10	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
490	11	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
491	12	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
492	13	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
493	14	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster



ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
SATURDAY, AUGUST 25, 2018 <i>Continued</i>				
Poster Session B: Pregnancy and Lactation				
494	15	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
495	16	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
496	17	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
497	18	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
498	19	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
499	20	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
500	21	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
501	22	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
502	23	8:00 AM – 6:00 PM	WITHDRAWN	
503	24	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
504	25	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
505	26	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
506	27	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
507	28	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
508	29	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
509	30	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
510	31	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
511	32	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
512	33	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
513	34	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
514	35	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
515	36	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
516	37	8:00 AM – 6:00 PM	WITHDRAWN	
517	38	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
518	39	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
519	40	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
520	41	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
521	42	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
522	43	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
523	44	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
524	45	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
525	46	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
526	47	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
527	48	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
528	49	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
529	50	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
530	51	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
531	52	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
532	53	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
533	54	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
Poster Session B: Pharmacovigilance - Methods/Data				
534	55	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
535	56	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
536	57	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
537	58	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
538	59	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
539	60	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
540	61	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
541	62	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
542	63	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster



Pub. #	Poster #	Presentation Time	Room	Format
SATURDAY, AUGUST 25, 2018 <i>Continued</i>				
543	64	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
544	65	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
545	66	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
546	67	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
547	68	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
548	69	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
549	70	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
550	71	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
551	72	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
552	73	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
553	74	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
554	75	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
555	76	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
556	77	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
557	78	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
558	79	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
559	80	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
560	81	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
561	82	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
562	83	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
563	84	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
564	85	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
565	86	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
566	87	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
567	88	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
568	89	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
569	90	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
570	91	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
Poster Session B: Pharmacovigilance - Musculo-skeletal				
571	92	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
572	93	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
573	94	8:00 AM – 6:00 PM	WITHDRAWN	
574	95	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
575	96	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
576	97	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
577	98	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
578	99	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
579	100	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
580	101	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
Poster Session B: Pharmacovigilance - Nervous system				
581	102	8:00 AM – 6:00 PM	WITHDRAWN	
582	103	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
583	104	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
584	105	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
585	106	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
586	107	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
587	108	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
588	109	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
589	110	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
590	111	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster



ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
SATURDAY, AUGUST 25, 2018 <i>Continued</i>				
591	112	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
592	113	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
593	114	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
594	115	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
595	116	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
596	117	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
597	118	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
598	119	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
599	120	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
600	121	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
601	122	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
602	123	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
603	124	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
Poster Session B: Pharmacovigilance - Other				
604	125	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
605	126	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
606	127	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
607	128	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
608	129	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
609	130	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
610	131	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
611	132	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
612	133	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
613	134	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
614	135	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
615	136	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
616	137	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
617	138	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
618	139	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
619	140	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
620	141	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
621	142	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
Poster Session B: Pharmacovigilance - Respiratory				
622	143	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
623	144	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
624	145	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
625	146	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
626	147	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
Poster Session B: Geriatric Pharmacoepidemiology				
627	148	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
628	149	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
629	150	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
630	151	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
631	152	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
632	153	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
633	154	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
634	155	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
635	156	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
636	157	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
637	158	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
638	159	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster



Pub. #	Poster #	Presentation Time	Room	Format
SATURDAY, AUGUST 25, 2018 <i>Continued</i>				
639	160	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
640	161	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
641	162	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
642	163	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
643	164	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
644	165	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
645	166	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
646	167	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
647	168	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
648	169	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
649	170	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
650	171	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
651	172	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
652	173	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
653	174	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
654	175	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
655	176	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
656	177	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
Poster Session B: Health Economics / Outcomes Research				
657	178	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
658	179	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
659	180	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
660	181	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
661	182	8:00 AM – 6:00 PM	WITHDRAWN	
662	183	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
663	184	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
664	185	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
665	186	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
666	187	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
667	188	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
668	189	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
669	190	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
670	191	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
671	192	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
672	193	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
673	194	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
674	195	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
675	196	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
676	197	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
677	198	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
678	199	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
679	200	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
680	201	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
681	202	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
682	203	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
683	204	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
684	205	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
685	206	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
686	207	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
687	208	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster



ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
SATURDAY, AUGUST 25, 2018 <i>Continued</i>				
688	209	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
689	210	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
690	211	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
691	212	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
Poster Session B: Drug Utilization - Nervous System				
692	213	8:00 AM – 6:00 PM	WITHDRAWN	
693	214	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
694	215	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
695	216	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
696	217	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
697	218	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
698	219	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
699	220	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
700	221	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
701	222	8:00 AM – 6:00 PM	WITHDRAWN	
702	223	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
703	224	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
704	225	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
705	226	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
706	227	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
Poster Session B: Drug Utilization - Opioids				
707	228	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
708	229	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
709	230	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
710	231	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
711	232	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
712	233	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
713	234	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
714	235	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
715	236	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
716	237	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
717	238	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
718	239	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
719	240	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
Poster Session B: Burden of Disease - Other				
720	241	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
721	242	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
722	243	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
723	244	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
724	245	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
725	246	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
726	247	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
727	248	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
728	249	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
729	250	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
730	251	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
731	252	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
Poster Session B: Burden of Disease - Respiratory				
732	253	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
733	254	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
734	255	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
735	256	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster



Pub. #	Poster #	Presentation Time	Room	Format
SATURDAY, AUGUST 25, 2018 <i>Continued</i>				
736	257	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
737	258	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
Poster Session B: Pharmacovigilance - Infections				
738	259	8:00 AM – 6:00 PM	WITHDRAWN	
739	260	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
740	261	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
741	262	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
742	263	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
743	264	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
744	265	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
745	266	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
746	267	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
747	268	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
748	269	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
749	270	8:00 AM – 6:00 PM	Congress Foyer 2A	Poster
SUNDAY, AUGUST 26, 2018				
A Methods Stew				
750		8:30 AM	Congress Hall	Oral
751		8:45 AM	Congress Hall	Oral
752		9:00 AM	Congress Hall	Oral
753		9:15 AM	Congress Hall	Oral
754		9:30 AM	Congress Hall	Oral
755		9:45 AM	Congress Hall	Oral
Yearning to Dig Deep: Adventures in Data Mining				
756		8:30 AM	Panorama Hall	Oral
757		8:45 AM	Panorama Hall	Oral
758		9:00 AM	Panorama Hall	Oral
759		9:15 AM	Panorama Hall	Oral
760		9:30 AM	Panorama Hall	Oral
761		9:45 AM	Panorama Hall	Oral

Pub. #	Poster #	Presentation Time	Room	Format
Renal Outcomes and Safety				
762		8:30 AM	South Hall 1 A&B	Oral
763		8:45 AM	South Hall 1 A&B	Oral
764		9:00 AM	South Hall 1 A&B	Oral
765		9:15 AM	South Hall 1 A&B	Oral
766		9:30 AM	South Hall 1 A&B	Oral
767		9:45 AM	South Hall 1 A&B	Oral
Drugs in Pregnancy - Metformin, Vareniclin, OCs, Methods				
768		8:30 AM	South Hall 2A	Oral
769		8:45 AM	South Hall 2A	Oral
770		9:00 AM	South Hall 2A	Oral
771		9:15 AM	South Hall 2A	Oral
772		9:30 AM	South Hall 2A	Oral
773		9:45 AM	South Hall 2A	Oral
Keep your Brain Under Control				
774		8:30 AM	South Hall 2B	Oral
775		8:45 AM	South Hall 2B	Oral
776		9:00 AM	South Hall 2B	Oral
777		9:15 AM	South Hall 2B	Oral
778		9:30 AM	South Hall 2B	Oral
779		9:45 AM	South Hall 2B	Oral
Cancer Treatment, Lessons from Three Continents				
780		8:30 AM	South Hall 3A	Oral
781		8:45 AM	South Hall 3A	Oral
782		9:00 AM	South Hall 3A	Oral
783		9:15 AM	South Hall 3A	Oral
784		9:30 AM	South Hall 3A	Oral
785		9:45 AM	South Hall 3A	Oral
Adventures in Replication: Initial Experiences Related to the Joint ISPE/ISPOR Guidance				
786		10:30 AM	Congress Hall	Symposia
Quantitative Benefit-Risk Assessment: Hands-On Workshop				
787		10:30 AM	Panorama Hall	Workshop
It Takes a Village Part II: Workshop to Reconsider Core Competencies for New Generations in the Global and Rapidly Changing Community of Pharmacoepidemiology				
788		10:30 AM	South Hall 1 A&B	Workshop
Increasing Access to Drug Utilization Data Globally: Developing an Action Plan				
789		10:30 AM	South Hall 2A	Workshop



ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
SUNDAY, AUGUST 26, 2018 <i>Continued</i>				
Challenges and Potential of Vaccine Post-Licensure Benefit-Risk Assessments in Resource Limited Countries				
790		10:30 AM	South Hall 2B	Symposia
Comparative Effectiveness: Heart & Flow				
791		1:30 PM	Congress Hall	Oral
792		1:45 PM	Congress Hall	Oral
793		2:00 PM	Congress Hall	Oral
794		2:15 PM	Congress Hall	Oral
795		2:30 PM	Congress Hall	Oral
796		2:45 PM	Congress Hall	Oral
Drug Utilization Research: Making It Count				
797		1:30 PM	Panorama Hall	Oral
798		1:45 PM	Panorama Hall	Oral
799		2:00 PM	Panorama Hall	Oral
800		2:15 PM	Panorama Hall	Oral
801		2:30 PM	Panorama Hall	Oral
802		2:45 PM	Panorama Hall	Oral
To Be or Not To Be: Is It Really Valid?				
803		1:30 PM	South Hall 1 A&B	Oral
804		1:45 PM	South Hall 1 A&B	Oral
805		2:00 PM	South Hall 1 A&B	Oral
806		2:15 PM	South Hall 1 A&B	Oral
807		2:30 PM	South Hall 1 A&B	Oral
808		2:45 PM	South Hall 1 A&B	Oral
Algorithms: Rarely Pure and Never Simple				
809		1:30 PM	South Hall 2A	Oral
810		1:45 PM	South Hall 2A	Oral
811		2:00 PM	South Hall 2A	Oral
812		2:15 PM	South Hall 2A	Oral
813		2:30 PM	South Hall 2A	Oral
814		2:45 PM	South Hall 2A	Oral
What's Harm Got To Do With It?				
815		1:30 PM	South Hall 2B	Oral
816		1:45 PM	South Hall 2B	Oral
817		2:00 PM	South Hall 2B	Oral
818		2:15 PM	South Hall 2B	Oral
819		2:30 PM	South Hall 2B	Oral
820		2:45 PM	South Hall 2B	Oral

Pub. #	Poster #	Presentation Time	Room	Format
Safety in Numbers: Assessing Interventions and Outcomes				
821		1:30 PM	South Hall 3A	Oral
822		1:45 PM	South Hall 3A	Oral
823		2:00 PM	South Hall 3A	Oral
824		2:15 PM	South Hall 3A	Oral
825		2:30 PM	South Hall 3A	Oral
826		2:45 PM	South Hall 3A	Oral
Poster Session C: Spotlight Session – Medications in Pregnancy and Lactation				
827	A	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
828	B	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
829	C	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
830	D	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
831	E	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
832	F	12:15 PM – 1:15 PM	WITHDRAWN	
833	G	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
834	H	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
Poster Session C: Spotlight Session – Molecular Epidemiology, Biomarkers and Pharmacogenetics				
835	I	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
836	J	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
837	K	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
838	L	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
839	M	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
840	N	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
841	O	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
842	P	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster



Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

SUNDAY, AUGUST 26, 2018 *Continued*

Poster Session C: Spotlight Session – Oncology

843	Q	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
844	R	12:15 PM – 1:15 PM	WITHDRAWN	
845	S	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
846	T	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
847	U	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
848	V	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
849	W	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
850	X	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster

Poster Session C: Spotlight Session – Pediatrics

851	Y	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
852	Z	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
853	AA	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
854	BB	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
855	CC	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
856	DD	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
857	EE	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster

Poster Session C: Spotlight Session – Vaccines

858	FF	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
859	GG	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
860	HH	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
861	II	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
862	JJ	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
863	KK	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
864	LL	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster
865	MM	12:15 PM – 1:15 PM	Congress Foyer 3A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

Poster Session C: Drug Effectiveness - Cardiovascular

866	1	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
867	2	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
868	3	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
869	4	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
870	5	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
871	6	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
872	7	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
873	8	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
874	9	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
875	10	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
876	11	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
877	12	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
878	13	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
879	14	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
880	15	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
881	16	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
882	17	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
883	18	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
884	19	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
885	20	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
886	21	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster

Poster Session C: Drug Effectiveness - Other

887	22	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
888	23	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
889	24	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster



ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

SUNDAY, AUGUST 26, 2018 *Continued*

891	26	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
892	27	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
893	28	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
894	29	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
895	30	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
896	31	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster

Poster Session C: Drug Utilization - Other

897	32	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
898	33	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
899	34	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
900	35	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
901	36	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
902	37	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
903	38	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
904	39	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
905	40	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
906	41	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
907	42	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
908	43	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
909	44	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
910	45	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
911	46	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
912	47	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
913	48	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

914	49	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
915	50	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
916	51	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
917	52	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
918	53	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
919	54	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
920	55	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
921	56	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
922	57	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
923	58	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
924	59	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster

Poster Session C: Drug Utilization - Policy

925	60	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
926	61	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
927	62	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
928	63	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
929	64	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
930	65	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
931	66	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
932	67	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
933	68	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
934	69	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
935	70	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
936	71	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
937	72	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
938	73	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster



Pub. #	Poster #	Presentation Time	Room	Format
SUNDAY, AUGUST 26, 2018 Continued				
Poster Session C: Drug Utilization - Quality of Use of Medicines				
939	74	8:00 AM – 1:45 PM	WITHDRAWN	
940	75	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
941	76	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
942	77	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
943	78	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
944	79	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
945	80	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
946	81	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
947	82	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
948	83	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
949	84	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
950	85	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
951	86	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
952	87	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
953	88	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
954	89	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
955	90	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
956	91	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
957	92	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
958	93	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
959	94	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
960	95	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
961	96	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
962	97	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
963	98	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
964	99	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
965	100	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
966	101	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
967	102	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
968	103	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
969	104	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
970	105	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
971	106	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
972	107	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
973	108	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
974	109	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
975	110	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
976	111	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
977	112	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
978	113	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
Poster Session C: Pharmacovigilance - Alimentary Tract and Metabolism				
979	114	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
980	115	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
981	116	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
982	117	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
983	118	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
984	119	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
985	120	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster



ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

SUNDAY, AUGUST 26, 2018 *Continued*

986	121	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
987	122	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
988	123	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
989	124	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
990	125	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
991	126	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
992	127	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
993	128	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
994	129	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
995	130	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster

Poster Session C: Pharmacovigilance - Cardiovascular

996	131	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
997	132	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
998	133	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
999	134	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1000	135	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1001	136	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1002	137	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1003	138	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1004	139	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1005	140	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1006	141	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1007	142	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1008	143	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1009	144	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

1010	145	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1011	146	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1012	147	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1013	148	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1014	149	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1015	150	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1016	151	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1017	152	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1018	153	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1019	154	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1020	155	8:00 AM – 1:45 PM	WITHDRAWN	
1021	156	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1022	157	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1023	158	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1024	159	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1025	160	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1026	161	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1027	162	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1028	163	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1029	164	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster

Poster Session C: Biologics/Biosimilars

1030	165	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1031	166	8:00 AM – 1:45 PM	WITHDRAWN	
1032	167	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1033	168	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1034	169	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster



Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

SUNDAY, AUGUST 26, 2018 *Continued*

1035	170	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1036	171	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1037	172	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1038	173	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1039	174	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1040	175	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1041	176	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1042	177	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1043	178	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1044	179	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster

Poster Session C: Burden of Disease - Infections

1045	180	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1046	181	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1047	182	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1048	183	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1049	184	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1050	185	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1051	186	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1052	187	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1053	188	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster

Poster Session C: Burden of Disease - Musculo-Skeletal

1054	189	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1055	190	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1056	191	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1057	192	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

1058	193	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1059	194	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1060	195	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1061	196	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster

Poster Session C: Drug Effectiveness - Diabetes

1062	197	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1063	198	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1064	199	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1065	200	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1066	201	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1067	202	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1068	203	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster

Poster Session C: Propensity Scores

1069	204	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1070	205	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1071	206	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1072	207	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1073	208	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster

Poster Session C: Quality of Life

1074	209	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1075	210	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1076	211	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster

Poster Session C: Vaccines

1077	212	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1078	213	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1079	214	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1080	215	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster



ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

SUNDAY, AUGUST 26, 2018 *Continued*

1081	216	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1082	217	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1083	218	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1084	219	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1085	220	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1086	221	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster

Poster Session C: Drug Utilization - Infections

1087	222	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1088	223	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1089	224	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1090	225	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1091	226	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1092	227	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1093	228	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1094	229	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1095	230	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1096	231	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1097	232	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster

Poster Session C: Drug Utilization - Interventions and implementations

1098	233	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1099	234	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1100	235	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1101	236	8:00 AM – 1:45 PM	WITHDRAWN	
1102	237	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1103	238	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

1104	239	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1105	240	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1106	241	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1107	242	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1108	243	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1109	244	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1110	245	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1111	246	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1112	247	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1114	249	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster

Poster Session C: Benefit-Risk Assessment, Communication, and Evaluation

1115	250	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1116	251	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1117	252	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1118	253	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1119	254	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1120	255	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1121	256	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1122	257	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1123	258	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1124	259	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1125	260	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1126	261	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1127	262	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster



Pub. #	Poster #	Presentation Time	Room	Format
SUNDAY, AUGUST 26, 2018 <i>Continued</i>				
1128	263	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1129	264	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1130	265	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1131	266	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1132	267	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1133	268	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1134	269	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1135	270	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1136	271	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1137	272	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1138	273	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1139	274	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1140	275	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1141	276	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster
1142	277	8:00 AM – 1:45 PM	Congress Foyer 2A	Poster

ADVERTISER'S INDEX

◆ Aetion	33
◆ Amgen	40
◆ Analysis Group	38
◆ Bayer	23
◆ BHE	27
◆ Biogen	52
◆ Boehringer Ingelheim	137
◆ Department of Clinical Epidemiology, Aarhus University Hospital	43
◆ Dove Medical Press Ltd.	48
◆ Eli Lilly & Company	15
◆ Evidera	9
◆ Department of Population Medicine	23
◆ HealthCore	13
◆ IBM Watson Health	52
◆ ICON	30
◆ IQVIA	19
◆ Kantar Health	27
◆ Optum	64
◆ Pfizer	34
◆ PharmaLex	63
◆ Reagan-Udall Foundation	30
◆ RTI Health Solutions	38
◆ Servier Pharmacoepidemiology	40
◆ Syneos Health	64
◆ Wiley Publications	138



If you encounter
each day with open-
minded curiosity.

Then
you're one
of us.



More than 130 years of experience, we remain intensely curious.

Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company **Boehringer Ingelheim** stands for. **Boehringer Ingelheim** is one of the pharmaceutical industry's top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.

The department **Global Epidemiology, Real World Evidence- Center of Excellence** contributes substantially to achieving these goals by evaluating patient populations and our products in real world settings and is currently expanding.

Would you like to join our team?

Please send an e-mail to epidemiology@boehringer-ingelheim.com indicating your interest.

www.boehringer-ingelheim.com

Official Journal of the International Society for Pharmacoepidemiology

Editor-in-Chief: Professor Brian L. Strom

Pharmacoepidemiology & Drug Safety provides an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology.

**Free online access for ISPE members
via the society website**

Congratulations to The Ronald D. Mann Best Article of 2017 Awards Winners

First Prize

Prevalent New-User Cohort Designs for Comparative Drug Effect Studies by Time-Conditional Propensity Scores

Janis Suissa, Erico E. M. Moodie, Sophie Dell'Ariella

Honorable Mention:

The Effect of Statins on Influenza-like Illness Morbidity and Mortality

Paul Brassard, Jennifer A. Wu, Pierre Crast, Sophie Dell'Ariella, Brian R. Quakenbush, Emily Suissa

Honorable Mention:


Relative Preferences in the Abuse of Immediate-release vs. Extended-release Opioids in a Sample of Treatment-seeking Opioid Abusers

Therese J. Cicero, Matthew S. Dick, Zachary A. Kasper

For more information on these top papers and other journal features, please visit:

www.pdsjournal.org

Print ISSN: 1053-8569 • Online ISSN: 1099-1557 • 2018 Volume: 27 • Frequency: Monthly



Impact Factor
2.314

**2017 Journal Citation Reports®*

Honorable Mention:

The Feasibility of Using Multiple Databases to Study Rare Outcomes: the Potential Effect of Long-Acting Beta Agonists With Inhaled Corticosteroid Therapy on Asthma Mortality

Christine A. Johannes, Lisa J. McGinn, Kirk D. McKiff, Brian C. Olincaert, Elizabeth B. Anderson, Patricia Tenorio, Jeffrey S. Brown, Carlos A. Comenzo, Jr., Rochael L. DiSantostefano, Kenneth J. Rothman, Till Stürmer, Stephen Lanes, Kimberly J. Davis

Honorable Mention:

Impact of an Opioid Risk Reduction Initiative on Motor Vehicle Crash Risk Among Chronic Opioid Therapy Patients

Ryan M. Hansen, Rod L. Walker, Susan M. Shortreed, Suscho Dublin, Catherine Saunders, Dorette J. Lunnon, Michael Van Korf



35TH ICPE

AUGUST 24-28, 2019

PENNSYLVANIA CONVENTION CENTER • PHILADELPHIA, PA

MEETING INFO: PHARMACOEPI.ORG

Scholarship Submission Deadline:
MARCH 1, 2019

ABSTRACT SUBMISSION DEADLINE: FEBRUARY 13, 2019

YOU ARE INVITED TO SUBMIT AN ABSTRACT

ISPE invites you to submit an abstract for an oral/poster presentation or a workshop/symposium at the 35th ICPE/Philadelphia. This pre-eminent conference on pharmacoepidemiology will be an invaluable scientific experience and an opportunity to experience Philadelphia—famous as the birthplace of life, liberty and the pursuit of happiness. Philadelphia delivers countless things to do: fascinating museums, vibrant parks, national historic sites and famous (and delicious) food. Yo, welcome to Philly!

GUIDELINES FOR SUBMISSIONS

The deadline for receipt of all abstracts is February 13, 2019. The online submission site will be operational by mid-December 2017 and will include submission guidelines.

Questions about abstract submissions should be directed to info@pharmacoepi.org. Note, submissions will not be accepted until the online submission site is open in December 2018. Late breaking abstracts will not be accepted.

REVIEWING REGISTRATION

The ISPE Scientific Program Committee will review all abstracts in April 2019. All submitters will be notified by email in early June 2019. All presenters and panelists (workshop/symposia) must register to attend the 2019 ICPE.

STUDENT AWARDS & SCHOLARSHIPS

ISPE will grant several student awards to recognize and encourage student excellence in pharmacoepidemiology. The 2019 ICPE Scientific Program Committee oversees the selection of awards, which will be presented at the 2019 ICPE Annual Meeting of ISPE Members & Awards Ceremony.

ISPE will award a limited number of scholarships to help defray conference expenses. Scholarship information will be posted on pharmacoepi.org. The ICPE 2019 scholarship submission deadline is March 1, 2019.

SPONSORSHIPS, EXHIBITS & ACADEMIC SHOWCASE

ISPE offers organizations, institutions and academic programs opportunities to support the conference while sharing their products and services with attendees. A Conference Sponsorship & Exhibitor Prospectus will be posted on pharmacoepi.org/meetings/35ICPE.

SAVE THE DATES

August 24-28, 2019

Pennsylvania Convention Center
Philadelphia, Pennsylvania


Please visit pharmacoepi.org/meetings/35ICPE for updated conference information.




FLOOR PLANS

Plány pater


4TH FLOOR | 4. patro




3RD FLOOR | 3. patro



2ND FLOOR | 2. patro



1ST FLOOR | 1. patro



GROUND FLOOR | Přízemí

